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ABSTRACT 
 
THE APPLICATION OF MASS SPECTROMETRIC MEASUREMENT 
TECHNIQUES FOR THE EVALUATION AND ASSESSMENT OF AUTISM 
SPECTRUM DISORDERS 
 
 
By 
Gregory M. Zinn 
May 2014 
 
Dissertation supervised by H.M. Skip Kingston 
Autism spectrum disorders (ASDs) are neurological developmental disorders that 
affect communication and social interaction.  They are becoming more important to 
society as their rate has risen dramatically over the past 30 years.  Presently, there is no 
known cure for ASDs and the current research focuses on improvements in diagnosis and 
different types of treatments.  The most significant contribution of the research described 
in this dissertation is the application of advanced mass spectrometric measurement 
techniques that provide higher accuracy and precision to the diagnosis and treatment of 
ASDs.  The treatment of ASDs was assessed through the evaluation of elemental 
contamination in dietary supplements.  Elemental contamination was discovered to exist 
in the dietary supplements through the application of standard United States 
 v 
Environmental Protection Agency methods for both sample preparation and analysis.  
The diagnosis of ASDs was evaluated through the search for biomarkers.  The plasma 
zinc/serum copper ratio may be a biomarker that indicates stress on the metallothionein 
system of children with ASDs.  Biomarkers during treatment in autism were sought in a 
cleanroom study demonstrating that the younger children responded better to the 
cleanroom experience compared to older children through noteworthy behavioral and 
physiological changes.  The comparative analysis of children with autism and controls 
had results indicating the possibility of children with autism showing characteristics of 
the toxicant-induced loss of tolerance theory of disease.  Measurement comparisons were 
performed between the analytical methods and the commercial clinical laboratory that 
demonstrated the superior quality of the analytical measurements.  Overall, the work 
described in this dissertation demonstrated the power of advanced mass spectrometric 
analysis techniques through the application to the diagnosis and treatment of ASDs.  A 
greater understanding of children with autism has been accomplished through the 
discovery of potential biomarkers and characteristics unique to them.  The work in this 
dissertation can be applied to other diseases and other types of measurements using the 
principles described throughout it.  Finally, the work has shown the importance of 
measurement in achieving accurate and precise data that leads to the greatest 
understanding and knowledge. 
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Chapter 1  
Introduction  
Autism spectrum disorders (ASDs) are neurological developmental disorders that 
affect communication and social interaction.  Current medical knowledge characterizes 
ASDs as psychological disorders which negatively affect development through social 
interaction, communication, and repetitive behaviors.  Autism spectrum disorders 
manifest biologically through immune system dysregulation, leaky gut syndrome, other 
digestive problems, and neurological effects.  They are becoming more important to 
society as their rate has risen dramatically over the past 30 years.  Presently, there is no 
known cure for ASDs and the current research focuses on improvements in diagnosis and 
different types of treatments.  This dissertation addresses these two major areas critical to 
autism through the application of advanced mass spectrometric measurement techniques 
which provide higher accuracy and precision. 
 First, Chapter 1 will provide a background of ASDs by reviewing the history of 
diagnosis, the changes in diagnosis rate, factors involved in the diagnosis of autism, and 
the behavioral rating scales used in clinical diagnosis.  In addition, important areas such 
as the immune system, immune dysregulation in autism, and problems with 
detoxification and digestion are examined.  Current autism treatments, notably dietary 
supplements, and biomarkers of autism are reviewed to provide foundation for this 
research.  The important components of analytical measurements are discussed along 
with the standard United States Environmental Protection Agency (EPA) methods used in 
sample preparation and analysis. 
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 The application of advanced mass spectrometric measurement techniques to the 
diagnosis and treatment of ASDs is the most significant contribution of the research 
described in this dissertation.  The novel application of these techniques involves using 
stable, anthropogenic enriched isotopes to improve the quantification of measurements 
achieving better accuracy and precision.  Chapter 2 describes the elemental 
contamination found in common types of dietary supplements from four different 
manufacturers.  Chapter 3 investigates a known contamination event of a dietary 
supplement through the quantification of the known impurity and the evaluation of the 
extent of other adulteration of the product.  The next three chapters focus on the 
discovery of biomarkers to be applied in the diagnosis of autism.  The first of these 
studies described in Chapter 4 involved a retrospective review of a clinical biomarker 
observed in children with ASDs.  Work was performed to establish the difference 
between healthy children and children with ASDs, and among the different diseases 
comprising the autism spectrum.  Chapter 5 evaluates the effects of the environment on 
children with ASDs through the use of a cleanroom where the children slept.  The clinical 
study described in Chapter 6 sought to determine the differences between children with 
autism and matched healthy controls.  The children were evaluated to find common 
biomarkers of diagnosis and to determine relationships between clinical data and 
environmental exposures. 
1.1 The Current State of Autism Spectrum Disorders 
Autism is currently listed as a psychological disorder in the Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) under the heading of 
Pervasive Developmental Disorders (PDDs).  PDDs, also known as ASDs, affect many 
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different areas of development, specifically social interaction and functioning, language 
skills, and repetitive behaviors.
1
  Five disorders comprise PDDs:  Autistic Disorder, 
Rett’s Disorder, Childhood Disintegrative Disorder, Asperger’s Disorder, and Pervasive 
Developmental Disorder-Not Otherwise Specified (PDD-NOS).  Many other conditions 
can be present with PDDs including genetic aberrations, inherited diseases, and physical 
defects of the central nervous system.
1
 
The three most common types of ASDs are Autistic Disorder, Asperger’s 
Disorder, and PDD-NOS.  Autistic Disorder has been called early infantile autism, 
childhood autism, or Kanner’s autism, and the social communication is aberrant and 
decreased while social interactions are limited.
1
  Asperger’s Disorder is illustrated by 
social impairment, improper spoken verbal content, and problems dealing with 
compulsive actions and thoughts in normal functioning with no language delays observed 
clinically.
1
  Children with Asperger’s Disorder do not display considerable delays in 
language and display at least average mental abilities which are not seen in children with 
Autistic Disorder.
2
  PDD-NOS is used when the criteria is not met for one of the other 
PDDs.  In PDD-NOS, which includes atypical autism, there is a strong and widespread 
deficiency of shared communal contact, both spoken and unspoken, and the actions and 
mannerisms are categorized.
1
  Autism spectrum disorders could be explained using either 
one or more than one etiology which result in the spectrum of symptoms seen in affected 
children.
2
 
Autism diagnoses typically occur during childhood and are believed to last the 
entire lifespan with not only the individual, but the entire family affected.
3
  There are two 
types of autism diagnoses:  classical autism, where a child develops autistic symptoms 
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from birth, and regressive autism, where a child develops normally for a period then 
experiences regression of abilities.
4
  Before age 3 is when normal symptoms are seen in 
children with autism.
5
  Rogers reviewed studies that found the percentage of children 
with autism who displayed regression varied from 25 to 50%.
6
  In children who 
underwent a regression, the loss of skills previously developed was abnormal for the 
majority of children from a multiple site study.
7
  Chakrabarti and Fombonne noted a 26% 
prevalence of mental retardation in a study, which was lower than the 40 and 55% 
reported in other studies and the traditional rate of 75%.
8
 
Over the past 50 years, a dramatic increase in the incidence of ASDs has been 
noted.  At the current time, autism is the fastest growing serious developmental disability 
in children.
9
  Children diagnosed with an ASD had medical expenses nine times greater 
than other children and 3.5 times higher than children with mental retardation.
10
  Autism 
is found in a ratio of 4:1 in males to females.
11-12
  Many different areas are being 
researched including genetic, neurologic, immunologic, and environmental, as causes for 
the dramatic increase in the incidence of ASDs,
13
 with autism likely being a combination 
of these factors.  Many different environmental aspects including vaccines, heavy metals, 
infections, and prenatal exposures have been explored as potential causes.
14
  The role of 
the environment is seen in the development of autoimmune diseases due to the high 
percentage of identical twins discordant for an autoimmune disease.
15
  At the molecular 
level, autism is heterogeneous, implying that the interaction between environment and 
genetics produces different gene expression in each individual twin’s brain.16  Many 
different factors, notably xenobiotics, pathogens, and immune system response, have 
been shown to have an impact on brain development.
17
  Genetic, epigenetic, 
  5 
environmental, and endogenous interactions can be seen in an “integrated metabolic 
profile”18 with the effects of the environment evidenced in the epigenetics, neurologic 
system, and immune system of children diagnosed with ASDs.  To reinforce the 
behavioral diagnosis of autism, there is no current biochemical test
18
 as autism has “no 
established genetic or biochemical biomarkers,” and only behavioral norms through 
observation are used in diagnosis.
19-20
 
1.2 The History of Autism Spectrum Disorders 
Autism was first described by Leo Kanner, a child psychiatrist from John Hopkins 
University, in his textbook Nervous Child in 1943.
4
  With over twenty years of 
experience as a child psychiatrist, Kanner had never observed a child with autism until 8 
years after he established the first psychiatric hospital unit for children in the United 
States.  Kanner’s book discussed case studies using broad descriptions that detailed some 
of the symptoms still used today and formed the foundation of “The Refrigerator Mother 
Theory.” 
In the 1950s, “The Refrigerator Mother Theory” spread in popularity.  Bruno 
Bettelheim, a University of Chicago educator and scholar, was a strong advocate of this 
theory.
4
  “The Refrigerator Mother Theory” worked under the belief that mothers 
withheld love from their children and the children sensed this lack of love with the 
outcome being the development of autism.  The decrease in social interaction caused by 
autism was believed to result from this lack of affection, and Bettelheim believed these 
children had to be removed from this environment.  The treatment of autism by the 
removal of a mother who did not love her child enough helped to cement “The 
Refrigerator Mother Theory” and slowed the real treatment of autism. 
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By the 1960s, “The Refrigerator Mother Theory” was beginning to become more 
questionable as doubts increased that bad parenting and a lack of affection were the true 
causes of autism.  An important book, Infantile Autism: The Syndrome and Its 
Implications for a Neural Theory of Behavior, was written by Bernard Rimland, who had 
a doctorate in experimental psychology.
4
  Rimland believed the cause of autism had 
origins in biology from genetic and neurological factors and not in psychology resulting 
from parental care, and he is recognized in shifting the thoughts of autism etiology away 
from psychology and towards biology.  This change in philosophy about the etiology in 
autism allowed for significant advances to be made in the development and 
understanding of autism diagnosis and treatments.  
In 1967, Dr. Rimland founded the nonprofit Autism Research Institute that has 
supported biological autism research.  The work by Dr. Rimland caused a change in the 
understanding and treatment of autism and allowed for future advances to be made.  
Soon, Dr. Eric Schopler developed the Treatment and Education of Autistic and related 
Communication-handicapped CHildren (TEACCH) program.
4
  TEACCH was the first 
wide-ranging program which educated children with autism at the state level and used 
parents as therapists. 
One important idea to come from Dr. Rimland was the shift toward developing a 
way to clinically diagnosis autism.  Dr. Rimland worked to develop the Rimland 
Checklist, which was published during the 1960s.
21
  Dr. Schopler expanded on the 
Rimland Checklist because he saw that most of the children he observed did not meet 
Kanner’s original criteria for autism.21  This observation led to the development of the 
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Childhood Autism Rating Scale (CARS) and helped shift towards finding an easier and 
faster way to diagnose children with autism.
21
 
1.3 The Change in the Diagnosis Rate of Autism Spectrum Disorders 
Over the past 50 years, the frequency of autism diagnoses has continued to rise at 
a rapid rate and is currently approaching epidemic proportions.  Before the 1970s, an 
autism diagnosis was rare and the diagnosis rate was relatively consistent.  The frequency 
of autism in studies from the 1960s to the 1980s ranged from 2 to 5 in 10,000 over this 
period, which could have been determined using a more classic definition of autism.
22
  In 
1978, one study assessed the rate of autism to be 4 in 10,000.
23
  In 1994, the DSM-IV 
listed the frequency of Autistic Disorder at between 2 and 5 in 10,000.
1
 
 Two large review studies were completed that looked at autism rates from the 
1960s to the 1990s.  One review investigated the rate of autism in over twenty studies 
from 1966 to 1998 where the epidemiological studies reviewed had a median value of 5.2 
occurrences per 10,000 (1 in 1,923).
24
  In the studies published after 1988 as part of this 
review, the median prevalence of autism increased to 7.2 per 10,000 (1 in 1,389).
24
  From 
reexamining these studies, it was determined that both autism definition and better 
awareness helped contribute to the increased autism diagnosis rate as time passed.
24
  
Another review discussed results from studies from 1966 to 1997.  The results in this 
review supported the increase over time with the rate of autism being less than 0.5 in 
1,000 children in the earlier studies and the later studies showed an average rate of about 
1 per 1,000.
25
 
 Another important place to look to compare the rate of autism over time is in 
California.  In 1969, California passed the Lanternman Developmental Disabilities 
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Services Act, which established places to provide services and allowed for the necessary 
records to be kept.
26
  Hertz-Picciotto and Delwiche published a study showing an 
increase in autism diagnosis from 6.2 in every 10,000 births for children born in 1990 to 
42.5 for children born in 2001.
26
  The authors noted that earlier diagnosis, population 
movement, adjustments in diagnostic requirements, and the addition of milder cases did 
not completely account for the increased prevalence of autism.
26
  This implication was 
supported in a study by Croen et al. that found the diagnosis of autism increased from 5.8 
to 14.9 occurrences per 10,000 children from 1987 to 1994.
27
  The authors stated that a 
real rise in autism rates may reflect only better recognition and changes in autism 
diagnosis criteria.
27
  In 2012, a study determined children born in 2003 had a 16.6 times 
increase in the likelihood of autism diagnosis compared to children born in 1992.
28
  
Additionally, this study noted that each successive cohort of children had a greater 
chance of being diagnosed with autism compared to the previous birth year.
28
  A 2003 
report from the California Department of Developmental Services saw that the rate of 
autism increased 634% from 1987 to 2002.
29
 
Many other studies produced in the United States have discussed the diagnosis 
frequency of autism.  A study of autism rates in North Dakota from 1987 found them to 
be 3.26 per 10,000 children for all PDDs.
30
  In 1989, a study from Utah determined the 
autism rate to be 4 in 10,000.
31
  In 1995, a study out of Arkansas observed 4 out of 
10,000 children, by the age of four, were diagnosed with autism or a PDD.
32
  In 2001, the 
Centers for Disease Control and Prevention (CDC) published a study from Brick 
Township, New Jersey, where the frequency of ASDs was determined to be 6.7 for every 
1,000 children.
33
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At the beginning of the 21
st
 century, the rate of autism occurrences continued to 
rise and were reported to be between 30 and 60 in 10,000.
22
  In 2007, the CDC 
determined that in data from 2000 the frequency of ASDs had reached 1 in 150 for 
children age 8 across the country.
34
  This held constant in 2002, but the highest rate of 
ASDs was found in New Jersey at 1 in 94.
35
  An update using 2006 data showed that 
children age 8 had autism at a frequency of 1 in 110.
36
  In 2012, the most recent reports 
from 2008 have put the occurrence of autism nationwide at 1 in 88 in children 8 years 
old, a 23% increase from 2006 data.
5
  The report noted that the assessment should not be 
extrapolated to the entire country as the samples do not equate to an equivalent sampling 
of the United States.
5
  Over the past decade, the national rate of autism has risen 78% 
from 1 in 150 children in 2000 and 2002 to 1 in 88 in 2008.  The most recent CDC report 
also determined the autism ratio between boys and girls to be 4.6:1.
5
 
 Other recent studies in the United States reflect the results of the studies from the 
CDC.  In a study using parent reported data from 2007, the National Survey of Children’s 
Health found the rate of autism to be 1 in 91 children ages 3 to 17.
22
  In this study, the 
odds of having a child with autism ages 6 to 8 were 54 and 83% higher when compared 
to children ages 9 to 11 and 15 to 17 years of age, respectively.
22
  The National Health 
Interview Survey observed an increase in autism prevalence from 0.19% (1 in 526) in 
1997-1999 to 0.74% (1 in 135) in 2006-2008.
37
 
 In the North American and European populations, the frequency of autism has 
been determined to be similar through research studies.
38
  In 2001, an English study 
published determined the rate of PDDs to be 62.6 per 10,000 children (1 in 160).
8
  
Another study from the United Kingdom using data from the 2003 and 2004 school years 
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found the prevalence of autism approached 1% of children ages 5 to 9.
23
  In comparison 
to this data, the first study from South Korea using children ages 7 to 12 assessed the rate 
of ASDs to be 2.64% or 1 in 38.
38
 
1.4 The Evolution of the Factors Influencing Diagnosis of Autism Spectrum 
Disorders 
Because of the increased prevalence in autism over the past 50 years, many 
variables have been cited as potential reasons for this rise in diagnosis frequency.  Some 
of these elements may have been adjusted and others may have grown and evolved over 
time contributing to an increased diagnosis rate, while there also may have been a true 
rise in autism incidence.  Many factors have been noted when comparing the rates of 
autism from the past and present including better identification and detection, study 
design differences, greater number of diagnostic services, higher level of consciousness 
in both parents and medical professionals, change in philosophy that autism can exist 
with other disorders, and a broadening of diagnostic measures.
23
 
For identification and detection, primary care physicians and pediatricians play a 
key role.  During the time when autism was first being studied in the 1960s and 1970s, 
there were not many child psychiatrists and pediatricians, and even a lesser number of 
general practitioners, who were familiar with and capable of identifying ASDs.
39
  During 
the 1960s, there was knowledge of the occurrence of diseases similar to autism in 
children, but they did not reach the standards for diagnosis.
39
  Over time, the level of 
education seen in pediatricians, psychiatrists, psychologists, social workers, and teachers 
has increased because of a larger social consciousness of autism.
39
  Since the 1960s, there 
has been a large expansion in the therapeutic and educational services along with a 
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greater social consciousness among medical professionals and the general public for 
children with ASDs.
39
  During this period, there was a large variation in the observation 
and examination procedures, obstacles involving financial compensation, and not enough 
attention paid to surveys completed by parents, with each of these areas having to be 
improved to more effectively diagnose autism.
40
  A study from 2005 demonstrated a 
correlation between the rate of autism and financial resources as a higher rate of autism 
was seen where increased financial support existed.
41
 
In addition to physician and professional screening, other possible reasons for 
delays in autism diagnosis included normal delays in receiving medical treatment, 
inefficient communication between parents and primary care providers, or adopting a 
philosophy of watching for further development before any action is taken.
42
  A study 
published in 2001 found that more attention needs to be paid to autism in medical school 
education as shortcomings were observed related to appearance, diagnosis, and treatment 
for ASDs.
43
  It also emphasized that medical education must include basic autism 
diagnosis standards so they can be applied clinically.
43
  In addition to medical education, 
the relationship between parents and primary care physicians may play a role in 
diagnosis.  A study found children with four or more different primary care physicians 
obtained an autism diagnosis 6 months later compared to other children, whereas 
pediatricians who noticed developmental apprehensions and referred children to 
specialists resulted in earlier diagnoses.
44
  Factors such as population mobility, decreased 
availability to health care, and lower emphasis on constant pediatric care are additional 
problems related to the age of autism diagnosis.
44
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Over the past 50 years, changes have been made that adjusted the diagnostic 
criteria for autism.  Although detailed changes have been made in diagnostic criteria, they 
have not been the main cause resulting in an increase in clinical diagnosis; however, a 
larger number of autism diagnoses are being made under the current standards than the 
previous ones.
39
  A true increase in the rate of ASDs cannot be eliminated because of 
better social awareness and broader diagnostic standards.
39
 
During this time, there have been two different types of diagnosis changes which 
may be playing a role in the increasing rates of autism:  diagnostic substitution and 
diagnosis accretion.  Diagnostic substitution occurs when there is a change in the 
diagnosis while diagnosis accretion happens when a second diagnosis is made and the 
original diagnosis is maintained.
45
  In the late 1980s, the Diagnostic and Statistical 
Manual of Mental Disorders, Third Edition, Revised (DSM-III-R) broadened the 
definition of autism.
26
  Compared to the DSM-III-R, the current DSM-IV definitions are 
closer to the ones from the International Statistical Classification of Diseases and 
Related Health Problems, 10
th
 edition (ICD-10).
26
  In 2000, The Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) 
updated the criteria for PDD-NOS, which could have changed the frequency of autism 
diagnoses.
45
   
From 1998 to 2002, the California Department of Developmental Services made 
diagnostic criteria changes.
45
  A study published in 2009 from California suggested a 
26.4% increase in autism diagnosis because of the changes in diagnostic criteria related to 
children with prior mental retardation diagnosis.
45
  Another study noted 12% of the 
increase in autism diagnosis can result from diagnosis at a younger age.
26
  This study also 
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noted a 56% increase because of the addition of milder cases of autism.
26
  Rutter noted a 
study from California where autism increased 210%, while mental retardation only 
increased 49% from 1987 to 1998.
39
  The largest increase in the diagnosis of ASDs 
seemed to have occurred in children with non-verbal IQ in the normal range, with all 
types of ASDs showing considerable increases in prevalence.
39
 
A couple of studies discussed the difference in diagnosis rates based on race.  A 
study from Mandell in 2002 found African-American children were diagnosed with 
autism an average of 1.6 years later compared to white children.
46
  A second study in 
2007 determined that African-American children were more likely to receive a diagnosis 
other than autism by a factor of 2.6 when compared to white children.
47
  In addition to 
race, cultural and social norms are factors which can affect the speed of autism diagnosis.  
A study about children in India demonstrated that cultural and social customs focused on 
social problems allowed for quicker parental recognition of autistic symptoms.
48
  In the 
United States, there is a greater focus on communication progression and this emphasis 
may drive parental concerns.
49
  Another study from the United States noted the presence 
of significant communication shortfalls allowed for a diagnosis of an ASD an average of 
1.2 years before other children.
44
  This study also noted shortcomings in the resources of 
rural regions and with families who are near-poor.
44
  The children in this category 
obtained a diagnosis nearly 11 months after children from families who were better-off 
financially, and this finding may relate to the insurance status of each family.
44
  In 
addition, children who had hearing problems or were adopted received an ASD diagnosis 
nearly 10 months after other children.
44
  Based on these studies, the social and cultural 
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traditions along with the race of each country need to be considered when performing 
screenings and diagnostic tests for autism.   
In addition to changes in the factors related to autism diagnosis, the stability of 
autism diagnosis has been evaluated.  Recent studies have shown that diagnoses in very 
young children hold up over time and are confirmed later in the child’s development.50-51  
Kleinman and colleagues evaluated the DSM-IV diagnosis between ages 2 and 4 and 
found the Autism Diagnostic Observation Schedule (ADOS) had an 83% diagnostic 
stability while the diagnostic stability for the CARS was 76%.
52
  A study in 2005 
determined the average age of diagnosis was lowest for Autistic Disorder (3.1 years) and 
highest for Asperger’s Disorder (7.2 years) with PDD-NOS in the middle (3.9 years).44  
A Canadian study in 2009 observed variation in the average age of diagnosis between 
four different areas.
53
  Similar results were seen in this study with Autistic Disorder being 
diagnosed earliest on average and Asperger’s Disorder the last of the three 
subcategories.
53
  It was also determined that boys were diagnosed on average earlier than 
girls in each region.
53
  A “zero” waitlist guideline for children in preschool also resulted 
in a lower mean diagnosis age.
53
  A review from a clinician’s perspective noted that focus 
needs to be on the recognition of initial non-verbal social interactions and behaviors in 
the second year of life and that the characteristics which define autism may change based 
on age.
54
  Based on the literature, all of these factors have contributed to the increased 
diagnosis of autism.  Despite these changes and advances, the rate of autism now has 
become a major public health concern. 
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1.5 The Behavioral Rating Scales Used in the Diagnosis and Assessment of 
Autism Spectrum Disorders 
Despite all of the scientific research going into discovering common 
characteristics of ASDs, there is no physical examination or set of tests that provide a 
definitive diagnosis of an ASD.  Physicians determine autism diagnosis based on the 
natural progression of development over time and the clinical observances of the child’s 
social activities.
55
  Without the availability of a physical test, the clinical diagnosis of 
ASDs is performed using psychological diagnosis where psychologists and physicians 
utilize behavioral rating scales to confirm the definition of autism.  The current gold 
standard in the diagnosis of ASDs is the ADOS.
56
  Over time, the ADOS has been a key 
component to both clinical and research procedures involving children with autism.
57
  
Both the ADOS and the Autism Diagnostic Interview-Revised (ADI-R) were created to 
quantitatively define the presence or absence of autism based on age and language 
development.
58
  The ADI-R gives insights into the past developmental progressions and 
different social interactions of the child while gaining the perspective of the child’s 
caregiver,
58
 and it was used for both the ICD-10 and DSM-IV autism diagnosis 
standards.
59
  However, both the ADOS and the ADI-R are time consuming and require 
the screening to be performed by someone who has received proper training.
60
  The 
ADOS relies heavily on the skill of the test administrator and does not include 
information on the history of the individual and cannot solely be used to diagnose a 
child.
61
 
After a parent has noticed a potential problem, the child is brought to a medical 
professional to begin the diagnostic process.  When a medical professional first observes 
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an individual and concludes that further action is necessary, a primary screening has 
occurred.
62
  A secondary screening would be performed after a developmental difference 
has been determined to exist and the specificity of the problem has not yet been 
determined.  It would be at this time that the child would be seen by a specialist.
62
  At 
both screening levels, the criteria for determining the proper diagnosis need to be rigid.  
Many important factors comprise these standards, especially behavioral rating scales, and 
they are:  easy to use, time efficient, low cost, age appropriate, and possess good 
sensitivity and specificity.  The percentage of children properly determined to have a 
problem is defined as the sensitivity and should be between 70 to 80% for children with 
disabilities,
63
 while specificity is described as the percentage of children accurately 
determined not to have a disability and it needs to be near 80% to prevent over referrals.
63
   
In addition to the ADOS and the ADI-R, there are many other rating scales which 
can be completed by physicians, psychologists, or parents.  Some of the other rating 
scales frequently used in the diagnosis and evaluation of treatments for autism include 
CARS, Gilliam Autism Rating Scale (GARS), Social Communication Questionnaire 
(SCQ), Aberrant Behavior Checklist (ABC), PDD Behavior Inventory (PDDBI), and 
Autism Treatment Evaluation Checklist (ATEC).  Each one of the rating scales used in 
the studies discussed in later chapters is described, and studies related to their evaluation 
or application are reviewed. 
1.5.1 Autism Diagnostic Observation Schedule 
The ADOS was developed by Catherine Lord, Michael Rutter, Pamela C. 
DiLavore, and Susan Risi in 1989.
64
  Designed to be applicable in clinical and research 
settings for children with a mental age of at least 3, the ADOS creates stresses through a 
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semi-structured evaluation of socialization, communication, play, and imagination.
64
  The 
ADOS gives a clinician’s perspective based on consistent clinical interpretations of the 
child’s social strengths and weaknesses.58  An expansion of the ADOS was created when 
the Pre-Linguistic Autism Diagnostic Observation Scale (PL-ADOS) was developed 
based on ICD-10 and DSM-IV criteria for children under the age of 6 and who have not 
developed speech at the phrase level with the focus of the PL-ADOS being the child’s 
communication and socializing.
65
 
In 2000, the Autism Diagnostic Observation Schedule-Generic (ADOS-G) came 
out as an expansion of the ADOS and the PL-ADOS, and it wanted to create stresses in 
regulated environments to monitor spontaneous actions in a broader age range of children 
who could potentially be diagnosed with autism.
61
  The ADOS-G created four modules 
for children of different ages and stages of language capabilities.
61
  Module 1 was 
modeled after the PL-ADOS, and Module 2 was designed for children who are not 
completely developed verbally, but possess some communication skills.
61
  Module 3 is 
aimed at the verbally competent and was constructed based on the original ADOS.
61
  
Module 4 evaluated the socioemotional aspects of the individual’s life and is meant for 
verbally competent adolescents or adults.
61
  Modules 1 and 2 are completed during 
activities in a room and Modules 3 and 4 occur while seated at a table.
61
  Using the 
ADOS-G, autism diagnosis is determined by exceeding the cutoff value for the social and 
communication domains and the sum of those domains, and it is not envisioned to be the 
sole criteria for autism diagnosis.
61
 
In 2007, the algorithms for the ADOS were altered to improve autism 
classification.
66
  Classification is now based on the sum of “social affect” and “restricted 
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repetitive behaviors” domains.66  The modules were also divided to better meet the needs 
of diagnosis as Module 1 was split into No Words and Some Words, while Module 2 was 
separated into children 4 years old and younger and 5 years of age and older.
66
  The 
Autism Diagnostic Observation Schedule-Toddler Module (ADOS-T) was proposed in 
2009 because the mean age of children where parents start to express apprehension about 
autism is between 15 and 18 months.
57
  The ADOS-T follows Module 1 and is applicable 
for children who are younger than 30 months old, 12 months old based on nonverbal 
evaluation, and walk independently.
57
  The ADOS is currently scored on a scale from 0 to 
3 where 0 shows no presence of the behavior and 3 indicates the presence of that 
behavior.  Sometimes a score of 3 is converted to a 2 to decrease the impact of singular 
items.
67
  A score of 7 is given when the abnormal behavior differs from the procedure 
and 8 is scored when it is not applicable.
68
  For the communication module, social 
interaction module, and the total ADOS, cutoff values exist for the diagnosis of an ASD 
or autism.  For the total ADOS, the cutoff for an autism diagnosis is a minimum score of 
12 and the cutoff is 7 for an ASD.
61
  The cutoff for an autism diagnosis for the 
communication module is 4 while it is 2 for an ASD.
61
  The social interaction module has 
a cutoff of 4 for an ASD and 7 for autism.
61
 
 Many studies have evaluated the application of the ADOS with the ADOS-G 
demonstrating both good sensitivity and specificity.  Across the different modules and 
comparisons, the sensitivities ranged from 80-100% and specificities varied from 68 to 
100% with high internal consistencies.
61
  A German study by Bolte and Poustka in 2004 
found sensitivity of 90% and a 48% specificity.
69
  According to the ADOS-G, Maxefsky 
and Oswald observed a 77% agreement with team diagnosis.
70
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In addition, many studies have compared the old and new ADOS algorithms.  
Using the original and updated algorithms, Gotham and colleagues observed similar 
values for the sensitivity and specificities for Modules 1-3.
66
  Gotham et al. completed 
another study that demonstrated better consistency between the modules and the 
diagnostic legitimacy based on the ADOS.
67
  This study also found an increase in the 
specificity of Module 1 to 50%.
67
  An ADOS-T study observed good sensitivity and 
specificity using the different modules.
57
  In a Dutch study, Modules 2 and 3 showed an 
increased balance of sensitivity and specificity with the revised algorithms, but decreased 
performance was seen from Module 1.
71
  Malloy and colleagues observed sensitivities 
between 67 and 91% for the autism versus non-spectrum groups using the original 
algorithms with specificities ranging from 65 to 95%.
56
  With the new algorithm, the 
sensitivities were between 72 and 94% with specificities fluctuating from 55 to 81%.
56
  
Sensitivities varied from 75 to 94% and specificities ranged from 29 to 81% when 
comparing the new non-autism ASD group versus the non-spectrum group for the old 
algorithm.
56
  The updated algorithm produced sensitivities from 72 to 100% and 
specificities from 29 to 60%.
56
  The study generally found modest to elevated sensitivities 
and poorer specificities compared to prior studies.
56
  In a study independent from the 
creators of the ADOS, Kamp-Becker et al. determined the revised algorithm had a higher 
sensitivity for autism and ASD against non-spectrum group using the higher cutoff 
value.
72
  For the autism versus non-spectrum comparison, the original algorithm had a 
sensitivity of 79% compared to the 93% for the updated algorithm, but the specificity 
decreased from 89 to 81%.
72
  These studies support the diagnostic capabilities of the 
ADOS, but note its shortcomings in classifying autism versus ASDs. 
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1.5.2 Childhood Autism Rating Scale 
The CARS was developed by Dr. Eric Schopler at the University of North 
Carolina at Chapel Hill to diagnose children with autism.  It uses a 15 point rating scale 
where scores range from 1 to 4 with half interval points with a score of 1 representing 
normal behavior and a score of 4 indicating severely abnormal behavior.
21
  The scores on 
the CARS range from 15 to 60 with children scoring 30 or higher being classified as 
autistic.  To be diagnosed with severe autism, a child must score greater than 36 and have 
scored at least a 3 on five or more of the 15 subscales.
21
  This information can also 
provide classification of the degree of autism and the type of symptoms.
73
  A criticism of 
the CARS by the National Research Council was that the diagnostic criteria do not 
accurately reflect the current standards because it was based on DSM-III criteria from 
1980.  But, the CARS was developed from both clinical experience and many different 
collections of measures that are related to three sections of DSM-IV criteria.
74
 
Many studies have investigated the application of the CARS for clinical diagnosis 
of autism.  Eaves and Milner found in a study that the CARS was able to diagnose 98% 
of the screened children with autism.
75
  In 1994, DiLalla and Rogers produced a study 
that discovered three distinct domains describing behavior and emotion: Social 
Impairment, Negative Emotionality, and Distorted Sensory Response.  The Social 
Impairment domain is associated with 10 of the 15 CARS scales.
73
  When factor scaling 
was applied to the subscales, they found the Social Impairment domain, with a cutoff 
value of 26, produced an autism diagnosis accuracy of 78% with a 64% sensitivity and 
92% specificity.
73
  Pilowsky led a study in 1998 that compared the CARS and the ADI-R 
autism diagnoses and observed an 85.7% agreement between the two rating scales.
76
  A 
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study from 2003 discovered an overlap in 66.7% of cases between the CARS and the 
ADI-R, and the CARS diagnosed more instances of autism than the ADI-R did.
77
  A 
study from Italy in 2004 found 100% agreement in the diagnosis of autism by the CARS 
using DSM-IV standards.
78
  In 2005, Perry and colleagues compared the CARS diagnosis 
to DSM-IV, and they determined an 88% concordance with a 94% sensitivity and a 85% 
specificity.
74
  A study from Mayes et al. published in 2009 found 97% of children with 
low functioning autism and 75% of children with high functioning autism were correctly 
determined using the CARS.
79
  Another study from Mayes and colleagues, where they 
used a cutoff value of 25.5 to separate high functioning autism or Asperger’s syndrome 
from attention deficit hyperactivity disorder (ADHD), saw 96% agreement using 
clinicians’ results and 72% using parents’ results.80 
1.5.3 Gilliam Autism Rating Scale 
The GARS was created by Dr. James Gilliam in 1995.  It can be used on patients 
from ages 3 to 22 and has 56 questions divided into four subscales:  Social Interaction, 
Communication, Stereotyped Behaviors, and Developmental Disturbances.
81
  The GARS 
is scored on a 4 point scale to produce a value that represents the Autism Quotient (AQ).  
The AQ is used to determine “the likelihood that a child has autism” and has a standard 
score of 100 with a standard deviation (SD) of 15.
81
  A child is determined to be 
“probably autistic” if the AQ is equal to or greater than 90.81  There are seven 
classifications for the AQ related to the likelihood of an autism diagnosis:  very low, low, 
below average, average, above average, high, and very high.  The AQ can be determined 
from using two, three, or four subscales.  The GARS is completed by a parent and has 
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been noted to be recommended for use in California.
81
  It is easy to use, has a low cost, 
and has been used in schools and research.
81
 
In 2006, the GARS was updated, and the name of the second edition is the 
GARS-2.  The GARS-2 follows the diagnostic criteria of the DSM-IV-TR and Autism 
Society of America.
82
  One of the major changes in the GARS-2 was the Parent Interview 
replacing the Developmental Disturbances subscale.  The Parent Interview determines 
lags in normal development or differences in socializing, communicating, and playing, 
prior to age 3 and is not a component of the new Autism Index (AI).
82
  The other three 
subscales are very similar to their original versions, and the subscales scoring is added 
and now called the AI.  An AI value equal to or greater than 85 evokes a “very likely” 
presence of autism, a total between 70 and 84 means a child “possibly” has autism, and a 
score of 69 or less indicates autism is “unlikely.”82 
Many studies have determined the clinical application of the GARS.  South et al. 
published a study in 2002 that found the average AQ to be 90.10.
81
  Following the cutoff 
for the AQ of equal to or greater than 90 for autism, they determined 52% of children 
would not have been determined to have autism using the GARS, which  produced a 48% 
GARS sensitivity for autism diagnosis.
81
  The study also noted low sensitivity for the 
ADOS-G and the ADI-R of 45%.
81
  Their analysis showed the Developmental 
Disturbances scale was not related to the other three subscales.
81
  Lecavalier noted the 
average AQ was below the cutoff of 90 for 62% of the participants resulting in a 38% 
sensitivity.
83
  Similar sensitivity was observed in the GARS as Mazefsky and Oswald 
reported a sensitivity of 39%.
70
  They also stated that the GARS was less effective in the 
diagnosis of PDDs compared to the ADOS-G and the ADI-R.
70
  Eaves led a study using 
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85 as the cutoff for the AQ and found a sensitivity of 83% and a specificity of 68%,
84
 
while the standard cutoff of 90 for the AQ produced a sensitivity of 79%.
84
  In 2008, 
Sikora et al. determined the sensitivity to be 53% and 54% for the specificity for the 
GARS.
85
  A review of these studies by Norris and Lecavalier showed overall poor 
sensitivity using the GARS.
60
 
In 2010, a study performed an exploratory and confirmatory factor analyses on 
the GARS-2.  The results did not provide additional backing of the three subscales of the 
GARS-2 and did not address the sensitivity or specificity of the GARS-2.
82
  Instead, the 
study found better diagnostic reliability with a four-factor model of stereotyped/repetitive 
behavior, stereotyped/idiosyncratic language, word use problems, and social 
impairment.
82
  No studies in the literature were discovered that address the sensitivity and 
specificity of the GARS-2. 
1.5.4 Social Communication Questionnaire 
Previously known as the Autism Screening Questionnaire, the SCQ was designed 
by Dr. Michael Rutter and Dr. Catherine Lord.
59
  Two versions of the SCQ were created, 
one for children 5 years old and younger and the other for children six years and older.
59
  
The SCQ is based on the ADI-R and is meant to be completed by the parent of the child 
with an ASD.
59
  It is comprised of 40 yes or no questions arranged in four subscales:  
social interaction, communication, abnormal language, and stereotyped behaviors.
60
  For 
each question, a value of 1 is scored for the presence of the abnormal behavior and 0 is 
recorded if it not present.
59
  The scores of the SCQ range from 0 to 39 (not including 
current language level), and a cutoff of 15 is used to differentiate ASDs from other 
clinical diagnoses with a value of 22 separating autism from other ASDs.
59
  The 
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maximum score for nonverbal individuals is 34.
59
  The SCQ requires a patient with a 
chronological age of at least 4 years old and a mental age of 2 years old.
62
  One important 
characteristic of SCQ is that it appears to include all of the DSM components for autism 
diagnosis.
60
 
Many studies have demonstrated the high sensitivities and specificities of the 
SCQ.  In the original study, the authors observed a sensitivity of 85% and a specificity of 
75%.
59
  A 2006 study led by Eaves determined acceptable sensitivity of the SCQ of 74%, 
but observed a lower than satisfactory specificity of 54%.
62
  Eaves published another 
study where the overall sensitivity for the SCQ was 71%, and the specificity varied based 
on the clinic.
86
  In 2007, Chandler et al. found usefulness in the application of the SCQ 
due to the high sensitivity and specificity results.  When using a cutoff of equal to or 
greater than the recommended value of 15, the sensitivity was 88% and the specificity 
was 72% for the presence and absence of ASDs.
87
  When the cutoff was changed to 22, 
the sensitivity increased to 90% and the specificity rose to 86%.
87
  The study also noted 
the potential bias in the original SCQ study due to the previous diagnosis on the ADI-R.
87
  
Witwer and Lecavalier in 2007 published a study showing the sensitivity of the SCQ 
being 92% with a specificity of 62%.
88
  The study also found a significant correlation 
between the SCQ and age.
88
  That year Corsello et al. determined the sensitivity and 
specificity of the SCQ for the determination of ASDs to both be 71% when a cutoff of 15 
was employed.
89
  When the cutoff was lowered to 12 and the SCQ was used with the 
ADOS, the sensitivity was similar to when the ADI-R and the ADOS were used together, 
and nearly the same specificity was reached when separating ASD from no ASD with the 
ADI-R and the ADOS.
89
  The study showed the SCQ being a better diagnostic tool in 
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children 8 years old or older compared to children age 7 and younger.
89
  An investigation 
in Australia of younger children ages 2-6 found the sensitivity to be 60% and a specificity 
of 70%.
90
  They determined the best sensitivity and specificity was achieved with a cutoff 
of 11 when they were 93 and 58%, respectively.
90
  Of note, the lower cutoff was effective 
in the age range of 3-5 with sensitivity of 100% and specificity of 62% and it was 
inadequate in the 2-3 year old range.
90
  A review by Norris and Lecavalier from 2010 
noted that many studies and generally found good performance by the SCQ.
60
 
Some studies have observed lower sensitivity and specificity than in the original 
study.  Wiggens led a study in 2007 which determined the sensitivity was 47% and the 
specificity was 89% for the determination of an ASD.
91
  The optimum cutoff value for 
this study was 11 where both the sensitivity and specificity were 89%.
91
  In 2008, Snow 
and Lecavalier found the SCQ, in establishing the presence or absence of an ASD, to 
have the sensitivity of 70% and the specificity of 52%,
92
 with 13 determined to be the 
optimum cutoff value.
92
 
1.5.5 Aberrant Behavior Checklist 
The ABC was developed by Michael Aman in 1985 and was originally designed 
to assess treatments in individuals with intellectual disabilities.
93
  It can be completed by 
parents, teachers, or anyone who knows the individual well.
94
  The ABC has 58 items 
organized into 5 subscales:  (I) Irritability, Agitation, Crying; (II) Lethargy, Social 
Withdrawal; (III) Stereotypic Behavior; (IV) Hyperactivity, Noncompliance; and  (V) 
Inappropriate Speech.
93
  Each item is scored from 0 to 3 on a 4-point scale with higher 
scores indicating a greater degree of problems.
93
  The ABC has demonstrated good 
internal consistency and retest correlations.
95
  It has been applied to many other diseases 
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such as Fragile X, Prader-Willi, Cri-du-Chat, Smith Magenis, and Angelman’s 
syndromes.
96
 
Many different studies have been performed using the ABC to evaluate 
treatments.  One of the most common applications of the ABC related to autism is in 
clinical drug trials.  Brinkley and colleagues noted numerous studies of clinical drug trials 
related to autism and the sensitivity of the ABC, especially the Irritability subscale.
96
  
Gabriels noted from a study that the Irritability and Lethargy subscales of the ABC did 
not find a significant link with repetitive behaviors.
97
  A study validating the ADI-R 
found strong correlation between the Social and total ADI-R values and the subscales for 
Irritability; Lethargy, Social Withdrawal; and Stereotypic Behavior of the ABC.
94
  Tse et 
al. used the ABC as one measure to evaluate a social skill curriculum, and all of the ABC 
subscales were sensitive enough to show significant improvements used to measure 
problem behaviors.
98
   
Many studies have demonstrated the sensitivity and diversity of application for 
the ABC.  In 2007, Cuccaro published a study which compared matched controls with 
Asperger’s Disorder and high functioning autism.  They focused on the Stereotype 
subscale of the ABC and determined no differences between the two groups for that 
subscale.
99
  The authors believed it further supported the literature that there is no 
difference between Asperger’s Disorder and high functioning autism.99  Brinkley led a 
study which showed the ABC’s factor structure was strong for a cohort of children with 
ASDs.  They found 4- and 5-factor components responsible for more than 70% of the 
change.
96
  The authors also noted many studies where the Irritability subscale of the ABC 
has demonstrated great sensitivity to treatment.
96
  The ABC has had increasing amount of 
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literature which support it is a good gauge of associated, non-diagnostic components of 
ASDs.
96
  A study published in 2009 from Turkey found good separation between autism 
and other behavior disorders and showed higher scores of the Lethargy, Social 
Withdrawal and Stereotypic Behavior subscales in children with autism.
100
  The study 
shows the application of the ABC to children as young as 14 months old and significant 
differences in the diagnostic groups for the ABC subscales.
100
  Hartley-McAndrew and 
Weinstock noticed elevated hyperactivity and irritability ABC subscales in children with 
ASDs who suffer seizures.
101
   
1.5.6 PDD Behavior Inventory 
The PDDBI was designed by Ira L. Cohen and Vicki Sudhalter in 1997.
102
  It was 
created to evaluate how children with PDDs responded to a treatment.
102
  The PDDBI is 
unique because it targets both adaptive and maladaptive behaviors and is arranged in a 
priori, or hierarchal structure.  It can yield standardized results based on age which many 
of the other rating scales cannot do.
102
  Two different versions of the PDDBI were 
created, one for parents and one for teachers,
102
 and it is separated into 10 domains in the 
parental version and eight in the teacher version.  The maladaptive domains are 
Sensory/Perceptual Approach Behaviors, Specific Fears, Arousal Problems, 
Aggressiveness, Social Pragmatic Problems, and Semantic/Pragmatic Problems.  The 
Specific Fears and Arousal Problems domains are not administered by teachers.  The 
adaptive domains are Social Approach Behaviors; Learning, Memory and Receptive 
Language; Phonological Skills; and Semantic/Pragmatic Ability.  Each domain is 
comprised of a varying number of categories which each contain four questions.  They 
are scored on a Likert scale from 0 to 3.  There are 176 items on parent version of the 
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PDDBI and 144 on teacher version.
102
  The PDDBI uses a standardized score like the 
GARS, and scoring in the PDDBI is based on the “Autism Score,” which uses the T-
score system.  In the T-score system, 50 is the average score and the SD is 10.  The T-
score is calculated using the DSM-IV related subscales and can be age referenced.
102
  The 
Autism Score is calculated by adding the T-score for Sensory/Perceptual Approach 
Behaviors, Social Pragmatic Problems, and Semantic/Pragmatic Problems and 
subtracting the T-scores from Social Approach Behaviors, Phonological Skills, and 
Semantic/Pragmatic Ability.
102
 
In 2005, the PDDBI was updated and modified.  It was separated into two 
dimensions called Approach/Withdrawal Problems (AWP), for the maladaptive 
behaviors, and the Receptive/Expressive Social Communication Abilities (REXSCA), for 
the determination of communication skills.
103
  The AWP is made up of the 
Sensory/Perceptual Approach Behaviors (SENSORY), Ritualisms/Resistance to Change 
(RITUAL), Social Pragmatic Problems (SOCPP), Semantic/Pragmatic Problems 
(SEMPP), Arousal Regulation Problems (AROUSE), Specific Fears (FEARS), and 
Aggressiveness (AGG) domains.  There are also two composite scores under the AWP.  
The first is the Repetitive, Ritualistic, and Pragmatic Problem Behaviors Composite 
(REPRIT/C) and is equal to the sum of SENSORY, RITUAL, SOCPP, and SEMPP.  The 
other composite is the Approach/Withdrawal Problems Composite (AWP/C) and is the 
summation of all of the domains.  The domains making up the REXSCA are the Social 
Approach Behaviors (SOCAPP); Expressive Language (EXPRESS); and Learning, and 
Memory, and Receptive Language (LMRL).  There are two composite scores under 
REXSCA called Expressive Social Communication Abilities Composite (EXSCA/C) 
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(SOCAPP + EXPRESS) and Receptive/Expressive Social Communication Abilities 
Composite (REXSCA/C) (SOCAPP + EXPRESS + LMRL).  There are also two 
discrepancy scores as a part of the new PDDBI:  the SOCAPP-SOCPP Discrepancy 
Score and the EXPRESS-SEMPP Discrepancy Score.  The dimensions are composed of 
independent behavioral domains, which are made up of clusters to characterize that 
domain.
103
  Each cluster is scored on the Likert scale and is comprised of four or more 
items.
103
  The teacher version is comprised of 180 items and the parent version is made 
up of 188.
103
  Each domain generates a T-score with the T-scores for the most important 
domains creating an Autism Composite score.
103
  The Autism Composite is still scored 
with a mean of 50 and an SD of 10, which should classify 68% of cases of autism.
103
  The 
Autism Composite is calculated by summing the T-scores from SENSORY, RITUAL, 
SOCPP, and SEMPP and subtracting the T-scores from SOCAPP and EXPRESS.
103
 
In 2003, the first study by Cohen et al. demonstrated good internal consistency 
between all of the subscales for both the parent and teacher versions.
102
  The study also 
found a high level of correlation among the maladaptive domains and all of the domains 
were unidimensional.
102
  A second study from that publication observed a higher Autism 
Score in children with autism compared to children with PDD-NOS in both versions of 
the original PDDBI.
102
  If 40 was used for the cutoff for the Autism Score, the sensitivity 
was 91% and the specificity was 80% on the parent version and the teacher version 
produced comparable sensitivity and specificity of 89 and 81%, respectively.
102
  A cutoff 
of 42 slightly increased sensitivity on both versions to 85%, but the specificity decreased 
to 50 and 52%.
102
  The adaptive subscales and Social Pragmatic Problems and 
Semantic/Pragmatic Problems maladaptive subscales displayed the expected increase 
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with age as reflective of an increase in development.
102
  The authors do not recommend 
the use of the original PDDBI for the diagnosis of PDD-NOS and the PDDBI does not 
provide the sensitivity to differentiate PDD-NOS from autism.
102
  The authors do note 
this differentiation is difficult for other rating scales such as the ADOS-G or the DSM-IV 
standards.  From these studies, the authors stress the importance of investigating the 
subscales and the potential they have for the discovery of subgroups.
102
 
Cohen completed another study comparing the PDDBI to other rating scales that 
found significant correlations between the ADI-R and PDDBI subscales.
104
  The different 
scoring methods between the ADI-R and the PDDBI may have limited the strength of the 
correlations.  The Autism Score from both the parent and teacher versions was 
significantly correlated to the CARS.
104
  From this study, Cohen determined the PDDBI 
to have prognostic, design, and developmental cogency, and the adaptive domain scores 
reflect real improvements in socialization and communication resulting from 
treatments.
104
  Cohen noted the PDDBI can play an important role in the future 
evaluation of children with PDDs undergoing treatments.
104
 
In a study with the updated PDDBI, Cohen et al. compared autism, PDD-NOS, 
and not spectrum groups.  The PDDBI provided distinctly different profiles for the autism 
and PDD-NOS groups compared to the not spectrum group.
103
  The measurements which 
showed the greatest differences were the overall Autism Composite score and the domain 
and composite scores related to social communication capability.
103
  The best cutoff 
value for the Autism Composite was 32 where the sensitivity was 100% and the 
specificity was 79%.
103
  Because of good sensitivity and specificity, the authors 
determined the updated PDDBI to be valuable in ASD diagnosis.
103
  Reel and colleagues 
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published a study which did not observe the diagnostic capabilities of the new PDDBI.
105
  
They determined the sensitivity of 74% and specificity of 62% were not high enough 
when the cutoff was set to 45.
105
  In this study, the results found children with ASDs were 
different from the non-ASD group only on the Autism Composite T-score and the 
SOCPP.
105
 
1.5.7 Autism Treatment Evaluation Checklist 
To find an easy way to determine small changes in response to treatment, the 
ATEC was developed by Bernard Rimland and Stephen M. Edelson in 1999.
106
  Non-
copyrighted, the ATEC is only one page long and can be completed by teachers, parents, 
or another person caring for a child.  The ATEC has 77 items divided into four subscales:  
(I) Speech/Language/Communication (14 items), (II) Sociability (20 items), (III) 
Sensory/Cognitive Awareness (18 items), and (IV) Health/Physical/Behavior (25 items).  
The first three subscales are scored from 0 to 2 and the last subscale is scored from 0 to 3, 
with a higher score indicating the more severe the problem or the greater the development 
of that respective characteristic.  The ATEC has a maximum score of 179.  It has been 
reported to have good internal consistency.
106
 
There have not been many studies that have evaluated the ATEC for diagnostic 
criteria, but it has been used to monitor autism treatments.  Magiati et al. noted studies 
where the ATEC was used to evaluate treatments of children with autism.
106
  However, a 
couple of studies have been published which used the ATEC to monitor developmental 
progress of children with autism.  Charman led a study that found the 
Social/Language/Communication subscale values were lower at the end of the school 
year than at the beginning for children with autism.
107
  The other subscales were not 
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significantly different, and the authors noted the ATEC may have some drawbacks.
107
  
Another study from 2011 showed good internal agreement at two independent follow up 
times.
106
  The total ATEC scores foretold 64% of the change between these two 
periods.
106
  The Social/Language/Communication subscale also showed significant 
decreases between these times.
106
  The authors believe the ATEC is a dependable 
measure over time, but more work is necessary to advance the legitimacy of the scale.
106
 
1.6 The Immune System and Autism Spectrum Disorders 
Now that the behavioral rating scales used to diagnose children with autism have 
been reviewed, the focus shifts to the immune system; an alteration in immune system 
functioning is one characteristic that children with autism commonly present clinically.  
The structure of the immune system is described to provide background information 
before discussing studies that describe immune dysregulation along with the impact 
genetics and the environment have in autism.  
1.6.1 The Structure of the Immune System 
The job of the immune system is to distinguish between the body and non-body 
and to remove any invading pathogens.
108
  The human immune system is composed of 
two parts:  the innate immune system and the adaptive immune system.  The innate 
immune system encompasses the cells and mechanisms that protect the body from 
infections caused by outside pathogens.  It is non-specific and provides only short term 
defense.  The adaptive immune system is comprised of cells with very particular 
functions and affords long term protection.  It possesses the ability to remember a 
pathogen and produce a stronger attack when it is encountered again at a later time.  
There are two types of adaptive immunity:  humoral immunity and cell-mediated 
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immunity.
109
  Humoral immunity is controlled by antibodies, whose production is 
regulated by B lymphocytes.  Antibodies, or immunoglobulins, are Y-shaped proteins 
which attack certain kinds of pathogens, which can be recognized through memory.  
There are five types of immunoglobulins (Ig):  IgA, IgD, IgE, IgG, and IgM.  IgG is the 
dominant antibody, accounting for nearly 80% of the total antibodies in humans,
4
 and it 
attacks viruses and bacterial toxins outside of cells.
4
  IgM makes up around 10% of the 
immunoglobulins and defends the body against blood-borne pathogens.  IgA comprises 
almost 15% of the antibodies and focuses on fighting bacteria which attack the mucosal 
barrier.
4
  IgE specializes in oversensitive responses to allergens and is attached to mast 
cells, which excrete histamine, and IgD acts in regulation of B cell initiation and 
termination.
4
  B cells are produced after T cells release interleukin (IL)-4, a cytokine 
produced by T-helper cells.  Cytokines, or interleukins, are important messengers of cells 
of the immune system involved in controlling leukocyte biology through receptors on 
their target cells.
110
  After being stimulated, B cells can be either plasma cells or memory 
cells.  Plasma cells are capable of generating vast quantities of antibodies very quickly 
and have a shorter life span.
4
  Memory B cells maintain specificity recognition with the 
ability to produce a large number of plasma cells to attack a pathogen.
4
 
T lymphocytes control cell-mediated immunity.  There are three types of T 
lymphocytes:  T-helper (CD4) cells, cytotoxic or killer (CD8) T cells, and T-suppressor 
cells.
4
  Sixty-five percent of the total number of T cells are helper-inducer cells.
111
  
Clusters of differentiation (CD) are used to describe molecules on the surface of white 
blood cells.  The CD4 lymphocytes assist B cells in reaching their complete functionality 
and in the making of antibodies.
109
  CD4 helper cells assist in the adaptive immune 
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reaction resulting from particular antigens,
112
 while CD8 cells destroy cells infected with 
viruses.
109
  T-helper lymphocytes can be divided into two groups, Type 1 helper (Th1) 
and Type 2 helper (Th2).  The Th1 lymphocytes function in cell-mediated immunity and 
the Th2 lymphocytes assist B cells in the production of immunoglobulins, most notably 
IgE.
108, 113
  Cytotoxic T lymphocytes attack and kill foreign pathogens in the body, and 
then T-suppressor lymphocytes signal the immune system to turn off when the pathogen 
has been eliminated from the body.  
1.6.2 The Cells of the Immune System 
The immune system requires many different types of cells to function properly.  
White blood cells, or leukocytes, protect the body from diseases and xenobiotics.  
Lymphocytes are a specific kind of leukocyte and are the only cells which possess unique 
receptors for specific antigens.  They play a large role in the adaptive immune system.
114
  
T and B cells are categorized as small lymphocytes, one of two categories, while the 
other is large granular lymphocytes, also called natural killer (NK) cells.  Natural killer 
cells destroy tumors and kill cells infected with viruses.
115
  They function as part of the 
innate immune system and do not possess any antigens on their surface like T and B 
cells.
114
  Natural killer cells possibly play a role in immune system control due to 
decreases in their number seen in lupus erythematous, multiple sclerosis, and rheumatoid 
arthritis;
115
 however, they do perform a role in controlling the number of antibodies being 
made.
108
  They have CD16 and CD56 or CD57, but do not have CD3 cell surface 
receptors.
109
 
Lymphocytes are classified as agranulocytes along with monocytes and 
macrophages.  Monocytes fight pathogens in blood and can respond quickly to where an 
  35 
infection occurs.  They can consistently change into macrophages after travelling to other 
nearby tissues.
116
  Macrophages engulf and consume pathogens, microorganisms, and 
other molecules that have assisted in phagocytosis.
109
  Agranulocytes are leukocytes with 
general azurophilic granules present in their cytoplasm.  Granulocytes are the other 
category of lymphocytes.  Granulocytes have granules attached to membranes, which 
help in the digestion of particles which have been engulfed as part of the immune 
response.  There are three types of granulocytes:  neutrophils, eosinophils, and basophils.  
Neutrophils are the most populous leukocytes and are found in pus and indicate acute 
inflammation.  Eosinophils block infections from parasites and control allergies and 
asthma.  Basophils produce IL-4, which plays a very important role in allergies and IgE, 
and mast cells are developed from them in tissues.
117
 
Antigliadin antibodies are an additional specific type of immunoglobulins which 
may play a role in immune system of children diagnosed with ASDs.  They are produced 
when exposed to gliadin, a glycoprotein found in wheat.  There are three classes of 
antiglidin antibodies:  antigliadin IgA, antigliadin IgG, and antigliadin IgE.  These 
antibodies can be produced during a response to gluten from the diet.  Another special 
type of antibody is called tissue transglutaminase (tTGA), which is commonly used as a 
marker for celiac disease. 
1.7 Evidence of Immune Dysregulation in Children with Autism Spectrum 
Disorders 
1.7.1 Autism and the Immune System 
Many studies have explored the effects autism has on the immune system, with 
the numerous findings focusing on immune dysregulation and dysfunction in ASDs.
13
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Autism has shown the presentation of multiple atypical values of the immune system and 
a large number of studies suggest a connection between autism and the immune 
system.
108
  Children with ASDs demonstrated an increased frequency of immunologic 
abnormalities including signs of irregular innate, humoral, and cell-mediated 
immunity.
118
  Successive adaptive immune reactions have resulted from previous innate 
immune system responses, and autoimmunity may be the consequence of an improperly 
regulated innate immune system.
119
  Children with autism show an abnormal innate 
immune system reaction, which may also cause adaptive immune system 
dysregulation.
119
  In most studies, fifteen to sixty percent of children with autism display 
immune system dysfunction.
14
 
A review of past studies regarding autism and the functioning of the immune 
system is discussed including B cells, T cells, NK cells, immunoglobulins, and other cells 
and components.  Next, genetic predisposition is reviewed because some important, 
specific genetic sites have been connected to the increased prevalence of autism.  Then, 
studies debating the impact the environment has on autism are examined.  Finally, autism 
rates and detoxification are demonstrated to be influenced by the environment. 
1.7.2 B Cells and Autism 
Results showing mixed B cell abnormalities in autism have been produced.  Yonk 
led a study which found decreased B (CD20) cells in children with autism.
120
  Gupta and 
colleagues supported this study by discovering that 60% of children with autism had 
irregular proportions and 64% had abnormal numbers of CD20 cells.
121
  Specifically, 
48% of the children had lower and 12% had higher proportions of B cells.
121
  In addition 
to these blood studies of B cell numbers, Ashwood and collaborators detected 
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significantly higher amounts of CD19 B cells in every area of the lamina propia studied 
when compared to controls.
122
 
Three different studies did not find any difference between autism patients and 
controls.  Separate studies led by Denney and Warren observed similar numbers of CD20 
B cells in children with autism and controls.
111, 123
  Stern et al. found no abnormalities in 
the total number of CD19 B cells.
12
   
1.7.3 Autism and T Cells 
Numerous studies have explored the relationship between T cells and autism. 
Stubbs et al. were the first to determine that children with autism displayed an 
insufficient number of T cells in 1977.
124
  In 1986, Warren and colleagues furthered the 
understanding of T cells in autism by finding a lower number of T cells and an altered 
ratio of helper T cells to suppressor T cells.
125
  Yonk et al. in 1990 discovered numerous 
findings including the decreased percentage and number of CD4 helper T cells and the 
lower percentage and number of all lymphocytes.
120
  They also noted that the CD8 
percent was significantly increased, but the CD8 number was not higher in children with 
autism compared to controls.
120
  That same year, Warren et al. showed that patients with 
autism had decreased numbers of total lymphocytes and CD4+ and a regular amount of 
CD8+.
123
  In 1994, Plioplys and colleagues found that the number and percentage of T 
and B cells, the CD4+, and CD8+ subsets were normal in patients with autism.
126
  While 
the mean CD4/CD8 ratio was normal for the cohort, 6 had higher ratios than normal, 5 
had lower values than usual, and only 4 were within the healthy range.
126
  This study also 
demonstrated a higher amount of activated T cells in children with autism; however, this 
study admits to using different methods in comparison to other studies.
126
  As of 1996, 
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the most frequent discoveries when evaluating the immune system of children with 
autism and controls were a decrease in the number or percentage of helper T cells which 
resulted in a lower “helper:suppressor ratio” (CD4/CD8) and a lower number of 
lymphocytes.
111
  A study by Denney et al. supported these findings of children with 
autism having a decreased percentage of CD4 cells and helper:suppressor ratio when 
compared to matched controls.
111
  The lower CD4 number was caused by the 
suppression-inducer subset, and not by the helper subset.
111
  Suppressor-cytotoxic T cells 
were not seen at statistically significant different levels between children with autism and 
controls.
111
  The children with autism displayed a minor decrease in total T cell (CD3) 
number.
111
  As part of a larger study looking at the immune system in children with 
autism, Gupta and colleagues observed abnormal numbers of total CD3 T cells in the 
children with autism, as 16% were decreased and 36% were increased.
121
  Helper/inducer 
T cells were abnormally distributed in 64% of the children with autism and 48% had an 
aberrant number of helper/inducer T cells.
121
  In this cohort, 60% had an aberrant 
CD4/CD8 ratio for T cells as 28% were elevated and 32% were decreased.
121
  Fiumara 
and colleagues led a study which found that female subjects with Rett’s Disorder all had 
a higher CD4/CD8 ratio caused by a lower percentage of CD8 suppressor-cytotoxic 
cells.
127
  In 2003, Ferrante and colleagues showed children with autism had  a notable 
reduction in CD4 naïve cells and an elevated number of CD4 memory T cells.
128
 
In addition to the blood studies previously discussed, Torrente et al. found that 
children with autism displayed a higher density of CD8 intraepithelial lymphocytes in 
comparison to controls.
129
  They also observed an overload of lymphocyte (CD3, CD4, 
and CD8) infiltration in the lamina propia in children with autism compared to 
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controls.
129
  The only study which showed normal numbers of T cell lymphocytes was 
led by Stern, where 96% of patients had regular CD3, CD4, and CD8 values.
12
 
In addition to the studies that have focused on the number and ratio of T cells, 
several studies have explored interleukins and other factors that affect T cells.  In autism, 
there is a problem with the cell-mediated immunity response.
130
  One way this finding 
can be seen is a shift in the ratio between Th1 and Th2 cytokines.  This change in Th1 
and Th2 responses alters the type of cell-mediated immune response, and it can be seen 
through the production of certain interleukins.  Th1 cells make IL-2 and interferon-
gamma (IFN-γ), which stimulate the production of T cells and macrophages.131  Th2 cells 
are responsible for making IL-4, IL-5, IL-6, IL-10, IL-13, and transforming growth 
factor-beta.
131
  In autism, both Th1 and Th2 cytokines have been found to be in higher 
amounts.
132
  Singh and colleagues found IL-2 at a significantly greater value in the serum 
of children with autism compared to healthy children.
133
  Both helper and suppressor cells 
need the unique signaling of IL-2 for production.
133
  In a second study, Singh observed 
IL-2 to have higher production in autism, and IL-2 is made by both the CD4 T 
helper/inducer cells and CD8 T suppressor/cytotoxic cells.
134
  IL-2 is made by T 
lymphocytes after interacting with antigen-presenting cells.
126
  In this study, Singh also 
demonstrated IL-12 and IFN-γ to be higher in children with autism, which may indicate 
increased Th-1 response resulting in autoimmunity.
134
  Both IL-12 and IFN-γ assist in 
regulation of the immune system, including CD4 T helper cells and this may signify T 
cell regulation deficiency.
134
 
Croonenberghs et al. reported that both IFN-γ and IL-1RA were significantly 
increased in children with autism along with a shift toward greater amounts of IL-6 and 
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tumor necrosis factor-alpha (TNF-α) in whole blood.135  Li and colleagues found that the 
brains of patients with ASDs had significantly higher amounts of TNF-α, IL-6, 
granulocyte macrophage colony-stimulating factor, IFN-γ, and IL-8 compared to 
controls.
112
  They also showed that the Th2 cytokines, IL-4, IL-5, and IL-10, were not 
significantly higher, and the Th1/Th2 ratio was statistically elevated in patients with ASD 
compared to controls.
112
  These results demonstrated a shift toward a Th1 response as 
seen in the adaptive immune system.
112
  Th-17 T lymphocytes, which release IL-17, 
TNF-α, and IL-6, have the survival factor IL-23, which has been seen to have a role in 
autoimmune disorders and chronic inflammatory diseases.
136
  Children with autism had 
lower amounts of IL-23 in comparison to normal developing, age matched controls.
136
  
IFN-α, IL-6 and TNF-α were not found to be significantly higher in children with 
autism.
134
  Activated T cells resulted in the increased production of TNF-α through the 
synthesis of different types of cytokines, which turn on macrophages and microphages 
that lead to the making of TNF-α.137  Cell-mediated immunity has been noted to be up-
regulated according to signs of increased CD3 TNF-α cells and decreased counter-
inflammatory CD3 IL-10 cells in the mucosal and lamina propria of the small intestine in 
children with autism suffering from gastrointestinal symptoms.
138
  In children with 
ASDs, both CD3 TNF-α and CD3 IFNγ were statistically higher than in non-inflamed 
controls in both peripheral blood and mucosa.
139
  In comparison to controls, CD3 IL-4 
was found to be elevated in children with ASDs.
139
  Ashwood and Wakefield showed that 
CD3 IL-10 was much lower in peripheral blood and mucosa in children with ASDs who 
suffered from gastrointestinal symptoms in comparison to non-inflamed and Crohn’s 
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disease control groups.
139
  In autism, cell-mediated or humoral reaction versus certain 
parts of the central nervous system may result from CD4 CD45RA shortage.
123
 
1.7.4 Natural Killer Cells in Autism 
Almost all of the previous studies that have focused NK cells and autism have 
found abnormalities in either the activity or number of NK cells.  In 1987, Warren and 
colleagues completed the first study, which found lower activity of NK cells in nearly 
40% of the patients with autism, and suggested that NK cell activity is decreased in 
autism.
115
  Reduced NK cell activity has also been seen in schizophrenia.
115
  Warren et al. 
hypothesized that an elevated likelihood of viruses seen in fetuses resulted from a 
predetermined inclination derived from decreased NK cell ability.
115
  Gupta led a study in 
1996 that supported the data from the study by Warren, which showed the proportion of 
CD3 CD16 NK cells was lower in 44% and higher in 8% of the children with autism.
121
  
Twenty-five percent of the children had a lower total NK cell number and in 12% the NK 
cell number was higher than normal.  In addition, 20% of the children had lower number 
and proportion of NK cells.
121
 
Vojdani and colleagues conducted a study showing that after using a correction 
factor, 45% of children with autism had low NK cell activity that was linked with the 
cellular glutathione concentration, compared to 8% of controls.
140
  They suggested that 
lower amounts of glutathione, IL-2, and IL-15 are responsible for the lower level of NK 
cell activity as both IL-2 and IL-15 along with other cytokines can activate the production 
of NK cells.
140
  Fiumara led a study that found decreased numbers of NK cells in 75% of 
children with Rett’s Disorder.127  They also showed that the younger patients had higher 
levels of IL-2.
127
  In addition, previous studies have demonstrated elevations and 
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decrements in NK cell production and increased blood monocyte creation, strongly 
supporting altered innate or first pass non-specific immunity, contributing to an increased 
multi-tissue inflammatory state.
115-116
 
In contrast to these studies, only two studies did not find any abnormalities in 
number of NK cells.  In 1990, Warren and colleagues found that there were no 
abnormalities in CD56 NK cells.
123
  Also, Stern et al. observed that all patients with 
autism had regular NK cell counts.
12
 
1.7.5 Immunoglobulins and Autism 
Immunoglobulins have been studied in numerous publications related to autism.  
The relationship between immunoglobulins and autism has been explored in blood, the 
brain, and in relation to diet.  Many studies have found both higher and lower than 
normal values in the blood, serum, and plasma of patients with autism.  Over-exuberant 
humoral immunity has been shown in several studies that demonstrated elevations in 
serum immunoglobulins and their subclasses in this group of children.
141
 
Different values of immunoglobulins and cytokines are commonly found in 
autism including lower levels of IgA, higher IgE and IgG amounts, and elevated IL-12 
and IFN-γ values.142  In 1996, Gupta and colleagues completed a study of many 
components of the immune system including immunoglobulins that found 56% of the 
children with autism had elevated amounts of serum IgM and IgE.
121
  Twenty percent 
lacked a normal concentration of serum IgA and 20% had decreased amounts of IgG 
subclasses.
121
  Singh et al. showed a significantly higher occurrence of IgG isotype 
antibodies to neuron-axon filament protein (anti-NAFP) and glial fibrillary acidic protein 
(anti-GFAP) in patients with autism in comparison to mentally retarded patients.
143
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Fifty-five percent and 32% of the subjects with autism had anti-NAFP and anti-GFAP 
antibodies, respectively.
143
  Jyonouchi et al. found in 2001 that 18% of children with 
autism showed higher amounts of IgE seen through allergen-specific IgE antibody or skin 
tests.
119
  The study also discovered that 55% of children with autism displayed the 
presence of positive IgG anti-myelin basic protein.
119
 
In 2002, Croonenberghs and colleagues found higher amounts of serum albumin 
and IgG in children with autism.
144
  The elevated levels of IgG suggested the presence of 
an autoimmune disease, which may lead to a higher likelihood of frequent illness caused 
by viruses.
144
  Autoimmune B cells may be affected by the abnormalities in the IgG 
subclasses seen in the cytokine-dependent effects.
144
  Statistically significant higher 
values of IgG, IgM, and IgA in children with autism in comparison to controls were 
found by Vojdani et al. in 2002.
145
  The next year Vojdani and colleagues showed that 
IgG, IgM, and IgA isotypes for both anti-CD26 and anti-CD69 autoantibodies were 
elevated in statistically significantly amount in autistic serum samples compared to 
controls.
146
  Trajkovski et al. noted IgM and IgG plasma levels in children with autism 
were statistically higher versus levels in their healthy sisters or brothers.
141
  IgA plasma 
amounts were not statistically significantly different in comparison to control siblings.
141
  
They found only IgG to be elevated in female patients with autism when compared to 
their healthy sisters.
141
 
In contrast to other studies that demonstrated higher levels of immunoglobulins, 
four studies illustrated lower than normal values in children with autism.  Warren and 
colleagues first saw that patients with autism had a significantly lower average amount of 
serum IgA compared to age- and sex-matched controls in 1997.
147
  They also showed 
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20% of these patients with autism had IgA concentrations below the normal lower 
bound.
147
  Additional findings included 42% having haplotypes connected to IgA 
shortages and 48% indicating C4B null alleles, with 15% of these individuals displaying 
decreased IgA numbers.
147
  Ashwood and colleagues found that 28% of children with 
autism had IgM amounts below the 5
th
 percentile of the pediatric reference values with 
only 14% above the 50
th
 percentile.
122
  Forty percent of IgA concentrations were below 
the 5
th
 percentile and no concentrations were above the 50
th
 percentile.
122
  They also 
discovered that serum IgA was negatively correlated with CD4% in blood.
122
  For IgE, 
39% of the amounts in children with autism were above the 95
th
 percentile.
122
  In 2005, 
Stern et al. saw 22 out of 24 patients had normal IgG and IgM levels within reference 
ranges and all 24 had normal IgA values.
12
  More recently, Heuer and colleagues found 
children with autism had lower concentrations of IgG and IgM when compared to 
typically developing age-matched controls.
148
  This study also showed that the ABC 
scores were correlated negatively with immunoglobulin concentrations for both children 
with autism and controls.
148
  The association between decreased IgG amounts and higher 
ABC scores is the best sign for a connection between autistic behavior and the function 
of the immune system.
148
  One study by Bakkaloglu and colleagues showed that serum 
amounts of IgG, IgA, and IgM were within age-appropriate bounds for children with 
autism, but 13.3% of subjects had higher than normal serum IgE.
149
 
In addition to the study of immunoglobulins in blood, three studies demonstrated 
higher amounts of them in the brains of children with autism.  Connolly and colleagues 
first saw this result in 1999 when they found 27% of children with ASDs had IgG anti-
brain autoantibodies and 36% had IgM autoantibodies in their sera, and both values were 
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significantly more than controls.
150
  Silva and coworkers supported Connolly’s work in 
2004 when finding children with autism exhibited a higher frequency of brain antibodies 
than controls at a significant level.
151
  Connolly et al. showed that brain derived 
neurotrophic factor (BDNF) and the average IgG and IgM BDNF autoantibodies (AA) 
were higher in children with autism and that IgM AA endothelial cells (EC) titers, IgG 
EC AAs, IgM EC AA, and anti-myelin basic protein IgG and IgM titers were greater in 
children with both autism and PDD-NOS.
152
  These results indicate the children with 
developmental disorders have greater quantities of AA than controls.
152
 
Immunoglobulins have also been studied to relate autism to the diet and 
gastrointestinal system.  Many regular dietary protein antigens cause an increased number 
of gastrointestinal problems in children with ASDs.
119
  Only 2-3% of the negative 
response dietary proteins are caused by IgE food allergies, with cell-mediated immunity 
playing a major role.
153
  Positive IgE antibodies against dietary proteins are rarely seen in 
children with autism during the first two years of their lives.
137
  One study found IFN-γ 
and TNF-α being made by peripheral blood mononuclear cells in opposition to gliadin, 
cow’s milk protein, and soy in comparison to dietary protein intolerance in children with 
ASDs.
137
  These children may have a bigger immune response to common dietary 
proteins as a result of an abnormal innate immune reaction to endotoxin found in the 
intestine.
137
  A higher rate of dietary protein responsive peripheral blood mononuclear 
cells was seen in children with ASDs and showed a connection between dietary proteins 
and gastrointestinal problems.
137
  Parents reported that the condition of children with 
autism improved after being on a casein- and gluten-free diet.
137
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Autism may result partially from food allergies.
154
  Behavior improved after an 
‘elimination diet,’ removing any food producing a positive cutaneous food allergy.155  
Compared to controls, children with autism displayed elevated quantities of IgA specific 
antibodies for lactalbumin, β-lactoglobulin, ovalbumin, and casein, and significantly 
larger amounts of IgG and IgM for casein and IgM for lactalbumin.
155
  Renzoni et al. 
published a study where the mean total IgE, the occurrence of higher than normal IgE 
counts, and the prevalence of IgE for specific foods showed there to be no significance 
between children with autism and mentally retarded, non-autism controls.
154
  This study 
did not find sensitivity to specific food allergens to be elevated in children with autism 
compared to controls.
154
  Children with autism did not demonstrate a significant, atypical 
IgG or IgM allocation.
129
  The most notable discovery was seen on the basolateral 
epithelial surface, where IgG deposition occurred in 92% of the children with autism 
studied, notably on C1q complimentarily.
129
  This finding implied the involvement of the 
immune system related to this disease.
129
  Kawashti and colleagues found that 83.3% and 
50% of children with autism had elevated IgG and IgA antibodies to casein and gluten, 
respectively.
156
  In comparison, only 10% of controls had higher antibodies in response to 
casein and 6.7% to gluten.
156
  A link may be seen between behavioral symptoms and 
gastrointestinal issues resulting from an abnormal innate immune system in children with 
ASDs.
157
 
1.7.6 Autism and Antigladin A and G 
In the entire population of children in North America, only about 10% have any 
sensitivity to glutens as marked by increased antigliadin IgG and/or antigliadin IgA 
antibody production.  There have only been a few studies which have focused on 
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antigliadin A and antigliadin G antibodies and autism.  Vojdani et al. found in 2003 that 
antigliadin IgG was significantly higher in 44% of children with autism versus 
controls.
146
  Antigliadin IgM was elevated significantly in 36% versus 10% for controls, 
and antigliadin IgA was higher in 46% of children with autism compared to 12% of 
controls.
146
  In 2004, Vojdani and colleagues conducted a study which demonstrated 
significantly greater amounts of antigliadin IgG, IgM, and IgA in 42%, 34%, and 36%, 
respectively, in children with autism.
158
  Age matched controls showed elevations in 16% 
for antigliadin IgG, 8% for antigliadin IgM, and 14% for antigliadin IgA.
158
  In another 
study that year, Vojdani et al. found children with autism had a statistically higher 
amount of antigliadin antibodies.
159
 
1.7.7 Tissue Transglutaminase and Autism 
There have not been many studies relating the association between tTGA and 
autism.  Levy and colleagues found children with autism had normal amounts of tTGA, 
gliadin IgA and gliadin IgG.
160
  Only 1% of the North American child population 
demonstrates elevated tTGA, suggesting the presence of celiac disease.
161
  From the 
largest multicenter epidemiologic study in the United States, celiac disease was found to 
occur in 1 in 133 individuals not in at risk groups.
162
  Fasano and Catassi suggest that the 
prevalence of celiac disease ranges from 0.5-1.0% of the population.
163
  In children age 
2.5 to 15, celiac disease occurrence ranges from between 1 in 80 to 1 in 300.
164
  No link 
between autism and celiac disease has been made.
165
 
1.7.8 Other Immune Cells in Autism 
Some studies have focused on the role of other cells in the immune system related 
to autism including eosinophils, monocytes, neutrophils, and basophils.  Renzoni et al. 
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found significance in the average eosinophic absolute number, average percentage of 
eosinophils in blood, and frequency of eosinophilia between retarded controls and 
children with autism.
154
  Another study showed children with autism displayed a higher 
total amount of eosinophils when evaluated against controls.
132
  Ninety-two percent of 
children with autism exhibited a higher number of non-specific mononuclear cells 
(agranulocytes), 56% had a higher number of intraepithelial lymphocytes, and pericryptal 
lymphocyte aggregates were discovered in 64% of children with autism.
129
  In a larger 
study, Sweeten and colleagues found that children with autism had a higher average 
number of monocytes compared to controls.
116
  This study also showed no significant 
disparity in the total absolute leukocyte count, in the number or percentage of 
neutrophils, eosinophils, basophils, or lymphocytes, or in monocyte percentage.
116
  These 
findings do not support autism as an autoimmune disease, as they result in a higher than 
normal blood monocyte number.
116
 
1.7.9 Zinc and the Immune System 
In addition to the cells of the immune system, many different components are 
necessary for the immune system to work optimally.  One of these parts needed for 
proper functioning of the immune system is zinc.  In the body, zinc is found mostly as a 
Zn
2+
 ion attached to cellular proteins and acts as an antioxidant.
110
  Zinc is required for 
normal human maturation and optimized performance of the immune system.
166
  Zinc 
deficiency results in shortcomings in the immune system,
167
 and lower concentrations 
have been connected to the damaged immune reactions in many diseases.
168
 
Zinc affects all of the different cells involved in immune response.
168
  The 
production of T cells is controlled by the amount of zinc;
168
 and they are the first cells 
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affected by zinc deficiency resulting in lower numbers.
167
  Zinc is required for the 
development and maturation of T cells.
168
  During times where zinc is only somewhat 
deficient, the function of T cells can be affected negatively.
168
  A shift toward a Th2 
helper cell response is seen with decreased zinc.  Activation, the making of Th1 
cytokines, and assistance of B lymphocytes are all functions of T lymphocytes affected 
by zinc shortages.
110
  Sazawal and colleagues found that in a group of children suffering 
from diarrhea, those on zinc supplementation had significantly higher CD3, CD4, and 
CD4/CD8 ratio means compared to controls.
169
   
Additional work has noted that zinc deficiency in utero can contribute to 
decreased communication between T and B cells of the immune system, leading to an 
overabundant humoral immune response to antigens in the mouse model and decreased 
splenic size.
170
  The ability of antibodies, especially IgG, to be produced is decreased 
during zinc shortages.
110, 167
  Naïve B cells suffer greater consequences in times of zinc 
scarcity in comparison to memory B cells.
167
  B lymphocyte production is hindered in the 
bone marrow thus reducing the number of B lymphocytes in the spleen.
110
  For cells 
involved in general immunity, including neutrophils and NK cells, zinc is necessary for 
proper maturation and performance.
110
  In addition, NK cells, monocytes, granulocytes, 
and macrophages all show decreased functionality in times of lower zinc 
concentration.
167
  Monocytes have a greater concentration of zinc than T cells.
168
  
Macrophage functioning involving the making of cytokines and phagocytosis is also 
negatively affected.
110
  In zinc shortages, the amount of neutrophils is decreased.
167
  
Peripheral blood mononuclear cells “take up” zinc.168  During the third trimester of 
pregnancy, the transferring of antibodies from mother to fetus may be compromised by 
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zinc deficiency.
110
  Child illness may be reduced due to zinc supplementation by mothers, 
and enhanced dietary zinc intake or supplements can correct for zinc deficiency.
166
  
Neither plasma nor hair zinc measurements can truly determine zinc status.
166
 
1.7.10 Autism, Metallothionein, and the Immune System 
In addition to zinc, metallothionein has a very important role in the immune 
system through the regulation of metals including zinc.  Metallothioneins are a group of 
low molecular weight proteins which are rich in cysteine and the proteins most 
responsible for the removal of heavy metals from the body.
171
  Cysteine contains thiol 
groups which have a high reactivity with metals.
171
  Four isoforms of metallothionein 
exist,
172
 and in humans, all four are closely located on chromosome 16.
173-174
  Both MT-I 
and MT-II are found in all tissues.
172
  In mice, the brain is the only organ where MT-III is 
expressed.
173
  MT-IV is observed only in stratified squamous epithelia in mice including 
in the oral epithelia, esophagus, and upper stomach.
174
  Quaife et al. have estimated that 
80% of all MTs are MT-IV.
174
  MT-I and MT-II levels are controlled by metals, 
hormones, and xenobiotics, and they are responsible for the detoxification of heavy 
metals and metalloprotein synthesis.
175
  MT-III is known to control zinc levels in 
neurons.
175
  MT-IV function is not known.
172
  The transcription of metallothionein genes 
and additional genes in response to heavy metal and oxidative stress are turned on by 
metal-regulatory transcription factor-1 (MTF-1).
176
 
In eukaryotes, zinc concentrations are controlled by metallothionein through 
evolution.
177
  Proteins which bind metals, notably metallothionein, control the amount of 
available zinc.
167
  Zinc ions are kept in reserve by metallothionein.
178
  Both zinc and 
metallothioneins have been used to determine zinc shortages.
171
  Both the amount and 
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oxidation state affect the amount of zinc bound to metallothionein.
167
  In addition, 
metallothionein dysfunction may result in improper heavy metal detoxification.
171
  MT-1 
can bind with many heavy metals including zinc, copper, cadmium, and mercury, and 
detoxify them from the body.
171
  Both the elemental and ionic species of divalent metals 
are deadly to cells.
171
  Russo found that members of autistic families had significantly 
higher amounts of serum anti-metallothionein IgG in comparison to controls; there was 
an association between the making of IgG antibodies and amounts of metallothionein.
171
  
In children with autism, many symptoms, including leaky gut, casein and gluten digestion 
problems, and other digestion issues, may result from improper MT functioning.
171
  Both 
the autoimmune reaction and anti-MT synthesis may result from either decreased 
metallothionein amounts or their improper synthesis.
171
  Both estrogen and progesterone 
improve metallothionein production.
171
 
1.7.11 The Plasma Zinc/Serum Copper Ratio as a Biomarker Linking 
Environmental Toxicity to the Immune System in Autism 
In a previous study, the plasma zinc/serum copper ratio (Zn/Cu) was proposed as 
a biomarker in ASDs.
179
  In this study, the average Zn/Cu ratio for the cohort of children 
with ASDs studies was 0.608.
179
  This value was below the 0.7 cutoff value due to 
previous reports in literature and clinical assessment marking the lowest 2.5% in healthy 
children.
179
  This study showed a very similar mean Zn/Cu ratio to a previous study of 
children with ASDs.  In a study of 503 patients with ASDs, Walsh and colleagues 
determined the mean Zn/Cu ratio to be 0.61 for the ASD patients and 0.87 for controls.
180
  
Walsh also studied the Zn/Cu ratio of assaultive young males and observed it to be 0.71 
with the controls’ mean ratio being 0.98.181  In a study of leishmaniasis patients, Van 
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Weyenbergh and colleagues found that humoral and cellular immune reaction was related 
to the copper/zinc (Cu/Zn) ratio.
182
  A disparity in the Cu/Zn ratio may be the result of a 
lower Th1 immune response and trace metals are needed for optimal immune response.
182
  
They also demonstrated a very strong association between plasma copper and both anti-
Leishmania IgG and humoral immune action.
182
  They saw that higher levels of plasma 
copper prevented the production of IFN-γ.182  A normal plasma zinc/serum copper ratio 
in a healthy child is 1.0 and it is seen in the assaultive young male study by Walsh and 
the leishmaniasis study by Van Weyenbergh.
181-182
 
The plasma zinc/serum copper ratio is important because it is a way to measure 
the metallothionein system.  Dr. Walsh suggested that patients with autism suffer from 
decreased metallothionein functioning and the observed characteristics seen in autism are 
the result.
180
  A metallothionein system resulting from genetic abnormalities could cause 
nearly all of the classic signs in autism.
180
  These functions include detoxification of 
heavy metals, development and optimal performance of immune system, gastrointestinal 
issues including those related to gluten and casein, and neurological functioning 
including production of brain neurons, action of the hippocampus, and socialization and 
emotional memory maturation.
180
  In a study, Walsh and colleagues found that over 99% 
of children with ASDs showed aberrant metal metabolism which results from decreased 
metallothionein functioning.
180
  They also showed the mean concentration of unbound 
copper to be four times higher in children with autism compared to controls.
180
  Walsh 
proposed that ASD patients suffer from a ‘universal’ metallothionein disease.180  Walsh 
indicated four examples of biochemical areas which can result in decreased 
metallothionein activity:  decreased zinc concentration, glutathione reduction-oxidation 
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(redox) system aberrations, lower cysteine concentrations, and anomalies in metal 
regulation.
180
  A hypothesis of genetic predisposition to abnormal metallothionein 
functioning and an environmental attack which hinders metallothionein was proposed by 
Walsh et al. and can account for the increased rate of autism diagnosis seen in recent 
years.
180
  Based on their structure and function along with their location in the body, a 
very strong relationship can be seen between metallothionein and autism.  There is more 
discussion on this topic in Chapter 4. 
1.7.12 Autism, the Immune System, and Genetic Susceptibility 
Many different areas of the human genome have been explored in relation to 
autism to explain a potential genetic susceptibility with autism.  One area of genetic 
predisposition relating autism and the immune system appears to be the major 
histocompatibility complex (MHC).  The MHC is composed of many genes which 
control the immune system including antigen arrangement, controlling peptide joining, 
and T cell identification.
183
  CD4 cells determine antigens sorted and processed by 
antigen-presenting cells only for MHC Class II antigens, while CD8 cells only do the 
same with MHC Class I antigens.
109
  Of importance are the C4 genes which are centrally 
located on the MHC on chromosome 6.
184
  The C4 proteins are made up of the products 
from the C4A and C4B genes and are involved in the innate immune system and the 
complementary cascade.
185
  Higher rates of bacterial and viral illnesses have been found 
with decreased C4 proteins, particularly C4B.
186
 
These components of autoimmune disorders include genetic predispositions such 
as the C4 null allele at the complement C4B locus.
187
  The ability to completely remove 
particular viruses before they attack the central nervous system may be affected 
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theoretically due to the presence of one or two C4B null alleles.
188
  Warren’s first study 
found no significance in the frequency of the C4A null allele, but found one with the C4B 
null allele.
187
  Fifty-eight percent of children with autism and their mothers had null C4B 
alleles while only 27% of controls did.
187
  Warren and colleagues conducted a second 
study which showed that subjects with autism had significantly lower plasma 
concentrations of the C4B protein in comparison to normal controls.
188
  This study 
demonstrated typical concentrations of plasma C4A protein and that parents and siblings 
had non-significantly lower amounts of C4B protein.
188
  A third study led by Warren 
observed that the C4B null allele was higher in patients diagnosed with autism, ADHD, 
and ‘reading-disabled subjects’ in comparison to controls.184  This study further 
reaffirmed a connection between the C4B gene and autism and noted that DRβ1 HVR-3 
was found to be significantly higher in children with autism than controls.
184
   
Both the C4A and C4B null alleles have been connected to autoimmune disorders 
and IgA insufficiency.
185
  It is common that either the C4A or C4B allele is null, but 
autoimmune diseases display a higher occurrence of C4 null alleles.
185
  Odell and 
colleagues completed a study which showed that 42.4% of children with autism had at 
least one null C4B compared to 14.5% of controls.
185
  Another study led by Sweeten 
observed that 50% of the patients with autism had C4B null alleles while only 16.7% of 
controls had C4B null alleles.
189
  This study did not find any connection between C4B 
null alleles and the CYP21A2 gene near the C4 gene.
189
  Warren led another study where 
54% of the patients with autism had DR+ T cells.
186
  DR+ T cells are a sign of activated 
T cells, and they were found to be inversely correlated with decreased C4B protein 
concentration in plasma.
186
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In addition to its association with the C4 genes and proteins, the MHC has also 
been found to have a connection to the neurotransmitter serotonin.  Warren and Singh 
showed that the average serum serotonin concentration was statistically significantly 
higher in children with autism than in controls.
190
  They also demonstrated that the 
patients with autism with a B44-DR4 extended haplotype or a C4B null allele also had 
statistically significantly greater concentrations of serotonin in serum.
190
 
A genetic susceptibility combined with an environmental prompt may explain the 
rise in autism over the last 15 years.
20
  Many different studies have both discovered and 
not discovered associations with certain genes involving detoxification and the immune 
system.  Rose and colleagues showed a significant increase of the delta aminolevulinic 
acid dehydratase (ALAD2) allele with an odds ratio of 1.66 and a significant decrease in 
the frequency of both coproporphyin oxidase (CPOX) variants, which is the opposite of 
the expected result for CPOX.
20
  Both ALAD2 and CPOX are enzymes which are 
impeded by lead and mercury, respectfully.
20
  Buyske and colleagues found a correlation 
between autism and a homozygous deletion genotype for glutathione S-transferase M1 
(GSTM1) as GSTM1 is one of the genes responsible for binding glutathione to toxins.
191
  
Glyoxalase I (Glo1) was demonstrated by Junaid et al. to have a 38% reduction in 
enzymic activity in brains of patients with autism.
192
  It is a dimer with each monomer 
binding to zinc and has a high propensity to bind to α-oxoaldehydes.193  Reduced 
glutathione is the cofactor for Glo1.
193
  D’Amelio and colleagues observed that 
Caucasian-Americans, but not Italians, had a correlation between paraoxonase gene 
(PON1) variations which had decreased activity for the organophosphate diazinon in 
vitro and autism.
194
  Decreased capacity to metabolize and eliminate toxins results from 
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lower PON activity.
195
  PON is involved in the eradication of neurotoxins including nerve 
gases and pesticides.
195
  PON1 uses the P450/PON1 pathway to remove organophosphate 
compounds from the body.
196
  Serajee et al. did not find any connection with PON1, 
SLC11A2 (a proton-coupled metal ion transporter), ABCC1 (a multispecific organic 
anion transporter), and glutathione S-transferase and autism, but did find one for MTF-1 
and SLC11A3, another proton-coupled metal ion transporter.
197
 
In addition to the studies relating autism to the genetic problems with 
detoxification, other studies have shown a connection between autism and genetic 
immune system abnormalities.  One of these genes which have been explored for a 
connection to autism involving the immune system is the gene for the MET receptor 
tyrosine kinase.  MET signaling is involved in gastrointestinal healing and the function of 
the immune system.
198
  A study determined a relative risk of 2.27 for autism with a 
frequently found functional form of the MET gene.
198
  Garbett and colleagues provided 
further support for the interaction of many genes involved in autism including MET, 
glutamic acid decarboxylase 1, glial fibrillary acidic protein, and reelin.
16
  They also 
proposed the involvement of the innate immune system and a T cell based response 
through changes in the IL2RB, TH1TH2, and FAS pathways.
16
  In addition, studies 
discovered a connection between cells of the immune system and autism.  Gregg et al. 
observed that children with autism differentially expressed the following genes which 
relate to NK/CD8+ cells:  PAM, SPON2, IL2RB, PRF1, GZMB, CX3CR1, and 
SH2D1B/EAT2.
199
  Also, Enstrom led a study which showed ‘clear and significant’ 
changes in NK cell gene expression, incidence, and function.
200
  Ashwood and colleagues 
also found children with autism had significantly decreased amounts of cytokine 
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regulating TGFβ-1 in comparison to normally developing controls which may indicate a 
dysregulated immune system resulting from lower TGFβ-1 levels.201 
1.8 Environmental Toxins and Autism Spectrum Disorders 
Since the beginning of the 20
th
 century, the use of chemicals has increased 
dramatically.  Currently, there are over 80,000 chemicals used in industrial processes,
202
 
but nearly all of these chemicals have not been thoroughly tested to evaluate their effects 
on human health. The use of chemicals has continued to increase in the last generation, 
and they are required in the production of many everyday goods.  However, only a small 
amount of testing has been performed on the effects of brain development resulting from 
chemicals commonly exposed to children.
203
  It has been suggested that developmental 
disabilities are partially the result of the interaction with household and environmental 
chemicals.
203
   
Studies have investigated the general exposure of children with autism to toxins 
and the effects they have on the immune system.  Landrigan and Goldman noted the 
importance of the 1993 National Academies report, Pesticides in the Diets of Infants and 
Children to realize the difference chemicals have on children and adults.
202
  The report 
resulted in a philosophical change in toxicity away from the “average adult” to a broader 
approach.
202
  Edelson and Cantor completed a study which found that in comparison to 
adult levels, 89% of patients with autism had levels of xenobiotics above those maximum 
values.
204
  Elevated concentrations of numerous toxins are seen in people with ASDs 
compared to controls, and their genotypes make them more susceptible to the effects of 
these toxins.
195
  The ability to detoxify the body from environmental interactions may be 
decreased due to many different genetic polymorphisms.
20
  Contact with toxic chemicals 
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including heavy metals, notably mercury and lead, and organics, including 
polychlorinated biphenyls (PCBs), are capable of changing the gene expression in the 
regional brain glial fibrillary acidic protein and astroglial glucose regulated protein.
145
  
Vojdani et al. hypothesized that elevated levels of antibodies (IgG, IgM and IgA) result 
from increased porosity of the blood-brain barrier resulting from toxins and infectious 
antigens.
145
 
Many studies have been published which implicated chemicals and toxin overload 
as a cause of autism.  These studies have looked at both the rates of autism as a result of 
this exposure and the physical effects the chemicals have in the etiology of autism.  
Studies have investigated prenatal exposures, mineral imbalance, immune system 
implications, and the detoxification of metals and chemicals. 
1.8.1 Environmental Toxins and the Rate of Autism 
Many studies have determined the rate of autism in relation to the exposure to 
various environmental toxins.  DeSoto analyzed the frequency of ASDs in Minnesota 
school districts in relation to Superfund sites.
195
  The rate of ASDs of school districts 
within 10 miles of a Superfund site was 1 in 92 while the rate was 1 in 132 in school 
districts without a Superfund site within 10 miles.
195
  These results are significant with 
ASD rates statistically higher in school districts close to a National Priority List 
Superfund site.
195
  Windham et al. completed a study which found higher rates of ASDs 
as a result of pollutants from the air.
205
  The pollutants which resulted in the increased 
risk of autism included the metals:  mercury, cadmium, and nickel, and the organic 
solvents:  trichloroethylene and vinyl chloride.
205
  Eskenazi and colleagues observed an 
approximate doubling of the possibility of PDDs when the amount of pesticide 
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metabolites was increased ten times.
206
  Roberts led a study in California which showed 
that the suggested odds ratio for ASDs was 6.1 for mothers who live close to fields using 
organochlorine pesticides.
207
  Palmer and colleagues found that every 1,000 pounds of 
mercury released into the environment resulted in a 43% higher special education rate 
and a 61% elevation in the autism rate.
208
  Palmer led a second study which saw 
significant increases of 2.6% and 3.7% in the rate of autism for every 1,000 pounds of 
industrial release and power plant emissions, respectively.
209
  Gbor determined Pittsburgh 
to be located in an area of the United States where 73% of total mercury exposure is the 
result of human activity.
210
 
1.8.2 Evidence of Prenatal Environmental Exposure to Toxins in Autism 
Chemical exposure has been found to affect development and begins prenatally.  
The uterus’s environment has been determined to have a growing significance in 
determining the long term health of the fetus.
211
  Lead, methylmercury, PCBs, arsenic, 
and toluene are among the industrial chemicals which result in developmental disorders 
and decreased brain function.
212
  In terms of development, the brain is one of the organs 
most affected in the body.
213
  Exposure from these chemicals to fetuses in the womb 
resulted in brain damage at lower concentrations compared to adults.
212
  Maternal illness 
during the early and middle parts of a pregnancy may also be linked to high likelihood of 
long term brain and behavior problems in children.
214
  In the general population, lead, 
mercury, and PCBs have been found to have negative effects on development.
203
  
Landrigan reviewed studies which showed a connection between autism and chemical 
exposure from thalidomide, misoprostol, valproic acid, maternal rubella infection, and 
chlorpyrifos, an organophosphate insecticide.
215
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1.8.3 Nutrient Status and Toxin Exposure in Children with Autism 
Many studies have investigated the mineral balance which exists in the body and 
how children with autism vary from the normal profile.  In 2004, Audhya presented 
results at The International Meeting for Autism Research about the metabolic profile of 
children with autism.  He demonstrated decreased concentrations of many vitamins in 
children with autism compared to controls.
216
  Children with autism had lower 
concentrations of zinc, selenium, magnesium, and copper and higher amounts of total and 
organic mercury, arsenic, and lead in red blood cells.
216
  Additionally, the organic toxins 
of perchlorethylene, hexane, pentane, and xylene were elevated in plasma.
216
  Yorbik et 
al. found statistically significantly lower concentrations of zinc in the plasma and red 
blood cells of children with autism compared to controls.
217
  Strambi and colleagues 
observed significantly lower levels of plasma magnesium compared to controls.
218
  Jory 
and McGinnis showed there was lower selenium and higher molybdenum amounts in red 
blood cells for children with autism.
219
  In children with autism, they also indicated a 
trend of decreased zinc and elevated cobalt and vanadium.
219
  Faber et al. observed zinc 
deficiency in 20% of children with ASDs and copper toxicity in 17%.
179
 
Mercury has been the subject of many publications to determine if it is the cause 
of the difference between normal developing children and children with autism.  In 2004, 
Ip et al. did not observe a relationship between blood mercury concentrations and autism 
diagnosis.
220
  DeSoto and Hitlan reanalyzed this data set in 2007 and did find a 
significant connection between mercury blood concentrations and the diagnosis of an 
ASD.
221
  Adams led a study which found mercury concentrations were significantly 
elevated in the baby teeth of children with autism, but lead and zinc were not 
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significantly different than controls.
222
  In 2010, Hertz-Picciotto led a study investigating 
blood mercury concentrations where the unadjusted mean for typically developing 
children was significantly greater than children with ASDs or developmentally delayed 
children.  When demographic was accounted for, only the difference between the control 
and developmentally delayed children maintained significance.
223
  The same year, Geier 
and colleagues published a study which found higher concentrations of mercury in blood 
in children with autism compared to controls along with the observation of a threshold 
effect.
224
   
Mercury has been investigated because of the many ways it negatively impacts 
the body.  Mercury has been known to cause changes in the immune system resulting in a 
change toward Th2 cytokines from Th1 cytokines, lower NK cell and T cell functioning, 
and the beginning of autoimmunity.
108
  In some vulnerable mice species, mercury causes 
an autoimmune disorder in vivo resulting in higher amounts of IgE and IgG1.
225
  Mercury 
can attach to and change the structure of proteins which have sulfhydryl or disulfide 
functional groups on the cell surface, which could modify certain key components of the 
immune system including MHC class II compounds, receptors of T cells, and other small 
proteins.
225
   
1.8.4 Environmental Toxicants Resulting in Oxidative Stress in Autism 
Compounds which have thiol groups can protect these proteins against 
oxidation.
225
  One of the most effective cellular systems against oxidation is 
glutathione.
226
  Glutathione is the primary method for heavy metal detoxification and is 
the natural chelator in humans.
20
  Both glutathione and metallothionein are the most 
effective detoxification systems of mercury in the brain.
226
  Environmental toxins 
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including heavy metals, PCBs, polycyclic aromatic hydrocarbons, and organophosphate 
pesticides among others result in lower cellular glutathione concentrations either directly 
or indirectly.
20
  Both lead and mercury have a high attraction to the thiol group of the 
cysteine in glutathione.
20
  In 2004, Dr. S. Jill James completed a study which showed that 
children with autism had lower total glutathione concentrations and higher amounts of 
oxidized glutathione in plasma than controls.
11
  Dr. James led another study in 2006 
which showed lower total glutathione and reduced to oxidized glutathione ratios in 
children with autism.
18
  These results show children with autism have experienced a 
greater amount of oxidative stress which may result from environmental toxicants. 
1.8.5 Detoxification Problems in Children with Autism 
One of the most common ways children with autism have been evaluated for 
exposure to environmental toxins is detoxification.  Two common matrices used in the 
evaluation of detoxification in children with autism are hair and fingernails, with hair 
being more common.  Studies involving the evaluation of detoxification in children with 
autism have been performed all around the world. 
The most studies have been performed in the United States.  In 2003, Holmes and 
colleagues completed a study which found significantly lower concentrations of mercury 
in the hair of children with autism in comparison to controls.
227
  When classifying the 
children with autism as mildly, moderately, or severely autistic, there were significant 
differences in mercury concentrations when pair-wise comparisons were performed.
227
  
Adams and colleagues explored the concentration of elements in hair.  They observed 
that children with autism had 45% less iodine, and children with autism who had pica had 
38% less chromium in their hair when compared to controls.
228
  A higher quantity of zinc 
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and a lower amount of potassium were found in the children with autism who had 
decreased muscle tone when compared to controls.
228
  Kern led a study which discovered 
significantly lower concentrations of arsenic, cadmium, and lead in hair of children with 
autism compared to matched controls.
229
  A non-statistically significant trend of lower 
mercury concentration in the hair of children with autism was observed.
229
  In 2008, 
Adams et al. supported the earlier studies by finding that children with lesser 
concentrations of mercury in their hair were 2.5 times more likely to develop autism.
230
 
Another area of the world that has produced many studies investigating 
detoxification is the Middle East.  In Kuwait, Fido and colleagues found significantly 
decreased concentrations of calcium, zinc, magnesium, copper, manganese, and 
chromium in children with autism compared to age and sex matched controls.
231
  In a 
second study, Fido and Al-Saad observed higher amounts of lead, mercury, and uranium 
in children with autism.
232
  In Egypt, El-baz et al. determined that there was a 
significantly elevated concentration of mercury in the hair of children with autism 
compared to controls.
233
  In another Egyptian study, Elsheshtawy and colleagues found 
higher concentrations of lead and copper in children with autism compared to controls, 
but mercury and zinc were significantly lower.
234
  The study also demonstrated a positive 
correlation between the CARS score and both copper and mercury levels.
234
 
Asia has also produced studies exploring the detoxification of children with 
autism.  Ip et al. did not observe a significant difference in mercury hair concentration of 
controls and children with autism.
220
  In 2005, Yasuda and colleagues found higher 
concentrations of selenium and iron in children with autism compared to controls.
235
  The 
children with autism demonstrated lower cobalt, chromium, iodine, molybdenum, 
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phosphorus, nickel, boron, cadmium, and lead hair concentrations.
235
  Mercury was not 
shown to be significantly different between the groups.
235
  In 2010, Lakshmi Priya and 
Geetha compared the hair and nail concentration of Indian children with autism and 
controls.  Copper, mercury, and lead were observed in higher concentrations in the hair 
and nails of children with autism compared to controls.
236
  In children with autism, 
magnesium and selenium were detected at significantly lower amounts.
236
  Low 
functioning children with autism demonstrated significantly decreased zinc 
concentrations in hair and nails compared to controls.
236
  Overall, the concentrations of 
copper, lead, mercury, magnesium, and selenium produced strong correlations to autism 
severity.
236
 
A couple of studies have been performed in Europe.  Lubkowska and Sobieraj 
found an elevated concentration of selenium and a decreased amount of iron in the hair of 
children with autism versus age matched controls.
237
  No significant differences were 
determined to exist for calcium and zinc.
237
  Another study from Poland investigated hair 
mercury levels.  It showed younger children with autism had decreased concentrations of 
mercury compared to controls while older children had elevated concentrations.
238
 
1.9 Treatments of Autism Spectrum Disorders 
While there is no universal cure or treatment for ASDs, many different types of 
treatments have been used, and treatments are best when employed early.
239
  Symptoms 
of ASDs have appeared as soon as 8 months of age, but are more commonly seen at about 
12 months.
239
  Children with ASDs can be separated from normally developing children 
and children with different developmental problems as the behavioral signs are easier to 
note after the first birthday.
240
  One study found that 87.5% of children showed indicators 
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of having an ASD during the first year of life.
241
  It has been suggested that screening for 
ASDs occur at 18, 24, and 36 months due to the increased consistency of diagnosis.
240
   
1.9.1 Types of Treatments for Autism Spectrum Disorders 
There are many different types of treatments used for ASDs.  This wide range of 
treatments includes acupuncture, yoga, meditation, a hyperbaric chamber, a cleanroom, 
prescription medication, Applied Behavior Analysis (ABA) treatment, elimination diet, 
chelation, dietary supplements, and many others.  The only prescription medication 
approved by the United States Food and Drug Administration for autism treatment is 
risperidone.
242
  Speech therapy, ABA, sensory integration therapy, and auditory therapy 
are included in the endorsed educational treatments for autism.
243
  For ABA treatment, a 
study from 2009 demonstrated improvement in 38 children with autism to reach normal 
functioning levels.
244
  Additional methods which have been used include food elimination 
and rotation and dietary supplementation.
243
  One common type of elimination diet is the 
gluten- and casein-free diet where foods containing the proteins gluten and casein are 
removed from consumption.   
Many of the treatments listed are part of complementary and alternative medicine 
(CAM).  It encompasses a wide variety of treatments which are not currently considered 
part of conventional medicine.  Complementary medicine is employed in conjunction 
with conventional medicine while alternative medicine replaces conventional 
medicine.
245
  In 2006, Hanson and colleagues determined 74% of families used a CAM to 
treat a child with an ASD, including 54% using a biologically based treatment.
245
  
Harrington et al. demonstrated even greater use of CAMs with 95% of parents reporting 
their inclusion in autism treatment.
246
  Senel produced a study which demonstrated 
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improvements in communication, learning, health, and behavior after 5 CAM 
treatments.
247
 
 One of the most debated types of CAM therapies is chelation.  Some studies have 
noted improvements after employing chelation.  Bradstreet led a study which showed 
children with autism had higher amounts of urinary mercury compared to controls after 
undergoing chelation.
248
  Adams and colleagues noted an increase in the elimination of 
heavy metals and a stabilization of red blood cell glutathione concentration after 
chelation.
249
  Another study by Adams et al. showed a significant positive correlation 
between the degree of autism and red blood cell glutathione concentration and the toxic 
metal levels in the body after completing chelation.
250
  Chelation has also had dramatic 
effects on the concentration of urinary porphyrins.  Multiple studies have shown 
decreases in their concentrations in children with autism after chelation has occurred.
251-
253
  The combination of these studies has demonstrated the application of chelation to 
mercury toxicity which has been described in children with autism. 
When implementing a treatment for ASDs, some of the key areas which the 
treatments should address are detoxification, gut flora equilibrium, decreasing oxidative 
stress, return toward normal immune system functionality, and nutrients for optimal 
digestion.
254
  With these treatment goals, the use of dietary supplements can improve all 
of these areas. 
1.9.2 Reasons for the Use of Dietary Supplements to Treat Autism 
Spectrum Disorders 
Just as children who suffer from ASDs display evidence of immune system 
dysregulation, they also commonly demonstrate indications of difficulties in their 
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digestive system.  Dietary supplements are commonly used to treat ASDs because of the 
problems children have in achieving sufficient dietary intake and the “leaky gut” seen 
due to digestion issues.  One study led by D’Eufemia found higher intestinal permeability 
in 43% of children with autism with no controls exhibiting “leaky gut.”255  In children 
with autism, gastrointestinal (GI) symptoms and pathology seem to appear in about 30-
40% of cases.
256
  Habitual constipation or diarrhea along with intestinal discomfort are 
the most frequent symptoms seen in children with autism.
256
  Seventy-six percent of 
children with autism with GI symptoms demonstrated intestinal porousness.
254
  In another 
study, only 28% of controls had a history of GI symptoms compared to 70% of children 
with ASDs.
257
  In a study led by Afzal, 36% of children with autism had mild or severe 
constipation compared to 10% of controls.
258
  The GI pathology symptoms of reflux 
esophagitis, chronic gastritis, and chronic duodenitis were found in over 40% of 
children.
254
  Weber noted a study from Rosseneu where dysbiosis, GI bacteria 
abnormality, could result from the production of endotoxin from gram-negative bacteria 
causing more continuing digestive impairment.
256
  These digestive problems make 
communication even more difficult due to the pain they cause.  Kaluzna-Czaplinska and 
colleagues demonstrated improved nutritional absorption in children with autism with 
lower concentrations of urinary homocysteine observed when folic acid was added to 
vitamin B6 and B12 supplementation.
259
  Adams et al. showed strong correlation in autism 
severity based on the ATEC and the degree of GI symptoms.
260
   
Some studies have investigated the specific types of bacteria which may relate to 
GI issues in children with autism.  Finegold et al. observed 9 species of Clostridium 
bacteria present in children with autism which were absent in controls, and 3 additional 
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species were discovered in controls, but were not found in patients.
261
  Song led another 
study which showed the cell counts for three species of Clostridium were significantly 
elevated in children with autism compared to controls.
262
  Clostridium histolyticum group 
bacteria were more frequently seen in the fecal flora in patients with ASDs compared to 
controls.
263
  
1.9.3 Types of Dietary Supplements Used to Treat Autism Spectrum 
Disorders 
There are many different types of dietary supplements which are used to treat 
ASDs.  Six of the most common types of supplements employed will be discussed in 
greater detail and their applications will be reviewed.  These six supplements were 
selected due to their application in the study in Chapter 2. 
1.9.3.1 Calcium 
Calcium has many vital roles in the body.  It is important in the movement of ions 
in cells and acts as a secondary messenger.  Bone growth incorporates calcium and 
numerous other processes use calcium to maintain optimum function.  Calcium is 
commonly used in the treatment of children with autism.  Many children with ASDs are 
on gluten- and casein-free diets and do not consume an adequate number of dairy 
products.  Many dairy products are formulated with the addition of calcium and other 
vitamins.  Calcium deficiency manifests because children with autism are particular with 
the food they consume and the special diets used in autism. 
Recently, a few studies have investigated the status of calcium in children with 
autism.  In 2006, Lindsay led a study which showed 45% of the children with autism 
studied had calcium dietary shortages.
264
  Calcium was determined to be among the 
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nutrients not sufficiently consumed in recommended quantities by Lockner et al.
265
  
Herndon and colleagues observed a decrease in the amount of calcium consumed and a 
lower number of dairy allocations in children with autism compared to control 
children.
266
 
1.9.3.2 Magnesium 
Both physiological and biochemical pathways require magnesium for optimal 
performance.
267
  For autism treatment, magnesium is thought to improve the pathway of 
magnesium in neurons.
267
  In membrane channels, magnesium has been shown to control 
the movement of ions.
267
  Low amounts of magnesium can negatively affect osmotic 
pressure, acid-base balance, and the amount of potassium and calcium resulting in many 
different health problems.
218
  In supplementation, magnesium is commonly used with 
Vitamin B6, which is also known as pyridoxine.  This combination of supplements has 
been noted to advance social receptiveness for more than 30 years.
267
  The number of 
seizures has been supported to decrease with B6 and magnesium.
267
  In 2006, Strambi and 
colleagues determined children with autism had decreased plasma concentrations 
compared to controls.
218
 
 Magnesium has a long history of being used in supplementation for autism.  
Rimland noted the importance of magnesium supplementation in 1974 especially when 
used in conjunction with vitamin B6 to decrease irritability and sensitivities to noise, 
while increasing control of urination.
268
  Two studies did not discover a significant 
difference when magnesium and B6 were used as supplementation in children with 
autism.
269,270
  However, one study noted a significant increase in verbal IQ when children 
with PDDs were supplemented with pyridoxine.
271
  A study from Mousain-Bosc and 
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colleagues noted an increase in red blood cell magnesium concentration after beginning a 
magnesium and B6 supplement program.
267
  Nearly 70% of the children had a significant 
decrease in the symptoms of PDDs and those symptoms returned soon after the 
supplementation schedule was ended.
267
  In a review by Rossignol, many open-label and 
double-blind crossover studies demonstrated improvements in speaking, social interface, 
and other behaviors common in autism after using a combination of magnesium and 
B6.
242
  A case study by Xia demonstrated an approximate 50% decrease in the ATEC 
score after 5 months of magnesium and B6 supplementation.
272
 
1.9.3.3 Zinc 
Zinc has many benefits in the body.  The importance of zinc related to the 
immune system has already been reviewed.  It is important to the function of many 
enzymes which affect metabolism and growth.  However, one additional area of 
importance of zinc related to children with autism is detoxification.  It has been proposed 
that children with autism suffer from insufficiencies in detoxification due to a suppressed 
metallothionein system.  Evidence of this has been presented by Walsh.  Walsh noted an 
increased serum copper/plasma zinc ratio in children with autism.
180
  This elevated ratio 
is indicative of a problem of detoxification through the metallothionein system.  Faber 
and colleagues supported this research noting a decreased plasma zinc/serum copper ratio 
in children with ASDs.
179
  They also noted a zinc deficiency in 20% of the children with 
ASDs.
179
 
 No studies have investigated zinc supplementation and how it affects children 
with ASDs, but there have been some investigations of zinc on children with ADHD.  
Bilici and colleagues observed decreased symptoms of hyperactivity, impulsivity, and 
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socialization difficulties in children with ADHD after zinc supplementation.
273
  
Akhondzadeh et al. found zinc supplementation lowered Parent and Teacher Rating Scale 
values in children with ADHD during the 6 week duration.
274
  These studies illustrated 
improvements in symptoms similar to what is seen in autism and the methods to evaluate 
changes in children with autism.  In addition, zinc is a common component of 
multivitamin supplements. 
1.9.3.4 Multivitamin 
One of the advantages of multivitamin supplements is the ability to provide many 
vitamins and minerals simultaneously.  Children with autism have demonstrated 
decreased concentrations of vitamins and minerals.
275
  The multivitamin supplements 
commonly contain the elements chromium, magnesium, manganese, molybdenum, 
potassium, selenium, and zinc along with numerous vitamins.  The benefit of these 
supplements is that they provide nutrients which improve the overall nutritional health of 
children with autism.  They can also make up for the restricted and particular diets 
common in children with autism. 
Studies have investigated the use of multivitamin supplements in children with 
autism as it occurs frequently.
276
  A survey from 2009 noted that multivitamins were 
suggested by 49% of physicians for the treatment of children with autism.
277
  Cornish 
investigated nutrition intake in children with autism.  The amount of zinc, calcium, iron, 
vitamin A, vitamin B12, and riboflavin were below the Lower Reference Nutrient Intake 
recommended levels.
278
  Fifty percent of children with autism on a gluten- and casein-
free diet were deficient in zinc and calcium.
278
  In 2004, Adams and Holloway 
demonstrated sleep and GI improvements in children with autism who were taking a 
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multivitamin/mineral supplement.
275
  Additionally, they showed significantly higher 
concentrations of vitamin B6 in children with autism.
275
  The vitamin B6 concentration 
related to the decreased amount of pyridoxal-5-phosphate and enzymatic activity of 
pyridoxal kinase.
275
  The children with autism had average amounts of vitamin C where 
control children had significantly decreased concentrations of vitamin C.
275
  Adams led 
another study from 2011 which showed that children with autism demonstrated improved 
methylation, sulfation, and oxidative stress using a multivitamin supplement compared to 
the placebo group.
276
  The markers which were significantly better included total sulfate, 
S-adenosylmethionine, reduced glutathione, oxidized/reduced glutathione ratio, 
nitrotyrosine, adenosine-5’-triphosphate, reduced nicotinamide adenine dinucleotide, and 
reduced nicotinamide adenine dinucleotide phosphate.
276
  Numerous other studies have 
investigated individual minerals and vitamins which are components of multivitamins, 
but they are too numerous to discuss in this setting. 
1.9.3.5 Essential Fatty Acids 
There are two types of fatty acids which have been determined to be essential:  
omega-3 and omega-6.
279
  Essential fatty acids are unable to be made in the body and 
their intake is required either in the diet or by supplementation for proper functioning and 
development of the body.
256
  An omega-3 fatty acid is a polyunsaturated fatty acid and 
the three types of components in the human diet are alpha-linolenic acid, which originates 
in plant and nut oils, and docosahexaenoic acid and eicosapentaenoic acid, that both 
come from seafood.
280
  Humans are not able to synthesize these three types of fatty acids 
from smaller components, but are capable of producing docosahexaenoic acid and 
eicosapentaenoic acid from alpha-linolenic acid.
280
  Essential fatty acids play a role in the 
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production of lipooxygneases and cyclooxygenases.
280
  It has been found that an anti-
inflammatory response occurs from omega-3 fatty acids.
280
  The importance of 
docosahexaenoic acid in growth and brain development and function is found in its high 
concentration in neural tissue.
280
  Omega-3 fatty acids are not a sufficient component of 
the diet for an average American, especially children with low fish consumption due to 
concerns over mercury concentrations.
256
   
Omega-3 fatty acids are regularly employed in the treatment of autism.
256
  
Twenty-five percent of physicians recommended their use as part of autism treatments 
based on a survey from 2009.
277
  Stevens led a study which demonstrated increased 
health and learning difficulties in boys with decreased omega-3 fatty acid levels.
279
  
Vancassel et al. observed that children with autism demonstrated 23% lower amounts of 
omega-3 fatty acids versus controls.
281
  In 2004, a parental survey indicated a higher 
frequency of an insufficient amount of fatty acids in children with autism and Asperger’s 
Disorder compared to controls.
282
  The ABC was used by Amminger and coworkers to 
find an increased reduction in hyperactivity of children with autism after taking omega-3 
fatty acids.
283
  Meguid and colleagues showed an increase in clinical and biochemical 
progress in 66% of children with autism after the use of a fish oil.
284
 
1.9.3.6 Probiotic 
Any dietary supplement which provides microbial benefits to the digestive system 
is defined as a probiotic.
285
  Lactobacillus and bifidobacterium genera bacteria are the 
most frequently employed probiotics.
285
  In addition to autism, probiotics have been used 
to treat allergies, cancer, AIDS, infections, aging, and fatigue.
285
  Probiotics provide 
benefits to the immune system by increasing the number of beneficial bacteria necessary 
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for optimal digestion of nutrients.  It has been documented that children with autism 
suffer from dietary problems which affect the immune system negatively.  In one study, 
19% of physicians advocated for probiotics to be a part of autism treatment.
277
 
 Although many studies have demonstrated problems with the digestive system in 
children with autism, not many studies have investigated the difference resulting from 
probiotic treatment.  A case study of a 6 year old boy demonstrated behavioral 
improvements during the use of a probiotic, but complete regression occurred only 4 days 
after the probiotic was stopped.
286
  In 2002, Brudnak led a study which determined 
improvements in all of the types of variables measured children with ASDs over a 12 
week period.
287
 
1.10 Biomarkers of Autism Spectrum Disorders 
As discussed earlier in this chapter, autism is a complex disease with many 
different ideas proposed for its etiology.  With this ambiguity, the search for common 
features and identifiers, or biomarkers, has taken on greater importance for autism.  A 
biomarker is a biological marker of a current biological status.
288
  Biomarkers are 
common physical signs which occur frequently and are unique to a disease.  Currently, 
autism diagnosis is made by clinical observation and psychological rating scales.  Neither 
of these methods is a physical test and provides no insights into the altered biochemistry 
of autism.  With the importance of early treatment, an earlier autism diagnosis can result 
in quicker intervention which can provide the best possibility for improvements. 
In support of clinical and psychological diagnosis, there has been a search for 
biomarkers in ASDs.  Biomarkers can be used as an early indicator of ASDs and as a 
physical test.  The search for biomarkers in autism began nearly twenty years ago when 
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Martineau and colleagues investigated urine for monoamine neurotransmitter 
metabolites.
289
  Some of the key characteristics for model biomarkers are a focus on a 
particular pathway in an accurate and quantitative manner, and they would be better if 
they were not invasive.
290
  Biomarkers which can be applied to clinical treatment are 
translational biomarkers as they evaluate response to treatment or lead to new ones.
290
  
Biomarkers must be quantifiable and relate to a specific disease state, constant, and 
prognosis.
288
  Instead of being inevitable or simplifying autism ideas, biomarkers should 
provide additional knowledge of the intricacy of ASDs.
288
  It is not necessary for 
biomarkers to be exclusive to one particular disease.
291
  Statistical analysis techniques 
such as cluster analysis and principle component analysis can also be used to determine 
biomarkers.
290
   
There could be multiple profiles in ASDs.  Certain markers may be able to be 
used to identify subgroups which lead to different types of analyses.  Schwarz and 
colleagues presented a study which noted gender specific biomarkers in autism with both 
high sensitivity and specificity.
292
  Decreased neural and synapse creation at the 
molecular and cellular level, immune susceptibility, and digestive issues are some of the 
areas where subgroups can be detected.
290
  Pierce and colleagues proposed a “1-Year 
Well-Baby Check-Up Approach” to monitor biomarkers in children with ASDs.293  
Walsh and colleagues urged caution in the search for biomarkers to maintain respect and 
understanding for the patients with autism and their families.
288
 
Many studies have been performed to investigate different areas of biomarkers in 
autism.  The areas covered by these studies include genetic, oxidative stress, methylation, 
transsulfuration, immune dysregulation, digestive, toxicological, neurological, and 
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mitochondrial dysfunction.  The clinical recognized biomarkers which can be analyzed 
for include genetics, oxidative stress, transsulfuration, porphyrins, neurologic, and 
mitochondrial dysfunction.
294
  The immune dysregulation, digestive, and toxicological 
biomarkers have been reviewed earlier in this chapter and these other possible biomarkers 
of autism will be discussed now. 
1.10.1 Genetic 
Genetic biomarkers were the initial focus in autism.  Over the past twenty years, 
many different genetic loci have been demonstrated to lead to susceptibility for autism.  
The extent of these genetic biomarkers has been great and all of the studies cannot be 
covered here.  Some of the important and frequently referenced studies are reviewed. 
From the genetic ASD biomarker research, the most frequently noted position of 
interest includes 15q pericentromeric 11-13 region, 17p11, 22q11, 22q13, 16p11.2, and 
2q37.
294
  Schaefer and Mendelsohn noted studies of high genetic variability of the 
16p11.2  in autism calling it a “hot spot of genetic instability.”295  They also referenced 
two studies which noted the mutations of the Methyl-CPG-Binding Protein 2 (MECP2) 
related to Fragile X.
295
  Genetic testing can account for some autism cases through array 
comparative genomic hybridization (10%), high resolution chromosomes (5%), Fragile X 
(5%), MECP2 (5% of female autism cases), phosphatase and tensin homolog (3% with 
head circumferences greater than 2.5 SDs), and other (10%).
295
  Another study noted that 
less than 10% of cases of autism result from genetic diseases.
11
 
One type of study in the search for genetic biomarkers in autism is to focus on 
specific chromosomes and locations on them.  In 2002, Badner and Gershon noted 
predisposition at the 7q locus through meta-analysis.
296
  Trikalinos and colleagues 
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supported the importance of the 7q locus in autism through additional meta-analysis.
297
  
Benayed et al. investigated the ENGRAILED 2 (EN2) gene which plays a role in the 
function of the cerebellum on chromosome 7.  They found nearly 40% of ASD 
incidences could be related to EN2.
298
  In 2006, Campbell led a study investigating the 
pleiotropic MET receptor in a promoter region on chromosome 7.  The study 
demonstrated the presence of a frequent C allele in 204 families and in a larger cohort of 
539 families.
299
  The autism diagnosis relative risk factor for the CC genotype was 2.27 
and 1.67 for the CG genotype in relation to the GG genotype.
299
  In contrast to increased 
expression, Morrow and colleagues observed deletions in protocadherin 10 and deleted 
in autism1, or c3orf58, which were related to the activity of neurons and synapses 
connected to learning.
300
  One important area in genetic exploration is related to the 
methylenetetrahydrofolate reductase (MTHFR) gene.  In folate metabolism, a key 
enzyme is metabolized by MTHFR.
301
  Two single nucleotide polymorphisms (677C>T 
and 1298A>C) are common in autism resulting in a decrease in the activity of MTHFR.
18, 
301
 
In addition to finding specific genes, studies have taken a broader gene expression 
approach to find genetic biomarkers.  Hu led a microarray study in 2006 in twins noting 
the important neurological genes including argininosuccinate synthetase and N-
acetylglucosaminidase alpha.
302
  Baron and colleagues completed another gene 
expression study and observed 48 genes which had statistically significant difference in 
regulation.  These genes were seen in many different pathways including signal 
transduction, metabolism, development and upkeep, and outside stimuli response.
303
  The 
types of commercial genetic biomarker testing available include blood chromosome, 
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chromosome microarray, DNA Rett syndrome, Angelman/Prader-Willi syndrome 
methylation assay, Fragile X syndrome, and MTHFR testing.
294
 
1.10.2 Oxidative Stress 
The surplus creation of reactive oxygen species (ROS), free oxygen radicals, 
results in oxidative stress.
290
  Normal oxygen metabolism produces ROS that are unstable 
atoms which can result in the interruption of cell metabolism and cause harm to them.
294
  
Increased amounts of oxidative stress could result from a higher reaction of cells in the 
immune system such as neutrophils and monocytes which respond to infection.
290
  
Biomarkers of oxidative stress have been seen in many different diseases including 
schizophrenia, Alzheimer’s disease, and HIV, and are not able to be included as an 
unique indicative marker in autism.
291
  Decreased methionine, folate, and vitamin B12 are 
noted in times of oxidative stress. 
The primary focus of oxidative stress biomarkers in ASDs has been on 
glutathione.  Glutathione and cysteine protect the body against heavy metal and 
xenobiotic exposures.
291
  Glutathione production is limited by the production of cysteine 
from homocysteine.
291
  Glutathione is part of the transsulfuration pathway.  In 2004, 
James and colleagues observed significantly decreased levels of total glutathione and 
increased levels of oxidized glutathione in plasma.
11
  The study also showed an increased 
quantity of oxidized stress seen through significantly higher oxidized glutathione and a 
decreased ratio of reduced to oxidized glutathione.
11
  These same results were reported in 
another study from James et al.
18
  In 2009, Geier et al. supported these results by finding 
lower concentrations of plasma reduced glutathione and higher amounts of oxidized 
glutathione in children with ASDs relative to controls.
304
  Another study led by Geier also 
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observed lower plasma reduced glutathione amounts and more oxidized glutathione in 
children with autism.
305
  A meta-analysis by Frustaci et al. showed reduced plasma 
glutathione (27%) and glutathione peroxidase (18%) and elevated oxidized glutathione 
(45%) in patients with ASDs.
306
 
The reduced to oxidized glutathione ratio is important for redox balance because 
of the numerous roles it controls which include nitrogen and oxygen free radical 
scavenging, protein status and enzyme activity, integrity of the cell membrane and signal 
transduction, binding of transcription factor and gene expression, phase II detoxification, 
and apoptosis.
18
  A high enough reduced to oxidized glutathione ratio is sustained under 
typical glutathione reductase enzyme activity.
18
  Higher amounts of oxidized glutathione 
in the plasma result when glutathione reductase is too overwhelmed to restore normal 
cellular redox homeostasis.
305
  Higher oxidized glutathione levels are a marker for 
oxidative stress and decreased quantities of glutathione in cells.
18
 
In addition to glutathione, many different studies have explored additional 
markers of oxidative stress in autism.  Plasma and red blood cell glutathione peroxidase 
and plasma superoxide dismutase, antioxidant enzymes, were all significantly decreased 
in children with autism compared to controls.
307
  Zoroglu and colleagues noted elevated 
levels of ROS and increased enzymatic activity for free radical scavenging in the red 
blood cells of children with autism.
308
  Elevated amounts of thiobarbituric acid-reactive 
substances are an indicator of higher lipid peroxidation.
308
  Chauhan led a study where 
concentrations of antioxidant proteins, transferrin and ceruloplasmin, were lower in 
children with autism versus siblings and where regression of language capabilities related 
to lower concentrations of these proteins.
309
  Ming et al. noticed the elevation of the lipid 
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peroxidation biomarker, 8-isoprostane-F2α, in the urine of children with autism versus 
controls.
310
  Compared to controls, elevated homocysteine, an oxidant which produces 
ROS, and decreased PON1 were observed to be lower in children with autism by Pasca 
and colleagues.
311
  Yao et al. found three markers, isoprostane F2α-VI (lipid 
peroxidation), 2,3-dinor-thromboxane (platelet activation), and 6-keto-prostaglandin F1α 
(endothelium activation), which were elevated significantly in the urine of children with 
autism.
312
  An oxidative stress panel and neopterin testing are commercially available.
294
 
1.10.3 Methylation/Transsulfuration 
One of the most important metabolic cycles which have been explored in autism 
is the methionine cycle.  The methionine cycle creates methionine by the movement of a 
methyl group to homocysteine from 5-methyltetrahydrofolate in a B12 dependent 
reaction.
11
  The principle donor of the methyl group for the intermediate S-
adenosylmethionine (SAM) is methionine, a key amino acid.
291
  SAM is the most 
important methyl donor involved in the methylation of DNA, RNA, proteins, 
phospholipids, and neurotransmitters.
11
  S-adenosylhomocysteine (SAH) is created from 
the transfer of a methyl group from SAM.
11
  SAH hydrolase catalyzes the reversible 
hydrolysis of SAH to homocysteine and adenosine.
11
  At this point in the cycle, 
homocysteine is either converted to methionine by remethylation or permanently 
removed from the cycle and begins cysteine and glutathione production as part of the 
transsulfuration pathway.
18
  The methionine cycle is hindered by an oxidized 
environment.
291
 
Metabolic studies have investigated alterations in this cycle in children with 
autism.  James and colleagues observed lower amounts of methionine, SAM, 
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homocysteine, cystathionine, cysteine and larger amounts of SAH and adenosine in the 
plasma of children with autism compared to controls.
11
  The significantly lower ratio of 
SAM/SAH indicates a problem with methylation.
11
  A second study led by James 
supported these results.  Children with autism had decreased plasma concentrations of 
cysteine, methionine, and SAM/SAH ratio compared to controls.
18
  Plasma cysteine, 
taurine, sulfate, and free sulfate were found to be lower in children with autism than 
controls by Geier et al.
304
  Geier and colleagues also showed significantly smaller 
amounts of cysteine and sulfate in the plasma of children with autism.
305
  Frustaci et al. 
completed a meta-analysis which demonstrated lower amounts of methionine (13%) and 
cysteine (14%) in children with autism.
306
  Megaloblastic anemia profiling, glutathione, 
and taurine testing are commercially available.
294
 
1.10.4 Porphyrins 
Porphyrins are intermediate products of the pathway for heme synthesis
313
 and 
provide a way to independently measure exposure to xenobiotics.
251
  The liver, kidney, 
and red blood cells are the location of most of the heme manufacturing.
251
  In urine, 
surplus porphyrinogen metabolites are removed as oxidized porphyrins.
251
  Woods and 
Miller showed that coproporphyrin and uroporphyrin are the most prominent porphyrins 
in the kidney cortex of rats.
313
  The interest in porphyrins resulted from the blocking of 
pathways due to heavy metal exposure.  Uroporphyrin decarboxylase and CPOX are the 
two most common enzymes which block the pathway causing coproporphyrin and 
pentacarboxyporphyrin concentrations to rise in urine.
251
  Porphyrinuria results from 
important steps in the pathway being blocked causing higher amounts of porphyrins 
expelled from the body.
251
  Nataf and colleagues noted studies where exposure to 
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mercury and lead correlated to porphyrinuria.
251
  Prior studies have noted the changes in 
porphyrin concentrations after chelation treatment.
251-253
  These studies have combined to 
provide a profile of porphyrins related to autism.
252
 
Many studies have noted the differences in urinary concentrations in children with 
autism.  In 2006, Nataf et al. published a study showing children with autism had 
significantly higher concentrations of coproporphyrin compared to controls.
251
  In 
Asperger’s Disorder, porphyrin amounts were not altered which created a different 
profile compared to autism.
251
  After chelation, the levels of urinary porphyrins decreased 
significantly.
251
  That same year Geier and Geier found that non-chelated children with 
autism had a 2.25-fold increase versus controls and non-chelated children with ASDs had 
a 2-fold increase for median coproporphyrin amounts.
252
  Children with PDD-NOS or 
Asperger’s Disorder did not have statistically significant elevated median amounts of 
coproporphyrin.
252
  Overall, the study seemed to determine a correlation between the 
severity of an ASD and porphyrinuria.
252
  When comparing chelated versus non-chelated 
patients with ASDs, the median coproporphyrin amounts were 1.7-fold higher in non-
chelated patients with ASDs.
252
  The next year Geier and Geier observed significantly 
higher amounts of coproporphyrin, pentacarboxyporphyrin, and precoproporphyrin in the 
urine of children with autism compared to controls.
253
  The increased concentrations of 
these three porphyrins has been linked to mercury toxicity.
253
  After chelation, 
coproporphyrin and pentacarboxyporphyrin concentrations decreased significantly in 
patients with ASDs.
253
  In 2009, Geier and colleagues noted an elevation of the 
concentration of pentacarboxyporphyrin, precoproporphyrin, and coproporphyrin, the 
mercury related porphyrins, in the urine of patients with severe ASDs versus patients 
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with mild ASDs.
305
  The study also found an association between these three urinary 
porphyrins and rising CARS scores.
305
  Another study by Geier, Kern, and Geier also 
found a correlation between coproporphyrin concentrations and the CARS scores.
314
  
This study saw increased concentrations of coproporphyrin I, coproporphyrin III, and 
total coproporphyrin in patients with severe ASD versus those with mild ASDs.
314
  Kern 
led a study in 2010 which showed a connection between urinary porphyrins and the 
ATEC and the four ATEC subscales.
315
  Kern and colleagues found patients with ASDs 
had significantly higher amounts of pentacarboxyporphyrin, precoproporphyrin, and 
coproporphyrin versus controls.
316
  Two studies noted no statistical difference in non-
mercury associated porphyrins.
305, 316
  The testing of porphyrins is commercially 
available in urine and red blood cells.
294
 
1.10.5 Neurologic 
Neurological biomarkers have been investigated due to the detrimental effects 
seen in children with autism compared to typically developing children.  One area of 
interest is the neurotransmitters glutamate, serotonin, and gamma-amino butyric acid 
(GABA).  With neurological differences seen in children with autism, many studies have 
explored the levels of these neurotransmitters.  In 1997, Cook Jr. and colleagues 
demonstrated a potential connection between the serotonin transporter gene and 
autism.
317
  Chugani led a study which showed significant differences between the 
epileptic and autistic groups for serotonin.
318
  The children with autism demonstrated an 
increase in serotonin from ages 2 to 15, reaching 1.5 times the average adult levels and 
demonstrating a developmental disturbance.
318
  Burgess et al. noted that elevated blood 
serotonin concentrations were commonly found in one third of children with autism.
319
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Glutamate is the main stimulating neurotransmitter in the brain.
320
  Jamain et al. 
demonstrated a connection between the glutamate receptor 6 gene and autism.
320
  Aldred 
and colleagues observed significantly decreased concentrations of glutamine in children 
with autism and their families compared to controls.
321
  However, Fatemi et al. noted that 
decreases in glutamic acid decarboxylase 65 and 67 could be the cause of increased blood 
glutamate levels.
322
  Irregular functionality of the GABA system in autism was first 
connected by Blatt et al. in 2001.
323
  The many subunits of the GABA receptor are coded 
for at 15q11-q13.
324
  The contributions of GABA inhibition to autism were noted by 
Belmonte and colleagues.
324
  Proteins involved in the metabolism of GABA may be 
connected to atypical amounts of GABA.
322
   
Additional studies have explored proteins related to neurological functioning.  In 
2006, Sokol et al. found that secreted beta-amyloid precursor protein was at least two 
times higher in children with severe autism and aggression compared to children with 
autism and up to four times in children with mild autism.
325
  One study observed a trend 
indicating greater amounts of two plasma neuronal proteins, secreted beta-amyloid 
precursor protein and nonamyloidogenic secreted beta-amyloid precursor protein, in 
children with autism.
325
  Bailey and colleagues noted significantly higher plasma 
concentrations of secreted amyloid precursor protein alpha in 60% of children with 
autism compared to age matched controls.
326
 
Studies have also investigated the brain functioning of children with autism using 
electroencephalography (EEG).  Oberman led a study which used EEG signals to provide 
additional evidence of children with high functioning autism possessing a dysfunctional 
mirror neuron system.
327
  Murias and colleagues determined differences in the brains of 
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children with autism by using different EEG frequencies.
328
  Bosl et al. proposed the use 
of multiscale entropy to judge development through EEG signals which differed in 
infants with significant probability of developing autism compared to controls.
329
 
1.10.6 Mitochondrial Dysfunction 
Mitochondrial dysfunction has been investigated because many of the symptoms 
are similar to autism.  Decreases in intellectual capability, communication shortcomings, 
different energy metabolism, frequent GI issues, fatty acid oxidation irregularities, and 
higher oxidative stress may be contributed by mitochondrial dysfunction in autism.
330
  
Environmental exposure to toxins has been implicated as the source.
330
  The higher ratio 
of males to females being diagnosed with autism has been proposed to be caused by 
oxidative stress and mitochondrial dysfunction.
330
  Filipek led a study in 2004 which 
evoked the presence of slight mitochondrial dysfunction as seen through lower 
concentrations of carnitine, mild elevation of lactate, and significantly higher amounts of 
alanine and ammonia.
331
  Carnitine plays an important role in the movement of fatty acids 
to the mitochondria from accumulations in the body in times of stress and fasting.
331
  
Pastural and colleagues observed significantly higher amounts of biomarkers of fatty acid 
elongation and desaturation in patients with autism compared to controls.
332
  The authors 
cited higher extracellular glutamate concentrations to neurons, astrocytes, and 
hepatocytes in vitro as the cause of the elevated lipid biomarkers.
332
  The study also noted 
lower plasma levels of reduced glutathione, methionine, and cysteine because of the 
elevated glutamate.
332
  Included among the commercially available laboratory tests for 
mitochondrial function evaluation are carnitine, pyruvic acid, lactic acid, and 
ammonia.
294
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1.11 Autism and Measurement 
Now that all of the important and relevant components of ASDs have been 
reviewed, attention shifts to measurement and its future application in this dissertation.  
Important characteristics of measurement and the methods are discussed before the novel 
application in the subsequent chapters. 
1.12 The Importance of Measurement 
One of the most important components of this dissertation is the application of 
measurement.  To be useful, a measurement must have both accuracy and precision.  
Accuracy is defined as how near a measurement is to the true value, and precision means 
how close they are to one another.  When performing a measurement, many important 
components are involved.  A numerical measurement must have a unit attached to it.  The 
unit provides a standard understanding of relationship between things.  The measurement 
must also report a confidence interval.  A confidence interval gives a defined range where 
the measurement would fall and the reliability of this occurring as a percentage.  Without 
a confidence interval, the accuracy and precision of a measurement cannot be completely 
determined.  In order to produce a confidence interval, the measurement must be taken 
more than one time.  The repeated sampling allows for proper statistical analysis to be 
performed.  The greater number of times a measurement is taken, the better the precision 
can be evaluated.  This process requires proper sampling necessary to get a representative 
sample.  A measurement must also have the right number of significant figures to provide 
the correct level of accuracy to the measurement. 
One inherent part of every measurement is its error.  In order to achieve the best 
possible measurement, all potential sources of experimental error must be accounted for 
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and either minimized or eliminated if possible.  A systematic error is one which results 
through the experimental design or problematic equipment.  It can be eliminated by the 
creation of a standard operating procedure which lists each of the optimal steps necessary 
to achieve the best measurement.  Random error is not able to be accounted for during the 
measurement process.  Systematic errors are likely to be biased in one direction while 
random errors have an equal probability of making a positive or negative contribution to 
the measurement.  Quality control can be seen through the development of standard 
operating procedures which maintain the accuracy and precision of measurements.  
Quality assurance is the quantitative measurement of quality control and makes sure that 
the standard operating protocol consistently produces accurate and precise measurements. 
With recent technological advances, the capabilities are now available to produce 
truly accurate and precise measurements and apply them clinically.  These capabilities 
are seen through the implementation of mass spectrometers.  Mass spectrometers base 
their analysis on the mass to charge ratio of an ion.  Common types include inductively 
coupled plasma, gas chromatography, liquid chromatography, quadrupole-time-of-flight, 
and tandem mass spectrometers.  In mass spectrometers, the types of mass analyzers used 
include quadrupole, time-of-flight, quadrupole ion-trap, and magnetic sector.  The 
analytical work described in this dissertation focuses on the inductively coupled plasma-
mass spectrometer (ICP-MS) which uses a quadrupole mass analyzer. 
Over the past forty years, standard analysis methods have been developed through 
the United States EPA.  These standard methods have been created for both sample 
preparation and analysis.  In this dissertation, EPA Method 3052 is used for some of the 
sample preparation.  The importance of sample preparation cannot be understated.  
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Without the proper sample preparation, the correct analysis of the sample cannot be 
achieved.  The recent development of techniques such as microwave enhanced chemistry 
and clean chemistry have made dramatic improvements in sample preparation.  EPA 
Methods 6020B and 6800 are employed to complete sample analysis described in 
subsequent chapters.  The measurements described in these methods are performed by 
mass spectrometers.  Each of these techniques and standard methods is reviewed. 
1.12.1 Microwave Chemistry 
Some of the sample preparation in this dissertation employs the microwave 
digestion of samples.  Microwave sample preparation relies on two major principles:  
dipole rotation and ionic conductance.  Dipole rotation allows molecules to arrange 
themselves parallel to the applied electrical field.
333
  With the variation of the electrical 
field, the molecules are forced to move and this movement results in the heating of the 
solution as the dipoles are rearranged 5 billion times each second.
333
  The electromagnetic 
field of the microwave forces ionic components to move based on polarity.
333
  These 
principles create unique temperature and pressure relationships which are only seen in 
microwaves.  With these unique principles, both the speed and efficiencies of processes 
can be increased by using a microwave as part of sample preparation.   
The first application of microwave chemistry occurred in 1975.
334
  Since this 
time, much advancement has been made in the field.  Current technological 
advancements have made microwave enhanced chemistry quick, economical, and 
repeatable.
333
  Microwave chemistry has been applied to the digestion of many different 
types of biological and environmental samples and many types of chemical testing 
including elemental analysis.  Digestion, extraction, and organic synthesis are among the 
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different applications of microwave chemistry.  Some syntheses can only be completed 
through the use of a microwave.   
1.12.2 Ultra-trace Analysis and Clean Chemistry 
The reproducibility of microwave chemistry has eliminated many sources of error 
during sample preparation.  Ultra-trace analysis is one area where this has occurred, and 
is one of the major types of analyses performed in this dissertation.  Microwave 
chemistry has been combined with clean chemistry to produce accurate and precise 
results which have reduced sources of contamination.  One major source of error in ultra-
trace analysis is the blank.  Clean chemistry has reduced the level of contamination in the 
blank during sample preparation by controlling the four major areas affect the amount of 
contamination:  the environment in which the sample was prepared, the reagent purity, 
the materials which directly interact with the sample, and the level of skill possessed by 
the analyst.
335
  For ultra-trace analysis, sample preparation occurs in cleanrooms which 
limit the amount of particles and contamination.  Cleanrooms are created by the use of 
high efficiency particulate air (HEPA) filters.  HEPA filters prevent particles of a certain 
size from passing through them.  The highest quality available reagents with the lowest 
concentration of elements present are employed along with materials that are chemically 
inert and do not contribute contamination to the sample such as Teflon, quartz, and 
fluoropolymers.  The analyst can be trained and taught techniques to minimize sample 
contamination.   
1.12.3 EPA Method 3052 
EPA Method 3052 focuses on the acid based digestion of organic samples.  The 
types of samples which can be analyzed by EPA Method 3052 include soils, sediments, 
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oils, ashes, and biological tissues.
336
  It is used for sample preparation for the total 
elemental content of a sample and has been approved for use in the analysis of over 25 
elements and can be applied to most others in the periodic table if reproducibility has 
been achieved.
336
  High pressure microwave vessels must be used to withstand the 
pressure generated by the microwave.  The reagents which can be used as part of EPA 
Method 3052 include nitric acid, hydrochloric acid, hydrofluoric acid, and hydrogen 
peroxide.  The reagents used can be adjusted to meet the needs for the digestion of the 
sample and for the analytes of interest.  The method uses a ramp from ambient 
temperature to 180 °C and a hold at 180 °C.
336
  This temperature allows for the complete 
digestion of the organic matrix and the ramp and hold times are flexible to meet the 
demands of each type of sample.  Current laboratory microwaves are capable of 
monitoring the temperature to within ± 2 °C.  Many different types of instruments can be 
used to analyze samples prepared by EPA Method 3052 including flame atomic 
absorption spectrometry, cold vapor atomic absorption spectrometry, graphite furnace 
atomic absorption spectrometry, inductively coupled plasma atomic emission 
spectrometry, and ICP-MS.
336
 
1.12.4 EPA Method 6020B 
One of the standard methods for the analysis of total elements is EPA Method 
6020B.
337
  Analysis of Method 6020B is performed on an ICP-MS at trace 
concentrations.  A wide range of elements have been approved for analysis by it, and it 
has been applied to over 60 elements with accuracy and precision established.  A wide 
range of samples can be analyzed including aqueous samples, which do not require 
digestion, or digested samples from soils, sludges, and other industrial, environmental, or 
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biological matrices.  Before analysis is undertaken, the proper sample preparation must 
have occurred. 
For EPA Method 6020B, quantitation is obtained through the use of external 
calibration curves for the analytes of interest.  A calibration curve consists of solutions of 
known concentrations to determine the relationship between the response of an 
instrument and the concentration of each analyte.  The method recommends a minimum 
correlation coefficient of equal to or greater than 0.998.
337
  EPA Method 6020B 
recommends the use of 
6
Li, 
45
Sc, 
74
Ge, 
89
Y, 
103
Rh, 
115
In, 
159
Tb, 
165
Ho, and 
209
Bi as internal 
standards.
337
  An internal standard is an element or compound of known concentration 
added to a sample and is used to monitor consistent response of the instrument detector. 
There are many ways quality control is maintained as a part of EPA Method 
6020B.  The internal standard is used as quality control to provide consistent instrument 
response to each analyte during sample analysis.  In addition, calibration standards and 
the calibration blank are repeated at regular intervals throughout the analysis.  The 
calibration standards are rerun at the end of the analysis sequence to compare instrument 
response during the period of analysis.  Despite quality control being addressed in EPA 
Method 6020B, there are still many sources of error which are inherent as part of mass 
spectrometric analyses.  These sources of error are addressed in the next section, EPA 
Method 6800. 
1.12.5 EPA Method 6800 
There are two components of EPA Method 6800:  Isotope Dilution Mass 
Spectrometry (IDMS) and Speciated Isotope Dilution Mass Spectrometry (SIDMS).
338
  
This method can be applied to the quantification of total elements, elemental species, or 
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molecular species.  The measurement of total elements is completed by IDMS and 
SIDMS is used for the quantification of species.  Both IDMS and SIDMS use isotopically 
enriched spikes to provide an additional mathematical degree of freedom for 
quantification.  In order to apply EPA Method 6800, an element must have two or more 
stable isotopes.  The work described in this dissertation only relates to total elemental 
IDMS quantification. 
The IDMS quantification as a part of EPA Method 6800 varies significantly from 
EPA Method 6020B.  The most dramatic difference is that EPA Method 6800 does not 
use calibration curves.  The quantification by IDMS is based on the ratio of isotopes in 
the natural sample and isotopically enriched spike seen in Equation 1.  The isotopically 
enriched spike has unique isotope abundances which do not exist in nature.  The addition  
    (
        (         )
  (       )
) 
 Where:  
Cs = concentration of sample 
Wsp = weight of spike solution  
Csp = concentration of spike  
Asp = atomic fraction of isotope A in spike 
Bsp = atomic fraction of isotope B in spike  
As = atomic fraction of isotope A in sample  
Bs = atomic fraction of isotope B in sample 
R = experimentally measured isotope ratio, A/B 
Ws = weight of sample 
 
Equation 1:  IDMS equation for calculating the concentration of the analyte from an isotope pair 
ratio measurement. 
of the isotopically enriched spike must be performed properly and its amount is 
determined by the error propagation factor (EPF), with the calculation shown in Equation 
2.  The ratio of two isotopes used in IDMS must fall within the proper dynamic range.  
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The highest level of accuracy is achieved at the optimal EPF and the amount of errors 
inherently increases the farther away from the ideal EPF ratio. 
    √
                        
                        
 
                       
                       
 
Equation 2:  The equation for the error propagation factor used in IDMS.  
Compared to other quantification methods such as standard addition and internal 
and external calibration, IDMS demonstrates better measurement quality.
339
  This 
superiority is seen through the mass spectrometric sources of error which are eliminated 
in EPA Method 6800, as seen in Figure 1.  This method is able to account for all but three 
sources of error:  mass bias, deadtime, and isobaric and polyatomic interferences.  For 
elemental analysis, mass bias can be corrected for by running natural elemental standards 
and comparing the ratio of the isotopes used in quantification.  Deadtime corrections can 
also be computed by using the ICP-MS.  Isobaric interferences are known and can be 
avoided or calculations can be used to determine the contribution of multiple elements at 
a single mass to charge ratio.  Modern technology, such as the Agilent 7700 ICP-MS, has 
collision/reaction cells which can eliminate the polyatomic interferences.  Therefore, the 
combination of EPA Method 6800 and modern instrumentation can eliminate or account 
for all sources of error in mass spectrometric analysis. 
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Figure 1:  The sources of error inherent to mass spectrometric analysis.  The errors found in EPA 
Method 6020B are shown at the top and the three errors found in EPA Method 6800 are at the 
bottom. 
 
1.13 Conclusions 
Autism spectrum disorders play a large role in our society.  Their importance has 
risen over the past 50 years as the current diagnosis rate is 1 in 88, and if the recent trends 
continue, it will only increase in the future.  The modern history of autism has played a 
role in how it is viewed by today’s society.  Initial thoughts hindered progress in truly 
understanding the disorder.  Once initial theories were overcome, true progress in the 
knowledge of autism increased and worked to develop some of the tools currently used in 
diagnosis. 
Autism is truly a spectrum disease which results in the presentation of many 
unique profiles in children.  The complexity of the disease requires the integration of 
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many areas for both diagnosis and treatment.  The factors seen in its diagnosis affect 
many different areas of the body including the immune, digestive, neurological, and 
detoxification systems and how they relate to each other.  There are many different 
treatments used to minimize the effects autism has on the body, and specifically, the 
dietary supplements commonly applied must be made of the highest quality for these 
children.  The standards of diagnosis require high levels of both sensitivity and 
specificity, and in the future, there is hope that diagnosis will rely more on biomarkers in 
conjunction with the current rating scales. 
 This dissertation demonstrates the application of advanced measurement 
techniques which improve both the diagnosis and treatment of autism.  Currently, the 
tools are available where this technology, instrumentation, and methodology can be 
employed in the clinical setting.  The findings described in the remainder of this 
dissertation demonstrate that these measurement techniques can have a significant impact 
on the future of autism. 
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Chapter 2  
Evaluation of Dietary Supplement Contamination by 
Xenobiotic and Essential Elements Using Microwave-
Enhanced Sample Digestion and Inductively Coupled Plasma-
Mass Spectrometry 
 
Dietary supplements were analyzed by evaluating the elemental content in six widely 
consumed products manufactured by four well-known companies.  The elements 
included the neurotoxic and carcinogenic elements cadmium, mercury, aluminum, lead, 
arsenic, and antimony, as well as the essential elements zinc, selenium, chromium, iron, 
and copper, which were often not listed as ingredients on the product labels.  
Contamination from either xenobiotic or essential elements was found in all samples 
analyzed.  The samples were prepared using United States Environmental Protection 
Agency (EPA) Method 3052, microwave-enhanced digestion.  The resulting digests were 
analyzed by Inductively Coupled Plasma-Mass Spectrometry based on EPA Method 
6020B.  The analytical protocols were validated by analyzing a multivitamin standard 
reference material, National Institute of Standards and Technology Standard Reference 
Material 3280.  The application of EPA standard methods demonstrated their utility in 
making accurate and precise measurements in complex matrices with multiple ingredients 
and excipients. 
2.1 Introduction 
Dietary supplements are products containing vitamins, minerals, amino acids, 
plant materials, and/or other nutritional additives consumed to complement the human 
diet.
1
  They are purchased by the public to resolve nutrient deficiencies, prevent birth 
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defects, treat diseases and symptoms, and improve athletic performance.
2-4  
Supplements 
are widely available in retail stores, shopping malls, gyms, gas stations, convenience 
stores, and on the internet.
5
  They continue to garner attention from media exposure from 
studies, articles, and advertisements.
6
  The reasons for the increased popularity of dietary 
supplements include hope for the conservation of intellectual capacity, increased energy, 
stress relief, mitigation of high healthcare costs, and a perception they contribute to a 
healthier lifestyle.
4
  Physicians routinely incorporate dietary supplements as part of their 
patient advice and clinical treatment.  It was estimated that globally consumers would 
spend at least US$ 60 billion on dietary supplements in 2006,
7-8
 with a more recent 
estimate suggesting that between 21 and 25 billion dollars were spent annually in the 
United States (US) alone.
9
  Based on a National Health Interview Survey, over half the 
US adult population includes supplements in their daily diets.
10
  The wide and growing 
consumption of dietary supplements makes it imperative for public health that existing 
quality control and assurance methods, some of which are decades old, are updated and 
streamlined utilizing advanced measurement tools that will produce consistent, reliable, 
and quality data.  Minimizing and avoiding unsafe levels of toxins and labeling errors 
require the quality control process to include the entire supply chain. 
The expectations of the general public for dietary supplements are the same as 
they are for food:  contribute nutrients and avoid any constituent that will have a negative 
health impact.  Many reported instances of tainted products suggest that the public’s 
expectations are not being met. It has been estimated that 50,000 unreported 
contamination incidences occur annually in dietary supplements.
10
  These contaminants 
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included heavy metals, bacteria, toxic plant matter, prescription medications, controlled 
substances, rejected drugs, and other compounds.
10
  
The toxic effects of xenobiotic metals on human health have been well 
documented in the literature.  These elements, including lead (Pb), mercury (Hg), 
cadmium (Cd), and arsenic (As), cause a wide variety of toxicological effects and 
symptoms affecting all organ systems, including the central nervous system.
11
  Lead has 
irreversible, detrimental effects that interfere with neuronal signaling in the central 
nervous system, heme synthesis, and calcium (Ca) metabolism and function.
12-13
  
Mercury exposure can cause kidney damage and neurological disorders.
14
  Cadmium 
results in reproductive disruption, kidney failure, and weakening of the bones.
1
  Arsenic 
has been connected to hypertension, hypotension, cardiomyopathy, cardiac disease, and 
peripheral neuropathy.
15
  Aluminum (Al) has also been associated with Alzheimer’s 
disease.
16
 
In parallel with the negative effects of toxic heavy metals, there is concern about 
improper labeling of dietary supplements that omits the presence of essential elements, 
such as zinc (Zn), selenium (Se), chromium (Cr), iron (Fe), and copper (Cu).  Although 
they may not be listed as supplement ingredients, their presence can cause adverse health 
consequences, including the disruption of nutritional regimens.  Adulteration related to 
these essential elements must be considered when evaluating dietary supplements for 
elemental contamination, in addition to xenobiotic elements. Essential elements are 
common ingredients of dietary supplements because they are needed to maintain crucial 
metabolism in the body.
17
  Human metabolism requires many different metal coenzymes 
for the optimal functionality of numerous proteins.  Although they are necessary, these 
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elements can have negative consequences if present in excess.  Zinc is required for the 
normal maturation and optimal performance of the immune system;
18
 however, patients 
that exceed the daily recommended allowance for Zn could experience leukopenia, 
neutropenia, anemia, sideroblastic anemia, and hypocupremia.
2, 19-21
  While Se exists 
naturally and is needed for proper cellular functioning,
22
 it is toxic at high levels resulting 
in vomiting, nausea, pulmonary edema, renal and liver damage, and death.
23-24
  
Chromium performs a key function in the metabolism of carbohydrates and fats, and 
increases cellular response to insulin;
25
 however, an overabundance can cause kidney 
failure, improper liver functioning, and gastrointestinal bleeding.
22
  Iron is well known 
for promoting oxygen transport and reducing oxygen shortages in cells, thereby 
preventing exhaustion and a compromised immune system.
25
  Excess Fe can negatively 
affect the metabolism of other closely related elements such as Zn, Cu, and Ca, and may 
result in oxidative stress, digestive disturbances and vomiting.
26
  Copper plays a role in 
many essential reactions needed for the survival of mammals,
27
 but Cu surplus can cause 
liver damage.
28
  It has been hypothesized that the consumption of inorganic Cu in dietary 
supplements might contribute to the development of Alzheimer’s disease.29-30 
Despite the known effects of xenobiotics, the regulation of dietary supplements 
has become less stringent in the US after the passing of the Dietary Supplement Health 
and Education Act (DSHEA) in 1994
10
 as a revision to the Federal Food, Drug, and 
Cosmetic Act.
31
  The testing requirements for the production and sale of dietary 
supplements were significantly relaxed in the DSHEA.
3
  Dietary supplements were 
previously classified as being “food additives,” which had mandated evidence of their 
safety before being released to consumers.
10
  The DSHEA created a special category of 
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food called “dietary supplements,”31 with provisions that were not applicable to 
conventional and functional foods.
5
  Since dietary supplements do not diagnose, prevent, 
or cure disease according to the US Congress, they are not required to have the same 
regulatory standards as pharmaceutical drugs.
32
  Subsequently, there is no US Food and 
Drug Administration (FDA) required testing of dietary supplements for safety and 
efficacy prior to market release, and approval is not needed before the manufacture and 
distribution of these products.
33
  Under the current guidelines, the FDA will only 
recommend testing after a dietary supplement has been determined to be unsafe.
34
  This 
relaxed regulatory requirement is very different from the treatment of prescription drugs, 
which require FDA review of safety and effectiveness before reaching the market.
33
  
Without providing specific guidelines of dietary supplement production, the DSHEA 
established Good Manufacturing Practices (GMPs) to maintain the quality of dietary 
supplements available to the general public.
33
  Extensive control over the entire 
manufacturing process is required for GMP compliance, including starting ingredients, 
finished goods, and quality control.
35
  The DSHEA does not specify standard analytical 
methods, such as those from the US Environmental Protection Agency (EPA), which can 
be adopted and implemented for quality assurance as a way to improve public safety and 
attain GMP compliance.  The US EPA is a globally recognized and respected repository 
of workgroup-tested and optimized methods which may be adopted as templates and 
optimized as standard quality assurance and testing protocols. 
Different government agencies have limits for exposure to certain elements 
referred to as maximum contaminant levels (MCLs), which are shown for each agency in 
Table 1.  The United States Pharmacopeia (USP) has set elemental maximum values in 
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dietary supplements for only inorganic As, Cd, Pb, total Hg, and methylmercury.
36
  This 
amount of regulation is much less stringent than what the USP requires for prescription 
drugs, where 15 elements are listed with concentration thresholds.
37
  The FDA does not 
have specific elemental limits for dietary supplements, but rather focuses on GMPs to 
prevent the adulteration of dietary supplements from heavy metals, pesticides, and other 
harmful contaminants, and to ensure the presence of only the listed ingredients.
38
  
California Proposition 65 regulations provide a list of chemicals and compounds which 
are known to cause cancer or reproductive toxicity.  Daily limits
39
 and MCLs
39
 are 
provided for some elements, but there is no specific information for dietary supplements.  
The EPA provides MCLs in drinking water, but the amount of drinking water consumed 
per day is typically much greater than the amount of dietary supplements ingested.
40
  
Recent papers investigating elemental contamination in dietary supplements have 
compiled tables with the advocated amounts of selected elements to be consumed each 
day.
41-42
  Commonly, these limits are calculated based on the average adult male; often 
they do not take into account women, children and developing fetuses who can be more 
susceptible to the effects of these potentially harmful elements and chemicals.  It is hard 
to assess the quality of dietary supplements based on the current guidelines provided by 
these regulatory agencies. However, the USP-published methods do not match the level 
of completeness and utility of the EPA methods as many USP methods are either too 
brief, inconsistent or too old to be practical or useful today to achieve GMP compliance. 
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Table 1:  List of inorganic contaminants and their MCLs by regulatory agency. 
Element 
USP Dietary 
Supplement 
Limit (µg g
-1
)
36
 
USP Drug 
Product Limit 
(µg g
-1
) 
37
 
Prop 65 NSRL 
or MADL 
(µg day
-1
) 
39
 
Prop 65 
MCL 
(mg L
-1
) 
39
 
EPA Drinking 
Water MCL 
(mg L
-1
) 
40
 
Aluminum No Limit No Limit No Limit 1 0.05 to 0.2 
Antimony No Limit No Limit No Limit 0.006 0.006 
Arsenic 1.5 0.15 
0.06 (Inhalation) 
10 (Except 
inhalation) 
0.01 
0.010 
Barium No Limit No Limit No Limit 1 2 
Beryllium No Limit No Limit 0.1 0.004 0.004 
Cadmium 0.5 2.5 
0.05 (Inhalation) 
4.1 (Oral) 
0.005 
0.005 
Chromium 
(Total) 
No Limit No Limit No Limit 
No Limit 
0.100 
Copper No Limit 100 No Limit 1.3 1.3 
Iridium No Limit 10 No Limit No Limit No Limit 
Iron No Limit No Limit No Limit No Limit 0.3 
Lead 1.0 0.5 
15 (Oral) 
0.5 
0.015 
0.015 
Manganese No Limit No Limit No Limit No Limit 0.05 
Mercury 
(inorganic) 
1.5 1.5 No Limit 
0.002 
0.002 
Molybdenum No Limit 10 No Limit No Limit No Limit 
Nickel No Limit 50 No Limit 0.1 No Limit 
Osmium No Limit 10 No Limit No Limit No Limit 
Palladium No Limit 10 No Limit No Limit No Limit 
Platinum No Limit 10 No Limit No Limit No Limit 
Rhodium No Limit 10 No Limit No Limit No Limit 
Ruthenium No Limit 10 No Limit No Limit No Limit 
Selenium No Limit No Limit No Limit No Limit 0.05 
Silver No Limit No Limit No Limit No Limit 0.10 
Thallium No Limit No Limit No Limit 0.002 0.002 
Uranium No Limit No Limit No Limit 25 0.030 
Vanadium No Limit 10 No Limit No Limit No Limit 
Zinc No Limit No Limit No Limit No Limit 5 
NSRL:  No significant risk level; MADL:  Maximum allowable dose level 
 Numerous studies have demonstrated the problem of harmful elemental 
contamination in dietary supplements.  Nearly 20 years ago, Pb was discovered in 
calcium supplements,
12
 while a more recent study determined that two-thirds of calcium 
supplements contained Pb concentrations that exceeded the 1999 California limits.
43
  
Another study found wide concentration ranges for As, Cd, Hg, and Pb in dietary 
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supplements.
44
  Studies from multiple countries noted xenobiotic and essential elemental 
contamination in natural drugs in China,
45
 herbal remedies in Nigeria,
46
 and dietary 
supplements in Mexico
1
 and the US.
41-42
 
Other researchers have investigated contamination from essential elements in 
dietary supplements.  A recent study discussed widespread Se toxicity resulting from 
elevated Se quantities in a liquid dietary supplement that also contained a high 
concentration of Cr.
22
  Additional case studies have documented the toxicity caused by Se 
in dietary supplements.
47-48
 
The project described in this paper started with an announcement from a US 
dietary supplement supplier that one of their supplements had been contaminated.  This 
study expanded on the original discovery by evaluating elemental content in six common 
types of dietary supplements (zinc, essential fatty acids, calcium, magnesium, 
multivitamins, and probiotics) from four different manufacturers.  The present study 
applied additional quality control parameters to the elemental analysis of dietary 
supplements through the use of EPA Method 3052 for sample preparation and EPA 
Method 6020B for analysis, with National Institute of Standards and Technology (NIST) 
Multivitamin/Multielement Tablets, Standard Reference Material (SRM) 3280 used for 
validation. 
2.2 Materials and Methods 
2.2.1 Materials 
2.2.1.1 Chemicals and Standards 
All reagents were of analytical grade.  ARISTAR ULTRA nitric acid (HNO3), 
ARISTAR ULTRA hydrochloric acid (HCl), ARISTAR ULTRA water, borosilicate glass 
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vessels, and 50 mL polypropylene centrifuge tubes were procured from VWR (Radnor, 
PA, USA).  Multi-element and single element standards of mercury, iodine, lithium, and 
yttrium were bought from Inorganic Ventures (Christiansburg, VA, USA).  The tuning 
mix for the ICP-MS consisting of 1 ng g
-1
 lithium, cobalt, yttrium, cerium, and tellurium 
in 2% (v:v) HNO3 was purchased from Agilent Technologies (Santa Clara, CA, USA).  
The internal standard solution containing 100 µg g
-1
 of 
6
lithium, scandium, germanium, 
rhodium, indium, terbium, lutetium, and bismuth was also obtained from Agilent 
Technologies.  Instrument grade liquid argon along with hydrogen and helium gases was 
procured from Airgas (Pittsburgh, PA, USA).  SRM 3280 was bought from NIST 
(Gaithersburg, MD, USA).   
2.2.1.2 Dietary Supplement Samples 
Six types of dietary supplements were purchased from four manufacturers in 
commercially available form (Table 2).  From Company 1, zinc, calcium, and magnesium 
supplements were obtained.  Zinc, essential fatty acids, calcium, magnesium, and 
multivitamin supplements were tested from Company 2.  All six supplement types were 
analyzed from Company 3 and Company 4. 
 
   
1
3
5
 
Table 2:  The dietary supplements analyzed in the study. 
Manufacturer Supplement Nutritional Ingredient Type Other Ingredients 
Company 1 
Zinc Mineral Cellulose, water 
Calcium Mineral Ascorbyl palmitate, cellulose, water 
Magnesium Mineral Ascorbyl palmitate, cellulose, water 
Company 2 
Zinc Mineral Plant cellulose, stearic acid, rice flour, carob 
Essential 
Fatty Acid 
Omega-3 fatty acids (Docosahexaenoic acid, 
eicosapentaenoic acid) 
Cholesterol, vitamin A, vitamin D3, vitamin 
E, natural lemon flavor 
Calcium 
Mineral Fructose, sorbitol, stearic acid, magnesium 
stearate, vanilla, silicon dioxide 
Magnesium Mineral Gelatin capsule 
Multivitamin 
Vitamins and Minerals (Vitamin A, vitamin C, vitamin D3, 
vitamin E, thiamin, riboflavin, niacin, vitamin B-6, folate, 
vitamin B-12, biotin, pantothenic acid, calcium, iodine, 
magnesium, zinc, selenium, copper, manganese, chromium) 
Microcrystalline cellulose, dicalcium 
phosphate, croscarmellose sodium, stearic 
acid, magnesium stearate, ethylcellulose, 
hydroxypropyl cellulose 
Company 3 
Zinc 
Mineral Vitamin C, vitamin B6, 
cellulose, vegetarian capsule, L-leucine 
Essential 
Fatty Acid 
Fatty acid 
(Marine oil concentrate, docosahexaenoic acid, 
eicosapentaenoic acid) 
Natural mixed tocopherol vitamin E from 
soy, natural lemon oil, rosemary extract 
Calcium 
Mineral Phosphorus, hydroxypropyl methylcellulose, 
water, L-leucine, cellulose 
Magnesium 
Mineral Hydroxypropyl methylcellulose, water, L-
leucine 
Multivitamin 
Vitamins and minerals (Vitamin A, vitamin C, vitamin D3, 
vitamin E, vitamin K1, thiamine, riboflavin, niacin, vitamin 
B6, folate, vitamin B12, biotin, pantothenic acid, calcium, 
iodine, magnesium, zinc, selenium, manganese, chromium, 
molybdenum, potassium, boron, vanadium, choline, inositol, 
citrus bioflavonoids) 
Natural citrus flavor 
Probiotic 
Probiotic (Probiotic blend, Lactobacillus acidophilus, 
bifidobacterium bifidum) 
Hydroxypropyl methylcellulose, water, L-
leucine 
   
1
3
6
 
Company 4 
Zinc 
Mineral Purified water, sorbitol, glycerine, citric acid, 
natural raspberry flavor, potassium sorbate 
Essential 
Fatty Acid 
Omega-3 fatty acid and vitamins 
(Docosahexaenoic acid, eicosapentaenoic acid vitamin A, 
vitamin D) 
Cod liver oil, purified water, gelatin, 
glycerine 
Calcium 
Mineral Calcium chelate, sodium starch, glycolate, 
magnesium stearate, vitamin D-3, plant 
cellulose capsule 
Magnesium 
Mineral Magnesium glycinate, L-leucine, plant 
cellulose capsule 
Multivitamin 
Vitamins and minerals (Vitamin A, vitamin C, vitamin D, 
vitamin E, vitamin B-1, vitamin B-2, niacinamide, vitamin 
B-6, folic acid, vitamin B-12, biotin, pantothenic acid, 
calcium, iodine, magnesium, zinc, selenium, manganese, 
chromium, molybdenum, coenzyme Q10) 
Dextrose, calcium carbonate, ascorbic acid, 
vitamin E acetate, magnesium oxide, zinc 
citrate, magnesium glycinate, calcium citrate, 
niacinamide, d-calcium pantothenate, 
manganese citrate, CoQ10, citric acid, natural 
peach mango flavor, starch, stearic acid, 
silicon dioxide, magnesium stearate, biotin, 
vitamin A acetate, pyridoxine, hydrochloride, 
riboflavin, thiamine mononitrate, glycerides 
of stearic and palmitic acids, mannitol, 
vitamin D-3, selenium chelate, di-calcium 
phosphate, beta carotene, cyanocobalamin, 
chromium chelate, molybdenum chelate, 
sucralose, folic acid, potassium iodide 
Probiotic 
Probiotic 
(Lactobacillus rhamnosus, lactobacillus acidophilus, 
bifidobacterium bifidum/lactis, lactobacillus casei, 
lactobacillus plantarum, streptococcus therophilus) 
Stabilized probiotic strains, microcrystalline 
cellulose, silicon dioxide, magnesium 
stearate, plant cellulose capsule 
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2.2.1.3 Instrumentation 
Sample preparation was accomplished by applying microwave-enhanced 
chemistry using a Milestone (Shelton, CT, USA) UltraWAVE laboratory microwave 
system equipped with temperature and pressure feedback control.  This device accurately 
monitored and controlled temperature to within ± 2 °C of the specified values, 
automatically adjusting the microwave field output power to achieve the preset 
temperatures.  The UltraWAVE allowed for extremely high temperature and pressure 
conditions of up to 300 °C and 199 bar to be maintained for extended periods during the 
digestion of the samples.  This capability allowed for different types of samples to be 
digested simultaneously since all samples were held under the same conditions.  In this 
study, borosilicate glass vessels were used for the digestion of 15 samples per batch.   
Mass spectrometric analysis was performed using an Agilent 7700 ICP-MS with a 
micromist nebulizer, quartz spray chamber, an octopole reaction system, and a 
quadrupole mass analyzer.  This instrument has a collision/reaction cell that uses 
hydrogen or helium gas for the elimination of polyatomic interferences.  All samples and 
the internal standard were introduced into the ICP-MS using the peristaltic pump at a 
speed of 0.1 revolutions per second (rps) via the micromist nebulizer of the spray 
chamber.  Before analysis, the samples were placed in a CETAC (Omaha, NE, USA) 
ASX-520 autosampler housed inside of an ENC-500 anti-contamination enclosure.  The 
ICP-MS and autosampler were located in an International Organization for 
Standardization Class 6 cleanroom laboratory.  The optimized parameters of the ICP-MS 
and autosampler are shown in Table 3. 
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Table 3:  Optimized operating conditions for the Agilent 7700 ICP-MS for the analysis of dietary 
supplement samples according to EPA Method 6020B. 
Agilent 7700 ICP-MS Parameter Method 6020B Analysis Setting 
Rf Power 1550 W 
Spray Chamber Temperature 2 °C 
Acquisition Mode Spectrum 
Peak Pattern 3 points mass
-1
 
Sample Depth 8 mm 
Plasma Gas 15 L min
-1
 
Carrier Gas 0.9 L min
-1
 
Makeup Gas 0.15 L min
-1
 
H2 Cell Gas Flow 4.5 mL min
-1
 
He Cell Gas Flow 5.5 mL min
-1
 
Gas Stabilization Time 30 sec 
Integration Time 0.1-1.0 sec mass
-1
 
Replicates 4 
Nebulizer Pump Speed 0.10 rps 
Uptake Time 30 sec 
Stabilization Time 30 sec 
 
2.2.2 Methods 
2.2.2.1 Homogenization of the Dietary Supplements 
Four different forms of dietary supplements were analyzed during this study:  
tablets, capsules, powders, and liquids.  The procedure given in the Certificate of 
Analysis for NIST SRM 3280 was followed for sample homogenization.  Fifteen SRM 
3280 tablets were homogenized with a clean mortar and pestle and stored in a 50 mL 
polypropylene centrifuge tube.  All of the tablet dietary supplement samples were 
prepared and stored in the same manner as SRM 3280.  For each capsule sample, the 
outer casing was removed for 15 capsules and the inside contents were emptied into a 50 
mL polypropylene centrifuge tube.  For the powder samples, a quantity similar to 15 
SRM 3280 tablets was poured into a 50 mL polypropylene centrifuge tube.  The liquid 
samples were shaken immediately before being added to the microwave digestion 
vessels.   
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2.2.2.2 Microwave-enhanced Digestion of the Dietary Supplements by EPA 
Method 3052 
The homogenized samples were digested according to EPA Method 3052
49-50
 to 
determine their total elemental content.  In each glass vessel, 0.25 grams of sample was 
combined with 8 mL HNO3 and 2 mL HCl.  Three subsamples were prepared for each 
dietary supplement.  The samples were digested in the microwave following a program 
that implemented a 10 minute ramp to 180 °C with a 10 minute hold at 180 °C.  
Complete digestion for all of the types of dietary supplements (tablets, capsules, powders, 
and liquids) was achieved resulting in the production of homogeneous, transparent, light 
yellow solutions that did not contain any solids.  After digestion, each sample was poured 
into a 50 mL polypropylene centrifuge tube and diluted with water to approximately 20 
mL.  The polypropylene centrifuge tubes were weighed before and after the addition of 
the sample digests.  Six analytical blanks consisting of HNO3 and HCl were digested with 
the samples.  The samples were stored in a cold room at 4 °C and usually analyzed within 
three days of digestion.  The microwave vessel caps were cleaned after digestion by 
soaking them in 1% HNO3 overnight to prevent cross contamination. 
2.2.2.3 Elemental Concentration Determination by ICP-MS Using EPA Method 
6020B 
The total concentrations of elements in the sample digests were determined 
according to EPA Method 6020B.
51
  On each day of analysis, the system was aspirated 
with 2% HNO3 for 30 minutes before tuning the instrument using the Agilent tuning 
solution at a concentration of 1 ng g
-1
 and determining the pulse/analog factor.  Analysis 
on the Agilent 7700 ICP-MS was performed in three modes:  hydrogen, helium, and no 
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gas.  The amount of hydrogen and helium gas was optimized to eliminate polyatomic 
interferences. Table 4 lists the analysis mode for each element.  Between analysis modes, 
a 30 second delay was employed to equilibrate the presence or absence of collision gas 
and/or reaction gas. 
Table 4:  The analysis information, correlation coefficient, DLs, and BECs for the xenobiotic and 
essential elements of interest determined by the Agilent 7700 ICP-MS. 
Element m/z Mode r
2
 DL (ng g
-1
) BEC (ng g
-1
) 
Mg 24 He 0.9976 25.7 13.15 
Al 27 H2 0.9995 3.44 0.6232 
Ca 40 H2 0.9983 110 93.86 
V 51 He 0.9999 0.0537 0.03871 
Cr 52 He 0.9999 0.961 3.761 
Mn 55 He 1.0000 0.346 0.2842 
Fe 56 He 0.9985 18.8 15.4 
Co 59 He 1.0000 0.0197 0.04378 
Ni 60 He 0.9994 0.411 1.784 
Cu 63 He 0.9999 0.309 0.6835 
Zn 66 He 0.9979 9.35 6.387 
As 75 He 0.9999 0.0187 0.3339 
Se 78 H2 1.0000 0.0178 0.02316 
Mo 95 He 1.0000 0.102 0.334 
Cd 111 He 1.0000 0.0477 0.05985 
Sn 118 He 0.9999 0.105 0.2946 
Sb 121 No gas 0.9998 0.0866 0.1299 
Hg 201 No gas 1.0000 0.0658 0.02458 
Pb 208 No gas 0.9999 0.00721 0.07522 
U 238 No gas 1.0000 0.000834 0.001746 
 
Due to the wide concentration range of the analytes of interest in SRM 3280 and 
the dietary supplement samples, calibration standards were prepared for 60 elements at 
three different concentration ranges (low, medium, and high) of 0-25, 0-50, and 0-150 
ng g
-1
, respectively.  The calibration standards were prepared by acid matching, which 
consisted of adding the appropriate percentage of microwave-digested reagent blank to 
each calibration standard.   
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The sample digests were diluted with water to total factors of 320, 8,000 and 
800,000 for the low, medium, and high calibration ranges, respectively.  They were 
analyzed in three separate sequences with four replicates taken from each subsample.  
Analyses were performed in spectrum mode using three points per mass.  The integration 
times for each element ranged from 0.1-1.0 seconds per point depending on the element’s 
ionization energy.  The measured concentration value for each element in SRM 3280 and 
each dietary supplement sample was determined based on the value that fell within the 
range of one of the three calibration curves.  After analysis was completed, the data was 
exported from the Agilent MassHunter software (version G7201A A.01.01) into 
Microsoft Excel for further data analysis. 
2.2.2.1 Quality Control 
The current study implemented numerous quality control measures previous 
mentioned that included the preparation of multiple subsamples, replicate analysis, 
preparation of analytical blanks, acid matched calibration standards, and SRM 3280.  It 
also utilized many of the measures described in EPA Method 6020B.  An Agilent internal 
standard solution was used at a concentration of 1 µg g
-1
 in 1% HNO3 and 0.5% HCl, and 
its acceptable recovery was maintained between 80 and 120% of the calibration blank.  
Between each sample, the autosampler probe was washed in three solutions of 1% HNO3 
and 0.5% HCl for 30 seconds each with a nebulizer pump speed of 0.5 rps.  After every 
nine samples, low- and midpoint calibration checks along with an SRM 3280 assessment 
were performed for additional calibration verification to ensure the consistency of the 
results during the complete duration of the sample run. 
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2.3 Results 
2.3.1 Analytical Figures of Merit and Validation of EPA Methods 
All elements displayed linearity on the six or seven point external calibration 
curves for each of the three calibration ranges (Table 4).  They had correlation coefficient 
(r
2
) values greater than the 0.998 specified in EPA Method 6020B except for magnesium 
(Mg, 0.9976) and Zn (0.9979) being just below the cutoff value only for the low 
calibration range.  When rounded to three significant figures, they meet the specified 
requirements of EPA Method 6020B.  The four replicates for each calibration point 
displayed a variation of less than 5% indicating that the obtained measurements were 
highly reproducible.   
The elemental detection limits (DL) were defined as the average of the blank 
concentration for each element plus three times the standard deviation of the blank 
measurements for that element.
52
  The DLs for all of the elements in Table 4 were below 
1 ng g
-1 
except for Al, Ca, Fe, Mg, and Zn.  The background equivalent concentrations 
(BECs) were calculated by multiplying the background intensity signal and the 
concentration of the analyte and dividing by the difference of the analyte intensity minus 
the intensity of the background.
53
  The BECs were under 1 ng g
-1
 for all elements other 
than Ca, Cr, Fe, Mg, Ni, and Zn (Table 4). 
Additional confidence in the accuracy and precision of the results of the present 
study was achieved by using SRM 3280 to validate the sample preparation and analysis 
protocols.  This SRM is certified for both xenobiotic and essential elements with their 
concentrations representing the wide range of values seen in commercially available 
products.  Results obtained for SRM 3280 during this study are shown in Table 5 and 
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Figure 2 with the mean (n = 12) and 95% confidence intervals (CIs).  The measured 
values are in strong agreement with the certified and reference values, within 10% for 
nearly every element.  The measured values overlapped the certified or reference CIs for 
14 elements with the intervals for 2 other elements nearly intersecting, which is the same 
number of elements provided in two other studies.
41-42
  The recovery efficiencies ranged 
from 68.2 to 124% based on a comparison of the mean listed values to the average 
measured quantities.  Only 3 of the 23 certified or reference elements had either 
recoveries that differed by more than 20% from the mean value or that did not overlap 
CIs.  This study provided measured values for the certified elements As, Cd, and Pb in 
SRM 3280 that were not included in two other studies.
41-42
  The value for As fell within 
the CI provided, while Cd had a 118% recovery and Pb had a 70.7% recovery.  The 
accuracy of all measurements in this study improves with the inclusion of the provided 
confidence intervals. 
The precision determined by the 95% CIs was within 10% of the measured mean 
values for all of the certified or reference elements in SRM 3280, with over half inside of 
5% (Table 5).  This level of precision for SRM 3280 was maintained for the remainder of 
the study as most results had 95% CIs that were less than 10% of their mean value.  A 
large number of them were lower than 5% and some approached 1%.  The other two 
studies
41-42
 which have evaluated elemental content in botanicals and dietary supplements 
supplied no standard deviation or confidence interval information for their sample 
measurements, listing only standard deviations for their SRM 3280 results.  The 
exclusion of standard deviation and confidence intervals provided no information on their 
ability to sustain precise measurements for their samples during the remainder of their 
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studies.  This study provided 95% CIs for all detectable elemental quantities in the 
dietary supplement samples. 
Table 5:  Concentrations of the certified and reference elements determined in SRM 3280 (n = 
12, 95% CIs). 
Element Certified Value (mg g
-1
) Measured Value (mg g
-1
) 
B 0.141 ± 0.007 0.1219 ± 0.0047 
Ca 110.7 ± 5.3 108.4 ± 8.3 
Cl 53.0 ± 2.3 Not Determined 
Cu 1.40 ± 0.17 1.591 ± 0.117 
I 0.1327 ± 0.0066 Not Determined 
Fe 12.35 ± 0.91 11.95 ± 0.17 
Mg 67.8 ± 4.0 72.60 ± 2.32 
Mn 1.44 ± 0.11 1.627 ± 0.161 
P 75.7 ± 3.2 80.39 ± 1.64 
K 53.1 ± 7.0 65.67 ± 4.37 
Zn 10.15 ± 0.81 11.54 ± 0.43 
 Certified Value (µg g
-1
) Measured Value (µg g
-1
) 
As 0.132 ± 0.044 0.1625 ± 0.0138 
Cr 93.7 ± 2.7 96.09 ± 2.03 
Pb 0.2727 ± 0.0024 0.1973 ± 0.0077 
Mo 70.7 ± 4.5 84.12 ± 1.16 
Ni 8.43 ± 0.30 5.861 ± 0.299 
Se 17.42 ± 0.45 17.98 ± 0.37 
 Certified Value (ng g
-1
) Measured Value (ng g
-1
) 
Cd 80.16 ± 0.86 95.79 ± 8.28 
 Reference Value (µg g
-1
) Measured Value (µg g
-1
) 
Sb 0.159 ± 0.008 0.1085 ± 0.0057 
Co 0.81 ± 0.01 0.8572 ± 0.0167 
La 0.70 ± 0.01 0.6151 ± 0.0118 
Si 2,010 ± 10 Not Determined 
Na 330 ± 20 301.7 ± 16.7 
Sr 29.8 ± 0.2 29.96 ± 1.24 
Sn 11.1 ± 0.9 11.74 ± 0.62 
V 8 ± 2 9.691 ± 0.635 
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Figure 2:  Concentrations of the certified and reference elements determined in SRM 3280 (n = 
12, 95% CIs) with the certified or reference values shown in black and the measured results 
shown in blue. 
 
2.3.2 Analytical Figures of Merit and Validation of EPA Methods 
The elemental analysis results from the four dietary supplement companies are 
shown in Tables 6-9, respectively.  The results are presented by company and separated 
into xenobiotic and essential elements.  Contamination from essential elements was 
considered to exist if that element was not listed as an ingredient on the label for that 
particular dietary supplement. 
2.3.2.1 Xenobiotic Elements 
The supplements from Company 1 were found to have less contamination from 
xenobiotic elements compared to the other companies (Table 6).  The calcium 
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supplement contained tin (Sn) at a concentration over 700 ng g
-1
 and Pb above 170 ng g
-1
.  
The magnesium supplement had a similar frequency of contamination with vanadium (V) 
found at more than 2 µg g
-1
 along with 23 ng g
-1
 of Sn and 9 ng g
-1
 of Pb.  The zinc 
supplement had concentrations of 117 ng g
-1
 of Cd and 22 ng g
-1
 of Sn. 
   
1
4
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Table 6:  Concentration (µg g
-1
) of xenobiotic and essential elements determined in dietary supplements from Company 1 (n = 12, 95% CIs). 
 Zinc Supplement Calcium Supplement Magnesium Supplement 
Xenobiotic Elements 
Al <DL <DL <DL 
As <DL <DL <DL 
Cd 0.1168 ± 0.0089 <DL <DL 
Hg <DL <DL <DL 
Pb <DL 0.1718 ± 0.0032 0.009087 ± 0.001802 
Sb <DL <DL <DL 
Sn 0.02260 ± 0.00895 0.7526 ± 0.0355 0.02330 ± 0.00553 
U <DL 0.0009512 ± 0.0001482 0.004564 ± 0.000150 
V <DL 0.02266 ± 0.00509 2.129 ± 0.050 
Essential Elements  
Ca <DL 257,500 ± 8,600 208.3 ± 14.3 
Co <DL <DL 0.05117 ± 0.00401 
Cr <DL <DL 2.430 ± 0.119 
Cu <DL 0.3349 ± 0.0236 0.2421 ± 0.0130 
Fe <DL 7.974 ± 1.439 15.81 ± 1.63 
Mg <DL 5,578 ± 807 138,900 ± 4,800 
Mn <DL 0.3570 ± 0.0306 3.192 ± 0.133 
Mo <DL 0.05454 ± 0.01049 0.5963 ± 0.0210 
Ni <DL <DL 1.774 ± 0.073 
Se <DL 0.04391 ± 0.00265 0.02158 ± 0.00451 
Zn 94,200 ± 1,100 83.28 ± 2.81 <DL 
<DL: below detection limit 
 
The bolded elements are not considered elemental contamination due to their inclusion on the ingredient list. 
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Similar results were found in the dietary supplements analyzed from Company 2 
with a high frequency of contamination by xenobiotic elements (Table 7).  The 
concentration of Al in the magnesium, zinc, and multivitamin supplements was 
determined to be greater than 10 µg g
-1
.  The magnesium supplement also contained more 
than 7.8 µg g
-1
 of V.  Except for the essential fatty acids supplement, Pb contamination 
was observed in all supplements, with the zinc supplement having a concentration of 738 
ng g
-1
, the highest of the dietary supplements tested in this study.  The multivitamin 
supplement had the greatest amount of contamination from xenobiotic elements with As, 
Cd, antimony (Sb), Sn, U, and V at concentrations ranging from 50 to 792 ng g
-1
.  The 
zinc supplement contained Cd, Sb, Sn, and V in the concentration range between 10 and 
70 ng g
-1
.  The calcium supplement had V and As at 53 and15 ng g
-1
, respectively.  The 
essential fatty acids supplement was not contaminated with any xenobiotic elements. 
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Table 7:  Concentration (µg g
-1
) of xenobiotic and essential elements determined in dietary supplements from Company 2 (n = 12, 95% CIs). 
 Zinc Supplement 
Essential Fatty 
Acid Supplement 
Calcium 
Supplement 
Magnesium 
Supplement 
Multivitamin 
Supplement 
Xenobiotic Elements  
Al 10.75 ± 2.92 <DL <DL 61.07 ± 15.91 12.20 ± 3.00 
As <DL <DL 0.01535 ± 0.00353 0.04374 ± 0.00499 0.1484 ± 0.0125 
Cd 0.07024 ± 0.01027 <DL <DL <DL 0.07948 ± 0.00890 
Hg <DL <DL <DL <DL <DL 
Pb 0.7384 ± 0.0193 <DL 0.03124 ± 0.00598 0.05145 ± 0.00232 0.2479 ± 0.0097 
Sb 0.01004 ± 0.00166 <DL <DL <DL 0.05058 ± 0.00363 
Sn 0.04709 ± 0.00619 <DL <DL <DL 0.09608 ± 0.01440 
U 0.003061 ± 0.000240 <DL 0.004006 ± 0.000166 0.007497 ± 0.000349 0.3710 ± 0.0159 
V 0.03149 ± 0.00577 <DL 0.05367 ± 0.00458 7.849 ± 0.114 0.7924 ± 0.0327 
Essential Elements  
Ca 547.3 ± 76.6 <DL 85,970 ± 1,500 815.1 ± 56.7 43,210 ± 2,340 
Co 0.009075 ± 0.002813 <DL <DL 0.1777 ± 0.0081 1.015 ± 0.069 
Cr 0.3442 ± 0.0370 <DL <DL 5.971 ± 0.332 97.07 ± 2.34 
Cu 3.853 ± 1.519 0.7182 ± 0.2176 <DL 0.5375 ± 0.0933 3,830 ± 193 
Fe 26.21 ± 0.83 <DL 0.7639 ± 0.2146 54.64 ± 1.89 40.27 ± 7.52 
Mg 318.8 ± 17.2 14.46 ± 5.84 855.0 ± 14.8 634,600 ± 6,248 73,190 ± 3,860 
Mn 1.080 ± 0.130 0.5131 ± 0.2153 4.855 ± 1.137 12.20 ± 0.81 3,226 ± 280 
Mo 0.1232 ± 0.0106 <DL <DL 2.154 ± 0.052 0.5949 ± 0.0483 
Ni <DL <DL <DL 6.153 ± 0.214 0.4588 ± 0.1118 
Se <DL 0.01464 ± 0.00514 <DL 0.05102 ± 0.00408 51.20 ± 3.05 
Zn 79,120 ± 1,710 25.800 ± 13.580 <DL <DL 29,070 ± 1,380 
<DL: below detection limit 
The bolded elements are not considered elemental contamination due to their inclusion on the ingredient list. 
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Among the products tested, Company 3 had the greatest frequency of xenobiotic 
contamination in its products (Table 8).  The calcium, magnesium, zinc, and multivitamin 
supplements contained high amounts of Al with the mean concentrations each above 15 
µg g
-1
.  Except for the essential fatty acids supplement, Pb was quantified in all of the 
samples with the zinc supplement having the highest concentration at nearly 410 ng g
-1
.  
Of all the supplements tested, the multivitamin supplement had the highest concentration 
of As at 513 ng g
-1
, and the magnesium supplement contained nearly as much As at 432 
ng g
-1
 along with 444 ng g
-1
 of Sn.  In both the calcium and zinc supplements, elemental 
contamination from V, As, and Cd was found between 11 and 331 ng g
-1
.  The probiotic 
had low concentrations of V, As, Sn, and U ranging from 15 to 47 ng g
-1
.  The essential 
fatty acids supplement was clear of contamination from xenobiotic elements with values 
below the respective detection limits.   
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Table 8:  Concentration (µg g
-1
) of xenobiotic and essential elements determined in dietary supplements from Company 3 (n = 12, 95% CIs). 
 Zinc Supplement 
Essential Fatty Acid 
Supplement 
Calcium 
Supplement 
Magnesium 
Supplement 
Multivitamin 
Supplement 
Probiotic 
Supplement 
Xenobiotic Elements  
Al 15.44 ± 6.29 <DL 26.09 ± 14.17 31.93 ± 4.82 20.88 ± 2.89 <DL 
As 0.01153 ± 0.00367 <DL 0.02067 ± 0.00647 0.4323 ± 0.0221 0.5132 ± 0.0238 0.04750 ± 0.00780 
Cd 0.03946 ± 0.00618 <DL 0.02777 ± 0.00334 0.06962 ± 0.00489 0.05674 ± 0.00992 <DL 
Hg <DL <DL <DL <DL <DL <DL 
Pb 0.4092 ± 0.0074 <DL 0.09268 ± 0.00328 0.02407 ± 0.00081 0.04092 ± 0.00155 0.05856 ± 0.00201 
Sb <DL <DL <DL 0.02754 ± 0.00169 <DL <DL 
Sn 0.1041 ± 0.0131 <DL <DL 0.01445 ± 0.00362 0.4440 ± 0.0260 0.02863 ± 0.01034 
U 0.0007583 ± 0.0001011 <DL 0.08226 ± 0.00141 0.5130 ± 0.0052 0.1032 ± 0.0017 0.02199 ± 0.00032 
V 0.01963 ± 0.00728 <DL 0.3309 ± 0.0123 2.833 ± 0.062 11.66 ± 3.27 0.01567 ± 0.00683 
Essential Elements  
Ca 87.87 ± 2.78 <DL 299,000 ± 79,600 1,150 ± 80 43,000 ± 740 614.9 ± 235.3 
Co <DL <DL <DL 0.02499 ± 0.00344 0.4791 ± 0.0120 0.07519 ± 0.00497 
Cr <DL <DL <DL 1.530 ± 0.091 27.21 ± 0.68 <DL 
Cu 0.1921 ± 0.0192 <DL 0.1949 ± 0.0535 0.5806 ± 0.0259 0.5046 ± 0.0392 0.9184 ± 0.0264 
Fe <DL <DL 21.18 ± 3.19 44.97 ± 1.02 43.61 ± 2.28 3.924 ± 0.802 
Mg 33.21 ± 3.68 2.480 ± 0.326 2,423 ± 41 179,400 ± 3,200 63,310 ± 1,830 708.5 ± 16.6 
Mn 1.206 ± 0.059 <DL 3.539 ± 0.090 7.663 ± 0.246 360.8 ± 4.8 293.5 ± 4.4 
Mo <DL <DL 0.09942 ± 0.00604 1.448 ± 0.065 18.30 ± 0.66 0.08321 ± 0.02328 
Ni <DL <DL <DL 0.8782 ± 0.0715 0.4698 ± 0.0798 <DL 
Se <DL 0.008819 ± 0.001073 0.02959 ± 0.00397 <DL 50.80 ± 2.73 0.01847 ± 0.00143 
Zn 72.08 ± 1.02 <DL 38.69 ± 1.67 4.337 ± 0.233 2,839 ± 123 24.62 ± 2.53 
<DL: below detection limit 
The bolded elements are not considered elemental contamination due to their inclusion on the ingredient list. 
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Similar to both Companies 2 and 3, Al was a common contaminant among 
Company 4’s products, as it was found at nearly 100 µg g-1 in the calcium supplement, 
over 30 µg g
-1
 in the multivitamin supplement, and above 3 µg g
-1
 in the essential fatty 
acids supplement (Table 9).  The zinc supplement contained nearly 15 µg g
-1
 of Sb.  In 
the calcium supplement, V was quantified at over 1.7 µg g
-1
 along with determining the 
presence of As, Cd, and U between 119 and 320 ng g
-1
.  Vanadium was found at 850 
ng g
-1 
in the magnesium supplement in addition to between 5 and 31 ng g
-1
 of U, As, and 
Sn.  An elevated V amount was also observed in the multivitamin supplement at 566 
ng g
-1
 along with Cd, Pb, U, and As ranging from 33 to 90 ng g
-1
.  In the probiotic 
supplement, As and U were found at 22 and 16 ng g
-1
, respectively.   
  
  
1
5
3
 
Table 9:  Concentration (µg g
-1
) of xenobiotic and essential elements determined in dietary supplements from Company 4 (n = 12, 95% CIs). 
 Zinc Supplement 
Essential Fatty Acid 
Supplement 
Calcium 
Supplement 
Magnesium 
Supplement 
Multivitamin 
Supplement 
Probiotic 
Supplement 
Xenobiotic Elements  
Al <DL 3.424 ± 1.208 91.74 ± 3.42 <DL 31.22 ± 3.050 <DL 
As <DL 0.007569 ±0.00 2793 0.2096 ± 0.0125 0.01163 ± 0.00413 0.09037 ± 0.00767 0.02217 ± 0.00572 
Cd <DL <DL 0.1194 ± 0.0077 <DL 0.03310 ± 0.00605 <DL 
Hg <DL <DL <DL <DL <DL <DL 
Pb 0.003119 ± 0.000568 <DL 0.05814 ± 0.00626 <DL 0.06468 ± 0.00132 <DL 
Sb 14.85 ± 0.15 <DL <DL <DL <DL <DL 
Sn <DL <DL <DL 0.03139 ± 0.00902 <DL <DL 
U <DL <DL 0.3197 ± 0.0057 0.004984 ± 0.000197 0.08917 ± 0.00175 0.01587 ± 0.00036 
V <DL 0.007211 ± 0.002768 1.719 ± 0.035 0.8498 ± 0.0284 0.5660 ± 0.0126 0.01093 ± 0.00424 
Essential Elements  
Ca <DL 6.153 ± 1.613 242,900 ± 4,100 198.7 ± 24.2 16,760 ± 1,230 73.11 ± 18.88 
Co <DL <DL 0.03813 ± 0.00433 0.05813 ± 0.00423 0.2548 ± 0.0055 0.05438 ± 0.00386 
Cr <DL <DL 2.430 ± 0.201 2.813 ± 0.096 14.32 ± 0.42 <DL 
Cu <DL <DL 0.2673 ± 0.0250 0.1516 ± 0.0153 0.08997 ± 0.01458 0.3461 ± 0.0134 
Fe <DL <DL 133.2 ± 2.8 29.04 ± 1.26 39.62 ± 1.22 <DL 
Mg <DL 5.518 ± 0.709 1,459 ± 23 196,500 ± 4,300 19,020 ± 970 1,440 ± 30 
Mn <DL <DL 44.68 ± 1.31 4.370 ± 0.147 920.2 ± 60.5 221.0 ± 3.5 
Mo <DL <DL <DL 0.6047 ± 0.0329 9.774 ± 0.742 <DL 
Ni <DL <DL <DL 1.164 ± 0.062 <DL <DL 
Se <DL 0.02422 ± 0.00209 0.006817 ± 0.001101 0.01070 ± 0.00145 12.44 ± 1.39 0.01334 ± 0.00159 
Zn 2,829 ± 81 <DL 4.298 ± 0.260 <DL 6,323 ± 220 10.65 ± 0.23 
<DL: below detection limit 
The bolded elements are not considered elemental contamination due to their inclusion on the ingredient list. 
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2.3.2.2 Essential Elements 
In addition to the presence of xenobiotic elements, each dietary supplement from 
Company 1 had notable contamination by essential elements that were not listed as 
ingredients on the dietary supplement labels (Table 6).  Overall, the calcium and 
magnesium supplements contained greater quantities of unlabeled essential elements 
compared to xenobiotic elements.  In the calcium supplement, Mg was found at a 
concentration over 5 mg g
-1
, Zn at greater than 80 µg g
-1
, and Fe at 8 µg g
-1
.  The amount 
of contamination in the magnesium supplement consisted of Ca quantified at 200 µg g
-1
, 
Fe at about 15 µg g
-1
 along with Cr, manganese (Mn), and nickel (Ni) between 1.8 and 
3.1 µg g
-1
.  In contrast, the zinc supplement contained no detectable quantities of any 
essential element. 
Similar to Company 1, essential elements not listed as ingredients were found in 
the dietary supplements from Company 2 (Table 7).  Overall, Company 2 had a high 
frequency of these elements at µg g
-1
 level.  Magnesium was quantified at 855 µg g
-1
 in 
the calcium supplement and 318 µg g
-1
 in the zinc supplement.  Calcium was found at 
815 and 547 µg g
-1
 in the magnesium and zinc supplements, respectively.  Except for the 
essential fatty acids supplement, Fe was observed in all of the samples with the highest 
concentration of 54 µg g
-1
 in the magnesium supplement. The magnesium supplement 
was also determined to contain Cr, Mn, molybdenum (Mo), and Ni at concentrations 
between 2.1 and 12.2 µg g
-1
.  The calcium supplement had a Mn concentration of nearly 
5 µg g
-1
.  Cobalt (Co), Mo, and Ni were detected at 1015, 595, and 459 ng g
-1
, 
respectively, in the multivitamin supplement.  The zinc supplement frequently contained 
essential elements, notably Cu at 3.8 µg g
-1
, Mn at 1 µg g
-1
, and Cr at 344 ng g
-1
.  The 
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essential fatty acids supplement was found to have 25 µg g
-1
 of Zn, 14 µg g
-1
 of Mg, and 
ng g
-1
 quantities of Cu, Mn, and Se.   
The products from Company 3 also had contamination from unlabeled essential 
elements (Table 8).  There was nearly 300 µg g
-1
 of Mn in the probiotic supplement.  
Magnesium was quantified at nearly 2.5 mg g
-1
 in the calcium supplement, 700 µg g
-1
 in 
the probiotic supplement, 33 µg g
-1
 in the zinc supplement, and 2.5 µg g
-1
 in the essential 
fatty acids supplement.  In the magnesium and zinc supplements, 1150 and 88 µg g
-1
 Ca 
was measured, respectively.  Zinc was also found in the calcium, magnesium, and 
probiotic supplements between 4 and 38 µg g
-1
.  Iron was detected at 44, 43, 21, and 4 
µg g
-1
 in the magnesium, multivitamin, calcium, and probiotic supplements, respectively.  
Manganese was observed at 7.7, 3.5, and 1.2 µg g
-1
 in the magnesium, calcium, and zinc 
supplements.  Copper was found in the calcium, magnesium, zinc, and probiotic 
supplements.  The magnesium supplement also had Cr at over 1.5 µg g
-1
, Ni at almost 
900 ng g
-1
, and a lower level of Co at 25 ng g
-1
.  In addition, the multivitamin supplement 
contained Co and Ni. 
As with the other three companies, the dietary supplements from Company 4 also 
contained contamination from essential elements (Table 9), with many at µg g
-1
 level or 
higher.  Similar to Company 3, the probiotic supplement from Company 4 had a Mn 
concentration close to 250 µg g
-1
.  Magnesium was quantified at greater than 1 mg g
-1
 in 
the calcium and probiotic supplements.  Calcium was measured to be 198 µg g
-1
 in the 
magnesium supplement and 73 µg g
-1
 in the probiotic supplement.  Of all the essential 
fatty acids supplements, the product from Company 4 was the most contaminated with 
essential elements including Ca (6 µg g
-1
) and Mg (5.5 µg g
-1
).  In the probiotic and 
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calcium supplements, Zn was quantified at 10 and 4 µg g
-1
, respectively.  Iron was found 
at 133, 39, and 29 µg g
-1
 in the calcium, multivitamin, and magnesium supplements.  In 
the calcium supplement, the Mn concentration was determined to be greater than 40 µg g
-
1
 with Cr at 2.4 µg g
-1
.  The magnesium supplement had Cr, Mn, and Ni at concentrations 
greater than 1 µg g
-1
.  Molybdenum was determined to be above 600 ng g
-1
 in the 
magnesium supplement with low ng g
-1
 amounts of Co and Se.  Except for the zinc and 
essential fatty acid supplements, all of the supplements from Company 4 contained 
between 90 and 346 ng g
-1
 of Cu.   
Comparisons of particular elemental concentrations in certain types of dietary 
supplements were provided to illustrate the differences between the supplement 
manufacturers.  Examples of these comparisons for the xenobiotics Pb and Cd are shown 
in Figures 3 and 4.  Figure 3 shows the amounts of Pb in the calcium supplements from 
the four supplement companies.  All four supplements had measureable quantities of Pb 
in their calcium supplements with the mean values ranging from 31 ng g
-1
 to 172 ng g
-1
.  
Company 1 had the highest concentration, while Company 2 had the lowest.  Another 
important toxicant comparison is the level of Cd in the zinc supplements seen in Figure 4.  
Company 1 had the highest concentration at greater than 117 ng g
-1
 while Company 4 had 
the lowest at below the detection limit, with both Companies 2 and 3 having quantifiable 
amounts of 70 and 39 ng g
-1
, respectively. 
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Figure 3:  Concentrations for lead in calcium supplements from the four dietary supplement 
companies (n = 12, 95% CIs). 
 
Figure 4:  Concentrations for cadmium in zinc supplements from the four dietary supplement 
companies (n = 12, 95% CIs).  The cadmium concentration for Company 4 was below the DL of 
0.0466 ng g-1. 
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2.4 Discussion 
The high fidelity results obtained in this study were accurate and precise based on 
validation with SRM 3280.  The microwave-enhanced sample preparation provided 
effective, consistent, and efficient sample decomposition that combined with the robust 
ICP-MS analysis demonstrating the feasibility of using EPA methods to routinely 
determine both the xenobiotic and essential elemental contamination in dietary 
supplements.
41-42
  Only two other studies have used SRM 3280 to validate the method 
protocols employed for multi-element quantification in dietary supplements or botanicals.  
This study demonstrated superior analytical and statistical procedures compared to the 
two previous studies by Avula et al. through increased quality control and inclusion of 
CIs for all sample results.  Another important improvement in the current study was 
related to the preparation of the calibration standards.  The previous studies used a 
calibration blank solution of 3.2% HNO3 and 0.8% HCl.
41-42
  Although these studies 
produced accurate results for SRM 3280, that method is not optimal in providing uniform 
acid content in all of the digested samples and calibration solutions.  However, the 
addition of the appropriate amount of an analytical blank solution to each calibration 
standard during the subsequent dilution as performed in the current study accomplished 
this goal. 
This study confirmed the presence of contamination from either xenobiotic or 
essential elements in all samples from all four suppliers.  The xenobiotic elements 
quantified in this study included Pb, Cd, Sb, Sn, and As, with their concentrations 
ranging from low ng g
-1
 to µg g
-1
 levels.  Only two supplements did not have xenobiotic 
elements detected in them, the zinc supplement from Company 1 and the essential fatty 
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acid supplement from Company 2.  Particularly alarming was the frequent presence of Al 
at µg g
-1
 quantities in half of the supplements tested.  The most common sources of 
xenobiotic elemental contamination were V and U.  Nearly two-thirds of the samples 
contained quantifiable amounts of Pb.  Antimony was found in only one supplement at a 
concentration greater than 50 ng g
-1
.  One positive note was that the Hg concentrations 
were below the detection limit in all of the samples tested. 
In addition to the presence of xenobiotic elements, most of the supplements 
contained essential elements such as Zn, Mg, Ca, Fe, Cu, Mo, and Se that were not listed 
as ingredients on the labels.  This study identified a greater frequency of adulteration 
from essential elements compared to xenobiotic elements, with Ca being the most 
frequent contaminant. The zinc supplements from Companies 1 and 4 were the only two 
that did not contain quantifiable amounts of any extra essential element.  Iron was almost 
always found in µg g
-1
 concentrations as an impurity.  The presence of either xenobiotic 
or essential elements in all of the dietary supplements raises the possibility of a systemic 
and persistent problem across the industry. 
The contamination observed in this study was examined through a comparison of 
the four manufacturers.  Company 3 had the highest occurrence of xenobiotic elemental 
content.  Except for the essential fatty acid, each supplement contained at least five 
xenobiotic elements.  It was also the only company that had four supplements with µg g
-1
 
quantities of Al along with the two highest As concentrations.  Their multivitamin 
supplement had the greatest amount of As and V quantified in the study while their zinc 
supplement had the second highest concentration of Pb.  The elemental adulteration for 
Company 4 was nearly as frequent as Company 3.  Their calcium supplement had the 
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highest concentration of Al with the greatest Sb concentration found in their zinc 
supplement.  Company 1 had the least amount of xenobiotic content.  However, its 
calcium supplement contained the highest concentration of Sn, and their zinc supplement 
had the second greatest concentration of Cd.  Both the calcium and magnesium 
supplements from Company 1 had a similar pattern of xenobiotic contamination from Pb, 
Sn, U, and V.  The company’s use of the same ingredients in different amounts in their 
supplements may provide one explanation (Table 2).  These supplement types from 
Companies 2 and 3 shared similar elemental adulteration, but this was not observed in 
Company 4.  Three out of five supplements from Company 2 had at least 10 µg g
-1
 of Al.  
The zinc supplement from Company 2 contained the greatest concentration of Pb. 
Some patterns appeared when the supplement types were compared.  The 
essential fatty acids were the cleanest for xenobiotic elements as only Company 4’s 
products contained over 3 µg g
-1
 of Al.  The essential fatty acids were more likely to 
contain essential elements with Mg detected at µg g
-1
 quantities in all three essential fatty 
acid supplements.  The zinc supplements were relatively clear of unlabeled essential 
elements, except for the one from Company 2 that contained 547 µg g
-1
 of Ca and 318 µg 
g
-1
 of Mg along with six other essential elements.  The contamination frequency was less 
for the zinc supplement from Company 3, but it still included µg g
-1
 quantities of Ca and 
Mg.  All of the calcium supplements were adulterated with at least 855 µg g
-1
 of Mg, with 
three in the mg g
-1
 range.  The four magnesium supplements contained at least 198 µg g
-1
 
of Ca and 15.8 µg g
-1
 of Fe.  Even though they had the most elements listed as 
ingredients, the multivitamins contained contamination from nearly all of the other 
essential elements, notably Fe at approximately 40 µg g
-1
 in all three.  Both of the 
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probiotics had over 200 µg g
-1
 of Mn.  Certain bacteria are known to produce Mn, 
especially the Lactobacillus genus,
54
 a common species in this type of supplement.  The 
bacteria also need the other essential elements that were quantified in the probiotics for 
survival, especially Ca and Mg that were found in high concentrations.  The media where 
the bacteria were grown is a possible contamination source. 
The findings of this study are significant because they reveal the quality of dietary 
supplements in the current marketplace and the possible threat they pose to public health 
as their use increases globally.  The long-term health effects from regular intake and 
exposure to elemental contaminants from dietary supplements are rarely studied and 
insufficiently understood.  One of the less publicized aspects of these quality deficiencies 
is the presence of essential elements not mentioned on content labels, potentially 
negatively affecting supplement regimens designed to improve human health through 
nutrient support.  With people taking multiple dietary supplements, potential negative 
synergistic effects are a realistic possibility and cumulative exposure to these xenobiotic 
elements may have long term adverse health outcomes.  In addition to the consequences 
from the cumulative exposure to these potentially harmful elements, over-
supplementation can result from the presence of essential elements that were not listed on 
the label, as demonstrated by this study. 
2.5 Conclusion 
This study demonstrated the application of standardized EPA methods for the 
evaluation of elemental contamination and content in dietary supplements.  The use of 
these methods resulted in finding xenobiotic and/or essential elemental contamination in 
all of the dietary supplements analyzed.  Their implementation in both sample 
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preparation and analysis to determine elemental concentrations could serve as the 
foundation of a reliable, consistent, and efficient quality assurance program for the 
dietary supplement industry and regulatory agencies. The overwhelming trend that 
emerged from this study was the widespread contamination in the products from the 
different suppliers.  The elemental adulteration observed could result from the 
manufacturing process or the raw ingredients that comprise the supplements.  It is 
difficult to completely know their sources, but many ingredients, such as Stevia, come 
from countries where regulation is not as stringent as in the US.  It is clear from this 
study that in order to provide the highest quality of dietary supplements possible, all final 
products and ingredients must be analyzed for elemental contamination to ultimately 
meet the intent of the Good Manufacturing Practice standards of the Dietary Supplement 
Health and Education Act of 1994.  Further studies are necessary to evaluate the type, 
level, and frequency of dietary supplement contamination throughout the industry. 
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Chapter 3  
An Investigation of a Contaminated Zinc Dietary Supplement:  
Total Elemental Quantification by EPA Method 6020B, Zinc 
and Antimony Quantitation by EPA Method 6800, and 
Qualitative Antimony Speciation 
 
A leading dietary supplement company recalled some of their products due to 
antimony (Sb) contamination, which the manufacturer reported to have resulted from one 
of their raw materials.  An investigation was performed into the adulteration of one of 
these items, a zinc liquid dietary supplement, and the suspected contamination source.  
Both commercially available products and samples were obtained directly from the 
manufacturer with the goal of quantifying the amount and identifying the type of species 
responsible.  The concentrations of 64 elements in the zinc supplement and the raw 
material were determined by United States Environmental Protection Agency (EPA) 
Method 6020B using Inductively Coupled Plasma-Mass Spectrometry.  Isotope Dilution 
Mass Spectrometry (IDMS), a component of EPA Method 6800, was used to quantify the 
concentrations of Sb and zinc (Zn) in these samples.  Antimony speciation was performed 
focusing on three species – inorganic forms, Sb (III) and Sb (V), and an organic species, 
trimethylantimony dichloride – with analysis by Ion-exchange Chromatography-
Inductively Coupled Plasma-Mass Spectrometry.   
The complete inorganic elemental analysis found xenobiotics such as aluminum, 
arsenic, cadmium, lead, mercury, tin, and uranium at nanogram gram
-1
 levels in the zinc 
dietary supplement and raw material, in addition to Sb concentrations as high as the 
microgram gram
-1
 range.  In the zinc dietary supplement, the Sb IDMS analysis revealed 
three different concentration levels, while the Zn IDMS quantification determined the Zn 
  
  168 
concentration to be at the labeled level.  The Sb speciation results showed only the 
presence of the more toxic Sb (III) and Sb (V) in both products.  This work discovered 
that there was wider contamination in the zinc dietary supplement and raw material 
beyond the previously admitted Sb, which was from the more toxic species.  It 
demonstrated the importance of evaluating dietary supplements for elemental 
contamination, including speciation analysis, to provide the most accurate understanding 
of the toxicological impact of adulteration on human health. 
3.1 Introduction 
3.1.1 Overview 
A background on dietary supplements including their use, regulation, and 
elemental limits from different government agencies is described in Chapter 2.
1
  Zinc 
(Zn) is a frequent and popular component of dietary supplements, and this study 
acknowledges its importance and impact on human health.  The health concerns resulting 
from antimony (Sb) exposure are reviewed along with the quantification methods 
employed. 
3.1.2 Zinc Functions and Supplementation 
Zinc dietary supplements are most commonly used because of dietary deficiencies 
and the beneficial effects Zn has on the body.  Zinc performs multiple functions in the 
body and is involved in many different systems.  These roles include involvement in the 
structure or catalysis of proteins; oxidative stress prevention; structural, regulatory, and 
anti-oxidant functionality; cytoskeleton composition; and cellular communication.
2
  It is 
also needed for proper DNA production and cell development and differentiation.
3
  Both 
higher and lower than normal concentrations of Zn can cause oxidative stress and 
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negatively affect the transcription factors responsible for cellular functions, propagation, 
and survival.
2
  Zinc may prevent oxidative damage through the activation of 
metallothioneins, a group of proteins with a high amount of cysteine, that combine with 
redox active metals and are capable of removing oxidizers.
2
  When free Zn ions exist in 
the cell, metallothionein genes are expressed, resulting in an increased number of 
metallothionein proteins.
4
 
In addition to all of these important biological functions, Zn is commonly 
supplemented because of the beneficial effects it has on the immune system.  Zinc is 
required for a fully functioning immune system, and people deficient in Zn are more 
vulnerable to disease.
5
  Some of the clinical signs of a slight Zn deficiency include a 
suppressed immune system, decreased smell and taste sensitivity, the beginnings of night 
blindness, diminishing memory, and lower sperm production in males.
5
  Serious Zn 
shortage is noted by significant reductions in immune system capabilities, higher rates of 
illnesses, bullous pustular dermatitis, diarrhea, alopecia, and mental instabilities.
5
  In the 
immune system, Zn scarcity decreases the resistance to diseases along with the 
capabilities of the whole immune system through suppressed thymus functioning, T-
lymphocyte growth, lymphocyte production, and the performance of T cell-dependent B 
cells.
3
   
Abnormal Zn concentration disrupts the performance of the innate immune 
system, the first and broad response to pathogens.
6
  Natural killer cells, one part of the 
innate immune system that plays a key role fighting tumors and providing protection 
against illnesses, have decreased activity with lower than normal Zn levels.
6
  Likewise, 
both B and T cells are negatively affected by Zn deficiency.  B cells, the main type of 
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humoral immune cells, undergo changes in their development based on the Zn 
concentration.  B lymphocytes and their predecessors, mainly pre-B and immature B 
cells, are lower in total amount when Zn levels are less than normal, but the change in the 
number of mature B cells is not as great.
6
  In addition, the response to neoantigens is 
decreased during Zn shortage due to a lower number of naïve B cells.
6
  Another way Zn 
deficiency manifests is through the deterioration of T cells.
4
  Zinc plays a role in the 
production of T cells and determines cytolytic T cell activity.
6
  Studies have also shown 
that both T cell and natural killer cell counts increase as a result of using zinc 
supplements along with improvement of cell-mediated immune response through 
significantly more CD4
+
 T cells and cytotoxic T lymphocytes.
6
  
Because the body does not store Zn, deficiencies must be overcome through diet 
and supplementation.
3
  The World Health Organization recommends 10 milligrams day
-1
 
(mg day
-1
) of Zn intake for children at least one year old.
3
  In the United States and 
Europe, the average Zn consumption is 8 to 14 mg day
-1
, while it is 5 to 11 mg day
-1
 in 
developing countries.
2
  In 2002, the World Health Report approximated worldwide Zn 
deficiency at an average of 31% with values ranging from 6 to 73%.
2
  In the body, 
normal plasma Zn concentrations range from 12 to 16 micromol Liter
-1
 (µmol L
-1
) with 
the total amount of Zn in the body being between 2 and 4 grams (g).
6
   
3.1.3 Antimony Toxicity, Regulation, and Speciation 
Antimony is a toxic element present in the environment due to both human 
activity and natural processes.  Around 3.8 × 10
10
 g of Sb are emitted into the 
environment each year from human activities alone.
7
  The manmade release of Sb results 
from mining, smelting, and the burning of fossil fuels and plastics.
8
  Antimony has also 
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been incorporated into the production of ceramics, semiconductors, pharmaceutical 
products, alloys, and glass fire retardants.
9
  Diesel soot, worn down tires, and used brake 
linings are additional automobile related sources of atmospheric Sb release.
8
  Along with 
the anthropogenic generation of Sb, it exists naturally in the environment.  The Sb 
concentration is near 0.2 parts per million (ppm) in the earth’s crust.7  Background Sb 
concentrations in plants were quantified between 0.2 and 50 parts per billion (ppb).
10
  
Typical concentrations in unpolluted waters are in the nanogram Liter
-1
 (ng L
-1
) range 
and are normally below 300 ng L
-1
.
11
  This value has also been reported to be below 1 
microgram Liter
-1
 (µg L
-1
) with a concentration of around 100 µg L
-1
 near natural 
contamination sites.
7
  Levels can be substantially higher in industrial areas near certain 
factories and industries.
11
 
Antimony is not necessary for biological functions in plants, animals, and 
humans, and exposure to it results in toxic consequences.
8
  Many diseases including 
fibrosis, pneumonitis, destruction of bone marrow, and carcinomas can result from 
breathing in Sb.
7
  Antimony and its species have been determined to be priority 
contaminants by the United States Environmental Protection Agency (EPA)
7, 12
 and the 
German Research Council.
12
  The EPA has proposed
13
 and set
14
 the allowable Sb 
concentration in drinking water to be 6 ppb.  The European Union has regulated a limit of 
5 µg L
-1
 for Sb in drinking water.
15
  Japan advocates a threshold below 2 µg L
-1
.
7
  The 
Council of the European Communities established the maximum admissible Sb 
concentration in water at 0.01 mg L
-1
.
11
  Antimony has chemical and toxicological 
properties similar to arsenic,
9
 and these permissible concentrations are all at or lower than 
the 10 ppb limit set for arsenic.
16
  In 1989, the International Agency for Research on 
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Cancer determined Sb, as antimony trioxide, was a possible carcinogen.
17
  With this 
classification for a Sb species, a complete toxicological profile cannot be determined by 
only quantifying total elemental Sb; speciation analysis is necessary to provide the most 
complete and accurate assessment. 
It is vital to study the various species of Sb, as their toxicity is directly related to 
their different possible forms.
8
  Antimony exists inorganically as Sb (III) and Sb (V), and 
many organic compounds have been discovered, with more than 3,000 reported in the 
literature.
11
  Three methylated species have been identified in soil along with a 
triethylantimony form.
18
  Organic Sb compounds have been detected in plant extracts.
7
  
In natural water, both methylstibonic acid and dimethylstibinic acid have been 
observed.
11
  In aquatic waters at pH 8, both inorganic oxidation states are significantly 
hydrolyzed with Sb (III) observed as Sb(OH)3 and Sb (V) as Sb(OH)6
-
.
11
  In neutral 
aqueous solutions, it was found that trimethylantimony dichloride ((CH3)3SbCl2) most 
likely exists as [(CH3)3SbOH]
+
.
12
  For high performance liquid chromatography analysis, 
trimethylantimony dichloride is one of two compounds used to represent the oxidized 
compound of trimethylstibine.
12
  In reduced water, Sb (III) is the dominant compound, 
while Sb (V) is the major species in oxygenated water.
7
  The toxicity of elemental Sb is 
similar to that of elemental arsenic, but Sb (III) is reportedly ten times more toxic than Sb 
(V).
7-8, 11 
 Sb (III) has a great attraction for thiol groups and red blood cells, whereas Sb 
(V) is impervious to red blood cells.
7-8, 12
  When comparing the toxicity of the different 
Sb species, the inorganic forms are considered to be more harmful than the organic 
species.
7
  The EPA has not set environmental limits on the amounts of individual Sb 
species.
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3.1.4 Analysis Methods:  EPA Method 6020B and EPA Method 6800 
Many analytical methods and techniques can be used to quantify elements or 
species.  Included among these are the two used in this study:  EPA Method 6020B
19
 and 
EPA Method 6800.
20
  These two EPA methods are both approved for total elemental 
determination with mass spectrometric detection.  EPA Method 6020B employs 
Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) and uses traditional external 
calibration curves to quantify the sample, and it is only capable of measuring the total 
amount of an element.  In contrast, EPA Method 6800 can either be used to determine the 
amount of the total element or a particular species.  Because it uses an anthropogenic 
enriched analog, the element or species of interest must be polyisotopic, or have more 
than one naturally occurring isotope.  One component of EPA Method 6800, Isotope 
Dilution Mass Spectrometry (IDMS), is the best method for quantifying individual 
elements in a sample because it is capable of eliminating many sources of error inherent 
in mass spectrometric analysis.
21
  In IDMS, an enriched spike of the analyte with unique 
isotopic ratios is added and equilibrated with the sample.  The isotopic ratio measured by 
the mass spectrometer is then used to quantify the element.  The amount of a species 
present can be determined using Speciated Isotope Dilution Mass Spectrometry 
(SIDMS), the other part of EPA Method 6800.  During this process, the samples are 
spiked with a known amount of each isotopically enriched species of interest and 
equilibrated with the sample.
22
  As in IDMS, the isotopic ratios are computed and used to 
quantify the species.  SIDMS is capable of accounting for any species interconversion 
during sample preparation and analysis,
23
 which is not capable by traditional analytical 
methods.
24
  The quantification abilities seen in EPA Method 6800 can improve and 
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support the measurements made by the more traditional EPA Method 6020B.  This 
principle is applied to the Sb contamination in the zinc liquid dietary supplement in the 
current study. 
3.2 Materials and Methods 
3.2.1 Materials 
3.2.1.1 Chemicals and Standards 
All reagents were of analytical grade.  Double-deionized (DDI) water with 
resistivity of at least 18 MΩ-cm was obtained from a Barnstead NANOpure water system 
(Dubuque, IA, USA).  Optima grade water, American Chemical Society (ACS) grade 
nitric acid (HNO3), ACS grade hydrochloric acid (HCl), and disodium dihydrogen 
ethylene diamine tetraacetate salt dihydrate (Na2H2EDTA·2 H2O) were purchased from 
Fisher Scientific (Pittsburgh, PA, USA).  Antimony oxychloride (SbOCl) was produced 
by Pfaltz and Bauer (Waterbury, CT, USA).  Antimony oxide (Sb2O5), potassium 
hexahydroxoantimonate (KSb(OH)6), diethyl ether, and methylmagnesium iodide 
solution were procured from Sigma Aldrich (St. Louis, MO, USA).  Antimony trichloride 
(SbCl3), potassium antimonyl tartrate sesquihydrate (PATS), diammonium hydrogen 
phosphate ((NH4)2HPO4), anhydrous antimony pentachloride (SbCl5), and potassium 
hydrogen phthalate (KHP) were manufactured by Acros (Morris Plains, NJ, USA).  
ARISTAR ULTRA grade HNO3 was purchased from VWR (Radnor, PA, USA).  
Electronic grade (99.99%) chlorine gas and ultra high purity grade (99.999%) liquid 
argon was acquired from Airgas (Pittsburgh, PA, USA).  Multi-elemental standards were 
procured from High Purity Standards (Charleston, SC, USA).  An inorganic mercury 
standard and isotopically enriched Zn and Sb were obtained from Applied Isotope 
  
  175 
Technologies (Pittsburgh, PA, USA).  The tuning solution for the ICP-MS consisting of 
10 nanogram gram
-1 
(ng g
-1
) of lithium, yttrium, cerium, and tellurium in 2% (v:v) HNO3 
was purchased from Agilent Technologies (Santa Clara, CA, USA).  Standard Reference 
Material (SRM) 1640a, Trace Elements in Natural Water, was procured from the 
National Institute of Standards and Technology (NIST, Gaithersburg, MD, USA). 
3.2.1.2 Dietary Supplement Samples 
The zinc liquid dietary supplements and the suspected contaminated raw material 
were obtained either from the manufacturer or in commercially available form.  Thirteen 
lots (Lot 387-001 through Lot 387-013) of the zinc liquid dietary supplement and the 
alleged contamination source, a Stevia extract (Lot R351-002), were received directly 
from the manufacturer (Figure 5).  The commercially available zinc liquid dietary 
supplement samples (Figure 6) obtained were Lots 387-003 (3 samples labeled as -1, -2, 
and -3), 387-011 (3 samples labeled as -1, -2, and -3), 487-003 (3 samples labeled as -1, -
2, and -3), and 487-004. 
 
Figure 5:  Supplement and Stevia samples obtained from the manufacturer. 
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Figure 6:  Some of the commercially available zinc liquid dietary supplements. 
3.2.1.3 Instrumentation 
An Agilent 4500 ICP-MS with a concentric nebulizer, Scott double-pass spray 
chamber, quartz torch, and quadrupole mass analyzer performed the total elemental 
quantification, Zn and Sb IDMS, and Sb speciation analyses.  The samples for total 
elemental and IDMS quantifications were stored in a CETAC (Omaha, NE, USA) 
ASX500 autosampler before being analyzed.  They were introduced into the ICP-MS 
using the peristaltic pump at a speed of 0.1 revolutions per second (rps) via the micromist 
nebulizer of the spray chamber.  Both the ICP-MS and autosampler were located in an 
International Organization for Standardization Class 6 cleanroom laboratory.  The 
optimized operating parameters of the ICP-MS and autosampler are shown in Table 10. 
Antimony speciation was completed using Ion-exchange Chromatography-
Inductively Coupled Plasma-Mass Spectrometry (IC-ICP-MS). The Metrohm-Peak 
(Riverview, FL, USA) Ion Chromatography (IC) System consisted of two 818 IC pumps, 
a 762 IC interface, and an 838 IC autosampler.  It included a separation center enclosure 
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including a six-port sample injector with a 100 microliter (µL) sample loop.  The IC 
column outlet was connected to the ICP-MS nebulizer inlet using a piece of 
perfluoroalkoxy tubing via a switching valve.  A Hamilton (Reno, NV, USA) PRP-X100 
(5 micrometer (µm) particle size, 4.1 millimeter (mm) × 100 mm) anion exchange 
chromatography column was used.  The complete chromatographic settings are listed in 
Table 10. 
Table 10:  Optimized settings for the Agilent 4500 ICP-MS and the Metrohm-Peak IC system for 
the total elemental quantification, antimony and zinc IDMS analysis, and antimony speciation. 
Agilent 4500 ICP-MS 
Rf Power 1475 W 
Spray Chamber Temperature 2 °C 
Plasma Gas 15.0 L min
-1
 
Auxiliary Gas 1.0 L min
-1
 
Acquisition Mode Spectrum*# 
Time Resolved Analysis† 
Peak Pattern 3 points mass
-1
 
Integration Time 0.30 sec mass
-1*† 
0.50 sec mass
-1
# 
Replicates 4 
Total Analysis Time 56 sec Standard A + Hg* 
14 sec Standard B* 
  8 sec Standard C* 
Nebulizer Pump Speed 0.10 rps 
Uptake Time 30 sec 
Stabilization Time 10 sec 
Metrohm-Peak IC System 
Column Hamilton PRP-X100 (5 µm, 4.1 mm × 100 mm) 
Mobile Phases A: 20 mM Na
2
H
2
EDTA·2 H2O and 2 mM KHP 
B: 50 mM (NH
4
)
2
HPO
4
 
Gradient Program 0 min, 0% B; 1 min, 0% B; 1.5 min, 100% B; 6 min, 
100% B; 6.5 min, 0% B; 9 min, 0% B 
Flow Rate 1.5 mL min-1 
Injection Volume 100 µL 
Column Temperature Ambient 
Total Analysis Time 9 min† 
* For total elemental analysis 
# For Zn and Sb IDMS analysis 
† For Sb speciation analysis 
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3.2.2 Methods 
3.2.2.1 Total Elemental Concentration Quantification by EPA Method 6020B 
For the zinc liquid dietary supplement samples, 1 g of sample was diluted twenty-
fold in Optima grade water, while 0.5 g of the solid Stevia extract was diluted forty-fold 
in Optima grade water and vortexed to produce a homogeneous solution.  For each 
sample, three subsamples were prepared and stored at ambient conditions until they were 
analyzed, typically within 24 hours. 
Total elemental quantification was performed according to EPA Method 6020B.  
On each day of analysis, the system was aspirated with 2% HNO3 for 30 minutes before 
tuning the instrument with the Agilent tuning solution at 10 ng g
-1
 and determining the 
pulse/analog factor.  External calibration curves were created at 0, 10, 25, 50, and 100 
ng g
-1
 for 64 elements using the three multi-element and inorganic mercury standards.  
Analysis was performed in spectrum mode using three points per mass.  An integration 
time of 0.3 seconds per point was used.  Four replicates were performed from each 
subsample, and between each replicate, the autosampler probe was washed with both 2% 
ACS grade HNO3 in DDI water and then Optima grade water for 30 seconds each. 
SRM 1640a was analyzed to validate the sample preparation and analysis 
methodologies.  The sample preparation was modified slightly because SRM 1640a is 
formulated in 2% HNO3 (v:v).  SRM 1640a was diluted four-fold in Optima grade water 
to maintain final elemental concentrations above instrument detection limits.  The 
calibration curve solutions at the previously mentioned concentrations were prepared in 
0.5% ARISTAR ULTRA grade HNO3 to acid match the SRM 1640a sample solutions.  
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All other sample preparation, instrument, and autosampler settings were the same as 
when the zinc liquid supplement and Stevia samples were analyzed. 
3.2.2.2 Zinc and Antimony IDMS Quantification 
Zinc and Sb IDMS analyses were completed according to EPA Method 6800.  For 
the Zn IDMS quantification, each zinc liquid supplement was diluted 1000-fold to make a 
stock solution due to the high Zn concentration in the sample.  Three subsamples were 
created by combining 0.1 g of the stock solution, 0.1 g of a 9.4239 microgram gram
-1
 
(µg g
-1
) 99.71% 
68
Zn isotopically enriched solution, and 10 g of Optima grade water.  For 
the Stevia, 0.1 g of sample was combined with 0.1 g of the same spike solution and 
diluted to 10 g using Optima grade water.  Elemental standards of naturally occurring Zn 
were prepared at 0, 20, 40, 60, 80, and 100 ng g
-1
 in Optima grade water.  Five IDMS 
blanks were also made by spiking 0.02 g of the Zn spike solution in 10 milliliter (mL) of 
Optima grade water.  The IDMS analysis was performed monitoring 
66
Zn and 
68
Zn, and 
both mass bias and deadtime correction were calculated. 
Antimony IDMS quantification was performed in a similar manner as 0.2 g of 
supplement and 0.2 g of a 99.32% 
123
Sb isotopically enriched solution were diluted to 10 
mL with Optima grade water.  Due to the distinct concentration ranges of Sb found in the 
EPA Method 6020B results, different concentrations of the spike solution were used to 
stay within the optimal sample to spike ratio required for IDMS analysis.
21
  For the Sb 
IDMS analysis of the Stevia, 0.1 g of sample was combined with 0.25 g of a 13.8031 
µg g
-1
 99.32% 
123
Sb spike and diluted to 10 mL with Optima grade water.  Naturally 
occurring elemental Sb solutions were made at 0, 20, 40, 60, 80, and 100 ng g
-1
 in Optima 
grade water.  As with the Zn IMDS analysis, five IDMS blanks were prepared using 0.02 
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g of the appropriate Sb enriched solution in Optima grade water.  During IDMS 
quantification, 
121
Sb and 
123
Sb were the isotopes used along with the determination of 
mass bias and deadtime correction. 
Both Zn and Sb IDMS quantification was performed on SRM 1640a using the 
same enriched spike solutions.  In separate analyses, 5 g of SRM 1640a and 0.1 g of each 
respective spike were diluted to 10 g with Optima grade water.  Natural standards were 
made for both Zn and Sb at 0, 20, 40, 60, 80, and 100 ng g
-1
 and five IDMS blanks were 
prepared as previously described.  Mass bias and deadtime correction were calculated in 
the same manner as with the samples. 
For all IDMS analyses, three subsamples were prepared with four replicates 
analyzed from each.  The integration time was increased to 0.5 seconds per mass in 
spectrum mode.  The same wash solutions, wash times, and autosampler settings were 
used for the IDMS quantification of Zn and Sb as during the EPA Method 6020B total 
elemental analysis 
3.2.2.3 Synthesis of Trimethylantimony Dichloride 
Trimethylantimony dichloride was synthesized using a modified protocol based 
on Doak et al.
25
  Before beginning, all glassware was flame dried and flushed with 
nitrogen.  Ten g (43.8 millimol (mmol)) of anhydrous SbCl3 was combined with 25 
milliliters (mL) of dry diethyl ether.  The solution was cooled to -20 °C in an acetone 
bath by the occasional addition of dry ice.  Once cooled, 45 mL of 3 molar (135 mmol) 
methylmagnesium iodide solution was added drop wise while the solution was stirred.  
After 4 hours, all of the SbCl3 was digested, and the mixture turned gray indicating the 
end of the reaction.  Two layers were formed with the top layer being clear and the lower 
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layer a brownish black.  The solution was then distilled for one hour at 80 °C in an 
oxygen- and moisture free ethanol distillation setup and the trimethylstibine was 
collected in a flask.  It was cooled in an ice bath, and chlorine gas was purged slowly to 
the stirring solution for fifteen minutes until the slurry turned yellowish in color.  (Note:  
This process must be controlled very carefully as the reaction is exothermic and the 
pressure generated by the chlorine gas can be very strong.)  The precipitate of 
trimethylantimony dichloride was filtered and washed with diethyl ether.  The solid was 
recrystallized from DDI water. 
3.2.2.4 Antimony Speciation 
The Sb speciation analysis focused on three forms, Sb (III), Sb (V), and 
(CH3)3SbCl2, to determine the type present in the zinc liquid dietary supplement and 
Stevia extract.  The Sb (III) species (antimony trichloride, antimony oxychloride, and 
PATS), Sb (V) species (potassium hexahydroxyantimonate, antimony pentoxide, and 
antimony pentachloride), and trimethylantimony dichloride were each dissolved in 
Optima grade water.  A small amount of HCl was used to help solubilize the SbCl3, while 
Sb2O5 was not able to be dissolved.  The structures for each of the analyzed Sb species 
are shown in Figure 7.  Each of the Sb species was run through the Hamilton PRP-X100 
anion exchange column at a concentration of 100 ng g
-1
 to determine the respective 
elution profile.  An isocratic elution of 20 millimolar (mM) Na2H2EDTA·2 H2O with 2 
mM KHP and 50 mM (NH4)2HPO4 was performed over a 9 minute period that was 
slightly modified from the literature.
26-27
  All chromatography solvents were filtered 
through a 0.45 µm membrane filter.  Antimony speciation was completed in time 
resolved analysis mode with an integration time of 0.3 seconds per mass.  After the 
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elution profile was established for all of the Sb compounds, the zinc liquid supplement 
and Stevia were diluted in Optima grade water so the Sb was present in the ng g
-1
 range, 
and analyzed using the previously described method.  The optimized elution conditions 
for these Sb species are listed in Table 10. 
    
1
8
3
 
 
Figure 7:  The chemical structure of the six antimony species investigated.
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3.3 Results 
3.3.1 Analytical Figures of Merit and Validation of EPA Methods 
All elements displayed linearity on the five point external calibration curves for 
each of the three standard solutions.  They had correlation coefficient values greater than 
the 0.998 specified in EPA Method 6020B.  The four replicates for each calibration point 
displayed a variation of less than 5% indicating that the obtained measurements were 
highly reproducible.  The elemental detection limits (DLs) were defined as the average of 
the blank concentration for each element plus three times the standard deviation of the 
blank measurements for that element.
28
  The DLs for all of the elements were below 1 
ng g
-1 
for nearly all elements.   
The validation of the sample preparation and analysis methodologies was 
performed by comparing the certified values for SRM 1640a to the measured values 
obtained using EPA Method 6020B.  The EPA Method 6020B results for all of the 
certified elements in SRM 1640a are shown in Table 11 and Figure 8 with the mean (n = 
12) and 95% confidence intervals (CIs).  The confidence intervals of the measured and 
certified values overlapped for iron (Fe), manganese (Mn), vanadium (V), and Zn.  
Nearly all of the other confidence intervals were within 10% of the certified values, 
validating the sample preparation and measurement protocols.  The recovery efficiencies 
ranged between 71.6 and 126.5% when comparing the mean certified values to the mean 
measured quantities.  Only 4 of the 20 certified elements had recoveries that differed by 
more than 20% when comparing average values.  The accuracy of all measurements in 
this study improved with the inclusion of the 95% CIs.  The precision determined by the 
95% CIs was within 10% of the measured average values for all of the certified elements 
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in SRM 1598a, with only 2 elements having values greater than 5%.  This precision level 
seen for SRM 1598a was sustained for the remainder of the study, as the results for most 
elements had CIs of less than 10% of the mean values.  This study provided 95% CIs for 
all detectable quantities in the dietary supplement and Stevia samples. 
Table 11:  Concentrations (ng g-1) of the certified elements determined in for SRM 1640a (n = 
12, 95% CIs) using EPA Method 6020B. 
Element Certified Value (ng g
-1) Measured Value (ng g-1) 
Ag 8.017 ± 0.042 5.79 ± 0.07 
Al 52.6 ± 1.8 44.9 ± 0.7 
As 8.010 ± 0.067 7.75 ± 0.12 
B 300.7 ± 3.1 252 ± 5 
Ba 150.60 ± 0.74 134 ± 1 
Be 3.002 ± 0.027 2.42 ± 0.14 
Cd 3.961 ± 0.072 5.01 ± 0.04 
Co 20.08 ± 0.24 19.4 ± 0.2 
Cr 40.22 ± 0.28 39.2 ± 0.6 
Cu 85.07 ± 0.48 81.9 ± 0.8 
Fe 36.5 ± 1.7 41.5 ± 3.2 
Mn 40.07 ± 0.35 39.3 ± 0.5 
Mo 45.24 ± 0.59 40.9 ± 0.5 
Ni 25.12 ± 0.12 23.7 ± 0.3 
Pb 12.005 ± 0.40 <DL 
Sb 5.064 ± 0.045 3.66 ± 0.04 
Se 19.97 ± 0.16 17.0 ± 0.5 
Sr 125.03 ± 0.86 120 ± 1 
Tl 1.606 ± 0.015 <DL 
U 25.15 ± 0.26 18.0 ± 0.2 
V 14.93 ± 0.21 15.0 ± 0.2 
Zn 55.20 ± 0.32 56.2 ± 1.1 
<DL: below detection limit, DL for Pb is 3 ng g
-1
 for Pb and 0.5 ng g
-1
 for Tl. 
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Figure 8:  Concentrations (ng g
-1
) of certified elements in SRM 1640a using EPA Method 6020B (n = 12, 95% CIs).  Measured values not shown 
are <DL. 
<DL: below detection limit, DL for Pb is 3 ng g
-1
 and 0.5 ng g
-1
 for Tl. 
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After determining the total elemental concentrations by EPA Method 6020B, EPA 
Method 6800 was used to quantify Sb and Zn by IDMS.  As with the elemental analysis, 
SRM 1640a was used to validate the sample preparation and analysis.  The EPA Method 
6800 results along with those from EPA Method 6020B for Sb and Zn are shown in Table 
12.  The quantification results for Sb by EPA Method 6800 are more accurate than 
Method 6020B results.  The Zn and Sb results by EPA Method 6800 are both more 
precise than those from EPA Method 6020B. 
Table 12:  EPA Method 6020B and EPA Method 6800 concentrations (ng g-1) for Sb and Zn in 
SRM 1640a (n = 12, 95% CIs). 
Element 
Certified Values 
(ng g
-1
) 
EPA Method 6020B  
Concentration (ng g
-1
) 
EPA Method 6800 
Concentration (ng g
-1
) 
Sb 5.064 ± 0.045 3.66 ± 0.04 4.768 ± 0.040 
Zn 55.20 ± 0.32 56.2 ± 1.1 52.16 ± 0.002 
 
3.3.2 Total Elemental Quantification Using EPA Method 6020B 
With the sample preparation and analysis methodologies validated using SRM 
1640a, the focus turned to the zinc liquid dietary supplements and Stevia extract.  The 
EPA Method 6020B elemental contamination results are shown in Tables 13 and 14 and 
Figures 9-11 for selected elements of interest.  Antimony was found in concentrations 
ranging from 11 to 26 µg g
-1
 in Lots 387-001 to 387-009.  Lots 387-010 to 387-013 had 
values between 105 and 450 ng g
-1
 with 11 and 15 ng g
-1
 of Sb in lots 487-003 and 487-
004, respectively.  The Stevia contained 27.1 µg g
-1
 of Sb.   
In addition to Sb, the xenobiotics aluminum (Al), arsenic (As), cadmium (Cd), 
lead (Pb), mercury (Hg), tin (Sn), and uranium (U) were found at ng g
-1
 amounts.  The Al 
levels in the zinc dietary supplement ranged from 27 to 97 ng g
-1
, and the Stevia had a 
concentration of 689 ng g
-1
.  Numerous lots had quantities below the DL for As, but 
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others were as high as 33 ng g
-1
.  The highest amount of As was discovered in the Stevia 
at 172 ng g
-1
.  The Stevia contained 83 ng g
-1
 of Cd, while the values ranged from below 
the DL to 45 ng g
-1
.  The greatest quantity of Pb was found in the Stevia at 105 ng g
-1
, 
while the levels in the zinc dietary supplement ranged from 24 to 41 ng g
-1
.  As with Pb, 
the highest amount of Hg was observed in the Stevia at 277 ng g
-1
.  All lots of the zinc 
dietary supplement contained Hg at quantities varying from 71 to 106 ng g
-1
, and the 
highest amounts of Sn and U were found in the Stevia at 120 ng g
-1
 and 29 ng g
-1
, 
respectively.  The level of Sn in the zinc dietary supplements ranged from 31 to 49 ng g
-1
 
with U concentrations fluctuating between 12 and 18 ng g
-1
.  In all of the samples 
analyzed, the amount of V present was determined to be below the DL. 
Beneficial elements were also detected in the zinc dietary supplement and Stevia.  
Chromium (Cr), which is a nutrient as Cr (III), had concentrations of 37 to 254 ng g
-1
 in 
the zinc dietary supplement and 553 ng g
-1
 in the Stevia.  Cobalt (Co) was observed to be 
below the DL in some lots of the zinc dietary supplement, but the detectable quantities 
ranged from 15 to 19 ng g
-1
.  Low amounts of copper (Cu) were found between 11 and 39 
ng g
-1
 in the zinc dietary supplement and at 401 ng g
-1
 in the Stevia.  Iron was determined 
to be 8,190 ng g
-1
 in the Stevia and the concentrations varied from 146 to 2,580 ng g
-1
 in 
the zinc dietary supplement.  Over 500 ng g
-1
 of (Mn) was observed in the Stevia and 
levels from 7 to 38 ng g
-1
 were seen in the zinc dietary supplement.  Molybdenum (Mo) 
was found at amounts from 22 to 50 ng g
-1
 in some lots of the zinc dietary supplement 
and at 64 ng g
-1
 in the Stevia.  Finally, selenium (Se), which is beneficial in moderation 
and toxic in excess, was discovered at quantities between 433 and 2,440 ng g
-1
. 
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Table 13:  Concentrations (ng g-1) for selected xenobiotic elements in the zinc liquid dietary supplements and Stevia extract using EPA Method 
6020B (n = 12, 95% CIs). 
Lot Al As Cd Hg Pb Sb Sn U V 
387-001 27.2 ± 3.4 <DL 9.87 ± 0.27 105 ± 0.4 28.3 ± 1.1 12,300 ± 300 49.5 ± 0.4 13.4 ± 0.1 <DL 
387-002 27.9 ± 3.0 <DL 11.5 ± 0.4 102 ± 0.4 29.6 ± 0.6 11,200 ± 500 49.2 ± 0.2 13.4 ± 0.03 <DL 
387-003 30.6 ± 3.7 <DL 11.7 ± 0.4 98.6 ± 0.4 29.8 ± 1.5 11,500 ± 100 48.3 ± 0.1 13.2 ± 0.04 <DL 
387-004 27.5 ± 2.4 <DL 8.14 ± 0.28 98.3 ± 0.9 34.2 ± 5.5 18,000 ± 100 49.0 ± 0.4 13.3 ± 0.1 <DL 
387-005 28.5 ± 2.7 <DL 9.34 ± 0.26 97.3 ± 0.8 28.0 ± 1.5 11,000 ± 100 48.4 ± 0.4 13.2 ± 0.1 <DL 
387-006 27.3 ± 3.2 <DL 9.12 ± 0.27 99.2 ± 0.2 27.8 ± 2.0 12,200 ± 100 49.4 ± 0.1 13.5 ± 0.04 <DL 
387-007 40.4 ± 9.6 <DL <DL 98.3 ± 11.3 28.4 ± 1.5 16,300 ± 100 38.6 ± 1.4 12.2 ± 0.4 <DL 
387-008 43.6 ± 8.4 <DL <DL 78.5 ± 1.9 27.7 ± 1.0 25,700 ± 300 38.7 ± 0.3 12.2 ± 0.1 <DL 
387-009 39.6 ± 3.4 <DL <DL 71.6 ± 1.4 27.3 ± 0.8 16,700 ± 300 37.4 ± 0.6 11.8 ± 0.2 <DL 
387-010 39.7 ± 4.6 <DL <DL 71.8 ± 0.5 25.5 ± 0.6 237 ± 15 38.9 ± 0.4 12.2 ± 0.1 <DL 
387-011 33.4 ± 5.8 <DL <DL 71.1 ± 0.6 25.0 ± 0.8 105 ± 2 38.6 ± 0.4 12.3 ± 0.1 <DL 
387-012 35.5 ± 5.6 <DL <DL 71.6 ± 1.1 24.3 ± 0.6 450 ± 9 39.1 ± 0.6 12.4 ± 0.2 <DL 
387-013 40.8 ± 2.3 <DL <DL 71.1 ± 0.9 24.8 ± 0.7 386 ± 6 38.8 ± 0.5 12.4 ± 0.1 <DL 
R351-002 689 ± 87  172 ± 21 <DL 277 ± 31 105 ± 7 27,100 ± 700 120 ± 1 28.9 ± 0.2 <DL 
387-003-1 87.5 ± 11.3 33.2 ± 2.1 83.5 ± 14.8 105 ± 1 38.7 ± 1.3 15,900 ± 200 31.7 ± 0.3 17.4 ± 0.2 <DL 
387-003-2 83.5 ± 7.5 30.8 ± 0.7 45.4 ± 6.7 104 ± 1 38.4 ± 0.4 16,600 ± 200 32.0 ± 0.2 17.5 ± 0.1 <DL 
387-003-3 75.6 ± 3.2 31.3 ± 0.9 34.2 ± 4.2 103 ± 2 38.8 ± 0.7 16,600 ± 200 32.1 ± 0.5 17.6 ± 0.3 <DL 
387-011-1 86.0 ± 3.4 26.2 ± 0.8 30.6 ± 1.2 106 ± 3 39.2 ± 0.6 110 ± 24 33.1 ± 1.0 18.1 ± 0.5 <DL 
387-011-2 88.3 ± 4.8 24.6 ± 0.5 29.2 ± 1.7 100 ± 1 37.6 ± 0.4 87.0 ± 1.8 31.6 ± 0.4 17.2 ± 0.2 <DL 
387-011-3 80.4 ± 5.1 24.7 ± 0.5 27.6 ± 0.9 103 ± 2 39.2 ± 0.4 85.9 ± 2.4 32.2 ± 0.7 17.7 ± 0.3 <DL 
487-003-1 88.7 ± 3.5 24.1 ± 0.3 30.5 ± 1.0 104 ± 1 40.2 ± 0.4 11.1 ± 0.8 32.5 ± 0.2 17.8 ± 0.1 <DL 
487-003-2 95.1 ± 5.1 24.5 ± 0.3 30.2 ± 1.3 106 ± 2 40.5 ± 0.4 11.6 ± 0.7 33.0 ± 0.6 18.1 ± 0.3 <DL 
487-003-3 97.0 ± 5.4 23.5 ± 0.3 33.2 ± 1.8 102 ± 1 40.2 ± 0.6 12.2 ± 1.0 32.2 ± 0.4 17.5 ± 0.2 <DL 
487-004 92.6 ± 5.7 24.0 ± 0.5 33.1 ± 1.4 105 ± 1 41.3 ± 0.7 15.4 ± 1.1 33.2 ± 0.3 17.9 ± 0.1 <DL 
<DL: below detection limit, DL is 1 ng g
-1
 for As, 0.5 ng g
-1
 for Cd, and 0.25 ng g
-1
 for V. 
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Figure 9:  Concentrations (ng g-1) for selected xenobiotic elements in the zinc liquid dietary supplements using EPA Method 6020B (n = 12, 95% 
CIs).  Values not shown are <DL.  DL is 1 ng g-1 for As and 0.5 ng g-1 for Cd.  The samples directly from manufacturer are lots 1-13 and the 
commercially available samples are lots 3, 11, 14, and 15. 
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Table 14:  Concentrations (ng g-1) for selected beneficial elements in the zinc liquid dietary supplements and Stevia extract using EPA Method 
6020B (n = 12, 95% CIs).  The samples directly from manufacturer are lots 1-13 and Stevia and the commercially available samples are lots 3, 11, 
14, and 15. 
Lot Co Cr Cu Fe Mn Mo Ni Se Zn 
387-001 <DL 173 ± 8 25.1 ± 1.3 1,130 ± 300 7.55 ± 1.98 23.5 ± 0.7 66.6 ± 16.2 433 ± 59 2,560,000 ± 180,000 
387-002 <DL 183 ± 3 25.7 ± 0.6 1,580 ± 150 9.33 ± 2.09 24.0 ± 1.3 42.7 ± 3.9 663 ± 235 2,840,000 ± 140,000 
387-003 <DL 254 ± 4 25.5 ± 0.7 2,110 ± 220 19.2 ± 1.3 22.9 ± 0.3 117 ± 21 1,360 ± 580 2,950,000 ± 140,000 
387-004 <DL 160 ± 5 21.3 ± 0.4 2,030 ± 190 13.2 ± 3.3 22.9 ± 0.5 47.5 ± 23.5 2,440 ± 940 2,560,000 ± 60,000 
387-005 <DL 154 ± 5 22.1 ± 0.5 1,880 ± 340 14.9 ± 2.5 22.2 ± 0.5 65.7 ± 21.4 2,330 ± 1,080 2,650,000 ± 270,000 
387-006 <DL 209 ± 5 22.2 ± 0.5 1,960 ± 180 27.7 ± 3.5 24.0 ± 0.4 94.6 ± 4.5 2,150 ± 870 2,780,000 ± 210,000 
387-007 <DL 108 ± 12 27.2 ± 13.3 1,200 ± 400 24.8 ± 3.1 46.8 ± 4.7 6.11 ± 3.71 1,040 ± 370 2,620,000 ± 80,000 
387-008 <DL 183 ± 19 22.7 ± 5.3 2,580 ± 780 38.4 ± 3.4 50.3 ± 1.9 102 ± 11 1,030 ± 440 2,480,000 ± 140,000 
387-009 <DL 99.9 ± 12.7 16.2 ± 2.7 1,650 ± 370 27.5 ± 1.3 46.4 ± 2.4 46.8 ± 7.4 730 ± 89 2,430,000 ± 130,000   
387-010 <DL 106 ± 14 12.6 ± 1.6 2,340 ± 370 24.6 ± 1.8 48.7 ± 1.7 43.5 ± 4.3 767 ± 128 2,490,000 ± 120,000 
387-011 <DL 57.4 ± 12.2 12.8 ± 4.1 2,000 ± 980 22.0 ± 1.8 47.9 ± 2.1 25.1 ± 11.1 854 ± 291 2,640,000 ± 120,000 
387-012 <DL 37.2 ±13.2 12.1 ± 3.2 1,310 ± 400 18.4 ± 1.6 48.2 ± 1.3 <DL 659 ± 169 2,410,000 ± 180,000 
387-013 <DL 59.3 ± 8.1 11.1 ± 3.1 1,120 ± 320 20.5 ± 2.0 47.7 ± 2.1 21.8 ± 8.6 652 ± 157 2,330,000 ± 110,000 
R351-002 15.2 ± 4.3 553 ± 116 401 ± 34 8,190 ± 1,230 525 ± 67 64.6 ± 3.5 272 ± 53 17.1 ± 10.5 765 ± 182 
387-003-1 18.6 ± 0.8 101 ± 24 39.0 ± 5.9 283 ± 165 35.2 ± 2.7 <DL 135 ± 26 987 ± 205 2,330,000 ± 90,000 
387-003-2 17.9 ± 0.4 67.9 ± 4.9 32.2 ± 0.9 146 ± 86 32.5 ± 1.2 <DL 66.4 ± 13.5 725 ± 54 2,240,000 ± 150,000 
387-003-3 18.3 ± 0.3 75.4 ± 6.4 33.8 ± 0.8 329 ± 106 33.6 ± 0.9 <DL 44.7 ± 7.5 883 ± 81 2,210,000 ± 100,000 
387-011-1 19.3 ± 0.7 85.5 ± 13.0 37.4 ± 1.2 472 ± 113 35.6 ± 1.5 <DL 48.6 ± 2.2 1,230 ± 80 2,010,000 ± 120,000 
387-011-2 18.7 ± 0.5 102 ± 11 35.2 ± 1.6 586 ± 132 34.9 ± 1.2 <DL 45.8 ± 2.5 1,300 ± 150 2,120,000 ± 90,000 
387-011-3 18.8 ± 0.5 92.0 ± 9.3 35.0 ± 0.9 749 ± 134 35.3 ± 1.8 <DL 46.2 ± 2.1 956 ± 142 1,970,000 ± 80,000 
487-003-1 18.6 ± 0.3 89.7 ± 9.2 36.3 ± 0.9 730 ± 156 34.6 ± 1.3 <DL 40.2 ± 1.9 858 ± 67 2,190,000 ± 180,000 
487-003-2 19.3 ± 0.6 92.6 ± 7.2 38.2 ± 0.5 884 ± 53 35.1 ± 1.0 <DL 40.3 ± 2.3 887 ± 36 2,200,000 ± 340,000 
487-003-3 18.7 ± 0.5 106 ± 7 39.0 ± 1.1 1,040 ± 160 35.9 ± 1.2 <DL 50.2 ± 5.2 978 ± 76 1,910,000 ± 130,000 
487-004 19.0 ± 0.5 118 ± 19 38.9 ± 2.3 1,190 ± 430 35.3 ± 1.5 <DL 52.4 ± 4.2 914 ± 143 3,670,000 ± 450,000 
<DL: below detection limit, DL is 0.8 ng g
-1
 for Co, 1 ng g
-1
 for Mo, and 0.1 ng g
-1
 for Ni. 
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Figure 10:  Concentrations (ng g-1) for selected beneficial elements in the zinc liquid dietary supplements using EPA Method 6020B (n = 12, 95% 
CIs).  Values not shown are <DL.  DL is 0.8 ng g-1 for Cd, 1 ng g-1 for Mo, and 0.1 ng g-1 for Ni.  The samples directly from manufacturer are lots 
1-13 and the commercially available samples are lots 3, 11, 14, and 15. 
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Figure 11:  Concentrations (ng g-1) for Fe and Se in the zinc liquid dietary supplements using EPA Method 6020B (n = 12, 95% CIs).  The 
samples directly from manufacturer are lots 1-13 and the commercially available samples are lots 3, 11, 14, and 15. 
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3.3.3 Antimony and Zinc IDMS Quantification 
The EPA Method 6800 results for Sb are shown in Table 15 with three distinct 
concentration ranges.  Lots 387-001 through 387-009 had Sb concentrations varying 
between 15 and 27 µg g
-1
.  Then, the next four produced (Lots 387-010 to 387-013) had 
Sb values ranging from 78 to 450 ng g
-1
.  Finally, Lots 487-003 and 487-004, produced 
after the initial Sb contamination was realized, had Sb concentrations of 335 and 630 
picogram gram
-1
 (pg g
-1
), respectively.  The Sb results for Lots 487-003 and 487-004 
differed between EPA Method 6020B and EPA Method 6800.  The Stevia had a Sb 
concentration of 31.6 µg g
-1
 according to EPA Method 6800.  This data indicates that the 
Stevia could be a source of contamination in the zinc dietary supplements.  A comparison 
of the EPA Method 6020B and EPA Method 6800 results for Sb are shown in Figures 12 
and 13 and Table 16. 
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Table 15:  Concentrations (ng g-1) for Sb in the zinc liquid dietary supplements and Stevia extract 
using EPA Method 6800 (n = 12, 95% CIs).  The samples directly from manufacturer are lots 1-
13 and Stevia extract and the commercially available samples are lots 3, 11, 14, and 15. 
Lot EPA Method 6800 Sb Concentration (ng g
-1) 
387-001 17,650 ± 150 
387-002 15,770 ± 250 
387-003 17,000 ± 70 
387-004 27,310 ± 280 
387-005 16,830 ± 240 
387-006 18,060 ± 80 
387-007 15,590 ± 90 
387-008 24,450 ± 160 
387-009 16,120 ± 60 
387-010 218.4 ± 24.5 
387-011 78.84 ± 1.34 
387-012 454.1 ± 12.2 
387-013 380.9 ± 29.2 
R351-002 31,620 ± 300 
387-003-1 14,430 ± 480 
387-003-2 15,720 ± 50 
387-003-3 15,370 ± 30 
387-011-1 96.15 ± 12.79 
387-011-2 79.55 ± 5.29 
387-011-3 65.00 ± 1.13 
487-003-1 0.4486 ± 0.1586 
487-003-2 0.3350 ± 0.0509 
487-003-3 0.3040 ± 0.0364 
487-004 0.6307 ± 0.0968 
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Figure 12:  Concentrations (ng g-1) for Sb in the zinc liquid dietary supplements and Stevia extract using EPA Method 6020B and EPA Method 
6800 (n = 12, 95% CIs).  The samples directly from manufacturer are lots 1-9 and Stevia extract and the commercially available samples are lots 3. 
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Figure 13:  Concentrations (ng g-1) for Sb in the zinc liquid dietary supplements using EPA Method 6020B and EPA Method 6800 (n = 12, 95% 
CIs).  The samples directly from manufacturer are lots 10-13 and Stevia extract and the commercially available samples are lots 11, 14, and 15. 
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Table 16:  Concentrations (ng g-1) for Sb in SRM 1640a, the zinc liquid dietary supplements, and 
Stevia extract using EPA Method 6020B (n = 12, 95% CIs).  The samples directly from 
manufacturer are lots 1-13 and Stevia and the commercially available samples are lots 3, 11, 14, 
and 15. 
Lot 
EPA Method 6020B Sb 
Concentration (ng g-1) 
EPA Method 6800 Sb 
Concentration (ng g-1) 
SRM 1640a 3.66 ± 0.04 4.768 ± 0.0396 
387-001 12,300 ± 300 17,650 ± 150 
387-002 11,200 ± 500 15,770 ± 250 
387-003 11,500 ± 100 17,000 ± 70 
387-004 18,000 ± 100 27,310 ± 280 
387-005 11,000 ± 100 16,830 ± 240 
387-006 12,200 ± 100 18,060 ± 80 
387-007 16,300 ± 100 15,590 ± 90 
387-008 25,700 ± 300 24,450 ± 160 
387-009 16,700 ± 300 16,120 ± 60 
387-010 237 ± 15 218.4 ± 24.5 
387-011 105 ± 2 78.84 ± 1.34 
387-012 450 ± 9 454.1 ± 12.2 
387-013 386 ± 6 380.9 ± 29.2 
R351-002 27,100 ± 700 31,620 ± 300 
387-003-1 15,900 ± 200 14,430 ± 480 
387-003-2 16,600 ± 200 15,720 ± 50 
387-003-3 16,600 ± 200 15,370 ± 30 
387-011-1 110 ± 24 96.15 ± 12.79 
387-011-2 87.0 ± 1.8 79.55 ± 5.29 
387-011-3 85.9 ± 2.4 65.00 ± 1.13 
487-003-1 11.1 ± 0.8 0.4486 ± 0.1586 
487-003-2 11.6 ± 0.7 0.3350 ± 0.0509 
487-003-3 12.2 ± 1.0 0.3040 ± 0.0364 
487-004 15.4 ± 1.1 0.6307 ± 0.0968 
 
Since this dietary supplement was found to be contaminated with many 
xenobiotics, IDMS was used to quantify the Zn in the dietary supplement to see if the 
concentration on the bottle was accurate.  According to the label, a serving size of the 
zinc dietary supplement is one teaspoon (5 mL), and a serving size is listed as 20 mg Zn 
serving
-1
.  Therefore, the concentration of Zn in the supplement should be no lower than 
4,000 µg g
-1
.  As Figure 14 and Table 17 show, the Zn concentrations were at or above 
4,000 µg g
-1
 for all the bottles tested as at least all of the 95% CI overlapped this level.
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Figure 14:  Concentrations (µg g-1) for Zn in the zinc liquid dietary supplement using EPA Method 6800 (n = 12, 95% CIs).  The samples directly 
from manufacturer are lots 1-13 and the commercially available samples are lots 3, 11, 14, and 15.  The line at 4,000 µg g-1 represents the 
concentration of Zn listed on the label corresponding to the serving size of the zinc dietary supplement. 
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Table 17:  Concentrations (µg g-1) for Zn in the zinc liquid dietary supplement and Stevia using 
EPA Method 6800 (n = 12, 95% CIs).  The samples directly from manufacturer are lots 1-13 and 
Stevia extract and the commercially available samples are lots 3, 11, 14, and 15. 
Lot EPA Method 6800 Zn Concentration (µg g
-1) 
387-001 4,332 ± 84 
387-002 4,223 ± 96 
387-003 4,307 ± 94 
387-004 4,128 ± 77 
387-005 4,173 ± 117 
387-006 4,340 ± 126 
387-007 3,930 ± 81 
387-008 4,232 ± 134 
387-009 4,203 ± 93 
387-010 4,198 ± 100 
387-011 4,115 ± 89 
387-012 4,174 ± 95 
387-013 4,170 ± 77 
387-003-1 4,150 ± 178 
387-003-2 4,034 ± 207 
387-003-3 4,105 ± 77 
387-011-1 4,121 ± 55 
387-011-2 4,146 ± 83 
387-011-3 4,041 ± 129 
487-003-1 3,935 ± 110 
487-003-2 4,142 ± 72 
487-003-3 4,131 ± 62 
487-004 4,656 ± 65 
R351-002 0.9347 ± 0.1085 
 
3.3.4 Antimony Speciation 
An overlay of the six Sb compounds (PATS, SbCl5, SbOCl, KSb(OH)6, 
(CH3)3SbCl2, and SbCl3) analyzed separately at a concentration of 100 ng g
-1
 by IC-ICP-
MS is seen in Figure 15.  All of the Sb (III) species and all of the Sb (V) species analyzed 
had the same elution profile, while (CH3)3SbCl2 had one different than either of the 
inorganic Sb species.  A chromatogram of the contaminated Stevia is seen in Figure 16, 
which illustrates that the Stevia contains some Sb (V) and a lesser amount of Sb (III).  
Figure 17 shows a chromatogram of a Lot 387-003-1 sample of the zinc dietary 
supplement that had both Sb (III) and Sb (V) in it, with more Sb (III) present.  It was also 
 201 
 
not possible to determine the chemical structure of the Sb (III) and Sb (V) present in the 
zinc dietary supplement and Stevia. 
 
Figure 15:  Overlaid IC-ICP-MS chromatograms of the six antimony compounds (KSb(OH)6, 
SbCl5, PATS, SbCl3, SbOCl, and (CH3)3SbCl2).  The chromatograms are smoothed using 
Savitzky-Golay smoothing with 13 points per peak for a 2
nd
 order polynomial. 
 
 
Figure 16:  Chromatogram of the Stevia using the IC-ICP-MS showing more Sb (V) than Sb 
(III) present. 
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Figure 17:  Chromatogram of Lot 387-003-1 of the zinc dietary supplement from the IC-ICP-MS 
indicating contamination from both Sb (III) and Sb (V), with more Sb (III) present. 
 
3.4 Discussion 
An investigation into a zinc liquid dietary supplement admitted to be 
contaminated with Sb by the manufacturer found three different concentration ranges in 
the lots of samples analyzed.  Most notably, Sb was discovered at µg g
-1
 levels in Lots 
387-001 to 387-009, while the Sb contamination in Lots 387-010 to 387-013 was found 
at ng g
-1
 concentrations.  Finally, Lots 487-003 and 487-004 contained pg g
-1
 quantities of 
Sb.  The results for the Sb concentrations for Lots 487-003 and 487-004 differed between 
EPA Method 6020B and EPA Method 6800 as the EPA Method 6020B findings 
indicated concentrations in the ng g
-1
 range, while EPA Method 6800 results were in the 
pg g
-1
 level.  The values from EPA Method 6020B may have been higher due to the use 
of the calibration curve, matrix effects, and the concentration of Sb in the blank solution.  
The manufacturer’s suspected source of contamination, the Stevia extract, contained 
approximately 30 µg g
-1
 Sb by both EPA Method 6020B and EPA Method 6800.   
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The Sb speciation analysis results showed only the presence of Sb (III) and Sb 
(V).  No detectable trimethylantimony dichloride was found in the Stevia extract or zinc 
liquid dietary supplement.  The zinc liquid dietary supplement contained more Sb (III) 
than Sb (V), while the opposite results were observed in the Stevia.  This discovery and 
the small difference in the total Sb concentrations in the zinc supplement and Stevia raise 
the possibility that there could be other sources of contamination.  These findings 
indicated a more toxic exposure from Sb due to the presence of only inorganic Sb 
species.  The overall knowledge of Sb speciation is lacking with the only commonly 
reported fact being that Sb (III) is ten times more toxic than Sb (V).
389-390, 393
 
In the zinc dietary supplement and Stevia, additional elemental contamination 
from many xenobiotics such as Al, As, Cd, Hg, Pb, Sn, and U were found at ng g
-1
 levels 
in addition to the Sb contamination admitted by the manufacturer.  The greatest quantities 
of each of these toxins were determined to be present in the Stevia.  In addition to these 
harmful elements, many beneficial elements such as Co, Cr, Cu, Fe, Ni, Mo, Mn, Ni, and 
Se were quantified in the zinc dietary supplement and Stevia.  These elements are 
necessary dietary components, but they should not be present in a zinc supplement 
similar to all of the other harmful contaminates since they were not listed as ingredients.  
All of these elements were not known to be present and raise additional contamination 
concerns about the quality of dietary supplements.  Physicians and the general public 
supplement diets with these other essential elements in addition to Zn for nutritional 
deficiencies.  When these elements are present, along with other dietary supplements 
being incorporated into nutritional regimens, the results may no longer be beneficial and 
may actually cause negative consequences in a patient. 
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In addition to the results obtained for the analyzed samples, further fidelity and 
confidence in them was achieved through the validation of the methods employed using 
SRM 1640a.  As certified standards, SRMs can be used to evaluate sample preparation 
and analysis techniques.  They can provide a similar matrix to the sample of interest 
along with known certified or reference values for elements and molecules at 
concentrations close to quantities see in real world samples.  The comparison of the 
measured quantities to the SRM values validated the procedures used in this study and 
gave greater support to the obtained results. 
In addition to evaluating the quality of a commercially available dietary 
supplement, one of the most important effects this study can have on the measurement 
and industrial communities is through the type of testing standards employed and the 
quality of analytical testing results obtained.  When performing analytical mass 
spectrometric measurements, there are many sources of error which can affect both the 
accuracy and precision of each measurement, notably matrix matching, instrument drift, 
ionization changes, and analyte stability.  These errors are inherent as a part of 
instrumentation and methodology no matter how skilled the analyst.  These sources of 
error can be eliminated through the use of EPA Method 6800 as it only has three sources 
of error and two of these errors (mass bias and deadtime) can be corrected for with the 
mass spectrometer.  The remaining source of error, isobaric interferences, can be 
determined before analysis, and can either be corrected for or adjustments can be made to 
avoid them. 
It is important to note that the applicability of the two elemental testing methods 
implemented in this study is significantly different.  EPA Method 6020B is appropriate 
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for total elemental analysis for mono- or polyisotopic elements.  EPA Method 6800 is 
only applicable to polyisotopic elements, which comprise over 60% of the periodic table.  
These polyatomic elements include xenobiotics such as Cd, Hg, Pb, Sb, and Sn as well as 
beneficial elements including Cr, Cu, Fe, Mg, Mo, Ni, Se, and Zn.  In addition, EPA 
Method 6800 allows for the quantification of species of elements such as chromium (III) 
and (VI) and inorganic, methyl, and ethyl Hg in addition to the Sb species discussed in 
this study.  EPA Method 6800 is also applicable to organic molecules as hydrogen, 
carbon, nitrogen, oxygen, chlorine, and sulfur are all polyatomic elements.  This recent 
advancement in methodology has given scientists the capabilities through standard testing 
protocols to address the major concern that caused this investigation: the contamination 
of dietary supplements. 
3.5 Conclusion 
Through this research, many contamination issues were found through the 
elemental analysis of a zinc liquid dietary supplement and the suspected source, a Stevia 
extract.  Antimony was found at three different concentration ranges in the zinc dietary 
supplement.  The Sb adulteration in the first nine lots (387-001 to 387-009) was over 
1000 times greater than the current regulatory limit for drinking water set by the US 
EPA.
14
  Despite the improvements made to eliminate the Sb contamination, Al, As, Cd, 
Cr, Hg, Pb, and Sn still were found at ng g
-1
 concentrations in all of the lots investigated.  
Selenium was observed at least ng g
-1
 levels in all lots of the zinc dietary supplement, 
despite not appearing on the label.  In addition, EPA Method 6800 methodology was used 
to quantify Sb and Zn by IDMS.  The IDMS results confirmed the levels of Sb 
contamination seen by EPA Method 6020B and provided more precise results for all lots 
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and increased accuracy for Lots 487-003 and 487-004.  The labeled Zn levels were 
confirmed by IDMS analysis.  The more recently developed EPA Method 6800 produced 
more accurate and precise results in comparison to EPA Method 6020B.  The Sb 
speciation analysis showed the presence of only inorganic Sb compounds, the most toxic 
Sb species.  There is not much information in the literature on the effects of Sb on human 
health, and further work is needed to expand the knowledge base of the toxicity of Sb 
species and the type of species present in aqueous solutions.  The Sb speciation analysis 
has shown how important this type of testing is to provide the most accurate toxicological 
impact on human health. 
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Chapter 4  
The Plasma Zinc/Serum Copper Ratio as a Biomarker in 
Children with Autism Spectrum Disorders
†1
 
 
The frequency of zinc deficiency, copper toxicity and low zinc/copper in children with 
autism spectrum disorders (ASDs) may indicate decrement in metallothionein system 
functioning.  A retrospective review of plasma zinc, serum copper and zinc/copper was 
performed on data from 230 children with autistic disorder, pervasive developmental 
disorder-NOS and Asperger’s syndrome.  The entire cohort’s mean zinc level was 77.2 
micrograms deciliter (µg dL
-1
), mean copper level was 131.5 µg dL
-1
, and mean Zn/Cu 
was 0.608, which was below the 0.7 cut-off of the lowest 2.5% of healthy children.  The 
plasma zinc/serum copper ratio may be a biomarker of heavy metal, particularly mercury, 
toxicity in children with ASDs. 
4.1 Introduction 
4.1.1 Overview 
In recent years, much attention has been given to a related group of child 
neurological disorders called pervasive developmental disorders, which include autistic 
disorder, pervasive developmental disorder-not otherwise specified (PDD-NOS) and 
Asperger’s syndrome.1  These disorders cause difficulties with production of language, 
the performance of social skills, and the inhibition of non-functional, repetitive behavior 
patterns.  Asperger’s Syndrome is characterized by impairment in social interaction, 
inappropriate speech and difficulty controlling obsessive thoughts and behaviors in the 
                                                 
†
Used with Permission from Informa Healthcare from Faber, S.; Zinn, G.M.; Kern II, J.C; Kingston H.M.S.  
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setting of normal overall cognitive ability.  During the 1970s, the prevalence of autism in 
the United States ranged from 1 to 3 in 10,000.
2
  In the early 21
st
 century the prevalence 
of all forms of autism had reached 1 in 150 children under 18.
3
  The state of New Jersey 
currently has the highest prevalence of autism in the United States at 1 in 94 births.
4
  
Recent research has sought to determine common characteristics in children with autism 
spectrum disorders (ASDs).  This study describes the status of plasma zinc and serum 
copper concentrations and the plasma zinc/serum copper ratio in children diagnosed with 
ASDs. 
4.1.2 Role of Zinc 
Zinc (Zn) has a central role in immune system functioning and individuals 
deficient in zinc experience an increased susceptibility to various pathogens.  Individuals 
who suffer from severe zinc deficiency often demonstrate severely suppressed immune 
function, repeated infections and emotional disturbances.
5
  Additionally, zinc provides an 
essential building block for metal responsive transcription factor-1 (MTF-1).  MTF-1 
enhances the transcription of metallothionein genes in response to heavy metal load and 
up- and down regulates numerous genes and enzymes responsible for elimination of 
heavy metals with potential deleterious effects on mammalian tissue.
6-7
  Metallothioneins 
(MTs) are cysteine-containing, low-molecular weight, intracellular proteins with high 
affinity for metals, being the most common intracellular proteins which bind to metals.
8
  
The MT system is essential to heavy metal detoxification throughout the body.
9
  Zinc is 
the most efficient MT producer.
10
  Zinc is essential to the transcription of MT-I and MT-
II present in all vertebrate tissues, including the cerebellum.  Increased concentrations of 
vesicular zinc support MT-III production in the hippocampus, amygdala and pyriform 
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cortex.  Zinc promotion of the MTs decreases the neurotoxicity of mercury exposures in 
rat models and increases the elimination of free radicals by MTs serving as 
antioxidants.
11
  Thimerosal, which metabolizes to ethyl mercury, can trigger intracellular 
zinc release from MT proteins which can be measured by fluorescent signals from 
lymphocytes.
12
  Mercury compounds may then replace zinc in the binding sites of MTs, 
leading to eventual removal of mercury from tissues. 
The effects of exposing cultured lymphocytes from children with autism and their 
siblings to thimerosal, containing 49.6% ethyl mercury by weight, and zinc were studied 
by Walker et al.
13
  Thimerosal exposure caused up regulation of mRNA leading to 
increases in several heat shock proteins, and ‘many of the several hundred up regulated 
genes represent neurodegeneration and apoptotic pathways, while many of the 
significantly down-regulated genes belong to metabolic and cell signaling pathways.’13  
Zinc exposure up regulated several genes that promoted MT protein production. 
Variations in the familial transmission of single nucleotide polymorphisms 
(SNPs) of the metal responsive transcription factor 1 (MTF1) gene were found in a recent 
study by Serajee et al.
14
  The GT haplotype was more frequently transmitted than the GC 
haplotype.  Given the importance of MTF1 for regulation of MT protein homeostasis in 
response to heavy metal exposure, these SNPs may be influencing the conformation of 
MT proteins, adversely affecting the efficient utilization of zinc stores for heavy metal 
detoxification. 
In mammalian models, total body zinc deficiency can be associated with T- and B 
cell dysregulation causing dysfunction of the immune system.
5
  During a state of zinc 
deficiency, T cell functionality is among the first lost among immune cells.
15
  A recent 
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study noted decreases in splenic size and lymphocyte number in the spleen and thymus in 
intrauterine growth-restricted mice who experienced zinc deficiency in utero.
16
  Zinc 
deficiency can occur in utero from malnutrition or from increased exposure to heavy 
metals.  Some mammals have decreased MT functionality, beginning in the early fetal 
developmental stages.
8
  In utero, mammals who have decreased functionality of their MT 
system may use up their zinc reserves faster than fetuses with normal MT function.  
Children who are born with decreased zinc stores remain at risk for zinc deficiency 
throughout childhood.  Zinc deficiency is associated with developmental delays, 
malabsorption secondary to decreased functioning of intestinal zinc-dependent enzymes, 
and postnatal immune dysregulation.
17
  Low plasma zinc can also lead to copper toxicity, 
which can cause liver dysfunction and neurological impairment in children. 
4.1.3 Role of Copper 
Copper (Cu) has many important roles in the body, including participation in 
mechanisms of cell propagation and growth.
18
  Copper supports an effective immune 
response through promotion of interleukin-2 production using lymphocytic cells.
19
  
Copper is involved in the synthesis of MT proteins.  These proteins have a high attraction 
for copper, and in times of high copper concentrations, MT levels rise.
19
  In addition to 
MT, glutathione peroxidase and superoxide dismutase may be up regulated during times 
of high copper concentration.
20
  Copper has an important role as a cofactor in many 
metalloenzymes including cytochrome c oxidase, copper/zinc superoxide dismutase and 
lysyl oxidase.  It affects responsiveness to oxidative stress, oxidative phosphorylation and 
collagen biosynthesis.
21
  Copper is a cofactor in proteins connected with neurological 
diseases including amyotrophic lateral sclerosis, Alzheimer’s disease and Creutzfeldt-
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Jacob disease.
20
  Oxidative damage to lipids, nucleic acids and proteins can result from 
increased copper concentrations.
22
  Free radical concentrations are increased in tissues 
that contain larger amounts of transition metals, including copper.
23
  Copper can exist in 
two different oxidation states, causing copper to be toxic in surplus, promoting the 
creation of reactive oxygen species.
24
  Serum copper concentrations increase as 
physiological stress becomes greater in magnitude because of higher concentration of 
ceruloplasmin, where most of the copper in serum is located.
25
 
Copper homeostasis needs to be controlled very closely, as copper becomes toxic 
in higher than normal concentrations.
24
  Copper is incorporated into the bloodstream from 
the gastrointestinal tract.
26
  To be excreted from the body, copper needs key contributions 
from the liver.
24
  In comparison to other necessary trace elements, very little copper is 
accumulated in the body and adult humans contain less than 100 mg of stored copper.
27
  
During infancy, higher copper levels become dangerously toxic due to incomplete liver 
function.
19
  Changes in the concentrations of heavy metals, including zinc and copper, 
have been noted in numerous neurological disorders, including Parkinson’s Alzheimer’s 
and Huntington’s Diseases.28  When copper concentrations are not controlled properly, it 
becomes toxic to the central nervous system and liver, as occurs in Wilson’s Disease.20 
4.1.4 Zinc to Copper Ratio 
In recent years, efforts have been made to establish normal values and ratios of 
metals in various human media including serum and plasma, with the aim of determining 
the ranges which best support mammalian enzymatic activity and health.  Zinc and 
copper have antagonistic effects with respect to each other.  A nearly 1:1 ratio of zinc to 
copper in the serum has been associated with more effective immune responsiveness to 
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infectious agents.
29
  Zinc maintains a balance with copper in blood, and the blood levels 
of the two tend to be inversely related, with low plasma zinc nearly always being 
associated with high serum copper.  The zinc/copper (Zn/Cu) ratio has been implicated as 
a rapid method of determining the functional state of the MT system.  Lower zinc/copper 
ratios may reflect total body zinc deficiency and decreased efficiency in eliminating 
deleterious heavy metals from tissues and blood through the MT system.  One of the 
main functions of MTs is to eliminate metal ions, primarily to maintain zinc and copper 
homeostasis.
11
  Since zinc and copper both interact with MT, the Zn/Cu ratio may be seen 
as a way to determine the state of MT system functioning. 
There are several published studies that state that the normal zinc to copper ratio, 
in children and adults, is close to 1:1.  In a recent study, Walsh et al.
30-31
 performed 
measurements of the copper/zinc (Cu/Zn) ratio on autistic, PDD-NOS and Asperger’s 
syndrome patients.  The mean Cu/Zn ratio for the 503 autism spectrum patients was 1.63 
and for the control patients was 1.15.
30-31
  When changed to Zn/Cu ratio, this data 
becomes 0.6135 for autism spectrum patients and 0.87 for the control patients.
30-31
  
Additionally, Van Weyenbergh et al.
29
 tested plasma zinc and copper concentrations and 
Cu/Zn ratios in adults with leishmaniasis and healthy controls.  In the control group of 
this study, it was found that the mean Cu/Zn ratio in plasma was approximately 1.
29
  
Leishmaniasis patients had lower Zn/Cu ratios than controls.
29
  Walsh et al. measured 
serum copper/plasma zinc ratios in assaultive young males.  Walsh found the average 
serum copper/plasma zinc ration in controls to be 1.02 while it was 1.40 in the assaultive 
subjects.
32
  When changed to a Zn/Cu ratio, the controls’ value was 0.98 and the 
assaultive subjects’ value was 0.71.  The subjects in this study ranged from 3 to 20 years 
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old with a mean of 9.5.
32
  This age range is very similar to the one in the current study.  
Plasma zinc was noted to be a better measure of zinc status than serum zinc.
32
 
Several studies suggest that mercury toxicity may be a major cause of MT 
dysfunction in children with ASDs, which may be reflected in the Zn/Cu ratio.  Geier et 
al. studied urinary porphyrins in children with mild versus severe ASDs as determined by 
the Childhood Autism Rating Scale (CARS) scoring.
33
  Urinary porphyrins associated 
with mercury toxicity displayed significantly greater elevations in the severe ASD group 
than the mild ASD group.  These urinary porphyrins were positively correlated with 
rising CARS scores and plasma oxidized glutathione levels, indicating that a measure of 
mercury toxicity was associated with a more severe autistic presentation and oxidative 
stress.  Decreased levels of trans sulfuration metabolites, cysteine, reduced glutathione 
and sulfur were present in children with ASDs compared with normal controls, 
suggesting that mercury-induced MT dysfunction contributed to decrements in these 
measures of chemical detoxification. 
Multiple previous studies strongly suggest that certain urinary porphyrins, 
including coproporphyrin and precoproporphyrin, are increased in children with ASDs 
compared to controls, supporting the presence of mercury toxicity in many children with 
ASDs.
34-37
 
Multiple publications have shown lower levels of mercury in samples of first-cut 
hair from children with autism, compared with controls.  Adams et al. found that children 
with lower levels of mercury in their hair were 2.5 times more likely to demonstrate 
autism, indicating that the development of autism may be associated with decreased 
ability to eliminate mercury from the body.
38
  Holmes et al. also noted lower 
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concentrations of mercury in the first-cut hair of children with autism compared with 
controls and described a pattern of decreasing severity of autism spectrum presentation 
with increasing levels of hair mercury.
39
  This study supported the perspective that 
increasing ability to efflux mercury was associated with less neurophysiological 
dysfunction in these children.  In contrast, a controlled study of toxic trace elements in 
the hair of Kuwaiti children found significantly higher concentrations of lead, mercury 
and uranium in children with autism.
40
  Kuwaiti children may be heavily exposed to 
mercury from bread containing methyl mercury fungicide, and their environment has 
been dramatically disrupted by war-related pollution.  These conditions may have caused 
autism in Kuwaiti children secondary to overwhelming mercury and other toxin 
exposures, even though they maintained adequate MT functioning as indicated by the 
efflux of mercury into their hair. 
Higher levels of mercury are found in the blood, teeth and chelated urine 
specimens of children with autism compared with controls.
41-43
  A case series of children 
with regressive autism described by Geier and Geier noted that these children displayed 
elevated androgen levels, which can adversely affect MT functioning, and evidence of 
decrease performance of glutathione metabolism necessary for mercury excretion.
44
 
Air pollution containing mercury has been strongly related to the incidence of 
autism in children in San Francisco and in Southeastern Texas.
45-46
  Although the Institute 
of Medicine concluded that there is no relationship between exposure to mercury from 
vaccines in the form of thimerosal and autism and other neurodevelopmental disabilities, 
studies continue to be published which provide concern that such exposure may be 
related to the development of neurological disorders.
47-49
  Thimerosal was present in 
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many Rho (D) immune globulin products given to pregnant Rh-negative women prior to 
2002.  Geier et al. demonstrated that a cohort of children born prior to 2001 with 
neurodevelopmental disorders were more frequently born to mothers with Rh negativity 
compared with controls, than children with neurodevelopmental disorders born after 
2001, when thimerosal was taken out of Rho (D) immune globulin products.
50
 
Given the importance of zinc and copper metabolism for healthy neurological 
functioning and heavy metal, including mercury, detoxification, blood zinc and copper 
concentrations were measured in the population of children with forms of autism 
followed by the Neurodevelopmental Service of The Children’s Institute (Pittsburgh, PA, 
USA).  This retrospective study sought to determine the frequency of zinc deficiency, 
copper toxicity and low plasma zinc/serum copper ratio (under 0.7) in a cohort of 
children with ASDs, which may indicate increased risk for decrement in MT system 
functioning and malabsorption created by low intestinal zinc-dependent enzyme 
concentration. 
4.2 Methods 
A retrospective review was performed on data from 230 children (179 male, 51 
female, mean age 6.3, standard deviation (SD) of 3.67) with autistic disorder, PDD-NOS 
and Asperger’s syndrome diagnosed by structured interview, play observation and rating 
scales (including the Childhood Autism Rating Scale and the Asperger’s Syndrome 
Diagnostic Scale).
51-52
  Diagnostic and Statistical Manual-IV (DSM-IV) criteria were met 
for these disorders and all children were placed in their diagnostic categories by Dr. Scott 
Faber’s post-review of the range of data acquired by Scott Faber and other evaluating 
clinicians, which often included Autism Diagnostic Observation Scale scores.
53
  When a 
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rare disagreement about diagnostic classification occurred among involved clinicians, 
Scott Faber utilized serial observations during follow-up visits to establish the diagnoses 
utilized in this study. 
This retrospective review of Scott Faber’s patient population was approved by the 
Research Committee of The Children’s Institute and the Duquesne University 
Institutional Review Board.  Plasma zinc, serum copper and plasma zinc/serum copper 
ratios were recorded for children with an autism spectrum diagnosis seen by the 
Neurodevelopmental Pediatrics Service from July 2004 to December 2006, where this 
information was available.  The testing was performed by the University of Pittsburgh 
Laboratory and Quest Labs (Pittsburgh, PA, USA).  The Associated Regional and 
University Pathologists, Inc. (ARUP) national reference laboratory manual states that the 
low plasma zinc level for children is 66 µg dL
-1
, and the high serum copper cut-off is 153 
µg dL
-1
.
54
  An Excel spreadsheet was created to determine the mean, SD and confidence 
intervals from the data.  Analysis of variance (ANOVA) studies were performed using 
the S Plus program.  Only the first plasma zinc and serum copper values obtained after 
the initial diagnostic visit were recorded.  None of the children were on supplements or 
restrictive diets at the time of the collection of the initial blood work. 
Recognizing a Zn/Cu ratio value that generally separates healthy from affected 
subjects can be accomplished through examination of the normal control groups in two of 
Walsh’s cohorts.31-32  In these separate studies, the values of 0.613 and 0.725 were 
identified to be exactly 2 SD below the mean Zn/Cu ratio of healthy subjects.  Through 
clinical assessment and the values of reported in both papers from Walsh et al., a Zn/Cu 
ratio of 0.7 was chosen as a cut-off.  The 0.7 value approximates the cut-off value 
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separating the upper 97.5% from the lower 2.5% of the healthy population, provided 
Walsh’s data is approximately normal. 
4.3 Results 
Analyses were performed to study the entire group as a whole, followed by 
parcellation of the data into three subgroups:  autistic disorder, PDD-NOS and Asperger’s 
syndrome, to determine if significant differences emerged in mean zinc levels, mean 
copper levels or zinc/copper ratios among the three groups using ANOVA. 
4.3.1 Entire Cohort 
Forty-seven children (20.4%) out of the entire group of 230 children with all 
forms of autism had low zinc levels below 66 µg dL
-1
.  One hundred seventeen children 
(50.8%) of the 230 had zinc levels in the lowest 10% (below 75 µg dL
-1
) of the normal 
range.  The mean zinc level of the 230 children was 77.2 µg dL
-1
 (minimum (min):  44 
µg dL
-1
, maximum (max):  130.4 µg dL
-1
, SD:  14.5 µg dL
-1
). 
Thirty-nine children (17%) of 230 had high copper levels over 153 µg dL
-1
.  
Seventy children (30.4%) of 230 had copper levels in the highest 10% (over 140 µg dL
-1
) 
of the normal range.  The mean copper level of the 230 children was 131.5 µg dL
-1
 (min:  
78.3 µg dL
-1
, max:  228 µg dL
-1
, SD:  25.7 µg dL
-1
). 
One hundred sixty seven out of 230 children (72.6%) had zinc/copper ratios under 
0.7.  The mean zinc/copper ratio of all of the children was 0.608 (min:  0.25, max:  1.01, 
SD:  0.16).  Male and female subjects did not significantly differ in mean zinc (p-value = 
0.326), mean copper level (p = 0.762) or in Zn/Cu ratios (p = 0.774) (Table 18 and 
Figures 18-21). 
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4.3.2 Children Diagnosed with Autistic Disorder 
The 78 children with autistic disorder had a mean zinc level of 76.9 µg dL
-1
 (min:  
54 µg dL
-1
, max:  113.2 µg dL
-1
, SD:  14.1 µg dL
-1
).  Fifteen children (19.2%) had low 
zinc levels below 66 µg dL
-1
.  Forty-one children (52.6%) had zinc levels in the lowest 
10% (below 75 µg dL
-1
) of the normal range. 
Their mean copper level was 129.7 µg dL
-1
 (min:  78.3 µg dL
-1
, max:  228 µg dL
-
1
, SD:  29.1 µg dL
-1
).  Twelve children (15.4%) had high copper levels over 153 µg dL
-1
.  
Twenty-four children (30.8%) had copper levels in the highest 10% (over 140 µg dL
-1
) of 
the normal range. 
This subgroup’s mean zinc/copper ratio was 0.618 (min:  0.32, max:  0.99, SD:  
0.1628).  Fifty-six children (71.8%) had zinc/copper ratios under 0.7 (with one at 0.7).  
Male and female children with autistic disorder did not significantly differ in mean zinc 
(p = 0.6324), copper levels (p = 0.1324) or in zinc/copper ratios (p = 0.2093) (Table 18 
and Figures 18-21). 
4.3.3 Children Diagnosed with PDD-NOS 
The 110 children with PDD-NOS had a mean zinc level of 77.1 µg dL
-1
 (min:  44 
µg dL
-1
, max:  116 µg dL
-1
, SD:  13.7 µg dL
-1
).  Twenty-one children (19.1%) had low 
zinc levels below 66 µg dL
-1
.  Fifty-four children (49.1%) had zinc levels in the lowest 
10% (below 75 µg dL
-1
) of the normal range. 
The mean copper level was 135.6 µg dL
-1
 (min:  90.7 µg dL
-1
, max:  197.9 µg dL
-
1
, SD:  23.1 µg dL
-1
).  Twenty-two children (20%) had high copper levels over 153 
µg dL
-1
.  Forty children (36.4%) had copper levels in the highest 10% (over 140 µg dL
-1
) 
of the normal range. 
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This subgroup’s mean zinc/copper ratio was 0.587 (min:  0.25, max:  1.01, SD:  
0.15).  Eighty-four children (76.4%) had zinc/copper ratios under 0.7 (one at 0.7).  Male 
and female children with PDD-NOS did not significantly differ in mean zinc (p = 
0.4433), copper levels (p = 0.2872) or in zinc/copper ratios (p = 0.1995) (Table 18 and 
Figures 18-21). 
4.3.4 Asperger’s Syndrome Patients 
The 42 children with Asperger’s disorder had a mean zinc level of 78.2 µg dL-1 
(min:  52.3 µg dL
-1
, max:  130.4 µg dL
-1
, SD:  17.2 µg dL
-1
).  Eleven children (26.2%) 
had low zinc levels below 66 µg dL
-1
.  Twenty-two children (52.4%) had zinc levels in 
the lowest 10% (below 75 µg dL
-1
) of the normal range. 
The children’s mean copper level was 124.4 µg dL-1 (min:  87.5 µg dL-1, max:  
194 µg dL
-1
, SD:  23.9 µg dL
-1
).  Five children (11.9%) had high copper levels over 153 
µg dL
-1
.  Six children (14.3%) had copper levels in the highest 10% (over 140 µg dL
-1
) of 
the normal range. 
This subgroup had a mean zinc/copper ratio of 0.644 (min:  0.36, max:  0.93, SD:  
0.157).  Twenty-seven children (64.3%) had zinc/copper ratios under 0.7 (one at 0.7).  
Male and female children did not significantly differ in mean zinc (p = 0.705) or copper 
(p = 0.5472) levels or in zinc/copper ratios (p = 0.9374) (Table 18 and Figures 18-21). 
 
  
 
2
2
2
 
Table 18:  Mean plasma zinc, mean serum copper and mean plasma zinc/serum copper ratio including number of patients in each group.  The 12 
groups include the entire cohort, separated by diagnosis, gender, and diagnosis and gender.  All confidence intervals are taken at the 95
th
 
percentile. 
 
Plasma Zn (μg dL-1) Serum Cu  (μg dL-1) Zn/Cu Ratio Number of Patients 
Entire data set 77.21 ± 1.87 131.37 ± 3.32 0.608 ± 0.020 230 
All autistic disorder patients 76.89 ± 3.18 129.68 ± 6.57 0.619 ± 0.037 78 
All PDD-NOS patients 77.07 ± 2.59 135.57 ± 4.37 0.585 ± 0.028 110 
All Asperger's syndrome patients 78.17 ± 5.36 124.41 ± 7.45 0.644 ± 0.049 42 
Male autistic disorder patients 77.26 ± 3.70 132.10 ± 6.62 0.607 ± 0.041 63 
Female autistic disorder patients 75.31 ± 6.36 119.49 ± 21.22 0.667 ± 0.084 15 
Male PDD-NOS patients 77.66 ± 2.92 134.19 ± 5.09 0.597 ± 0.034 82 
Female PDD-NOS patients 75.35 ± 5.85 139.59 ± 8.88 0.555 ± 0.054 28 
Male Asperger's syndrome patients 78.67 ± 6.48 125.50 ± 8.60 0.644 ± 0.058 34 
Female Asperger's syndrome patients 76.06 ± 8.26 119.75 ± 17.81 0.648 ± 0.101 8 
All male patients 77.71 ± 2.17 131.81 ± 3.61 0.610 ± 0.023 179 
All female patients 75.45 ± 3.71 130.57 ± 8.25 0.602 ± 0.041 51 
PDD-NOS:  pervasive developmental disorder-not otherwise specified. 
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Figure 18:  The plasma zinc concentrations for each patient in the cohort.  The line at 66 µg dL
-1
 represents the low cut-off value according to 
ARUP.
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Figure 19:  The serum copper concentrations for each patient in the cohort.  The line at 153 µg dL
-1
 represents the high cut-off value according to 
ARUP.
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Figure 20:  The mean plasma zinc/serum copper ratio and confidence intervals (95%) for Asperger’s syndrome, pervasive developmental 
disorder-not otherwise specified (PDD-NOS) and autistic disorder patients.  The confidence interval lengths are represented by the purple bars.  
The mean values for each group are inscribed within each bar.  The black vertical line at 0.8697 is the control mean value from the Walsh et al. 
study.
31
  The dotted lines (0.7947 and 0.9445) represent the 95% confidence limits from the Walsh study.  The red line at 0.7 represents the cut-off 
line for a significantly low (bottom 2.5%) plasma zinc/serum copper ratio.  The green line at 1 represents the normal value for zinc/copper ratio in 
children. 
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Figure 21:  The plasma zinc/serum copper ratio for each individual patient separated by disease.  Reference values and intervals are the same as in 
Figure 20. 
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4.3.5 Comparison of Cohort Groups 
An ANOVA test for equality of the mean zinc/copper ratio across the three 
groups was significant at the 10% level; multiple comparisons revealed a significant 
difference only between the mean zinc/copper ratio of the children diagnosed with PDD-
NOS and Asperger’s syndrome patients, with the PDD-NOS children having the lower 
mean ratio (p = 0.03574).  However, a Kruskal-Wallis test for equality of mean age 
across groups was found to be significant at the 1% level (p = 2.2 ×10
-16
); multiple 
comparisons reveal the mean age of the Asperger’s syndrome group to be greater than 
both the PDD-NOS group (p = 2.38 × 10
-8
) and the autistic disorder group (p = 0.00036).  
Zinc/copper ratio was significantly positively correlated with collection age (r = 0.375, p 
= 5.24 × 10
-9
), and regression analyses show disease category to be a non-significant 
predictor of the zinc/copper ratio in the presence of age.  Therefore, the difference in 
mean zinc/copper ratios among the groups cannot be attributed solely to disease type at 
this time. 
Some significant differences were noted in mean plasma zinc levels and serum 
copper levels among all three groups.  PDD-NOS patients demonstrated higher copper 
levels on average than children with Asperger’s syndrome.  The p-value when the mean 
copper values for the PDD-NOS and the Asperger’s syndrome children were compared 
pair wise was 0.009.  There was no significant difference found when the mean copper 
concentrations for PDD-NOS patients were compared with the autistic disorder group (p 
= 0.1241) or when the autistic disorder group was evaluated against the Asperger’s 
Syndrome patients (p = 0.317).  When all three group’s mean copper concentrations were 
compared, there was a significant difference found (p = 0.041). 
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When the mean zinc concentrations of each of the three groups were evaluated, 
there was no significant difference found (p = 0.89).  There were no significant 
differences found when each of the group’s mean zinc concentrations were compared:  
PDD-NOS vs. autistic disorder (p = 0.9267), autistic disorder vs. Asperger’s syndrome (p 
= 0.6599), and PDD-NOS vs. Asperger’s syndrome (p = 0.682).  The autistic disorder 
group contained the only two children with very elevated serum copper levels over 200 
µg dL
-1
. 
Overall, 221 out of 230 patients (96.1%) had zinc concentrations below 105 
µg dL
-1
 (the midpoint of normal zinc concentration) with 20.4% below the lower bound 
of the normal range.  For copper, 223 out of 230 children (96.9%) had concentrations 
above 90 µg dL
-1
 (the midpoint of normal copper concentration) with 17% above the 
upper bound of the normal range.  For zinc/copper ratio, 229 out of 230 patients (99.6%) 
had a ratio below 1.0 and 170 out of 230 (73.9%) had a zinc/copper ratio at or below 0.7. 
4.4 Discussion 
Children with ASDs from Western Pennsylvania, West Virginia and Southeastern 
Ohio, frequently demonstrated low plasma zinc/serum copper ratios compared with 
previously determined norms from the literature.
29-32
  In addition, their plasma zinc/serum 
copper ratios frequently fell below 0.7, a demarcation line that was chosen to represent a 
significant difference from the near 1:1 ratios seen in previous studies on child and adult 
controls.  The plasma zinc/serum copper ratio for the entire cohort of the present study 
was 0.608, a figure that was quite similar to the ratio, 0.6135, noted on a previous dataset 
presented by Walsh et al. in children with ASDs.
30-31
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Twenty percent of the entire cohort of children with autism spectrum disorders 
was zinc deficient and 17% of the cohort displayed copper toxicity based on normal 
ARUP Laboratory ranges.  The autistic group contained two children with very high 
copper levels and extremely low zinc/copper ratios.  Extreme elevations of serum copper 
may indicate extraordinary stress on the MT system and may have contributed to the 
severity of these children’s presentations.  The Asperger’s syndrome and PDD-NOS 
groups did not contain any children with this severity of copper toxicity.  Zinc deficiency 
and copper toxicity contribute to dysregulated neurotransmitter system functioning, 
decreased zinc finger protein activity and diminished zinc-dependent gastrointestinal 
enzymatic activity.  The activation of the glutamatergic neurotransmitter system has been 
shown to require zinc uptake to be triggered.
55
  Synaptic neurotransmission needs zinc as 
an intracellular signal factor with its involvement with numerous proteins.
55
  Low zinc 
concentrations can lead to oxidative stress which can change zinc finger motifs involved 
as transcription factors in cell signaling.
56
  Zinc ions control, either directly or indirectly, 
the molecular structures of zinc finger proteins.
15
  Previous literature showed zinc finger 
DNA repair proteins could be inhibited by many toxic metals including copper.
57
  Copper 
and other heavy metals prevent the activation of metal-responsive promoters.
58
 
There were no significant differences between the zinc/copper ratios of males 
versus females in the overall cohort (p = 0.7744) or in the autistic disorder (p = 0.2093), 
PDD-NOS (p = 0.1995) and Asperger’s syndrome (p = 0.9374) groups.  Autistic children 
appear to demonstrate a similar degree of stress on their MT systems, regardless of their 
sex.  The 3.53 to 1 ratio of males to females in the study may be partially caused by sex 
differences in metalloprotein functioning, as even very low dose pre-pubertal estrogen 
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production in human females has been noted to have a salutary effect on metalloprotein 
production and performance.
59
  There was a significant, positive correlation between 
zinc/copper ratio and age of collection (r
2 
= 0.14), which may indicate improved MT 
functioning in this study’s children as they age. 
Zinc/copper ratios averaged below 0.7 in the autistic disorder, PDD-NOS and 
Asperger’s syndrome subgroups.  These groups, with significantly different behavioral 
phenotypes, may share some degree of common etiology involving different levels of MT 
system dysfunction.  The conclusions of this study are limited by the selection of a 
control group taken from the literature.  Nonetheless, several previous studies suggest 
that a plasma zinc to serum copper ratio of about 1:1 is normative in children and 
adults.
29-32
  The children with ASDs in this study averaged a plasma zinc to serum copper 
ratio of 0.608, suggesting a very significant difference in MT functioning compared with 
healthy subjects.  This value is below the 0.7 demarcation line indicating the lowest 2.5% 
of zinc/copper ratios determined from the Walsh et al. studies.
31-32
 
Western Pennsylvania has been noted to be in the high heavy metal pollution zone 
of the United States according to data from the Environmental Protection Agency of the 
USA.  Pittsburgh is located in a region of the country where industry is responsible for 
73% of the total atmospheric mercury emissions.
60
  Published studies have shown links 
between exposure to airborne mercury emissions from coal-fired power plants and 
increased autism rates.
46, 61
  Stress on the MT system of humans triggered by heavy metal 
exposure may cause faster use of zinc reserves.  This cohort’s overall propensity for 
demonstrating decreased zinc levels, elevated copper levels and low zinc/copper ratios 
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may be reflective of exposure beginning in utero, and may be affected by their mother’s 
lifetime exposure to ambient heavy metals from the environment. 
Zinc’s ability to up regulate MT gene expression and reduce toxicity from heavy 
metal exposure suggests that the provision of zinc to children with ASDs may be an 
important component of a treatment protocol, especially in children with zinc deficiency 
(plasma zinc under 66 µg dL
-1
 according to ARUP) or Zn/Cu ratio under 0.7.
54
 
The plasma zinc/serum copper ratio may be a biomarker that indicates stress on 
the MT system of children with ASDs.  Children with ASDs, according to data from the 
studied cohort, appear at risk for zinc deficiency, copper toxicity, the demonstration of 
low zinc/copper ratio, and decreased MT-system functioning.  The results of this study 
suggest that further work is required to explore MT dysfunction and zinc/copper 
metabolism in children with forms of ASDs. 
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Chapter 5  
A Cleanroom Sleeping Environment’s Impact on Markers of 
Oxidative Stress, Immune Dysregulation, and Behavior in 
Children with Autism Spectrum Disorders 
 
Ten children with autism slept in a cleanroom for two weeks to evaluate changes in toxin 
levels, oxidative stress, immune dysregulation, and behavior.  Before and after children 
slept in the cleanroom, samples of blood and hair and rating scale scores were obtained to 
assess these changes.  Five children significantly lowered their concentration of oxidized 
glutathione, a biomarker of oxidative stress.  The younger cohort, age 5 and under, 
showed significantly greater mean decreases in two markers of immune dysregulation, 
CD3% and CD4%, than the older cohort.  Changes in serum magnesium correlated 
negatively while changes in serum iron correlated positively with age.  The younger 
children demonstrated significant improvements on behavioral rating scales compared to 
the older children.  In a younger pair of identical twins, one twin showed significantly 
greater improvements in 4 out of 5 markers of oxidative stress, which corresponded with 
better overall behavioral rating scale scores than the other twin.  The cleanroom may 
have altered elemental levels, lowered oxidative stress, decreased immune dysregulation, 
and improved behavioral rating scales in the younger children. 
5.1 Introduction 
Autism spectrum disorders (ASDs) cause dysfunction in the areas of expressive 
language production and quality, socialization ability, and control of excessive repetitive 
thoughts and behaviors.
1
  Over the past two decades, worldwide incidence and prevalence 
of these disorders have increased; however, scholarly opinion varies as to whether this 
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rise is due to improved awareness, better age-related screening efforts, higher quality and 
quantity of diagnostic centers, an expansion of the spectrum definition, the types of study 
methods used, or a true escalation in the incidence and prevalence of autism.
2-8
  Although 
much research has focused on finding a genetic cause of autism, it has not been 
successful in explaining a majority of the diagnoses.  In children with ASDs, only 21% 
display genetic differences from the typically sequenced human DNA.
9
  Copy number 
variants and losses have been strongly associated with the development of autism,
10
 
potentially indicating a mechanism for genetic/environmental interaction. 
5.1.1 Effects of Toxin Exposure 
A recent review noted the possible contributions of toxin exposure during 
gestation and early childhood to the development of autism.
11
  Emerging literature on the 
exposome, which measures environmental, extracellular, and intracellular influences on 
the expression of the genome, strongly suggests that adverse neurological outcomes can 
be created by pre- and postnatal exposure to toxins.
12
  With the lack of success in finding 
a purely genetic cause for autism, an emerging paradigm suggests that one of the causes 
of the increased prevalence of ASDs could be difficulties in heavy metal and chemical 
detoxification.
13
  Multiple studies have previously correlated proximity to coal fired 
power plants, pesticide-rich agricultural fields, known toxic chemical sites, and traffic-
related air pollution with the prevalence of ASDs.
14-18
  It has been hypothesized that 
difficulties in detoxification can cause oxidative stress
19-23
 and immune dysregulation,
24-28
 
leading to or exacerbating ASDs phenotypic presentation.
29-30
 
Exposure to environmental toxins, including heavy metals and chemicals, have 
been shown to negatively affect systems of detoxification, involving glutathione
31-33
 and 
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metallothionein,
34-35
 of which both zinc and selenium are key cofactors.
36
  Glutathione is 
the central antioxidant responsible for environmental toxin detoxification
37
 and has been 
used as a biomarker of oxidative stress to evaluate the methylation and sulfation 
systems.
38-39
  The metallothionein system is also necessary for heavy metal 
detoxification
40
 and can be assessed by the plasma zinc/serum copper ratio.
35, 41
  Studies 
have shown that total glutathione, reduced/oxidized glutathione ratio, and zinc/copper 
ratio are often lower in children with ASDs.
35, 38-39, 41
  Lower amounts of total 
glutathione, triggered by increased environmental toxin exposure, have been shown to 
also affect the immune system of children with autism, as evidenced by lower natural 
killer (NK) cell activity.
42
 
Difficulties in detoxification of heavy metals and chemicals can lead to 
autoimmunity
43-44
 and immune dysregulation.
24-25, 27
  Forms of autoimmunity which use 
NK cells to attack brain tissue
45
 may contribute to the under-connectivity between distant 
areas of the brains of children with autism.
46
  Certain markers of immunological 
regulation and function,
47-49
 such as the T cell helper/suppressor (CD4:CD8) ratio and 
CD4%,
50
 are indicative of dysregulated innate and humoral immunity.
51
  Both the 
CD4:CD8 ratio and CD4% have been shown to correlate with performance on the Autism 
Behavior Checklist,
50
 indicating a link between immunological function and phenotypic 
presentation.  In addition, altered cytokine profiles in the immune systems of children 
with ASDs have been connected to behavioral instabilities.
52
  Immune dysfunction has 
been found in 15% to 60% of children with ASDs,
53
 and it was recently shown that, when 
compared with controls, children with ASDs exhibited greater evidence of increased 
detoxification difficulties, oxidative stress, and immune dysregulation.
54
 
 240 
 
 
5.1.2 Cleanrooms and Detoxification  
 Given the emerging evidence connecting poor detoxification of environmental 
toxins to the biomedical and clinical presentation of ASDs, an intervention that 
temporarily decreases environmental exposure may positively impact phenotypic 
presentation.
55
  Concentrations of fine particles and gaseous chemicals can be reduced in 
cleanrooms by using high efficiency particulate air (HEPA) filters and activated carbon.  
Individuals who have spent time in a cleanroom have presented reduced symptoms 
associated with immunological response to IgE mediated allergies and mold.
56-58
  These 
unique allergic and immunological responses cause the release of mast cell mediators that 
can affect the central nervous system resulting in detrimental behavioral effects in certain 
children with autism.
59
 
 The application of cleanroom technology in the treatment of children with ASDs 
has been previously undertaken.
60-63
  These children improved significantly and 
obviously in areas of expressive language, socialization, and obsessiveness after the first 
several weeks of detoxification in their cleanrooms, and appeared to maintain these gains 
even once removed from the clean environment.
60-63
  It was discovered that children with 
milder forms of autism appeared to improve when exposed to lesser levels of 
environmental cleanliness, while children with more severe autism needed to be fully 
removed from environmental toxicity before gains could be seen.  These studies suggest 
that a cleanroom, which reduces the burden on detoxification systems, may lead to 
decreased oxidative stress and improved immunological and neurological functioning in 
children with autism.  Multiple studies have demonstrated the importance of early 
treatment interventions.
64-66
  It has been shown that younger children with autism display 
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greater and more rapid response to intensive treatments, and that there may be a crucial 
time interval for intervention before the end of early life developmental plasticity.
64
 
This study sought to demonstrate the effects of a cleanroom sleeping environment 
on toxin levels and markers of oxidative stress, immune dysregulation, and behavioral 
presentation in ten children with autism, ages 3 to 12.  These effects were evaluated by 
quantifying changes in blood toxin concentrations, glutathione levels, and markers of 
immune function, and determining the correlation between age and improvement in these 
markers. 
5.2 Materials and Methods 
5.2.1 Materials 
5.2.1.1 Chemicals and Standards 
All reagents were of analytical grade.  ARISTAR ULTRA nitric acid (HNO3), 
ARISTAR ULTRA hydrochloric acid (HCl), and ARISTAR ULTRA H2O that were used 
only during sample analysis were procured from VWR (Radnor, PA, USA).  American 
Chemical Society (ACS) grade HNO3 and ACS grade HCl that were only used for 
cleaning were obtained from Fisher Scientific (Pittsburgh, PA, USA).  Multi-elemental 
standards were purchased from High Purity Standards (Charleston, SC, USA).  Applied 
Isotope Technologies (AIT, Pittsburgh, PA, USA) provided the inorganic mercury 
standard along with all of the isotopically enriched elemental solutions. The Inductively 
Coupled Plasma-Mass Spectrometry (ICP-MS) tuning solution consisting of 1 nanogram 
gram
-1
 (ng g
-1
) of lithium, cobalt, yttrium, cerium, and tellurium in 2% (v:v) HNO3 and 
an internal standard solution containing 100 microgram gram
-1
 (µg g
-1
) of 
6
lithium, 
scandium, germanium, rhodium, indium, terbium, lutetium, and bismuth were procured 
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from Agilent Technologies (Santa Clara, CA, USA).  Standard Reference Material 
(SRM) 1598a, Inorganic Constituents in Animal Serum, was purchased from the National 
Institute of Standards and Technology (NIST, Gaithersburg, MD, USA) and Certified 
Reference Material (CRM) GBW09101b was obtained from the Shanghai Institute of 
Nuclear Research of the Chinese Academy of Sciences (Shanghai, China). 
5.2.1.2 Materials and Supplies 
All tetrafluorometoxil (TFM™) microwave vessels, inserts, and lids were 
obtained from Milestone Inc. (Shelton, CT, USA) and the magnetic stir bars were 
procured from Big Science Inc. (Huntersville, NC, USA).  VWR supplied the 50 mL 
polypropylene centrifuge tubes.  AIT provided the Isotope Dilution Mass Spectrometry 
(IDMS) software.  A Thermo Scientific (Pittsburgh, PA, USA) Barnstead EASYpure II 
RF/Ultraviolet (UV) Model D7035 water purification system was used to further clean 
double-deionized (DDI) water to a minimum resistivity of 18 MΩ-cm from a Barnstead 
(Dubuque, IA, USA) NANOpure water system. 
5.2.1.3 Instrumentation 
The sample preparation for the analytical elemental analysis of the blood and hair 
samples was performed using microwave-enhanced chemistry in a Milestone ETHOS 1 
laboratory microwave system equipped with temperature and pressure feedback control.  
This device accurately monitored and controlled the temperature to within ± 2 °C of the 
preset values by automatically adjusting the microwave field output that has a maximum 
power of 1500 Watts.  The closed ETHOS 1 system allowed for extremely high 
temperature and pressure conditions of up to 300 °C and 100 bar to be maintained for 
extended periods of time.  The ten TFM™ microwave digestion vessels used in this study 
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each contained three 6 mL TFM™ inserts with lids.  The TFM™ inserts also have the 
capability of withstanding the same temperature and pressure conditions as the digestion 
vessels while increasing the number of samples from 10 to 30 per batch. 
Mass spectrometric analysis was completed using an Agilent 7700 ICP-MS with a 
micromist nebulizer, quartz spray chamber, an octopole reaction system, and a 
quadrupole mass analyzer.  It possesses a collision/reaction cell that uses hydrogen or 
helium gas to eliminate polyatomic interferences.  The samples and internal standard 
were introduced into the ICP-MS through the micromist nebulizer of the spray chamber 
using the peristaltic pump at a speed of 0.1 revolutions per second (rps).  The samples 
were stored in Agilent’s Integrated Autosampler before being analyzed.  Both the ICP-
MS and autosampler were located in an International Organization for Standardization 
(ISO) Class 6 cleanroom laboratory.  The optimized parameters of the ICP-MS and 
autosampler during analyses are shown in Table 19. 
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Table 19:  The optimized settings for the Agilent 7700 ICP-MS for EPA Method 6020B in blood, 
EPA Method 6800 in blood, and EPA Method 6020B in hair. 
Agilent 7700 ICP-MS 
EPA Method 
6020B Blood 
EPA Method 
6800 Blood 
EPA Method 
6020B Hair 
Rf Power 1600 W 1600 W 1600 W 
Spray Chamber Temperature 2 °C 2 °C 2 °C 
Acquisition Mode Spectrum Spectrum Spectrum 
Peak Pattern 1 point mass
-1
 1 point mass
-1
 1 point mass
-1
 
Sample Depth 9 mm 9 mm 9 mm 
Plasma Gas 15 L min
-1
 15 L min
-1
 15 L min
-1
 
Carrier Gas 0.9 L min
-1
 0.9 L min
-1
 0.9 L min
-1
 
Dilution Gas 0.1 L min
-1
 0.1 L min
-1
 0.1 L min
-1
 
H2 Cell Gas Flow 2 mL min
-1
 2 mL min
-1
 1.5 mL min
-1
 
He Cell Gas Flow 2 mL min
-1
 2 mL min
-1
 1.5 mL min
-1
 
Gas Stabilization Time 30 sec 30 sec 30 sec 
Integration Time 0.1-1.0 sec mass
-1
 0.5-1.0 sec mass
-1
 0.1-1.0 sec mass
-1
 
Replicates 4 4 4 
Nebulizer Pump Speed 0.10 rps 0.10 rps 0.10 rps 
Uptake time 30 sec 30 sec 30 sec 
Stabilization time 30 sec 30 sec 30 sec 
 
5.2.2 Methods 
The current study was approved by the Institutional Review Board (IRB) of 
Duquesne University (Pittsburgh, PA, USA) (IRB #09-131).  The study was conducted at 
The Children’s Institute (TCI, Pittsburgh, PA, USA).  Before enrolling in the study, each 
parent was presented with a consent form and each child was offered an assent form. 
5.2.2.1 Subject Enrollment and Study Design 
Ten children, ages 3-12, with certified psychologist confirmed Autism Diagnostic 
Observation Scale (ADOS)
67
 autistic disorder were recruited from Dr. Scott Faber’s 
practice at the Neurodevelopmental Service of TCI.  Eligible children had prior evidence 
of heavy metal and chemical toxicity and immune dysregulation seen through low plasma 
zinc/serum copper ratios and abnormal T and B cell subsets, respectively.  With stringent 
recruitment due to funding from the Health Resources and Services Administration 
(HRSA), the study included six Caucasian males, two females, one African American 
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male, and one Asian male.  Child #2 was unable to participate in the study because of the 
inability to complete a blood draw.  The group intentionally contained two sets of 
identical twins with autism (ages 5 and 12).  All children selected lived within a thirty 
minute drive of TCI.  Children were not eligible if they had severe behavioral 
dysregulation, uncontrolled seizure activity, or any other severe chronic medical 
condition, other than autism, that required frequent management by general pediatricians.   
After signing the consent and being provided the opportunity for child assent, 
each child and their family were given a tour of the cleanroom.  Each child and a parent 
spent two consecutive weeks sleeping in the cleanroom from May to October 2010.  
During the day, the child and parent went about their normal activities and therapies.  
Each evening, the child and parent arrived at TCI and spent approximately ten hours in 
the cleanroom while wearing silk or cotton clothes.  A research assistant recorded each 
child’s sleep behaviors through an observation window.  The children and family’s 
adjustment to the study was monitored by a Family Advocate Psychologist who had no 
academic involvement in the study.  Diet, medications, nutrients, and experiential 
services were held constant throughout the study. 
5.2.2.2 Cleanroom Design 
The cleanroom was designed and built at TCI in a modified hospital room.  The 
cleanroom floor was modified with Ohm-Shield (Static Solutions Inc., Marlborough, 
MA, USA) Anti-Static Restorer/Cleaner FC-4500 followed by Ohm-Shield Static 
Dissipative AF-6000/AF-6005 No VOC Floor Finish.  The walls were covered with 
Benjamin Moore (Montvale, NJ, USA) low odor, no VOC acrylic interior latex semi-
gloss paint.  Armstrong (Lancaster, PA, USA) Health Zone™ Ultima® cleanroom ceiling 
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tiles were also installed.  HEPA filters (99.99% efficient for 0.3 µm particles) were fitted 
in each of the four air intakes in the room.  A Model 7512 Second Wind Air Purifier 
(Buffalo, NY, USA) was placed in the room and set to the lowest setting.  These 
modifications allowed the cleanroom to have positive pressure compared to the hallway 
outside.  The room was furnished with ash furniture consisting of two twin beds, a 
nightstand, and a table with two chairs from Stevens Woodworks (Allison Park, PA, 
USA) which was only kiln dried and sealed with water soluble polyurethane and not 
stained.  The cleanroom bedding including the mattresses, pillows, pillowcases, mattress 
pads, mattress toppers, and sheets was purchased from Naturepedic (Chagrin, OH, USA).  
The room used incandescent lighting.  An ultraviolet water purification system was 
installed in the adjoining bathroom. 
5.2.2.3 Cleanroom Classification 
The classification of the cleanroom was performed according to ISO 14644, 
“Cleanrooms and associated controlled environments.”  The cleanroom classification 
from the ISO has been applied to microelectronics, pharmaceuticals, medical devices, 
aerospace, and others.
68
  Part 1 of ISO 14644, ISO 14644-1:1999, “Classification of air 
cleanliness,” defines the testing parameters which need to be followed in order for a room 
to be classified according to ISO standards.  Specifications for testing include the size of 
the room, classification level, sample time, sample volume, and number of sampling 
locations.  The determining factor in the classification of cleanrooms is the concentration 
of the particles in the room.  Many different particle sizes have been selected with 
defined limits for each classification level.  Table 20 shows the classification standards 
based on the concentration of different particle sizes for cleanrooms according to ISO. 
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Table 20:  Cleanroom classification table with particle size and concentration according to ISO 
14644-1.
68
 
 
The cleanroom testing was performed using a Hach (Loveland, CO, USA) Met 
One HHPC-6 Handheld Airborne Particle Counter.  This particle counter is capable of 
measuring particles at 0.5, 0.7, 1.0, 2.0, 5.0, and 10.0 micrometers (µm).  Data were 
reported in concentration mode.  The relative humidity and temperature were also 
measured during sampling.  All data were downloaded into PortAll software and 
analyzed using PortAll software and Microsoft Excel. 
The cleanroom classification was performed at two different stages as defined by 
the ISO:  ‘as-built’ and ‘at-rest’.  After the hospital room at TCI was finished being 
modified, the cleanroom was at the ‘as-built’ stage meaning the room is at a “condition 
where the installation is complete with all services connected and functioning but with no 
production equipment, materials, or personnel present.”68  Once the cleanroom had been 
furnished with furniture and bedding, the cleanroom was at the ‘at-rest’ stage.  This stage 
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is where “installation is complete with equipment installed and operating in a manner 
agreed upon by the customer and supplier, with no personnel present.”68  An adjacent 
room and the hallway outside of the cleanroom were also classified ‘at-rest.’ 
Calculations were performed to determine the testing criteria for the cleanroom, 
adjacent room, and hallway.  The first variable to be established is the particle limit for 
each ISO class because the classification of a cleanroom is based on the concentration of 
particles.  For classification in this study, 0.5 µm particles were used.  Under the old 
Federal Standard 209, the classification of a cleanroom is based on the amount of 
particles ≥ 0.5 µm in one cubic foot of room air which does not exceed the classification 
limit.
69
  This equivalent was converted to the current ISO 14644-1:1999 standards.  The 
ISO established limits for cleanroom particle concentration using Equation 3, 
       
  (
   
 
)
    
 
Equation 3:  The equation for calculating the maximum number of particles at a particular 
particle size for cleanroom classification according to ISO.
68
 
 
where Cn is “the maximum permitted concentration of airborne particles that are equal to 
or larger than the considered particle size”, N is the ISO classification number, D is the 
particle size measured, and 0.1 is a constant.
68
  In accordance with the testing 
classification, both the average particle concentration and 95% upper confidence limit are 
calculated using the appropriate statistical equations.
68
  Both the average particle 
concentrations and the 95% upper confidence limit must not exceed the particle limits for 
that classification level as shown in Table 20. 
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The next factor to be determined is the number of sampling locations.  The size of 
the cleanroom dictates the number of sampling locations.  Equation 4 shows the 
calculation for the number of sampling locations, 
    √  
Equation 4:  The equation for determining the number of sampling locations for cleanroom 
classification.
68
 
 
where NL is the minimum number of sampling locations and A is the area of the room in 
square meters.
68
  The cleanroom is 12’ × 16’ with an area of 192 ft2 or 17.84 m2.  From 
this equation, it is ascertained that five sampling locations are required by rounding up to 
the next whole number as shown in Equation 5. 
   √  √        √        √               
Equation 5:  The application of the sampling location equation to the cleanroom built at The 
Children’s Institute. 
With the number of sampling locations determined, it was necessary to classify the room 
according to ISO standards.  The room will be attempted to be classified at ISO Class 5 
as it is a reasonable classification level for the room in its current condition based on the 
improvements made to the room.  If the room does not meet ISO Class 5 classification, it 
will meet ISO Class 6 level or higher standards. 
The first parameter needed to determine class level is the sample volume.  The 
sample volume is calculated using Equation 6, 
   
  
   
       
Equation 6:  The equation for the determination of the minimum sample volume in a single 
sample according to ISO.
68
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where Vs is the minimum sample volume per location in liters, Cn,m is the limit of the 
number of particles for the class, and 20 is the number of particles counted if the room 
was at the class limit.
68
  For ISO Class 5, C = 3,520 and for ISO Class 6 C is 35,200 for 
0.5 µm particles.  The calculations are shown below in Equation 7. 
   
  
     
                               
   
  
      
                            
Equation 7:  The determination of the minimum sample volume for ISO Class 5 and 6 
cleanrooms. 
The minimum sampling requirements for the ISO are a one minute sampling time 
and two liters of air sampled.
68
  The particle counter samples at 2.83 L minute
-1
; 
therefore, a 2 minute sample is sufficient to meet ISO Class 5 and higher classification 
levels because a sample of 2 minute produces a count of 19.92 particles at the minimum 
particle concentration for ISO Class 5.  The sampling parameters of 5.66 L sampled over 
a two minute time period exceed the minimum criteria.  With these calculations, all of the 
sampling parameters have been determined for ISO Class 5 and are acceptable to all 
higher ISO classification cleanrooms. 
The cleanroom classification began by sampling the cleanroom, the room adjacent 
to the cleanroom, and the hallway outside of the cleanroom.  The adjacent room was 
evaluated for the improvements made to the cleanroom and the hallway was sampled to 
provide a control for both the cleanroom and the adjacent room.  The sampling was 
performed by placing the particle counter on a 46” ladder to simulate breathing and 
sleeping levels.  At each of the five sampling locations, three different trials were taken.  
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The same random sampling order was used for all three locations.  When sampling was 
performed in the cleanroom, a ten minute equilibration time interval was used to allow 
the room to return to equilibrium before testing began.  The testing was performed while 
the analyst was wearing a full cleanroom coverall, bouffant, facemask, gloves, sleeve 
covers, shoe covers, and goggles to prevent any possible contamination from the analyst.  
A zero count filter reading was performed before the sampling began.  All of the 
sampling locations were at least one foot away from an air inlet.  The bathroom door 
remained closed during the testing as it did during the clinical application of the 
cleanroom.  The layouts of the three sampling areas along with the airflow diagrams are 
shown in Figures 22-26. 
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Figure 22:  Diagram of the airflow of the cleanroom at The Children’s Institute. 
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Figure 23:  Sampling diagram of the cleanroom at The Children’s Institute. 
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Figure 24:  Diagram of the airflow of the room adjacent to the cleanroom at The Children’s 
Institute. 
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Figure 25:  Sampling diagram of the room adjacent to the cleanroom at The Children’s Institute.
  
2
5
6 
 
Figure 26:  Sampling diagram of the hallway outside of the cleanroom at The Children’s Institute. 
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5.2.2.4 Blood Draw, Hair Collection, and Clinical Testing 
Within 24 hours before and after the two week study period, approximately 30 
milliliters of blood were drawn by a phlebotomist who specialized in working with 
children with developmental disabilities.  The draws were completed at the child’s home, 
and the blood was processed and stored within 2 hours at Duquesne University.  The 
blood was separated with a calibrated centrifuge and aliquoted for testing by Quest 
Diagnostics (Pittsburgh, PA, USA) and Duquesne University.  In addition, a hair sample 
was obtained from the back of the head, and it was placed in a clean, sealable 
polyethylene bag for transport to Duquesne University for analysis.  The Quest 
Diagnostics testing included plasma zinc; serum copper; T and B lymphocyte subsets; 
serum IgA, IgG, and IgM immunoglobulins; and complete blood count including 
differential and platelets.  The Duquesne University analyses included elemental analysis 
in serum, plasma, red blood cells (RBCs), and hair; total, oxidized, and reduced 
glutathione in RBCs; and benzene, toluene, and o-xylene along with selected 
polychlorinated biphenyls (PCBs) in serum.  The glutathione and organic chemical 
testing will not be discussed in detail in this chapter as it is part of a larger study.  The 
remaining serum, plasma, and RBCs to be tested by Duquesne University were stored at -
80 °C.   
5.2.2.5 Microwave Closed Vessel Preparation and Cleaning 
The sample preparation procedures for the elemental analysis in blood and hair 
were performed in an ISO Class 6 cleanroom using microwave digestion vessels and 
inserts.  The 6 mL microwave inserts and lids were cleaned before each digestion with 3 
mL of HNO3 and 1 mL of HCl.  Outside of the three inserts, 5 mL of HNO3 was added to 
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each digestion vessel to allow the temperature of the vessels to be monitored and ensure 
that the inserts maintained the proper temperature.  The vessels were microwaved 
according to United States Environmental Protection Agency (EPA) Method 3052
70
 using 
a 10 minute ramp to 180 °C with a 10 minute hold at 180 °C.  After microwaving, the 
vessels, lids, and stir bars were rinsed inside and outside with DDI water and dried on 
cleanroom wipes overnight. 
5.2.2.6 Elemental Analysis of Blood 
5.2.2.6.1 Sample Digestion for Elemental Analysis by External Calibration Curve 
Three different sample matrices were analyzed: serum, plasma, and RBCs.  For 
each matrix, child, and sampling time, two subsamples were prepared in clean 6 mL 
microwave vessel inserts.  After a stir bar was added to each insert, 0.2 grams of sample 
from the respective matrix was combined with 3 mL of HNO3 and 0.25 mL of HCl.  For 
each batch of samples, two subsamples of SRM 1598a were prepared in the same manner 
as the samples for quality control.  Similar to the vessel cleaning, 5 mL of HNO3 was 
added to the microwave digestion vessels outside of the 6 mL inserts.  The samples were 
microwaved according to EPA Method 3052 resulting in a complete digestion seen 
through the production of homogenous, transparent, light yellow solutions that did not 
contain any solids.  After microwaving, each sample was poured into a 50 mL centrifuge 
tube and diluted with a 1% HNO3 and 0.5% HCl solution until the final volume was 10 
mL.  The centrifuge tubes were weighed before and after the addition of the digests along 
with being pre-rinsed with the 1% HNO3 and 0.5% HCl solution.  Ten analytical blanks 
consisting of HNO3 and HCl were prepared for each set of samples.  The microwave 
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vessels were rinsed with DDI water after being used and cleaned as previously described.  
The samples were stored in a cold room at 4 °C until analysis, typically within 3 days. 
5.2.2.6.2 Total Elemental Quantification by EPA Method 6020B 
 The total elemental concentrations in the sample digests were determined 
according to EPA Method 6020B.
71
  On each day of analysis, the system was aspirated 
with 2% HNO3 for 30 minutes before tuning the instrument using the Agilent tuning 
solution at a concentration of 1 ng g
-1
 and determining the pulse/analog factor (P/A).  
Analysis on the Agilent 7700 ICP-MS was performed in three analysis modes:  hydrogen, 
helium, and no gas.  The amount of hydrogen and helium gas was optimized to minimize 
polyatomic interferences.  Between analysis modes, a 30 second delay was employed to 
equilibrate the presence or absence of collision gas and/or reaction gas.  The analysis 
mode for each element is listed in Table 25. 
 Calibration curves were created for 58 elements using solutions from the sing and 
multi-element standards.  The calibration solutions were prepared at concentrations of 0, 
2.5, 5, 7.5, and 10 ng g
-1
 in a 1% HNO3 and 0.5% HCl solution by serial dilution.  In the 
first two sample sequences, four children’s before and after samples (serum, plasma, and 
RBCs) were analyzed per run with four replicates taken from each subsample.  The last 
sequence included all of the samples from the last two children.  Analysis was performed 
using spectrum mode with one point per mass.  The integration times ranged from 0.1-1.0 
seconds per point depending on the element’s ionization energy.  After analysis, the data 
was taken from Agilent MassHunter software (version G7201A A.01.01) and exported 
into Microsoft Excel for further data processing. 
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5.2.2.6.3 Sample Digestion for Elemental Analysis by IDMS 
 The blood samples to be analyzed according to EPA Method 6800 were also 
prepared using microwave sample digestion.  Similar to the EPA Method 6020B sample 
preparation, two samples of each matrix, child, and sampling time were prepared.  Using 
clean microwave vessels, 0.2 grams of sample were combined in each insert with a stir 
bar, the appropriate amount of isotopically enriched analyte, 3 mL of HNO3, and 0.25 mL 
of HCl.  SRM 1598a was also used for quality control of each batch.  Similar to the EPA 
Method 6020B sample preparation, 5 mL of HNO3 was added to each digestion vessel 
outside of the inserts.  The samples were digested following EPA Method 3052 with the 
same parameters as the EPA Method 6020B sample preparation.  The same post 
microwave sample protocol was followed as EPA Method 6020B preparation.  After 
completing the post microwave procedure, samples were stored at 4 °C in a cold room 
until analysis, usually within 2 days.  With each batch of samples, ten analytical blanks 
consisting of HNO3, HCl, and isotopically enriched versions of the elements of interest 
were prepared. 
5.2.2.6.4 Total Elemental Quantification by EPA Method 6800 
 Total elemental quantification using IDMS, a component of EPA Method 6800
72
 
was performed for nine elements (antimony, cadmium, chromium, copper, lead, mercury, 
molybdenum, selenium, and zinc).  On each day of analysis, the ICP-MS was tuned and 
the P/A factor was determined as previously described.  The IDMS analysis was also 
completed using the three different modes with the same collision/reaction gas 
parameters.  Analysis was performed in spectrum mode with one point per peak with 
integration times between 0.5-1.0 seconds per point for each element.  Each subsample 
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had four replicates analyzed.  The first two sequences contained four children’s sample 
while the last one contained the samples from the last two children.  Natural abundant 
standards of the nine elements were analyzed at 0, 2, 4, 6, 8, and 10 ng g
-1
 to determine 
the mass bias and deadtime correction factors.  The Agilent 7700 ICP-MS’s default 
deadtime of 38 nanoseconds was used for the IDMS calculations.  The concentrations for 
each of the isotopically enriched elements were calculated by reverse IDMS analysis 
using the multi- or single element standard solutions.  The completed data was exported 
into the IDMS software provided by AIT in Microsoft Excel from Agilent MassHunter.  
The analyte concentrations in the sample solutions were determined by the IDMS 
equation (Equation 1). 
5.2.2.7 Elemental Analysis of Hair 
5.2.2.7.1 Sample Decomposition for Total Elemental Analysis by External 
Calibration Curve 
The hair elemental analysis samples were also prepared using microwave-
enhanced chemistry.  Two subsamples of each child and sampling time were analyzed for 
the hair analysis.  Using clean microwave inserts, 0.1 grams of sample were combined 
with a stir bar, 0.5 mL of HNO3, and 0.2 mL of HCl.  CRM GBW09101b was used for 
quality control with all of the same sample preparation parameters, except 0.2 grams of 
CRM GBW09101b were used to meet the specifications of the CRM certificate.  As in 
the blood analysis, 5 mL of HNO3 was added to the microwave digestion vessels outside 
of the inserts.  The hair samples were microwaved according to the previously described 
parameters of EPA Method 3052.  The same post microwave procedure as during the 
blood analysis was employed.  Eight analytical blanks consisting of HNO3 and HCl were 
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digested with each sample batch.  The samples were stored in a cold room at 4 °C until 
the day of analysis, usually within 3 days. 
5.2.2.7.2 Quantification of Total Elemental Concentrations by EPA Method 6020B 
The total elemental concentrations in hair were determined in the digests using 
EPA Method 6020B.  The ICP-MS was tuned and the P/A factor was determined on each 
analysis day as previously described.  Similar to the blood analysis, the three different 
collision/reaction gas modes were used with the previously described parameters. 
Using the single and multi-element standards, calibration curves were prepared 
for 58 elements.  Due to the wide range in concentrations of the elements of interest in 
CRM GBW09101b and the hair samples, the analysis performed at two different 
calibration ranges as the digests were diluted an additional 100:1 using a 1% HNO3 and 
0.5% HCl solution on the day of analysis.  Calibration solutions were prepared at 
concentrations of 0, 5, 10, 25, 50, and 100 ng g
-1
 through serial dilution using the 1% 
HNO3 and 0.5% HCl solution. 
During each sequence, five children’s before and after hair samples were analyzed 
with four replicates taken from each subsample.  The analyses were completed in 
spectrum mode using one point per mass.  The integration times for each element ranged 
from 0.1-1.0 seconds per point based on the ionization energy of each element.  The 
measured concentration value for each element in CRM GBW09101b and each hair 
sample was determined based on the value that fell within the range of one of the two 
calibration curves.  After analysis, additional data analysis was performed in Microsoft 
Excel after being exported from Agilent MassHunter. 
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5.2.2.7.3 Quality Control 
The current study implemented numerous quality control measures that were 
previously mentioned including the preparation of multiple subsamples, replicate 
analysis, preparation of analytical blanks, acid or solution matched calibration standards, 
and reference materials.  It also utilized many of the quality control measures described 
in EPA Method 6020B.  The Agilent internal standard solution was used at a 
concentration of 100 ng g
-1
 in a 1% HNO3 and 0.5% HCl solution, and its acceptable 
recovery was maintained between 80 and 120% of the calibration blank.  Between 
samples, the autosampler probe was washed in three 1% HNO3 and 0.5%  HCl solutions 
for 30 seconds each with a nebulizer pump speed of 0.5 rps.  After every ten samples 
during EPA Method 6020B analysis, calibration checks and either SRM 1598a or CRM 
GBW09101b assessments were performed as additional calibration verification.  During 
EPA Method 6800 analysis, SRM 1598a checks were performed at the beginning, 
middle, and end of each analysis sequence.  These checks ensured the consistency of the 
results during the complete duration of the sample runs. 
5.2.2.8 Behavioral Rating Scales 
The same parent filled out multiple behavioral rating scales within 24 hours of the 
beginning and end of the cleanroom experience.  The rating scales completed included 
the Social Communication Questionnaire (SCQ),
73
 PDD Behavioral Inventory 
(PDDBI),
74
 Aberrant Behavior Checklist (ABC),
75
 Gilliam Autism Rating Scale-2 
(GARS-2),
76
 Autism Treatment Evaluation Checklist (ATEC),
77
 and Childhood Autism 
Rating Scale (CARS).
78
  The SCQ is used to assess the social interactions, language and 
communication aptitude, and stereotyped and repetitive behaviors of children with an 
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autism spectrum disorder.
79
  The PDDBI has multiple domains and composites that 
measure both adaptive and maladaptive behaviors,
80
 and the Autism Composite is 
calculated using selected domains.  The total ABC is the summation of five subscales:  (I) 
Irritability, Agitation, Crying; (II) Lethargy, Social Withdrawal; (III) Stereotypic 
Behavior; (IV) Hyperactivity, Noncompliance; and (V) Inappropriate Speech.
75
  The 
results of these rating scales were recorded and pooled for statistical analysis. 
5.2.2.9 Statistical Analysis 
All statistical analyses were performed using the R statistical software package.  
To investigate an overall cleanroom impact, the n = 10 pre-cleanroom measurements 
were subtracted from the corresponding post-cleanroom measurements for each variable.  
Paired t-tests were used to identify whether the observed mean differences deviated 
significantly from zero.  Two separate statistical analyses were performed to investigate 
the relationship between measurement change and subject age.  Preliminary statistical 
analysis indicated the necessity to divide the entire study population into younger and 
older cohorts.  An independent sample t-test was implemented for each variable to assess 
whether the average difference observed for subjects in the younger cohort, age 5 and 
under, was significantly different than for subjects in the older cohort, who were age 6 
and older.  A Pearson correlation between measurement difference and subject age was 
also computed for each variable. 
Replicate analyses were performed for all chemical and elemental tests, allowing 
for confidence intervals to be used as a means of comparing difference in values.  The 
rating scale and commercial laboratory measurements are single-measurement results and 
do not provide such statistical power.  An independent samples t-test was used to 
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determine whether the average of the pre-cleanroom replicate measurements for a 
particular subject differed significantly from the average of the post-cleanroom replicate 
measurements for that subject.  The fact that funding constraints allowed for only n = 10 
subjects is the greatest statistical limitation of this study.  This sample size provided 
relatively weak statistical power (as compared to larger sample sizes) for recognizing 
small or moderate differences when they exist.  This issue, combined with the 
exploratory nature of this study and the fact that variables within a category are often 
correlated (as with the rating scale variables), has prompted the authors to consider p-
values at or below the 0.05 significance level as indicative of a noteworthy result. 
5.3 Results 
5.3.1 Cleanroom Classification 
The three different areas were classified according to ISO standards:  the 
cleanroom, the adjacent room, and the hallway.  After the results were obtained using the 
Met One particle counter, they were downloaded in the PortAll software and then 
exported to Microsoft Excel.  In Excel, the averages of the five sampling locations were 
calculated.  The standard deviation and confidence interval (CI) were determined using 
the five averages.  The confidence interval is calculated as a 1-sided confidence interval 
since the results are only concerned with the maximum possible value to meet the ISO 
classification standards and not with how low the value is for the lower bound.  The 1-
sided confidence interval means that the results are 95% confident that the results are 
below the numeric value of 95% upper confidence interval bound.  In a 2-sided 
confidence interval, the results are 95% sure they fall within a range symmetric to the 
mean.  In the initial testing, the cleanroom was at the ‘as-built’ stage and the adjacent 
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room and hallway were at the ‘at-rest’ stage.  The Excel results from the initial testing are 
shown in Tables 21-23.  Reports were also made in the PortAll software.  
The particle counting results for the cleanroom at the ‘at built’ stage are shown in 
Table 21, which indicated that the particle concentration for 0.5 μm particles met the 
standards for ISO Class 6 classification with both the average and the 95% upper 
confidence limit below the 35,200 0.5 μm particles m-3 threshold.  Of the selected 
sampling locations, location #2 was near the window in the room and location #4 was 
near the door.  The higher particle counts at these locations could have been the result of 
outside air entering the room near these sampling locations, but the elevated counts at 
these locations did not affect the classification of the room. 
Table 21:  Particle concentration results for the classification of the ‘as-built’ cleanroom at The 
Children’s Institute. 
Location 0.5 μm m-3 0.7 μm m-3 1 μm m-3 2 μm m-3 5 μm m-3 10 μm m-3 
Cleanroom #1 5,343 4,580 3,934 3,464 1,468 352 
Cleanroom #2 18,142 14,854 13,327 10,685 4,580 939 
Cleanroom #3 8,631 7,632 6,693 5,460 2,290 822 
Cleanroom #4 18,024 16,674 15,147 13,504 6,693 1,938 
Cleanroom #5 14,932 13,053 11,723 9,883 4,521 1,233 
Average 11,355 9,981 8,936 7,621 3,511 916 
Standard 
Deviation 
6,253 5,427 4,980 4,268 2,116 617 
95% Upper 
Confidence 
Limit 
17,311 15,150 13,680 11,686 5,526 1,503 
 
For the adjacent room, the classification results seen in Table 22 meet the 
qualifications for an ISO Class 7 cleanroom.  Both the average of the sampling locations 
and the 95% upper confidence interval bound were less than the 352,000 0.5 μm particles 
m
-3
 limit.  All of the sampling locations produced relatively equivalent data, indicating 
that the concentration of particles is distributed consistently throughout the room.  In 
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comparison to the adjacent room, the cleanroom had a twenty-fold decrease in 0.5 μm 
particles for the ‘as-built’ results. 
Table 22:  Particle concentration results for the classification of the ‘at-rest’ adjacent room at The 
Children’s Institute. 
Location 0.5 μm m-3 0.7 μm m-3 1 μm m-3 2 μm m-3 5 μm m-3 10 μm m-3 
Adjacent 
Room #1 
236,429 135,622 104,799 71,040 20,842 8,220 
Adjacent 
Room #2 
203,845 109,085 81,373 54,777 16,087 6,106 
Adjacent 
Room #3 
232,085 128,753 96,227 62,762 17,848 6,869 
Adjacent 
Room #4 
230,147 131,865 98,634 66,226 19,844 7,632 
Adjacent 
Room #5 
240,715 136,327 101,570 68,046 21,077 7,280 
Average  228,644 128,331 96,521 64,570 19,140 7,221 
Standard 
Deviation 
14,452 11,182 9,056 6,242 2,129 796 
95% Upper 
Confidence 
Limit 
242,410 138,982 105,147 70,516 21,168 7,980 
 
The classification results for the hallway outside of the cleanroom and adjacent 
room are displayed in Table 23.  The hallway met the classification standards for ISO 
Class 7.  The hallway air quality was equivalent to the adjacent room based on the ISO 
classification standards, and this result is logical as these areas were unmodified in 
comparison to the cleanroom.  The distribution of particles is relatively consistent 
throughout the hallway. 
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Table 23:  Particle concentration results for the classification of the ‘at-rest’ hallway at The 
Children’s Institute. 
Location 0.5 μm m-3 0.7 μm m-3 1 μm m-3 2 μm m-3 5 μm m-3 10 μm m-3 
Hallway #1 195,860 102,627 75,209 50,257 15,735 6,634 
Hallway #2 256,391 143,666 107,735 72,860 20,784 7,632 
Hallway #3 200,146 106,149 78,027 53,838 18,259 7,398 
Hallway #4 238,954 136,562 105,328 74,035 23,778 10,862 
Hallway #5 224,804 126,111 93,938 63,525 22,251 9,452 
Average 223,231 123,023 92,047 62,903 20,161 8,396 
Standard 
Deviation 
25,648 18,164 15,051 10,788 3,204 1,723 
95% Upper 
Confidence 
Limit 
247,663 140,325 106,384 73,180 23,213 10,037 
 
After the furniture and bedding had been installed, the cleanroom was at the ‘at-
rest’ stage.  The testing methods for the ‘at-rest’ cleanroom were the same as the ‘as-
built’ stage.  The same testing protocols were followed, except the particle counter was 
held by the analyst at a height approximate to the level during the ‘as-built’ testing 
instead of being placed on a ladder. 
The ‘at-rest’ results for the cleanroom are shown in Table 24.  The results 
indicated that the cleanroom met the criteria for ISO Class 5 classification as both the 
average of the five sampling locations and 95% upper confidence limit bound are below 
the ISO Class 5 limit of 3,520 0.5 μm particles m-3.  The data indicated an increase in the 
cleanliness of the air in the cleanroom despite the addition of furniture and bedding.  The 
five sampling locations also produced more equivalent data in comparison to the ‘as-
built’ data, suggesting that the air quality is more consistent throughout the room. 
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Table 24:  Particle concentration results for the classification of the ‘at-rest’ cleanroom at The 
Children’s Institute. 
Location 0.5 μm m-3 0.7 μm m-3 1 μm m-3 2 μm m-3 5 μm m-3 10 μm m-3 
Cleanroom #1 1,057 646 528 352 117 0 
Cleanroom #2 1,703 998 881 587 235 0 
Cleanroom #3 1,057 705 411 294 117 59 
Cleanroom #4 470 470 411 294 176 0 
Cleanroom #5 2,172 1,350 939 587 176 117 
Average 1,292 834 634 423 164 35 
Standard 
Deviation 
658 346 257 152 49 53 
95% Upper 
Confidence 
Limit 
1,918 1,163 879 567 211 85 
 
Upon the completion of cleanroom classification testing, the cleanroom was 
classified at ISO Class 6 for the ‘as-built’ state and ISO Class 5 for the ‘at-rest’ status.  
The improvements made to the cleanroom improved the air cleanliness from the ISO 
Class 7 levels found in the hallway and the adjacent room.  The overall air quality in the 
cleanroom was approximately twenty times cleaner during the initial ‘as-built’ stage and 
175 times better during the ‘at-rest’ testing compared to the unmodified adjacent room. 
5.3.2 Elemental Analysis of Blood and Hair 
5.3.2.1 Analytical Figures of Merit and Validation of EPA Methods  
All elements displayed linearity on the five or six point external calibration curves 
for the EPA Method 6020B blood and hair analysis, respectively.  They had correlation 
coefficient (r
2
) values greater than the 0.998 specified in EPA Method 6020B, except for 
Mg in the blood analysis, which was just below this cutoff at 0.9935 (Tables 25 and 26).  
The obtained measurements were highly reproducible because the four replicates for each 
calibration point displayed a typical variation of less than 5%. 
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Table 25:  The analysis information, correlation coefficient, DLs, QLs, and BECs for elements of 
interest in blood determined by EPA Method 6020B using the Agilent 7700 ICP-MS. 
Element m/z Mode r
2
 DL (ng g
-1
) QL (ng g
-1
) BEC (ng g
-1
) 
Mg 24 He 0.9935 2.09 5.17 0.885 
Al 27 No gas 0.9983 16.3 35.0 2.33 
V 51 He 1.0000 0.191 0.268 0.0565 
Cr 52 He 1.0000 19.9 46.2 0.391 
Mn 55 He 0.9999 1.33 3.59 0.184 
Fe 56 He 1.0000 84.2 195 1.19 
Co 59 He 0.9999 69.6 195 0.0163 
Ni 60 He 0.9996 38.2 98.0 1.67 
Cu 63 He 1.0000 10.1 28.1 0.159 
Zn 66 He 0.9993 5.41 10.3 0.639 
As 75 He 1.0000 0.0296 0.0598 0.0132 
Se 78 H2 0.9999 0.0225 0.0544 0.00806 
Rb 85 He 0.9998 0.00231 0.00733 0.0129 
Mo 95 He 1.0000 0.248 0.579 0.00934 
Cd 111 He 0.9999 0.420 0.802 0.0491 
Sb 121 No gas 1.0000 0.605 1.41 0.0139 
Te 125 No gas 0.9997 0.0544 0.140 0.0151 
Cs 133 No gas 0.9999 0.000649 0.00193 0.00170 
Hg 202 No gas 0.9999 0.205 0.376 0.0199 
Pb 208 No gas 0.9999 0.225 0.506 0.0658 
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Table 26:  The analysis information, correlation coefficient, DLs, and BECs for elements of 
interest in hair determined by EPA Method 6020B using the Agilent 7700 ICP-MS. 
Element m/z Mode r
2
 DL (ng g
-1
) QL (ng g
-1
) BEC (ng g
-1
) 
Na 23 No gas 0.9995 31.7 70.0 4.22 
Mg 24 No gas 0.9999 3.06 5.95 1.30 
Al 27 No gas 0.9998 6.03 14.9 4.46 
P 31 No gas 0.9997 13.0 14.9 18.5 
K 39 No gas 0.9988 6.87 15.6 78.5 
Ca 40 H2 0.9958 4.95 13.8 93.0 
V 51 He 1.0000 0.376 0.300 0.339 
Cr 52 He 1.0000 2.05 2.62 0.587 
Mn 55 He 0.9999 0.123 0.306 0.105 
Fe 56 He 0.9986 1.76 4.71 6.34 
Co 59 He 1.0000 0.0339 0.0679 0.00855 
Ni 60 He 0.9999 1.82 4.28 0.595 
Cu 63 He 0.9999 0.0766 0.255 0.791 
Zn 66 He 1.0000 0.416 1.21 1.73 
As 75 He 1.0000 0.140 0.172 0.113 
Se 78 H2 0.9999 0.0426 0.110 0.0778 
Sr 88 No gas 0.9999 0.0246 0.0739 0.0619 
Mo 95 He 1.0000 0.117 0.330 0.0549 
Ag 107 No gas 0.9999 0.0994 1.95 0.00583 
Cd 111 He 1.0000 0.857 0.263 0.0269 
Sb 121 No gas 0.9998 0.552 1.33 0.0355 
Ba 137 No gas 1.0000 0.546 1.48 0.191 
La 139 No gas 1.0000 0.0000235 0.0000729 0.00208 
Hg 202 No gas 1.0000 0.297 0.517 0.177 
Pb 208 No gas 0.9999 0.177 0.431 0.0293 
U 238 No gas 0.9997 0.000389 0.00130 0.000603 
 
The detection limits (DLs) were defined as the average of the blank concentration 
for each element plus three times the standard deviation of the blank measurements for 
that respective element.
81
  The DLs for all elements were below 1 ng g
-1
 except for Mg, 
Al, K, V, Cr, Mn, Fe, Co, Ni, Cu, and Zn for the EPA Method 6020B blood analysis 
(Table 25); Cr, Zn, and Se for the EPA Method 6800 blood testing (Table 27); and Na, 
Mg, Al, P, Ca, Cr, Fe, and Ni for the EPA Method 6020B hair analysis (Table 26).  The 
quantification limits (QLs) were determined by taking ten times the standard deviation of 
the blank measurements for each respective element.
81
  The QLs were all under 5 ng g
-1
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except for Mg, Al, K, Cr, Fe, Co, Ni, Cu, and Zn for the EPA Method 6020B blood 
testing (Table 25); Cr for the EPA Method 6800 blood analysis (Table 27); and Na, Mg, 
Al, P, and Ca for the EPA Method 6020B hair testing (Table 26).  The background 
equivalent concentrations (BECs) were calculated by multiplying the background 
intensity signal with the concentration of the analyte and dividing by the difference of the 
analyte intensity minus the intensity of the background.
82
  The BECs were below 1 ng g
-1
 
for all elements except for Al, Fe, and Ni in the EPA Method 6020B blood testing (Table 
25); all elements in the EPA Method 6800 blood analysis (Table 27); and Na, Mg, Al, P, 
K, Ca, Fe, and Zn in the EPA Method 6020B hair testing (Table 26). 
Table 27:  The analysis information, correlation coefficient, DLs, QLs, and BECs for elements of 
interest in blood determined by EPA Method 6800 using the Agilent 7700 ICP-MS. 
Element Natural 
m/z 
Enriched 
m/z 
Mode DL (ng g
-1
) QL (ng g
-1
) BEC (ng g
-1
) 
Cr 52 50 He 4.25 5.40 0.461 
Cu 63 65 He 0.186 0.560 0.997 
Zn 66 68 He 5.74 11.1 0.604 
Se 78 77 H2 1.42 2.53 0.0700 
Mo 95 97 He 0.0363 0.0646 0.0168 
Cd 114 112 He 0.414 0.881 0.00381 
Sb 121 123 No gas 0.117 0.159 0.0144 
Hg 202 199 No gas 0.635 1.31 0.145 
Pb 208 206 No gas 0.712 1.24 0.0166 
 
Additional confidence in the accuracy and precision of the results from the 
present study was achieved by using SRM 1598a and CRM GBW09101b to validate the 
sample preparation and analysis protocols.  These standards are certified for multiple 
elements at concentrations similar to those found in representative blood and hair 
samples, respectively.  Results obtained for SRM 1598a during this study using EPA 
Method 6020B and EPA Method 6800 are shown in Table 28 with the mean (n = 12) and 
95% confidence intervals (CIs).  The measured values are in strong agreement with the 
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certified and reference values for the EPA Method 6020B analysis, with overlapping CIs 
for nearly half of the elements determined above the respective DL.  The percent 
recoveries ranged from 64.1 to 205.6% when comparing mean values, but these 
recoveries improved when including the CIs.  Mercury had the highest percent 
recoveries, but the CIs overlapped for the reference and measured values.  Only Fe had a 
recovery that differed by more than 20% from the certified, reference or informational 
mean value or that did not overlap CIs.  For the EPA Method 6800 testing, the measured 
CIs overlapped with the certified or reference CIs for 3 of the 4 elements that were able 
to be quantified above the respective DL, with Zn being the only exception.  The 
recovery for Zn was 111.4%, but improved to 107.7% when including CIs. 
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Table 28:  SRM 1598a results by EPA Method 3052 sample preparation and analysis by either 
EPA Methods 6020B or 6800.  All certified, reference, information, and measured values in ng g
-
1
 (n = 8, 95% CIs).  All values below detection limit are reported as <DL. 
Element 
Certified Value 
(ng g
-1
) 
EPA Method 6020B 
(ng g
-1
) 
EPA Method 6800 
(ng g
-1
) 
Cd 0.047 ± 0.004 <DL <DL 
Co 1.21 ± 0.07 <DL Not Determined 
Cs 0.62 ± 0.10 0.7404 ± 0.0928 Not Determined 
Cu 1,538 ± 88 1,746 ± 69 1,605 ± 10 
Fe 1,635 ± 58 1,048 ± 99 Not Determined 
Mn 1.73 ± 0.32 <DL Not Determined 
Ni 0.91 ± 0.18 <DL Not Determined 
Rb 267 ± 18 317.4 ± 16.0 Not Determined 
Sb 0.973 ± 0.15 <DL <DL 
Se 130.8 ± 5.6 152.2 ± 8.4 132.3 ± 4.2 
V 1.83 ± 0.11 <DL Not Determined 
Zn 857 ± 23 959.2 ± 42.1 954.8 ± 7.3 
 
Reference Value 
(ng g
-1
) 
EPA Method 6020B 
(ng g
-1
) 
EPA Method 6800 
(ng g
-1
) 
Al 2.2 ± 0.6 <DL Not Determined 
Ca 93 ± 7 (µg g
-1
) Not Determined Not Determined 
Cr 0.32 ± 0.08 <DL <DL 
Hg 0.31 ± 0.18 0.6376 ± 0.2785 <DL 
Mo 5.4 ± 1.0 3.841 ± 0.707 7.209 ± 1.041 
 
Information Value 
(ng g
-1
) 
EPA Method 6020B 
(ng g
-1
) 
EPA Method 6800 
(ng g
-1
) 
As 0.3 0.3783 ± 0.1355 Not Determined 
K 258 (µg g
-1
) Not Determined Not Determined 
Na 3,115 (µg g
-1
) Not Determined Not Determined 
P 136 (µg g
-1
) Not Determined Not Determined 
S 915 (µg g
-1
) Not Determined Not Determined 
Te 0.032 <DL Not Determined 
 
There were four elements which were measured by both EPA Methods 6020B and 
6800 at detectable quantities:  Cu, Mo, Se, and Zn.  Figure 27 shows the results from 
each of the two EPA methods for these four elements.  The results from EPA Method 
6800 for all of the four elements provided better precision seen through smaller CIs for 
Cu, Se, and Zn.  Better accuracy was seen for Cu and Se by EPA Method 6800.   
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Figure 27:  Comparison of EPA Methods 6020B and 6800 results for copper, molybdenum, 
selenium, and zinc from SRM 1598a (n = 8, 95% CIs). 
Similar accuracy was achieved for CRM GBW09101b during the hair analysis.  
Table 29 and Figure 28 show a comparison of the reference and informational values 
with the measured results including means (n = 12) and 95% CIs.  The measured values 
are in strong agreement with the certified and informational values, as the CIs for the 
measured values overlapped the certified CIs for 10 out of 21 elements.  The recovery 
efficiencies ranged from 49.5 to 146.0% based on a comparison of the mean listed values 
to the average measured quantities.  Only 9 of the 21 elements with certified values had 
either recoveries that differed by more than 20% from the mean value or that did not 
overlap CIs.  The overall accuracy of the elemental measurements in this study improves 
with the inclusion of the provided CIs. 
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Table 29:  CRM GBW09101b results in µg g
-1
 by EPA Method 3052 sample preparation and 
analysis by EPA Method 6020B (n = 8, 95% CIs). 
Element Certified Value (µg g
-1
) EPA Method 6020B (µg g
-1
) 
Ag 0.037 ± 0.002 0.03257 ± 0.00255 
Al 23.2 ± 2.0 21.92 ± 0.51 
As 0.198 ± 0.023 0.2246 ± 0.0209 
Ba 11.1 ± 1.3 8.739 ± 0.311 
Ca 1,537 ± 68 1,334 ± 178 
Cd 0.072 ± 0.010 0.05506 ± 0.00712 
Co 0.153 ± 0.015 0.1123 ± 0.0057 
Cr 8.74 ± 0.97 6.466 ± 0.415 
Cu 33.6 ± 2.3 24.56 ± 2.30 
Fe 160 ± 16 131.9 ± 5.3 
Hg 1.06 ± 0.28 1.094 ± 0.095 
I 0.96 ± 0.20 Not Determined 
Mg 248 ± 14 187.4 ± 18.7 
Mn 3.83 ± 0.39 2.602 ± 0.173 
Mo 1.06 ± 0.12 0.6944 ± 0.0409 
Na 445 ± 40 380.1 ± 41.2 
P 174 ± 43 86.21 ± 9.28 
Pb 3.83 ± 0.18 3.673 ± 0.282 
Sb 0.12 ± 0.02 0.1296 ± 0.0039 
Se 0.59 ± 0.04 0.8616 ± 0.0631 
Sr 8.17 ± 0.69 7.949 ± 0.620 
Zn 191 ± 16 161.2 ± 11.5 
 Information Value (µg g
-1
) EPA Method 6020B (µg g
-1
) 
K 14.4 12.14 ± 0.28 
La 0.029 0.02182 ± 0.00042 
S 4.62 Not Determined 
Cl 48.2 Not Determined 
Ti 2.1 Not Determined 
V 0.089 0.06349 ± 0.00337 
Br 0.59 Not Determined 
Ni 5.77 4.232 ± 0.327 
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Figure 28:  Comparison of the EPA Method 6020B results to the CRM GBW09101b certified 
and information values (n = 8, 95% CIs). 
The precision determined by the 95% CIs was within 10% of the measured mean 
values for a large majority of the certified, reference, or information values for elements 
in SRM 1598a and CRM GBW09101b, with nearly a third inside of 5% (Tables 28 and 
29).  This level of precision observed for these reference standards was maintained for 
the remainder of the study as most results had 95% CIs that were less than 10% of their 
mean value, including a large number of them within 5%.  The EPA Method 6800 results 
for SRM 1598a were more precise compared to EPA Method 6020B for 5 of the 6 
elements that were able to be quantified by both methods.  The blood measurements in 
this study obtained by EPA Method 6800 were more precise for Cu, Se, and Zn compared 
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to those from EPA Method 6020B.  The current study also supplied 95% CIs for all 
detectable elemental quantities in the blood and hair samples. 
5.3.2.2 Elemental Analysis of Blood 
Significant results were observed when the two types of age analyses were 
performed (Figures 29 and 30).  Significant negative correlations with age were found for 
changes in serum magnesium (p=0.047, r= − 0.64).  Conversely, serum iron significantly 
correlated positively with age (p=0.050, r=0.63).  The RBC selenium was nearly 
significantly positively correlated with age (p=0.051, r=0.63).  In addition, the younger 
cohort decreased both their RBC zinc (p=0.028) and RBC selenium (p=0.011) to a 
greater degree on average when compared to the older cohort. 
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Figure 29:  Changes in serum magnesium, serum iron, and RBC selenium versus age.  Younger 
children had a greater tendency to raise their serum magnesium than older children as it was 
negatively correlated with age (p=0.047).  There was a significant positive correlation between 
the change in iron and age (p=0.050).  There was a near significant positive correlation between 
age and change in RBC selenium concentration (p=0.051).  There are two points at 0 for age 12 
for the serum iron change. 
 
 
Figure 30:  Elemental analysis results in RBCs for zinc and selenium.  When applying a cutoff at 
age 5 which separated the younger four children from the older six children, significant decreases 
were seen for RBC selenium (p=0.011) and RBC zinc (p=0.028) in the younger cohort. 
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Due to prior research and publications, special attention was paid to the plasma 
zinc/serum copper ratio which has been reported to be 1.0.
83
  Previous research has 
shown that plasma zinc/serum copper ratio is below 0.7 only in the lowest 2.5% of 
healthy children.
41
  According to commercial clinical laboratory data, five children had a 
plasma zinc/serum copper ratio below 0.7 before participating in the study (Figure 31).  
Five out of ten children had a plasma zinc/serum copper ratio below 0.7 based on EPA 
Method 6020B data.  According to EPA Method 6800 data, eight of ten children had a 
plasma zinc/serum copper ratio above 0.7 before participating in the study as they were 
taking zinc supplementation which was maintained at the same level throughout the 
study.  Five out of ten children increased their plasma zinc/serum copper ratio according 
to the commercial clinical results.  The commercial clinical results saw four out of the 
older six children increase their zinc/copper ratio.  EPA Method 6020B data saw an 
increase in four of ten children.  According to EPA Method 6020B, four of the older six 
children increased their zinc/copper ratio with one being significant by independent 
samples t-test.  All four of the younger children decreased their plasma zinc/serum copper 
ratio, with two being significant by independent samples t-test.  Five of the children 
increased their zinc/copper ratio according to EPA Method 6800 during the study.  Four 
out of the older six children increased their zinc/copper ratio during the study.  There 
were no significant differences in pre- versus post-zinc/copper ratios in any of the 
children on independent samples t-test. 
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Figure 31:  Before and after cleanroom plasma zinc/serum copper ratio according to the 
commercial clinical laboratory, EPA Method 6020B, and EPA Method 6800.  Results for Method 
6020B and Method 6800 are with n = 8 and 95% CIs. 
Plasma zinc increased in seven of ten children by commercial results (Figure 32).  
Five out of the six older children increased their zinc.  By EPA Method 6020B, three out 
of ten increased plasma zinc, with one being significant by independent samples t-test.  
Two out of the six older children increased their plasma zinc, including the significant 
increase.  EPA Method 6800 IDMS plasma zinc results saw increases in six of ten 
children.  There were no significant changes, but four of six older children raised their 
plasma zinc. 
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Figure 32:  Before and after plasma zinc results (ng g
-1
) for commercial clinical laboratory, EPA 
Method 6020B, and EPA Method 6800 results for the ten children who participated in the 
cleanroom study.  Commercial clinical laboratory results were divided by 1.025 to produce 
comparable units.  Results for Method 6020B and Method 6800 are with n = 8 and 95% CIs. 
Serum copper dropped in five out of ten children by commercial laboratory results 
(Figure 33).  Three of the older six children dropped their serum copper.  By EPA 
Method 6020B, five out of ten lowered serum copper.  Four out of older six lowered their 
serum copper, including one significantly by independent samples t-test.  EPA Method 
6800 IDMS copper results saw decreases in six of ten children.  Four out of the older six 
children lowered their serum copper.  In the older children, three of the decreases were 
significant while one of the increases was significant by independent samples t-test.  
There was one significant increase and decrease in serum copper for the younger 
children. 
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Figure 33:  Serum copper results (ng g
-1
) for commercial clinical laboratory, EPA Method 
6020B, and EPA Method 6800 for the ten children before and after experiencing the cleanroom.  
Commercial clinical laboratory results were divided by 1.025 to produce comparable units.  For 
EPA Method 6020B and Method 6800, results are shown with n = 8 and 95% CIs. 
 
After reviewing the before and after results for plasma zinc, serum copper, and 
the plasma zinc/serum copper ratio, trends in the data emerged after comparing the three 
different measurement techniques:  the clinical commercial laboratory, EPA Method 
6020B, and EPA Method 6800 (Figures 31-33).  The commercial clinical laboratory 
results for zinc and copper were divided by 1.025, the density of serum, to produce 
comparable units of mass.  For the plasma zinc values, the commercial clinical laboratory 
had the lowest mean for 16 of the 20 measurements.  EPA Method 6020B was greatest on 
1 result and EPA Method 6800 was the highest on the other 3 measurements.  The 
commercial clinical values were never the highest in any of the 20 results, with EPA 
Method 6020B the greatest for 12 measurements and EPA Method 6800 for the other 8 
results.  For serum copper, the commercial clinical laboratory results were the lowest for 
15 measurements, with the EPA Method 6800 values the least for the other 5.  EPA 
Method 6020B had the highest average copper values for all 20 results.  For ratio values, 
 284 
 
the commercial clinical laboratory had the lowest results for 10 measurements, EPA 
Method 6020B for 9 measurements, and EPA Method 6800 for 1 measurement.  The 
clinical laboratory had the highest ratio 2 times while EPA Method 6800 had the highest 
ratio for the other 18 values.  Figure 34 displays the plasma zinc/ serum copper ratio 
results for Child 6 illustrating an example of a comparison between the 3 measurement 
techniques, as the commercial clinical laboratory did not provide CIs as were done by 
EPA Methods 6020B and 6800, along with the improved precision seen in EPA Method 
6800 versus EPA Method 6020B. 
 
 
Figure 34:  The before and after plasma zinc/serum copper ratio measurements from the 
commercial clinical laboratory, EPA Method 6020B, and Method 6800 for Child 6 from the 
cleanroom study.  EPA Methods 6020B and 6800 results provided 95% CIs based on 8 
measurements. 
5.3.2.3 Elemental Analysis of Hair 
No significant changes or age correlations were observed for hair elemental 
concentrations.  It was noted that each of the children had a unique profile of heavy 
metals in their hair as they displayed varying concentrations of aluminum, antimony, 
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arsenic, cadmium, chromium, lead, manganese, mercury, nickel, and tin in their hair 
before beginning the study. Child 1 had over 200 percent more mercury in hair than any 
of the other 9 children.  Child 11 was found to have the most aluminum, cadmium, 
chromium, lead, manganese, and vanadium of all the children.  For the entire cohort, 
trends towards post-cleanroom elevations in hair aluminum, chromium, cobalt, and 
mercury were noted, while cadmium, lead, tin, and zinc all trended lower in the post 
sample.  The before and after hair results for notable elements are in Figures 35 to 37. 
When correlating age and change in hair concentration, selenium was the only 
trend observed (p = 0.118, r = - 0.56).  When the younger three (one insufficient sample) 
versus the older six children were compared on changes of elemental concentrations in 
hair, no significant findings or trends were observed. 
 
Figure 35:  EPA Method 6020B cleanroom hair results for aluminum, arsenic, cadmium, lead, 
and mercury in ng g
-1
 (n = 8, 95% CIs).  Any values not shown were below detection limits.  
There was no after hair sample for Child 9. 
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Figure 36:  Cleanroom hair results for antimony, cobalt, manganese, nickel, tin, and vanadium in 
ng g
-1
 by EPA Method 6020B (n = 8, 95% CIs).  Any values not shown were below detection 
limit.  There was no after hair sample for Child 9. 
 
Figure 37:  EPA Method 6020B cleanroom hair results for copper, selenium, and zinc in ng g
-1
 (n 
= 8, 95% CIs).  The after cleanroom hair value for zinc for child 5 was 10,770,000 ± 1,260,000 
ng g
-1
.  There was no after hair sample for Child 9. 
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5.3.3 Markers of Immune Dysregulation 
Significant clinical results for several markers of immune regulation are 
summarized in Table 30.  When separated into cohorts, the younger children significantly 
decreased their CD3% (p=0.036) and CD4% (p=0.028) compared to the older children.  
Total white blood cell (WBC) count significantly increased in the younger children and 
decreased in the older children (p=0.031).  The younger cohort tended to increase their 
IgA levels, while the older cohort tended to lower their IgA levels (p=0.059).  The 
clinical laboratory plasma zinc/serum copper ratio exhibited a tendency to increase in the 
older six children compared to the four younger children (p=0.061).  The results for these 
markers of immune dysregulation for the two cohorts are shown in Figure 38. 
Table 30:  Statistically significant and trends in the commercial laboratory results of mean 
differences between age groups when a cutoff is applied separating children ages 3-5 from 
children ages 6-12. 
Commercial Laboratory Variable 
Mean Change 
Younger Cohort 
Mean Change 
Older Cohort 
p-value 
CD3% − 2.75     2.33 0.036 
CD4% − 2.50     1.67 0.028 
WBC    2.13          − 0.70 0.031 
IgA    4.25 − 13.17 0.059 
Zinc/Copper Ratio − 0.08      0.13 0.061 
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Figure 38:  Results of the clinical laboratory differences for CD3%, CD4%, WBCs, IgA, and 
zinc/copper ratio when applying a cutoff at age 5, separating the younger four children from the 
older six children.  Significant decreases were seen for CD3% (p=0.036) and CD4% (p=0.028), 
and a significant increase was seen for WBC (p=0.031).  Trends for increased IgA (p=0.059) in 
the younger cohort and elevated zinc/copper ratios (p=0.061) in the older cohort were present.  
For CD3% change, two points overlap at +2 in the older cohort.  For CD4% change, two points 
overlap at both – 1 and +1 in the older cohort.  In the older cohort for IgA change, two points 
overlap at – 15. 
5.3.4 Behavioral Rating Scales 
The before and after cleanroom rating scale results for all 10 children are 
summarized in Table 31 with significant correlation coefficients (r) and p-values listed in 
Table 32.  The younger cohort demonstrated significant decreases in SCQ means 
(p=0.025).  The changes in SCQ versus age were also significant, with a positive 
correlation (r=0.68, p=0.030) seen in Figure 39.  Additional positive correlations with age 
were found in the changes in Autism Composite of the PDDBI (r=0.64, p=0.046) and the 
Sensory/Perceptual Approach Behaviors (SENSORY) subscale of the PDDBI (r=0.64, 
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p=0.045).  The Receptive/Expressive Social Communication Abilities Composite 
(REXSCA/C) showed significant negative correlations with age (r= −0.66, p=0.037), 
which indicates language improvement in the younger cohort.  None of the other domains 
or composites of the PDDBI produced significant results.  The change in the total ABC 
by age of the ten children was nearly statistically significant with a p-value of 0.054 
(r=0.62).  Furthermore, three of the five subscales of the ABC were significantly 
positively correlated with age (p=0.034 for subscale III, p=0.024 for subscale IV, and 
p=0.035 for subscale V) seen in Figure 40.  The two remaining subscales of ABC showed 
no significant correlations. 
 
Figure 39:  Differences for the SCQ, Autism Composite of PDDBI, and the total ABC rating 
scales versus age.  The results display significance or near significance for each rating scale with 
a p-value of 0.054 for total ABC, 0.030 for SCQ, and 0.046 for Autism Composite.  Two points 
overlap at age 5 with a difference of +1 for total ABC. 
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Figure 40:  The change in ABC III (p = 0.034), ABC IV (p = 0.024), and ABC V (with p = 
0.035) versus age after the cleanroom experience.  For age 12 on ABC V, there are two points at 
+4.
  
2
9
1 
Table 31:  Child number, age, and rating scale results for the children who experienced the sleeping cleanroom environment.  Child 2 was unable 
to participate in the study.  Children 3 and 4 and Children 6 and 8 were identical twins. 
  Child Number 1 3 4 5 6 7 8 9 10 11 
Rating Scale Subscale Age 6 12 12 11 5 8 5 4 3 12 
ADOS 
Composite Before 17 13 15 14 14 16 12 16 17 14 
Communication Before 6 4 4 4 6 5 5 4 5 7 
Social Interaction Before 11 9 11 10 8 11 7 12 12 7 
SCQ  
Before 22 20 28 25 27 30 21 23 26 13 
After 24 27 30 24 20 30 20 14 23 13 
ATEC 
Total 
Before 51 85 101 59 62 95 55 55 52 51 
After 60 96 96 44 58 108 54 57 59 49 
I 
Before 9 15 21 5 16 11 17 8 6 16 
After 10 15 18 6 16 10 16 7 6 15 
II 
Before 12 16 24 18 14 24 7 12 12 1 
After 15 20 25 9 9 31 10 11 14 1 
III 
Before 19 14 22 14 26 14 25 19 17 31 
After 19 12 18 8 28 14 24 27 20 31 
IV 
Before 11 40 34 22 6 46 6 16 17 3 
After 16 49 35 21 5 53 4 12 19 2 
ABC 
Total 
Before 38 92 69 65 12 116 13 57 64 5 
After 34 118 91 50 13 128 14 27 42 3 
I 
Before 11 13 17 11 6 37 6 21 5 1 
After 16 22 21 4 6 42 7 9 9 1 
II 
Before 8 23 22 24 4 18 1 2 19 1 
After 2 26 26 16 4 25 3 1 7 1 
III 
Before 7 18 11 10 0 18 4 6 10 2 
After 4 21 16 13 1 18 4 4 6 0 
IV 
Before 10 33 14 20 1 43 2 26 30 1 
After 10 40 19 17 2 43 0 12 20 1 
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V 
Before 2 5 5 0 1 0 0 2 0 0 
After 2 9 9 0 0 0 0 1 0 0 
CARS  
Before 36 47 46.5 40 34 51 33.5 39 39 21 
After 34 49.5 48 43 36.5 50.5 33 26.5 38 22 
GARS 
Autism Index 
Before 85 119 106 100 79 112 64 82 94 76 
After 91 126 117 103 74 115 81 64 87 85 
Stereotyped 
Behaviors 
Before 8 15 11 12 7 13 5 7 9 7 
After 11 16 14 13 7 14 8 5 7 9 
Communication 
Before 0 11 11 0 9 0 4 0 0 8 
After 0 13 12 0 7 0 7 0 8 9 
Social Interaction 
Before 7 13 11 8 4 11 4 7 9 4 
After 6 13 12 8 4 11 6 4 9 5 
PDDBI 
Autism 
Composite 
Before 57 76 73 61 50 65 45 41 57 41 
After 54 84 75 59 44 66 47 39 53 42 
Approach/Withdrawal Problems 
SENSORY 
Before 57 76 66 60 44 61 42 44 54 52 
After 52 83 72 65 42 57 48 38 46 50 
RITUAL 
Before 38 69 57 45 43 68 38 39 53 42 
After 37 71 65 43 37 65 41 37 48 43 
SOCPP 
Before 40 58 66 54 50 63 47 42 51 39 
After 41 62 64 44 40 66 47 39 54 43 
SEMPP 
Before 50 62 72 34 42 34 39 38 42 38 
After 50 70 71 34 42 34 43 48 42 38 
AROUSE 
Before 51 65 56 63 54 59 33 45 61 40 
After 54 66 56 59 38 59 35 41 48 35 
FEARS 
Before 43 68 73 39 40 53 37 48 52 47 
After 45 68 67 39 37 52 37 54 48 44 
AGG 
Before 43 48 57 42 46 73 38 44 40 42 
After 47 58 54 36 41 75 38 41 41 44 
  
2
9
3 
REPRIT/C 
Before 47 76 73 50 42 61 38 37 50 41 
After 45 84 78 48 37 59 43 36 46 42 
AWP/C 
Before 45 71 71 48 43 63 35 40 50 41 
After 47 78 72 45 35 62 38 40 45 41 
Receptive/Expressive Social Communication Abilities 
SOCAPP 
Before 33 39 38 29 40 38 42 46 45 57 
After 35 35 42 31 38 30 46 54 46 59 
EXPRESS 
Before 31 40 49 27 41 40 41 48 35 45 
After 33 39 48 26 42 40 43 43 36 41 
LMRL 
Before 25 43 49 35 40 43 42 40 48 53 
After 29 38 43 30 36 46 39 44 42 53 
EXSCA/C 
Before 30 39 49 26 40 39 41 47 39 50 
After 32 37 45 27 39 35 44 48 40 49 
REXSCA/C 
Before 29 40 48 27 40 39 41 46 40 51 
After 31 37 45 27 39 37 43 47 40 50 
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Table 32:  Statistically significant difference correlations comparing child age and difference in 
rating scale scores.  The correlations and p-values are shown for each significant variable. 
Rating Scale r p-value 
SCQ 0.68 0.030 
PDDBI Autism Composite 0.64 0.046 
Total ABC 0.62 0.054 
ABC III 0.67 0.034 
ABC IV 0.70 0.024 
ABC V 0.67 0.035 
 PDDBI REXSCA/C  − 0.66 0.037 
PDDBI SENSORY 0.64 0.045 
 
There were no significant differences in rating scales results in the paired t-test 
analyses of pre- and post- results.  The GARS-2, ATEC, and CARS produced no 
statistically significant results for change or age correlation.  In total, six scales, 
subscales, domains, or composites used as markers of ASD behavioral presentation 
agreed in finding a statistically significant correlation with age between pre-and post-
cleanroom ratings.  Of note, each of the four younger children improved on the SCQ 
scale.  Of these four, two raised their GSH/GSSG ratio, with one significant by 
independent samples t-test.   
5.3.5 Twins 
The study contained two sets of identical twins, one younger and one older set.  
Children 6 and 8 were five-year-old females.  Child 6 significantly improved on four out 
of five markers of oxidative stress (reduced glutathione, oxidized glutathione, reduced 
glutathione/oxidized glutathione ratio, and total glutathione/oxidized glutathione ratio).  
This improvement was mirrored in an improvement or better performance in the rating 
scales SCQ and PDDBI; the subscales ATEC I, ATEC II, ABC I, ABC II, ABC V, 
GARS-2 Communication, GARS-2 Social Interaction; as well as the Autism Index, 
Autism Composites, Approach-Withdrawal Problem domains and composites of PDDBI. 
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The corresponding twin, Child 8, did not improve on any markers of oxidative stress and, 
likewise, poorer performance on rating scales, subscales, composites, and indexes was 
generally observed compared with Child 6.  
 Children 3 and 4 were twelve-year-old male identical twins.  Both children raised 
their GSH/GSSG, with Child 4 showing greater improvement. This disparity in 
improvement, again, was mirrored in a better performance or more positive change in 
many rating scales, subscales, and composites. Child 4 demonstrated a better 
performance in the PDDBI and SCQ; ATEC total and subscales; ABC total, I, and IV; 
CARS; Communication subscale of GARS-2; SENSORY, and the Social Pragmatic 
Problems, Semantic/Pragmatic Problems, Arousal Regulation Problems, Specific Fears, 
Aggressiveness, Social Approach Behavior domains along with the Repetitive, 
Ritualistic, and Pragmatic Problem Behaviors, Approach/Withdrawal, and Autism 
Composites of the PDDBI.  In both sets of identical twins, the child with the greatest 
improvement in markers of oxidative stress showed the greatest improvements in 
behavioral markers of ASDs phenotypic presentation following the study.   
5.4 Discussion 
(Note:  The findings in the discussion section are the professional opinion of Dr. 
Scott Faber, MD, developmental pediatrician at The Children’s Institute, as the attending 
physician and co-principle investigator at the time of publication and are subject to 
further data analysis and interpretation.) 
During this study ten children with ADOS certified autism slept in a hospital 
cleanroom for a two week period.  The cleanroom maintained ISO Class 5 certification, 
which minimized the nighttime exposure of both children and parents to heavy metals 
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and VOCs.  Given the emergent data linking exposure to environmental toxins with 
autism etiology, experiencing a cleanroom environment during sleep was hypothesized to 
begin the process of detoxification by mobilizing heavy metals and chemicals into the 
blood and hair.  
Five children significantly lowered their oxidized glutathione (GSSG) 
concentrations in RBCs, the component of blood with the highest glutathione 
concentration.
84
  The decrease in GSSG concentrations could indicate a reduction of 
oxidative stress, suggesting an increased ability to eliminate inflammation, prevent 
infections, and detoxify environmental toxins.
85
  Three children raised their tGSH/GSSG 
ratio, an improvement in an indicator of the balance of glutathione species,
86
 which was 
driven by a decrease in GSSG.  In all ten children, an inverse relationship was observed 
between the change in glutathione ratios, tGSH/GSSG and GSH/GSSG, and the change 
in GSSG concentration.  High GSH/GSSG ratios preserve the necessary reducing 
environment inside of cells;
87
 abnormally low GSH/GSSG ratios may indicate an 
inadequacy of glutathione reductase.
85
  Numerous studies have noted the multiple 
functions regulated by the redox balance of GSH/GSSG.
33, 85, 88
  Decreases in GSSG may 
have been the result of improved transulfuration reducing the demand for adenosine,
86
 the 
nucleoside that prevents oxidative damage.
89-90
 
The younger cohort showed significantly greater decreases in RBC zinc and 
selenium concentrations than the older cohort.  The younger children may have moved 
selenium and zinc more rapidly from red blood cells to tissues, increasing metalloprotein 
functioning more than the older children.  In addition, serum magnesium changes were 
significantly negatively correlated with age, increasing in concentration in the younger 
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children.  Magnesium is a critical micronutrient that is essential in the maintenance of the 
calcium/magnesium flow across neuronal cell membranes.
91
  It also plays a key role in 
enzymes related to ATP and nucleic acid metabolism.
92
  Proper brain development and 
homeostasis require magnesium resulting from copper-zinc superoxide dismutase 
activity.
93
  When given as a supplement, magnesium has been shown to have a calming 
effect on the behavior of children and adults,
94-95
 which may explain the link between 
increased serum concentrations and improved behavioral presentations observed in this 
study.  Additionally, iron concentration changes correlated positively with age.  The 
younger children decreased and the older children increased their respective 
concentrations.  Iron is critical for erythrocyte production and the promotion of 
oxygenation of tissues; its effects on metabolism depend on local concentration.
96
  At 
higher levels, though, iron can cause an excessive production of reactive oxygen species, 
digestive problems, vomiting, and the alteration of other closely related elements such as 
zinc, copper, and calcium.
97
  The observed positive age correlation in serum iron may be 
explained by a faster upregulation in the metallothionein system of the younger children.  
This upregulation would lead to an increased need for erythrocyte production to enhance 
oxygen distribution to tissues, depleting serum iron.  Hair selenium concentrations tended 
to correlate negatively with age.  The younger children had either increases or small 
decreases in their hair selenium concentrations compared to the older ones.  The 
increased release of selenium in the hair in the younger children may have been 
secondary to increased absorption of selenium. 
 Prior to exposure to the cleanroom, VOCs and PCBs were quantified at 
concentrations above the national averages for adolescents
98
 in many of the children.  Out 
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of the ten participants, eight decreased mean serum benzene,  six increased mean serum 
toluene and five increased serum xylene, although none significantly.  One possible 
explanation for these results is that, throughout the study, VOCs were mobilized from 
tissues into the serum at varying rates.  In this scenario, benzene would be mobilized and 
released from the body first, leading to decreased serum concentrations.  Toluene and o-
xylene, however, could require more time to mobilize and result in the tendency for 
increased serum concentrations following the two week exposure to the cleanroom.  
Likewise, mean PCB-28 concentrations rose in six out of seven children, which 
significantly negatively correlated with age, with three children falling below the 
analytical quantification limit.  This result is consistent with the hypothesis of the 
cleanroom beginning the process of mobilization of PCB-28 from tissue to serum, but 
requiring more time for elimination from the serum. 
Following exposure to the cleanroom environment, the children demonstrated 
changes in markers of immune system functioning.  These changes indicate a decrease of 
T cell subtypes instructing B cells to make antibodies.  Notably, the younger children 
decreased CD3% (total T cell percent) and CD4% (total helper T cell percent) 
significantly more than the older cohort.  This data provides evidence that the cleanroom 
may have decreased dysregulation of the immune system, especially in the younger 
children.  B cells promote immunoglobulin synthesis and are regulated by CD4 cells.  
The observed decrease in CD4% may have lessened cross reactive antibody production in 
the younger children, leading to a brief period of decreased brain inflammation.  This is 
one possible explanation of the significant, but transient, improvement seen in the 
behavioral rating scale performances of the younger cohort.   
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Significant changes in before and after cleanroom results were seen for rating 
scale performance when compared with age.  Specifically, the younger children in the 
study tended to improve on the behavioral rating scales SCQ, sub-domains of the PDDBI, 
and ABC while the older children tended to do slightly worse on these rating scales.  The 
PDDBI was created specifically to evaluate how children with pervasive developmental 
disorders respond to a treatment, with the unique capability to standardize results by 
age.
80
  In contrast with other scales and indices, the PDDBI assesses both adaptive and 
maladaptive behaviors, giving a quantitative definition to positive improvements.  A 
significant age-correlation was noted in the Autism Composite of the PDDBI, with the 
younger children showing greater improvements in non-verbal communication, repetitive 
behaviors, social interaction, and spoken language.  The SENSORY domain of the 
PDDBI produced a significant negative correlation with age indicating more 
improvement of nonverbal communication in the younger children compared to the older 
children.  The negative correlation with age on the REXSCA/C demonstrates 
significantly more improvement in receptive and expressive language attainment in the 
younger children compared to the older children. The improvements on the total ABC, 
designed to assess treatments for individuals with intellectual disabilities,
75
 were 
primarily driven by the significant improvements on the stereotypical behavior, 
hyperactivity, and speech subscales.  One possible explanation of these rating scale 
results is that the younger children may have had less of an initial body burden of heavy 
metals and chemical toxicants, allowing the brief two week period of sleeping in the 
cleanroom to have a slightly more positive behavioral effect.  The older children, who 
may have had a larger body burden of toxicants initially, may have just begun the process 
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of mobilization of chemicals and metals as the study ended, resulting in worse behavioral 
result changes in relation to the younger children.  Younger children may have felt an 
extra closeness to their parents during the study, leading to positive behavioral change.  
However, age-correlated findings involving changes in elemental, glutathione, and 
immune markers observed in this study provide support for physiological change driving 
the behavioral improvements in the younger children.   
One of the unique results of this study involved the responses of two sets of 
identical twins and the manner in which changes in glutathione species corresponded 
with behavioral rating scale results.  In both sets, one twin demonstrated greater 
improvement in oxidative stress, as evidenced by glutathione markers, and corresponding 
greater improvement in behavioral rating scale scores.  The GSH/GSSG ratio is a critical 
biomarker for determining healthy functioning of the methylation system in children with 
autism.
99
  In the 5-year-old female identical twin pair, the twin who raised her 
GSH/GSSG ratio also performed better on two behavioral rating scales, the SCQ and 
PDDBI.  Notably, this female twin displayed the greatest improvement of oxidative stress 
in the study, significantly lowering GSSG and increasing GSH, tGSH/GSSG, and 
GSH/GSSG values.  In the older male identical twin pair, both children worsened on the 
behavioral scales, but the twin with greater GSH/GSSG ratio improvement displayed less 
worsening on the SCQ and PDDBI.  Despite identical home settings and genomes, it was 
found in both sets that each twin responded uniquely to sleeping in the cleanroom, 
displaying varying degrees of change in GSH/GSSG levels and behavioral rating scale 
performance.  These differences suggest that still unknown epigenetic mechanisms 
mediated the varying results between the twins in the study.  This study provides further 
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support to the assertion of a relationship between glutathione biomarkers and behavioral 
rating scores in children with autism. 
In this study, ten children with ADOS certified autism spent two weeks sleeping 
in a cleanroom.  The overall pattern of results indicates greater improvements in immune 
dysregulation and behavior in the younger children, age 5 and under.  Half of the children 
significantly decreased their oxidative glutathione concentrations in addition to 
improving other glutathione markers of oxidative stress.  The relationship between 
GSH/GSSG and the identical twins’ behavioral performances, the opposite movements of 
serum iron and magnesium compared to age, and the tendency for the younger children to 
reduce their CD3% and CD4% all suggest the possibility of a significant physiological 
role for the cleanroom in explaining some of the behavioral changes.  Younger children 
performed better on rating scales after their two week exposure, while the older children 
performed slightly worse on rating scales.  Psychological issues, such as greater 
attachment towards the parent in the cleanroom, may explain some of this difference; 
however, the noted biological differences in how the younger children performed versus 
older children suggest that the cleanroom may have had a more than psychological effect.  
The children only slept or stayed for approximately ten hours a night in a cleanroom for 
two weeks; yet, significant changes in markers of oxidative stress, immune dysregulation, 
and behavior were observed.  In addition, an age correlated difference in detoxification 
physiology is suggested by the results.  At the age of 5, a significant difference tended to 
occur in the direction of change for some elemental nutrients (iron, magnesium, 
selenium, and zinc), organic toxicants (benzene and PCB 28), and immune markers 
(CD3% and CD4%).  The younger children may have started their detoxification process 
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faster or had less to detoxify, thus explaining their significant improvement in global 
rating scales (SCQ, PDDBI, and ABC) compared with the older children.  The 
differential response to the cleanroom by the identical twins suggests that epigenetic 
changes may be playing a role in affecting responses to a detoxifying environment. The 
performance of a controlled study of 24 hour per day cleanroom exposure for children 
with autism appears to be an appropriate next step, given the physiologic changes from 
the limited exposure to a cleanroom environment noted in this study. 
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Chapter 6  
Elemental Quantification in the Blood and Hair of Children 
with Autism and Controls 
 
Autism spectrum disorders (ASDs) are characterized by social defects and expressive 
language problems along with abnormal cognitive functions and repetitive behaviors.  
Over the last 30 years, the frequency of autism has risen dramatically and now is greater 
than 1 percent.  During this time, an emerging paradigm has suggested that the majority 
of children with autism display a pattern of genetic/environmental interactions that makes 
them susceptible to difficulties with detoxification of the in utero and post birth heavy 
metal and chemical environment.  Children with autism have demonstrated increased 
difficulty with the performance of methylation and sulfation systems that are required for 
the elimination of chemicals from human tissue and dysfunction of their metalloprotein 
systems necessary for the elimination of heavy metals from their bodies.  They have also 
demonstrated important differences in oxidative stress and immune dysregulation.  
Current research has focused on understanding the mechanisms of these systems and the 
resulting biomarkers to comprehend why autism rates have increased and improve 
diagnosis and treatments.  A new theory of disease was proposed by Dr. Claudia Miller in 
1996 called toxicant-induced loss of tolerance (TILT), to reflect the impact the 
environment has on human health.
1
  To evaluate this disease theory, 30 children, ages 2-9 
years old, recently diagnosed with an ASD had their serum, plasma, red blood cells, and 
hair analyzed for elemental content along with 30 age, gender, and socioeconomically 
matched controls.  For the analytical measurements completed in blood and hair, the 
samples were prepared using United States Environmental Protection Agency (EPA) 
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Method 3052, microwave-assisted digestion.  After sample preparation, the samples were 
analyzed by either EPA Method 6020B or EPA Method 6800 using Inductively Coupled 
Plasma-Mass Spectrometry.  EPA Method 6020B uses external calibration curves that 
determined the concentration of 58 elements in each sample while EPA Method 6800 
utilizes enriched, stable isotopes of unique ratios to quantify elements directly through 
mathematical solutions.  In addition to the elemental testing, behavioral rating scales 
were completed, clinical blood testing including T and B cell subsets was performed, and 
the content of glutathione and organic toxins were evaluated.  These results were 
analyzed using paired samples t-tests to determine any potential significant differences 
between the groups and cross correlations of the results were performed between the 
different types of analysis to determine potential connections between the different 
variables.  EPA Method 6020B and EPA Method 6800 results for selected variables were 
also compared to commercial clinical results to evaluate quality control.  From this study, 
the results and analyses demonstrated that the children with autism illustrated the TILT 
theory of disease according to the attending physician, and they could potentially be used 
to determine a biomedical screening diagnostics test and more effective treatments for 
ASDs. 
6.1 Introduction 
6.1.1 Background 
Autism spectrum disorders (ASDs) are characterized by social defects and 
expressive language problems along with abnormal cognitive functions and repetitive 
behaviors manifested through a wide range of symptoms with differing severity.  Over 
the last 30 years, the frequency of autism has risen dramatically and now is greater than 1 
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percent.  The most recent data from the Centers for Disease Control and Prevention 
(CDC) using data from 2008 noted the overall rate of autism to be 1 in 88 children in 8 
years old.
2
  Compared to data from 2000 and 2002, this frequency is a 78% increase 
when the rate was 1 in 150.
3-4
  Because of this dramatic escalation in recent years, 
worldwide incidence and prevalence of these disorders have increased; however, 
scholarly opinion varies as to whether this rise is due to improved awareness, better age-
related screening efforts, higher quality and quantity of diagnostic centers, an expansion 
of the spectrum definition, the types of study methods used, or a true escalation in the 
incidence and prevalence of autism.
5-11
  More recently, greater attention has been given to 
an emerging paradigm that presents the view that one of the causes of the increased 
prevalence of ASDs is the children’s difficulties with detoxification of heavy metals and 
chemicals.
12
 
During this time, an emerging paradigm has suggested that the majority of 
children with autism display a pattern of genetic/environmental interaction that makes 
them susceptible to difficulties with detoxification of the in utero and post birth heavy 
metal and chemical environment.  Children with autism have demonstrated increased 
difficulty with the performance of methylation and sulfation systems that are required for 
the elimination of chemicals from human tissue and dysfunction of their metalloprotein 
systems necessary for the elimination of heavy metals from their bodies.  Children with 
autism have also demonstrated important differences in oxidative stress and immune 
dysregulation.  With all of these different areas affected in children with autism, current 
research has focused on understand the mechanisms of these systems and the resulting 
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biomarkers to understand why autism rates have increased and improve diagnosis and 
treatments. 
6.1.2 Autism: The Manifestation of a New Disease Theory 
Within the last 20 years, a new theory of disease was presented in response to the 
increased rate in many different diseases.  Proposed by Dr. Claudia Miller in 1996, this 
new theory called toxicant-induced loss of tolerance (TILT) reflects the impact the 
environment has on human health.
1
  In the scientific literature, many studies had 
presented the idea of the development of disease symptoms in response to being exposed 
to extremely low quantities of chemicals in the environment.
13
  The sensitivity of people 
to food and chemicals was first discussed by Randolph in 1962.
13
  Dr. Miller proposed 
TILT to describe a new disease theory where patients clinically presented symptoms in a 
two-step progression.
13
  The first step, called initiation, occurs when vulnerable people 
lose tolerance after an acute or chronic exposure to different toxins.
13
  The second step, 
triggering, is the resulting symptoms that are activated after the previous tolerance of 
these compounds, medications, foods, or combinations of them is lost.
13
  TILT replaced 
the previous terminology of multiple chemical sensitivity (MCS) because the important 
initiation that is started by the toxic exposure was not described by the prior term.
13
  
TILT also provided a bigger scope of susceptibility after an exposure that is not limited to 
food, caffeine, drugs, and alcohol.
13
  The manifestation of a TILT state has been 
determined to cause autoimmunity as the result of exposure to detrimental foreign agents 
and environmental toxins such as infection, xenobiotics, and implants.
14
  Reflecting the 
modern environment, TILT is a theory of disease, which Dr. Miller proposes to be similar 
to the germ theory and immune theory that have developed over the past century.
13
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Miller noted that support of TILT as a mechanism for a group of disorders would result in 
seeing TILT as a validated disease theory.
13
  In recent times, TILT has become an 
accepted method of the advancement of disease
14
 with the TILT concept has been 
determined to exist in twelve countries by multiple researchers.
15
 
TILT and the resulting sensitivity-related illness (SRI) are becoming a greater 
proportion of modern diseases as the result of the increased amount of contact with toxins 
and their ensuing bioaccumulation.
14
  SRI results in unfavorable clinical conditions 
caused by allergens, chemicals, food, biological mixtures, or responses to electrical 
impulses.
14
  The clinical presentation of SRI results from the insult of a primary toxin.  
This foreign insult could be biological, chemical, surgical, or radiological.
14
  This 
exposure results in TILT causing hypersensitivity to chemicals and a reduction in the 
tolerance to chemicals which occurred during the initiation step through exposure to 
chemicals, allergens, food, biologicals, or electronic stimuli.
14
  The resulting clinical 
reaction is observed through immunoglobulins, cytokines, and other signs and symptoms 
that affect multiple organ systems.
14
  Theories of MCS focus on changes of the immune 
system, the nervous system, biochemical metabolism, and psychological and 
neurobehavioral capabilities.
16
  Caress and Steinemann cite studies connecting MCS to 
neurological disorders and immune system dysfunction.
17
  A biomarker specifically 
linking decreased tolerance and increased immune dysregulation would be the perfect 
way to relate the environmental toxin exposure to SRI through the TILT mechanism.
14
 
The increased prevalence of autism has created a greater emphasis and awareness 
possibly relating it as an effect of the modern environment.  The environment has 
changed over time while the genome has remained relatively static.
14
  The natural 
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environmental levels of toxic metals and nearly all metals have been exceeded through 
the industrial emissions of the past 200 years.
18
  Miller noted the difference in 
environmental exposures between rural and urban areas.
13
  The interaction of the 
environment with a vulnerable genome is becoming the emerging hypothesis of chronic 
diseases in the scientific literature.
14
  The field of epigenetics focuses on the changes 
made to a genome due to interactions with the environment.  Over the past 20 years, the 
occurrence and rate of many illnesses related to allergies such as asthma, hay fever, 
atopic dermatitis, food allergens, conjunctivitis, and eosinophilic esophagitis have 
increased dramatically.
14
  Attention deficit hyperactivity disorder, autoimmune disorders, 
and depression rates have also increased during this time.
15
  Currently, the most 
predominant illnesses caused by the environment may follow the TILT mechanism.
15
   
Chemical sensitivity manifests itself through many different systems of the body 
including neuropsychological, cardiovascular, respiratory, gastrointestinal, 
musculoskeletal, skin, and others.
13
  Many of these symptoms are seen in children with 
autism, notably the neuropsychological and gastrointestinal difficulties.  Common 
neuropsychological symptoms of TILT include sensitivity to many different chemicals, 
attention deficit hyperactivity disorder, depression, migraines, and seizures.
13
  Irritable 
bowel syndrome and reflux are frequently observed gastrointestinal indicators of TILT.
13
  
People who frequently comprise chemically sensitive groups include industrial workers, 
office workers, and contaminated communities.
16
  The children with autism would fall 
into the last group who have exposures to chemicals from indoor air, pesticides, drugs, 
and other products.
16
  Children can be more sensitive to the effects of TILT as the result 
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of age-specific behaviors of children that can put them at greater risk of pesticide 
toxicity.
19
 
6.1.3 Genetic Predisposition to Autism 
Much research has been published that attempt to explain a potential genetic 
predisposition to autism.  However, in children with ASDs, only about three percent 
demonstrate positive genetic findings on high resolution chromosome, Fragile X, and 15 
q duplication studies.  When genomic microarray studies are added, another 18% of 
children with autism display some area of genetic difference from the normal sequenced 
human DNA, although these findings often come with the caveat that they have not been 
correlated with any known human pathology.
20
  Recently, copy number variants and 
losses have been strongly connected to the development of autism.
21
  These copy number 
variants may be contributing to an adverse genetic/environmental interaction, likely 
beginning in utero.  The genetic, epigenetic, environmental, and endogenous interactions 
can be seen in an “integrated metabolic profile” that affects metabolic pathways.22  The 
effects of the environment are seen in the epigenetics, neurologic system, and immune 
system of children diagnosed with ASDs.  A hypothesis of genetic predisposition to 
abnormal metallothionein functioning combined with an environmental attack which 
hinders metallothionein was proposed by Walsh et al. and can account for the increased 
rate of autism diagnosis seen in recent years.
23
   
6.1.4 Exposure to Environmental Toxins in Autism 
Two areas have demonstrated a potential TILT relationship between 
environmental toxins and autism:  increased autism rates correlated to environmental 
toxin exposure and elevated concentrations of toxins in children with autism.  In Texas, 
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two studies showed a connection between a higher rate of autism and the amount of 
mercury released from coal fired power plants.
24-25
  A study led by Gbor found that 
human activities are responsible for 73% of the mercury released around the Pittsburgh 
area.
26
  Another study noted Minnesota school districts near National Priority List 
Superfund sites had significantly greater rates of autism.
27
  Studies have also 
demonstrated elevated autism rates resulting from organic toxins.  In California, a study 
found pollutants in the air raised the rate of ASDs.
28
  Roberts led another study in 
California that demonstrated a higher occurrence of autism in mothers who lived closer to 
agricultural sites during pregnancy which used organochlorine pesticides.
29
  Eskenazi et 
al. discovered the possibility of developing a pervasive developmental disorder 
approximately doubled every time the amount of pesticide metabolites increased ten 
times in the environment.
30
 
 Also, many studies have compared the amounts of specific chemicals and toxins 
in children with autism and controls.  One study noted higher amounts of total and 
organic mercury, arsenic, and lead in the red blood cells of children with autism 
compared to controls.
31
  This same study found children with autism had greater 
concentrations of plasma perchlorethylene, hexane, pentane, and xylene.
31
  DeSoto and 
Hitlan completed a reanalysis of a prior data set and discovered a significant correlation 
between diagnosis of an autism spectrum disorder and the concentration of mercury in 
blood.
32
  Hertz-Picciotto and colleagues observed controls having higher concentrations 
of mercury in the blood than children with autism spectrum disorders
33
 while Geier et al. 
found the opposite in another study.
34
  Another study investigating mercury content saw 
greater amounts of it in the baby teeth of children with ASDs compared to controls.
35
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6.1.5 Detoxification Difficulties in Autism 
Many studies have investigated the detoxification capabilities of children with 
autism through the study of elemental concentrations in hair.  In 2003, Holmes led a 
study that discovered children with autism had significantly less mercury in their hair 
compared to controls.
36
  When pair wise comparisons were performed between children 
with mild, moderate, and severe cases of autism, significant differences were observed.
36
  
The more severe children had lower concentrations of mercury in their hair indicating a 
decreased ability to move xenobiotics to their effluent.  Compared to matched controls, 
Kern et al. found significantly lower amounts of arsenic, cadmium, and lead in the hair of 
children with autism.
37
  Another study found children with lower amounts of mercury in 
their hair were 2.5 times more likely to be diagnosed with autism.
38
  
One biomarker that has been suggested for evaluating heavy metal toxicity and 
metallothionein capabilities is the plasma zinc/serum copper ratio.  The discovery of a 
lower plasma zinc/serum copper ratio in children with ASDs was first discovered by 
Walsh and colleagues.
23
  They found the average plasma zinc/serum copper ratio to be 
0.613 in over 500 children with ASDs while controls had an average ratio of 0.870.
23
  In 
a paper discussing leishmaniasis patients, controls had a plasma zinc/plasma copper ratio 
of approximately 1.
39
  Additional evidence of a decreased plasma zinc/serum copper ratio 
was provided by Faber et al., where an average plasma zinc/serum copper ratio of 0.608 
was observed in 230 patients with ASDs.
40
 
The status of the metallothionein system could be seen through the plasma 
zinc/serum copper ratio.  Metallothioneins are proteins which have many cysteines and 
remove heavy metals from the body.
41
  In cells, metallothionein is the primary protein 
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that binds with zinc.
42
  The homeostasis of zinc and copper are also regulated by 
metallothioneins.
43
  Along with glutathione, metallothionein is the best detoxifier of 
mercury in the brain.
44
  A study from Walsh et al. observed a metallothionein problem in 
over 99% of children with ASDs.
23
  A reduction in the removal of heavy metals, immune 
system dysfunction, and neurological changes are seen through abnormalities in the 
functioning of the metallothionein system in children with ASDs.
41
  Children with autism 
demonstrated some of the following symptoms that could be the result of metallothionein 
function:  leaky gut syndrome, digestion difficulties with casein and gluten, yeast 
difficulties, decreased stomach acid production, and lower secretin from the pancreas.
41
  
Metallothionein production is increased by both estrogen and progesterone.
41
 
6.1.6 Oxidative Stress and Autism 
Another area where studies have seen differences in children with autism and 
typical developing children is related to oxidative stress.  One marker of oxidative stress 
commonly seen to be differentiated in children with autism is glutathione.  Glutathione is 
a tripeptide which uses the thiol group of cysteine to have a great attraction for toxins.  
Because glutathione is a natural chelator, glutathione is the primary way heavy metals are 
removed from the body.
45
  Contact with heavy metals, polychlorinated biphenyls, 
polyaromatic hydrocarbons, and organochlorine and organophosphate pesticides has 
resulted in lower glutathione concentrations.
45
  Lower amounts of total glutathione and 
higher levels of oxidized glutathione in plasma have been seen in children with autism 
compared to controls.
22, 46
  Other studies have shown elevated quantities of oxidized 
glutathione with lower amounts of reduced glutathione in plasma in children with autism 
compared to controls.
47-48
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6.1.7 Immune Dysregulation in Autism 
Based on the TILT mechanism, the exposure to environmental toxins and the 
ensuing oxidative stress is manifested through dysregulation of the immune system in 
children with autism.  Many atypical values have been seen in children with autism that 
suggest a connection between environmental toxins and the immune systems of children 
with autism.
49
  Children with autism spectrum disorders demonstrated an increased 
frequency of immunologic abnormalities of innate, humoral, and cell-mediated 
immunity.
50
  Successive adaptive immune reactions resulting from previous innate 
immune system responses and autoimmunity may be the outcome of an improperly 
regulated innate immune system.
51
  Children with autism show an abnormal innate 
immune system reaction that may also cause adaptive immune system dysregulation.
51
  In 
most studies, fifteen to sixty percent of children with autism display immune system 
dysfunction.
52
  Autoimmune attack by the innate immune system, as performed by 
natural killer cells, has been shown to be present in the brains of children with autism.
53
  
A study of immune functioning of children with ASDs at The Children’s Institute 
demonstrated that 49% of the studied children had increased T cell helper/suppressor 
(CD4/CD8) ratios, causing many of the children to display over-reactive innate and 
humoral immunity, seen through higher serum immunoglobulin levels and the number 
and percent of natural killer cells.
54
  This study also noted that 4.5% of the children 
demonstrated low CD4/CD8 ratios, a finding that the World Health Organization has 
determined may result from chemical toxicity.
55
  In leishmaniasis patients, a lower Th1 
immune response and immunodeficiency could be caused by a lower zinc/copper ratio, 
suggesting the zinc/copper ratio could be a marker of immune dysfunction.
39
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With the growing importance of the TILT mechanism relating the modern 
environment to the increased prevalence of autism, a study was designed to test the 
previously described theory of disease in children with autism.  It involved 30 newly 
diagnosed children with autism and 30 matched controls that were tested for behavioral 
rating scales, glycophorin A (GPA) analysis, elemental concentrations in blood and hair, 
selected organic toxins, glutathione status, and clinical laboratory testing.  Statistical 
analysis evaluated the differences between the two groups and correlations were 
completed to evaluate potential pathophysiological relationships. 
6.2 Materials and Methods 
6.2.1 Materials 
6.2.1.1 Chemicals and Standards 
All reagents were of analytical grade.  ARISTAR ULTRA nitric acid (HNO3), 
ARISTAR ULTRA hydrochloric acid (HCl), and ARISTAR ULTRA H2O that were used 
only during sample analysis were procured from VWR (Radnor, PA, USA).  American 
Chemical Society (ACS) grade HNO3 and ACS grade HCl that were only used for 
cleaning were obtained from Fisher Scientific (Pittsburgh, PA, USA).  Multi- and single 
element standards of iodine, lithium, and yttrium along with the isotopic standards for 
lithium and tin came from Inorganic Ventures (Christiansburg, VA, USA).  The mercury 
standard was obtained from High Purity Standards (Charleston, SC, USA).  Applied 
Isotope Technologies (AIT, Pittsburgh, PA, USA) provided the remaining isotopically 
enriched elemental solutions.  The Inductively Coupled Plasma-Mass Spectrometry (ICP-
MS) tuning solution consisting of 1 nanogram gram
-1
 (ng g
-1
) of lithium, cobalt, yttrium, 
cerium, and tellurium in 2% (v:v) HNO3 and an internal standard solution containing 100 
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µg g
-1
 of 
6
lithium, scandium, germanium, rhodium, indium, terbium, lutetium, and 
bismuth were procured from Agilent Technologies (Santa Clara, CA, USA).  Standard 
Reference Material (SRM) 1598a, Inorganic Constituents in Animal Serum, was 
purchased from the National Institute of Standards and Technology (NIST, Gaithersburg, 
MD, USA).  Certified Reference Material (CRM) GBW09101b was from the Shanghai 
Institute of Nuclear Research of the Chinese Academy of Sciences (Shanghai, China). 
6.2.1.2 Materials and Supplies 
All tetrafluorometoxil (TFM™) microwave vessels, inserts, and lids were 
obtained from Milestone Inc. (Shelton, CT, USA) and the magnetic stir bars were 
procured from Big Science Inc. (Huntersville, NC, USA).  VWR supplied the 50 mL 
polypropylene centrifuge tubes.  AIT provided the Isotope Dilution Mass Spectrometry 
(IDMS) software.  A Thermo Scientific (Pittsburgh, PA, USA) Barnstead EASYpure II 
RF/Ultraviolet (UV) Model D7035 water purification system was used to further clean 
double-deionized (DDI) water to a minimum resistivity of 18 MΩ-cm from a Barnstead 
(Dubuque, IA, USA) NANOpure water system. 
6.2.1.3 Instrumentation 
The sample preparation of the blood and hair samples was performed using 
microwave-enhanced chemistry in a Milestone ETHOS 1 laboratory microwave system 
equipped with temperature and pressure feedback control.  This device accurately 
monitored and controlled the temperature to within ± 2 °C of the preset values by 
automatically adjusting the microwave field output that has a maximum power of 1500 
Watts.  The closed ETHOS 1 system allowed for extremely high temperature and 
pressure conditions of up to 300 °C and 100 bar to be maintained for extended periods of 
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time.  The ten TFM™ microwave digestion vessels used in this study each contained 
three 6 mL TFM™ inserts with lids.  The TFM™ inserts also have the capability of 
withstanding the same temperature and pressure conditions as the digestion vessels while 
increasing the number of samples from 10 to 30 per batch. 
Mass spectrometric analysis was completed using an Agilent 7700 ICP-MS with a 
micromist nebulizer, quartz spray chamber, an octopole reaction system, and a 
quadrupole mass analyzer.  It possesses a collision/reaction cell that uses hydrogen or 
helium gas to eliminate polyatomic interferences.  The samples and internal standard 
were introduced into the ICP-MS through the micromist nebulizer of the spray chamber 
using the peristaltic pump at a speed of 0.1 revolutions per second (rps).  The samples 
were stored in a CETAC (Omaha, NE, USA) ASX-520 autosampler housed inside of an 
ENC-500 anti-contamination enclosure before being analyzed.  Both the ICP-MS and 
autosampler were located in an International Organization for Standardization (ISO) 
Class 6 cleanroom laboratory.  The optimized parameters of the ICP-MS and autosampler 
during analyses are shown in Table 33. 
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Table 33:  The optimized settings for the Agilent 7700 ICP-MS for EPA Method 6020B in blood, 
EPA Method 6800 in blood, and EPA Method 6020B in hair. 
Agilent 7700 ICP-MS 
EPA Method 
6020B Blood 
EPA Method 
6800 Blood 
EPA Method 
6020B Hair 
Rf Power 1550 W 1550 W 1550 W 
Spray Chamber 
Temperature 
2 °C 2 °C 2 °C 
Acquisition Mode Spectrum Spectrum Spectrum 
Peak Pattern 1 point mass
-1
 1 point mass
-1
 1 point mass
-1
 
Sample Depth 8 mm 8 mm 10 mm 
Plasma Gas 15 L min
-1
 15 L min
-1
 15 L min
-1
 
Carrier Gas 0.7 L min
-1
 0.7 L min
-1
 0.99 L min
-1
 
Makeup Gas 0.2 L min
-1
 0.2 L min
-1
 0.15 L min
-1
 
H2 Cell Gas Flow 2 mL min
-1
 2 mL min
-1
 4 mL min
-1
 
He Cell Gas Flow 2 mL min
-1
 2 mL min
-1
 4.5 mL min
-1
 
Gas Stabilization Time 30 sec 30 sec 30 sec 
Integration Time 0.1-1.0 sec mass
-1
 0.5-1.0 sec mass
-1
 0.1-1.0 sec mass
-1
 
Replicates 4 4 4 
Nebulizer Pump Speed 0.10 rps 0.10 rps 0.10 rps 
Uptake time 30 sec 30 sec 30 sec 
Stabilization time 30 sec 30 sec 30 sec 
 
6.2.2 Methods 
The study was approved by the Institutional Review Board (IRB) of Duquesne 
University (Pittsburgh, PA, USA) (IRB #10-36) and it was conducted at The Children’s 
Institute (TCI, Pittsburgh, PA, USA) and Duquesne University. 
6.2.2.1 Subject Enrollment 
Thirty children with autism or Pervasive Developmental Disorder-Not Otherwise 
Specified (PDD-NOS), who were seen for their first visit at Dr. Scott Faber’s 
Neurodevelopmental Disabilities Service at TCI, participated in this study along with 
thirty age, sex, and socioeconomic status (SES) matched controls.  From May 2010 to 
May 2012, Dr. Faber asked the parents of each child who was newly diagnosed with 
autism or PDD-NOS and who achieved the study criteria met with a research coordinator 
where consent was achieved and the child’s assent was obtained whenever possible.  The 
  
 327 
children then met with a psychologist with research certification in the performance of 
the Autism Diagnostic Observation Scale (ADOS),
56
 where they were successfully 
enrolled once exceeding the total ADOS cutoff for an autism diagnosis.  Two children 
who demonstrated autistic features did not meet ADOS criteria for a diagnosis on the 
autism spectrum and did not participate further in the study. 
Each child with autism or PDD-NOS was paired with an age, gender, and SES 
matched control child who was recruited by a poster that was approved by the Duquesne 
IRB from May 2010 to June 2012.  After talking to the research coordinator and 
reviewing the inclusion and exclusion criteria, a parent or guardian consented to the study 
and each control child assented to the study.  A meeting with Dr. Faber occurred to 
perform a brief history and physical examination; to rule out presence of a genetic, 
developmental, or neuropsychiatric disorder; the presence of a nuclear family member 
who met criteria for an ASD; and assess other exclusionary items.  After each control 
child joined the study, an appointment with a psychologist was made to undergo ADOS 
evaluation.  Once the child scored below the cutoff for an ASD on the total ADOS, the 
child became eligible to participate. 
None of the children who partook in the study used dietary supplements, were on 
an exclusionary diet, had a significant traumatic brain injury, or had a known genetic 
disorder.  Children who had mercury amalgam dental fillings, any form of liver or kidney 
disease, or a diagnosis of inflammatory bowel disease or celiac disease was not eligible to 
participate.  For the three months prior to the study, none of the children received 
systemic steroids or immune compromising drugs.  All children selected for this study 
lived within a sixty minute drive of TCI.  Based upon their SES, the children were 
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separated into three groups: household income below $30,000, between $30,000 and 
$100,000, and over $100,000 per year, per parental or guardian self-disclosure.   
6.2.2.2 Blood Draw, Hair Collection, and Clinical Testing 
Two blood draws consisting of approximately 30 mL each, occurring within two 
to four weeks of each other, were obtained by a phlebotomist who specialized in working 
with children with development disabilities.  The blood was drawn at the child’s home 
and then brought to Duquesne University for preprocessing within two hours.  The blood 
was centrifuged and aliquoted for testing at Quest Diagnostics (Pittsburgh, PA, USA), 
Duquesne University, and Nova Southeastern University (Fort Lauderdale, FL, USA).  
The Quest Diagnostics testing from the first blood draw included a complete blood count 
(CBC) with differential; erythrocyte sedimentation rate; T and B cell lymphocyte subsets; 
serum IgA, IgG, and IgM immunoglobulins; total protein and albumin; aspartate 
aminotransferase; alanine transaminase; alkaline phosphatase; tissue transglutaminase; 
antigliadin IgG and IgA antibodies; anti-casein, anti-gluten, and anti-soy IgG antibodies; 
thyroid functioning tests; and iron studies.  On children diagnosed with autistic disorder 
or PDD-NOS, high resolution chromosomes, Fragile X, and oligomeric microarray 
analyses were also performed.  One milliliter of whole blood from the first blood draw 
was aliquoted for analysis of glycophorin A (GPA), a measure of somatic mutation, by 
Nova Southeastern University.   
From the second blood draw, Quest Diagnostics performed plasma zinc and 
serum copper and selenium analyses.  They also analyzed serum folate and serum 
methylmalonic acid.  The Duquesne University analyses from the second blood draw 
included elemental analyses in serum, plasma, and red blood cells (RBCs); total, 
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oxidized, and reduced glutathione; the organic toxins benzene, toluene, o-xylene, and 
selected polychlorinated biphenyls (PCBs), certain polybrominated diethyl ethers 
(PBDEs), carefully chosen organochlorine and organphosphate pesticides, and a 
phthalate.  The glutathione, organic chemical testing, and GPA analysis will not be 
discussed in further detail in this chapter as it is part of a larger study.  The remaining 
serum, plasma, and RBCs to be tested by Duquesne University were stored at -80 °C until 
analysis.  After the second blood draw for each child, a hair sample was obtained from 
the back of the head.  The hair sample was placed in a plastic bag for transport to 
Duquesne University where it underwent elemental analysis. 
6.2.2.3 Behavioral Rating Scales 
During the time period when the blood draws were obtained, multiple behavioral 
rating scales were filled out by a parent or guardian, as required by the directions of the 
rating scales.  For this study, the rating scales completed were the Social Communication 
Questionnaire (SCQ),
57
 Aberrant Behavior Checklist (ABC),
58
 Gilliam Autism Rating 
Scale (GARS),
59
 Autism Treatment Evaluation Checklist (ATEC),
60
 PDD Behavior 
Inventory (PDDBI),
61
 and Childhood Autism Rating Scale (CARS).
62
  After they were 
completed, the results were recorded and pooled for future statistical analysis. 
6.2.2.3.1 Autism Diagnostic Observation Scale 
The ADOS is a measure that remains the clinical gold standard for autism 
diagnosis.
63
  In this study, two ADOS modules were scored, communication and social 
interaction, which were summed to provide the total ADOS score.  The cutoff for an 
autism diagnosis is a minimum score of 12 and the cutoff is 7 for an ASD diagnosis.
64
  
For the communication module, the cutoff for an autism diagnosis is 4 while it is 2 for an 
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ASD.
64
  The cutoff for the social interaction module for the confirmation of an ASD is 4 
and it is 7 for autism.
64
 
6.2.2.3.2 Social Communication Questionnaire 
The SCQ is used to evaluate the social relationships, language and 
communication ability, and stereotyped and repetitive activities of children with an 
ASD.
65
  It is an important behavioral rating scale because it takes into account all of the 
previous Diagnostic and Statistical Manual of Mental Disorders diagnostic components 
for autism.
66
  The SCQ consists of 40 yes or no questions arranged in four subscales:  
social interaction, communication, abnormal language, and stereotyped behaviors.
66
  For 
each question, a value of 1 is scored for the presence of the abnormal behavior and 0 is 
recorded for it not being present.
65
  For the SCQ, scores range from 0 to 39 and a cutoff 
of 15 is used to separate ASDs from other clinical diagnoses and a cutoff of 22 is used for 
separating autism from other ASDs.
65
 
6.2.2.3.3 Autism Treatment Evaluation Checklist 
The ATEC was created to monitor the implementation of treatments in children 
with autism and is typically not used in diagnosis.  The ATEC is a one page survey that is 
divided into four subscales:  (I) Speech/Language/Communication, (II) Sociability, (III) 
Sensory/Cognitive Awareness, and (IV) Health/Physical/Behavior.  The first three 
subscales are scored from 0 to 2 and the last subscale is scored from 0 to 3, with a higher 
score indicating a more severe the problem or greater development of that respective 
characteristic with a maximum score of 179. 
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6.2.2.3.4 Aberrant Behavior Checklist 
The ABC rating scale was designed to evaluate treatments in individuals with 
intellectual disabilities.
58
  The ABC has 58 items organized into 5 subscales:  (I) 
Irritability, Agitation, Crying; (II) Lethargy, Social Withdrawal; (III) Stereotypic 
Behavior; (IV) Hyperactivity, Noncompliance; and (V) Inappropriate Speech.
58
  Each 
item is scored from 0 to 3 on a 4-point scale with higher scores indicating a greater 
degree of problems.
58
  The Total ABC is determined by adding up each of the subscale 
scores and has a maximum value of 174. 
6.2.2.3.5 Childhood Autism Rating Scale 
The CARS was created as a way to diagnose children with autism.  It uses a 15 
point rating scale with scores ranging from 1 to 4 with half interval points.
67
  A score of 1 
represents normal behavior and a score of 4 indicates severely abnormal behavior.
67
  The 
scores on the CARS range from 15 to 60 with children scoring 30 or greater being 
classified as autistic.  To be diagnosed with severe autism, a child must score higher than 
36 and have scored at least a 3 on five or more of the 15 subscales.
67
  The information 
can also provide classification on the degree of autism and the type of symptoms.
68
 
6.2.2.3.6 Gilliam Autism Rating Scale-2 
The GARS was designed to monitor and diagnose autism in children.
69
  It can be 
used on patients from ages 3 to 22 and has 56 questions divided into 4 subscales:  Social 
Interaction, Communication, Stereotyped Behaviors, and Developmental Disturbances.
69
  
The GARS is scored on a 4 point scale to produce a score which represents the Autism 
Quotient (AQ).  The AQ is used to determine “the likelihood that a child has autism” and 
has a standard score of 100 with a standard deviation of 15.
69
  A child is determined to be 
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“probably autistic” if the AQ is equal to or greater than 90.69  In 2006, GARS-2 was 
created and it follows the diagnostic criteria of the Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition, Text Revision and the Autism Society of America.
70
  
One of the major changes in the GARS-2 was that the Parent Interview replaced the 
Developmental Disturbances subscale.  The Parent Interview determines lags in normal 
development or differences in socializing, communicating, and playing, prior to age three 
and is not a component of the new Autism Index (AI), which replaced the AQ.
70
  The 
Parent Interview was not included in the study design.  The scores from the other three 
subscales are very similar and the scores from the other three subscales are added and 
give the value for the AI.  An AI value equal to or greater than 85 evokes a “very likely” 
presence of autism, between 70 and 84 mean a child “possibly” has autism, and a score of 
69 or less means autism is “unlikely.”70 
6.2.2.3.7 PDD Behavior Inventory 
The PDDBI was designed to evaluate how children with pervasive developmental 
disorders responded to a medication.
71
  The PDDBI is unique because it targets both 
adaptive and maladaptive behaviors and is arranged in a priori, or hierarchal structure.  It 
can yield standardized results based on age which many of the other rating scales cannot 
do.
71
  The PDDBI is separated into two dimensions called Approach/Withdrawal 
Problems (AWP), for the maladaptive behaviors, and the Receptive/Expressive Social 
Communication Abilities (REXSCA), for the determination of communication skills.
72
  
The dimensions are composed of independent behavioral domains, which are made up 
clusters to characterize that domain.
72
  The AWP is made up of the Sensory/Perceptual 
Approach Behaviors (SENSORY), Ritualisms/Resistance to Change (RITUAL), Social 
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Pragmatic Problems (SOCPP), Semantic/Pragmatic Problems (SEMPP), Arousal 
Regulation Problems (AROUSE), Specific Fears (FEARS), and Aggressiveness (AGG) 
domains.  There are also two composite scores under the AWP.  The first composite is 
the Repetitive, Ritualistic, and Pragmatic Problem Behaviors Composite (REPRIT/C) and 
is equal to the sum of SENSORY, RITUAL, SOCPP, and SEMPP.  The other composite 
is the Approach/Withdrawal Problems Composite (AWP/C) and is the summation of all 
of the domains.  The domains making up the REXSCA are the Social Approach 
Behaviors (SOCAPP), Expressive Language (EXPRESS), Learning, and Memory and 
Receptive Language (LMRL).  There are two composite scores under REXSCA called 
Expressive Social Communication Abilities Composite (EXSCA/C) (SOCAPP + 
EXPRESS) and Receptive/Expressive Social Communication Abilities Composite 
(REXSCA/C) (SOCAPP + EXPRESS + LMRL).   
The PDDBI uses a standardized score like the GARS to determine autism 
diagnosis called the Autism Composite.  Each cluster is scored on a Likert scale from 0 to 
3 and is comprised of four or more items.
72
  Each domain generates a T-score with the T-
scores from most important domains creating the Autism Composite score.
72
  The Autism 
Composite is scored with a mean of 50 and a standard deviation of 10 which should 
classify 68% of cases of autism.
72
  The Autism Composite is calculated by summing the 
T-scores from SENSORY, RITUAL, SOCPP, and SEMPP and subtracting the T-scores 
from SOCAPP and EXPRESS.
72
 
6.2.2.4 Microwave Closed Vessel Preparation and Cleaning 
All sample preparation procedures for the elemental analysis in blood and hair 
were performed in an ISO Class 6 cleanroom using microwave digestion vessels and 
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inserts.  The 6 mL inserts and lids were cleaned before each digestion using 3 mL of 
HNO3 and 1 mL of HCl.  Outside of the three inserts, 5 mL of HNO3 was added to each 
digestion vessel to allow the temperature of the vessels to be monitored and ensure that 
the inserts maintained the proper temperature.  The vessels were microwaved according 
to EPA Method 3052
73
 following a program of a 10 minute ramp to 180 °C with a 10 
minute hold at 180 °C.  After microwaving, the vessels, lids, and stir bars were rinsed 
inside and outside with DDI water and dried on cleanroom wipes overnight. 
6.2.2.5 Elemental Analysis of Blood 
6.2.2.5.1 Sample Digestion for Elemental Analysis by External Calibration Curve 
Three different blood matrices were analyzed for elemental analysis:  serum, 
plasma, and RBCs.  For each patient and matrix, three subsamples were prepared in clean 
6 mL microwave vessel inserts.  After placing a stir bar inside each insert, 0.2 grams of 
sample was combined with 3 mL of HNO3 and 0.25 mL of HCl.  For each sample batch, 
three subsamples of SRM 1598a were prepared in the same manner as the patient samples 
for quality control.  Similar to when the vessels were cleaned, 5 mL of HNO3 was added 
to the microwave digestion vessels outside of the 6 mL inserts.  Each batch of samples 
was microwaved following EPA Method 3052 resulting in a complete digestion through 
the production of homogenous, transparent, light yellow solutions that did not contain 
any solids.  After digestion, each sample was poured into a 50 mL centrifuge tube and 
diluted to 10 mL with a 1% HNO3 and 0.5% HCl solution.  They were weighed before 
and after the addition of the sample digests along with being pre-rinsed with the 1% 
HNO3 and 0.5% HCl solution.  Twelve analytical blanks consisting of HNO3 and HCl 
were prepared for each set of analyzed samples.  The microwave vessels were rinsed with 
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DDI water after being used and cleaned as previously described.  The samples were 
stored in a cold room at 4 °C until analysis, typically within 2 days.   
6.2.2.5.2 Total Elemental Quantification by EPA Method 6020B 
The total elemental concentrations in the sample digests were determined 
according to EPA Method 6020B.
74
  On each day of analysis, the system was aspirated 
with 2% HNO3 for 30 minutes before tuning the instrument using the Agilent tuning 
solution at a concentration of 1 ng g
-1
 and determining the pulse/analog (P/A) factor.  
Analysis on the Agilent 7700 ICP-MS was performed in three analysis modes:  hydrogen, 
helium, and no gas.  The amount of hydrogen and helium gas was optimized to minimize 
polyatomic interferences.  Between analysis modes, a 30 second delay was employed to 
equilibrate the presence or absence of collision and/or reaction gas.  The analysis mode 
for each element is listed in Table 35. 
Calibration curves were created for 58 elements using solutions prepared from the 
single and multi-element standards.  The calibration solutions were prepared at 
concentrations of 0, 2.5, 5, 7.5, 10, and 25 ng g
-1
 in a 1% HNO3 and 0.5% HCl solution 
through serial dilution.  In each sequence, five children’s samples (serum, plasma, and 
RBCs) were analyzed per run with four replicates taken from each subsample.  Analyses 
were performed in spectrum mode using one point per mass.  The integration times for 
each element ranged from 0.1-1.0 seconds per point depending on the element’s 
ionization energy.  After analysis was completed, the data was exported from the Agilent 
MassHunter software (version G7201A A.01.01) into Microsoft Excel for further data 
analysis.  
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6.2.2.5.3 Sample Digestion for Elemental Analysis by IDMS 
The blood samples to be analyzed according to EPA Method 6800 were also 
prepared using microwave sample digestion.  Using clean microwave vessels, three 
subsamples of each child and matrix were prepared in the 6 mL microwave vessel inserts.  
After adding a stir bar, 0.2 grams of sample was combined in each insert with the 
appropriate amount of each isotopically enriched analyte, 3 mL of HNO3, and 0.25 mL of 
HCl.  Three subsamples of SRM 1598a used for quality control of each batch.  Similar to 
the EPA Method 6020B analysis, 5 mL of HNO3 was added to the microwave digestion 
vessels outside of the 6 mL inserts.  The samples were digested following EPA Method 
3052 according to the previously described parameters and the same post microwave 
sample protocol was followed as the EPA Method 6020B sample preparation.  The 
samples were subsequently stored at 4 °C in a cold room until analysis, which usually 
occurred within 2 days.  With each batch of analyzed samples, twelve analytical blanks 
consisting of HNO3, HCl, and isotopically enriched versions of the elements of interest 
were prepared. 
6.2.2.5.4 Total Elemental Quantification by EPA Method 6800 Quantification 
 Total elemental quantification using IDMS, a component of EPA Method 6800,
75
 
was performed for twelve elements (antimony, cadmium, chromium, copper, iron, 
lithium, lead, mercury, molybdenum, selenium, tin, and zinc).  On each day of analysis, 
the ICP-MS was tuned and the P/A factor was determined as previously described.  The 
IDMS analysis was also completed using the three different modes with the same 
collision/reaction gas parameters.  Analysis was performed in spectrum mode with one 
point per peak, and the integration time was set to 0.5-1.0 seconds per point for each 
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element.  Each subsample had four replicates analyzed with five children’s samples 
comprising each sequence.  Naturally abundant standards of the twelve analytes were 
analyzed at 0, 2, 4, 6, 8, and 10 ng g
-1
 to determine the mass bias and deadtime correction 
factors.  The Agilent 7700 ICP-MS’s default deadtime of 38 nanoseconds for the detector 
was used for the IDMS calculations.  The concentrations for each of the isotopically 
enriched elements were measured and verified by reverse IDMS analysis using the multi- 
or single element natural abundant standard solutions.  The completed data was exported 
into the IDMS software provided by AIT in Microsoft Excel from Agilent MassHunter 
software.  The concentrations of the analytes in the sample solutions were obtained using 
the IDMS equation (Equation 1). 
6.2.2.6 Elemental Analysis of Hair 
6.2.2.6.1 Sample Decomposition for Total Elemental Analysis by External 
Calibration Curve 
The hair elemental analysis samples were also prepared using microwave-
enhanced chemistry.  Using clean inserts, a stir bar was added to each insert and 0.1 
grams of sample was combined with 0.5 mL of HNO3 and 0.2 mL of HCl.  Three 
subsamples were prepared for each child.  For quality control, CRM GBW09101b was 
used with all of the same parameters as the samples except for using 0.2 grams to meet 
the CRM certificate specifications.  Similar to the blood analysis, 5 mL of HNO3 was 
added to the microwave digestion vessels outside of the inserts.  The hair samples were 
microwaved according to EPA Method 3052 as previously described.  The same post 
digestion procedure was followed as during the blood analyses.  Nine analytical blanks 
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consisting of HNO3 and HCl were digested with each sample batch.  Prior to analysis, the 
samples were stored in a cold room at 4 °C until analysis, usually within 3 days.   
6.2.2.6.2 Quantification of Total Elemental Concentrations by EPA Method 6020B 
The hair elemental concentrations were determined in the digests using EPA 
Method 6020B.  The ICP-MS was tuned and the P/A factor was determined on each day 
of analysis as previously described.  Similar to the blood analysis, the three different 
collision/reaction gas modes were used with the previously described parameters.   
Using the single and multi-element standards, calibration curves were prepared 
for 58 elements.  The analysis was performed at two different calibration ranges due to 
the wide concentration range of the analytes of interest in CRM GBW09101b and the hair 
samples.  The solutions for the low concentration range were prepared at 0, 5, 10, 15, 20 
and 25 ng g
-1
 in a 1% HNO3 and 0.5% HCl solution.  The high concentration range 
solutions were also made in a 1% HNO3 and 0.5% HCl solution at concentrations of 0, 5, 
10, 25, 50, and 100 ng g
-1
.  The calibration standards were prepared by acid matching, 
which consisted of adding the appropriate percentage of microwave-digested reagent 
blank to each calibration standard.   
The post microwave sample digests were diluted an additional 10:1 for the low 
concentration analytes and an additional 100:1 for the high concentration analytes in the 
1% HNO3 and 0.5% HCl solution.  The low and high concentration analytes were 
analyzed in independent runs with four replicates taken from each subsample.  The 
children’s samples were analyzed in four separate sequences with 18 in each of the first 
three sequences and 6 in the last one.  Analyses were completed using spectrum mode 
with one point per mass.  The integration times for each element varied from 0.1-1.0 
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seconds per point based on the ionization energy of each element.  The measured 
concentration value for each element in CRM GBW09101b and each hair sample was 
determined based on the value that fell within the range of one of the two calibration 
curves.  Following analysis, additional data processing was performed in Microsoft Excel 
after being exported from Agilent MassHunter.   
6.2.2.7 Quality Control 
The current study implemented numerous quality control measures that were 
previously mentioned including the preparation of multiple subsamples, replicate 
analysis, preparation of analytical blanks, acid or solution matched calibration standards, 
and reference materials.  It also utilized many of the quality control measures described 
in EPA Method 6020B.  The Agilent internal standard solution was used at a 
concentration of 100 ng g
-1
 in a 1% HNO3 and 0.5% HCl solution, and its acceptable 
recovery was maintained between 80 and 120% of the calibration blank.  Between 
samples, the autosampler probe was washed in three 1% HNO3 and 0.5% HCl solutions 
for 30 seconds each with a nebulizer pump speed of 0.5 rps.  After every nine samples 
during EPA Method 6020B analysis, low- and midpoint calibration checks along with 
either SRM 1598a or CRM GBW09101b assessments were performed as additional 
calibration verification.  During EPA Method 6800 analysis, SRM 1598a checks were 
performed at the beginning, middle, and end of each analysis sequence.  These checks 
ensured the consistency of the results during the complete duration of the sample runs. 
6.2.2.8 Statistical Analysis 
Differences between the control subjects and their paired child with autism 
counterparts were computed for each variable.  The resulting thirty differences for a 
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given variable were then used to conduct a paired-samples t-test.  This test determines 
whether the observed average difference is far enough from zero to conclude a 
statistically significant difference between the control and autistic responses for that 
variable.  In this study, far enough from zero is represented by the 0.05 significance level. 
Correlation analyses were also performed as a part of this study.  For a given 
variable, correlations were computed between the thirty measurements on children with 
autism and the thirty corresponding subject ages, and for the thirty measurements on 
children with autism with every other variable measured in the study.  Correlations were 
also computed between the thirty control measurements and the thirty corresponding 
subject ages and with the control measurements of every other variable. 
For nearly all variables, there were no significant correlations between the 
measurements for the children with autism and corresponding control measurements, nor 
was there a significant correlation between either set of measurements and age.  In such 
cases, there is no evidence that the subject pairing matters.  That is, the data for several 
variables suggests knowing the control subject measurement provides no information 
about the corresponding measurement of the child with autism.  The control 
measurements and measurements on children with autism for such variables can therefore 
be viewed as independent, and used to conduct a logistic regression analysis.  Since the 
number of control subjects is fixed to equal the number of subjects with autism, the 
logistic regression analysis must be adjusted to reflect an assumed autism 
prevalence.
76
  These analyses provide an autism diagnosis probability as a function of a 
particular variable of interest. 
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In addition to comparisons made between the children with autism and their 
matched controls, measurement comparisons were completed between three different 
measurement techniques:  the commercial clinical laboratory, EPA Method 6020B, and 
EPA Method 6800.  Among these three analysis methods, comparisons were completed 
for four variables:  plasma zinc, serum copper, plasma zinc/serum copper ratio, and 
serum selenium.  The correlation was determined for each variable comparing each pair 
of the three measurement techniques along with the resulting p-value.  This p-value 
represents how closely the measurement values by two different techniques are related to 
each other and the value for a variable by one technique provides information about what 
the value is by the other measurement technique.  Additionally, histograms were created 
to display the relative percent differences between a given pair of measurement 
techniques for each variable.  The p-value from the histogram determines whether the 
average difference between the two measurement techniques contains zero, which means 
there is no average difference between the measurement techniques for that variable.  Just 
as in the previously described comparisons, significance was based on 0.05 level. 
6.3 Results 
6.3.1 Behavioral Rating Scales 
The means (n = 30 pairs) and 95% CIs were determined for all of the behavioral 
ratings scales with the results seen in Table 34.  All of the children with autism or PDD-
NOS (mean: 5.5, SD: 2.1, 95% CI: 0.8) met the criteria for an ASD by ADOS.  All 
potential control children had total ADOS scores that were below the cutoff for an ASD.    
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Table 34:  The behavioral rating scale results (n = 30 pairs, 95% CIs) for children with autism 
and controls, with the p-value representing the difference between the two groups. 
Rating Scale Subscale Control Autism P-Value 
ADOS 
Total 2.6 ± 0.7 14.6 ± 1.3 5.1 × 10
-16
 
Communication 0.7 ± 0.2 4.9 ± 0.7 2.8 × 10
-13
 
Social Interaction 2.0 ± 0.6 9.7 ± 0.9 2.5 × 10
-15
 
SCQ  2.8 ± 0.9 18.4 ± 2.6 2.8 × 10
-11
 
ATEC 
Total 66.1 ± 1.2 75.3 ± 5.0 9.3 × 10
-4
 
I 27.9 ± 0.1 17.4 ± 2.8 1.5 × 10
-8
 
II 0.8 ± 0.4 14.4 ± 2.7 5.7 × 10
-11 
III 35.8 ± 0.2 23.8 ± 2.3 4.8 × 10
-12
 
IV 1.6 ± 0.9 19.6 ± 3.7 4.7 × 10
-10
 
ABC 
Total 4.4 ± 2.8 57.5 ± 9.4 3.0 × 10
-11
 
I 1.9 ± 1.1 14.5 ± 3.3 1.1 × 10
-7
 
II 0.2 ± 0.2 11.9 ± 2.8 3.1 × 10
-9
 
III 0.03 ± 0.07 6.5 ± 1.6 6.5 × 10
-9
 
IV 2.0 ± 1.4 21.4 ± 3.6 1.4 × 10
-10
 
V 0.2 ± 0.2 3.3 ± 1.1 1.5 × 10
-6
 
CARS  15.4 ± 0.3 32.5 ± 2.7 2.5 × 10
-13
 
GARS 
Autism Index 29.9 ± 9.6 86.8 ± 6.8 8.6 × 10
-10
 
Stereotyped Behaviors 1.8 ± 0.7 7.9 ± 1.0 6.6 × 10
-11
 
Communication 1.2 ± 0.7 8.4 ± 1.5 8.1 × 10
-9
 
Social Interaction 1.0 ± 0.06 7.3 ± 1.2 2.3 × 10
-9
 
PDDBI 
Autism Composite 18.1 ± 1.1 51.1 ± 4.8 3.1 × 10
-14
 
Approach/Withdrawal Problems 
SENSORY 35.2 ± 0.8 48.4 ± 3.4 2.2 × 10
-8
 
RITUAL 35.7 ± 1.1 53.2 ± 4.7 7.1 × 10
-8
 
SOCPP 31.8 ± 1.3 50.7 ± 3.7 1.2 × 10
-10
 
SEMPP 37.9 ± 1.5 52.3 ± 3.4 8.9 × 10
-9
 
AROUSE 29.6 ± 1.9 51.0 ± 3.9 6.5 × 10
-11
 
AGG 38.1 ± 1.6 51.2 ± 4.5 1.1 × 10
-7
 
REPRIT/C 28.9 ± 1.0 51.8 ± 4.4 2.9 × 10
-11
 
AWP/C 29.5 ± 1.5 52.5 ± 4.2 3.2 × 10
-11
 
Receptive/Expressive Social Communication Abilities 
SOCAPP 73.6 ± 1.7 51.3 ± 4.5 1.8 × 10
-10
 
EXPRESS 71.7 ± 2.5 51.2 ± 4.0 2.0 × 10
-9
 
LMRL 65.5 ± 1.8 51.6 ± 3.2 2.1 × 10
-8
 
EXSCA/C 74.9 ± 2.5 51.4 ± 4.2 3.0 × 10
-10
 
REXSCA/C 73.5 ± 2.3 51.5 ± 4.0 2.6 × 10
-10
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6.3.1.1 Autism Diagnostic Observation Schedule 
The children with autism had higher mean scores than controls on the Total 
ADOS and the two modules (Table 34 and Figure 41).  The children with autism had an 
average Total ADOS composite score of 14.6 ± 1.3, while controls had a mean of 2.6 ± 
0.7.  For the communication module, the mean for the controls was 0.7 ± 0.2, and the 
average for children with autism was 4.9 ± 0.7.  The children with autism had a mean 
score of 9.7 ± 0.9 for the social interaction module while controls averaged 2.0 ± 0.6.   
 
Figure 41:  The mean values for the communication module, social interaction module, and total 
ADOS for each of the two groups (n = 30 pairs, 95% CIs). 
6.3.1.2 Social Communication Questionnaire 
The children with autism had an average SCQ score of 18.4 ± 2.6, while controls 
had a mean score of 2.8 ± 0.9 (Table 34 and Figure 42).  The average SCQ score for 
children with autism is above the cutoff for an ASD, but below the cutoff for autism. 
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Figure 42:  For the control and autism groups, the mean Social Communication Questionnaire 
results (n = 30 pairs, 95% CIs). 
6.3.1.3 Autism Treatment Evaluation Checklist 
The results for the four ATEC subscales and total ATEC score are shown in Table 
34 and Figure 43.  The total ATEC was higher in the autism group with an average of 
75.3 ± 5.0 compared to 66.1 ± 1.2 for controls.  For subscales II and IV, the autism group 
had the greater mean score; however, the control group had the larger average for 
subscales I and III. 
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Figure 43:  The mean results (n = 30 pairs, 95% CIs) for the ATEC subscales and total ATEC. 
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6.3.1.4 Aberrant Behavior Checklist 
For the Total ABC, the children with autism demonstrated a greater mean score of 
57.5 ± 9.4 compared to the controls that averaged 4.4 ± 2.8 (Table 34 and Figure 44).  
The children with autism had a higher mean score compared to the control children for 
each of the five subscales. 
 
Figure 44:  For the control and autism groups, the ABC subscale and total ABC results.  The 
average values are shown for each group (n = 30 pairs) with 95% CIs. 
  
 347 
6.3.1.5 Childhood Autism Rating Scale 
The children with autism had a mean CARS score of 32.5 ± 2.7 while controls 
averaged 15.4 ± 0.3 (Table 34 and Figure 45).  The average score for the children is 
above the autism cutoff of 30, but it is below the cutoff of 36 for severe autism.  The 
controls’ average score was very close to the lowest possible value of 15. 
 
Figure 45:  The results for each group (n = 30 pairs, 95% CIs) for the Childhood Autism Rating 
Scale. 
6.3.1.6 Gilliam Autism Rating Scale-2 
For the Autism Index of GARS-2, the children with autism averaged 86.8 ± 6.8 
and the controls had a mean value of 29.9 ± 9.6 (Table 34 and Figure 46).  The value for 
the children with autism indicates the “very likely” presence of autism, while the score 
for the control children suggests that autism is “unlikely.”  The children with autism 
scored higher than the control children for each of the three scored subscales.  
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Figure 46:  For the GARS-2, the results for the stereotyped behaviors, communication, and social 
interaction subscales and the Autism Index for the control and autism group.  The average and 
95% CIs are shown for each group of 30 children. 
6.3.1.7 PDD Behavior Inventory 
The PDDBI behavioral rating scale results are shown in Table 34 and Figures 47-
49.  On the Autism Composite, the children with autism had a mean value of 51.1 ± 4.8, 
while the control children had an average of 18.1 ± 1.1 (Figure 47).  The children with 
autism had higher average scores for each of the domains and composites of the 
Approach/Withdrawal problems dimension of the PDDBI (Figure 48).  The results for the 
domains and composites for the Receptive/Expressive Social Communication Abilities 
dimension of the PDDBI showed that the control children had greater mean values 
compared to the children with autism (Figure 49). 
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Figure 47:  The Autism Composite results for the PDDBI (n = 30 pairs, 95% CIs). 
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Figure 48:  The mean and 95% CIs of each group for the domains and composites for the 
Approach/Withdrawal Problems dimension of the PDDBI. 
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Figure 49:  For the control and autism groups, the results (n = 30 pairs, 95% CIs) of the domain 
and composites for the Receptive/Expressive Social Communication Abilities dimension of the 
PDDBI. 
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6.3.2 Elemental Analysis 
6.3.2.1 Analytical Figures of Merit and Validation of EPA Methods  
All elements displayed linearity on the six point external calibration curves for the 
EPA Method 6020B blood and hair analysis.  They had correlation coefficient (r
2
) values 
greater than the 0.998 specified in EPA Method 6020B, except for Ca in the blood 
analysis, which was just below this cutoff at 0.9974 (Tables 35 and 36).  The obtained 
measurements were highly reproducible because the four replicates for each calibration 
point displayed a typical variation of less than 5%. 
Table 35:  The analysis information, correlation coefficient, DLs, QLs, and BECs for elements of 
interest in blood determined by EPA Method 6020B using the Agilent 7700 ICP-MS. 
Element m/z Mode r
2
 DL (ng g
-1
) QL (ng g
-1
) BEC (ng g
-1
) 
Mg 24 He 0.9998 6.58 9.02 0.632 
Al 27 H2 0.9999 8.82 16.7 3.69 
Ca 40 H2 0.9974 57.6 139 177 
V 51 He 0.9998 4.80 8.12 1.99 
Cr 52 He 0.9998 0.306 0.572 0.698 
Mn 55 He 0.9998 0.0903 0.207 0.306 
Fe 56 He 0.9999 12.2 29.1 8.03 
Co 59 He 0.9998 0.370 1.11 0.0144 
Ni 60 He 0.9998 0.0666 0.206 0.652 
Cu 63 He 0.9994 0.114 0.278 6.42 
Zn 66 He 0.9998 2.52 3.98 1.29 
As 75 He 0.9999 1.04 1.84 0.999 
Se 78 H2 0.9999 0.0710 0.164 0.129 
Rb 85 He 0.9999 0.0000472 0.000150 0.0228 
Mo 95 He 0.9998 0.0218 0.0604 0.0548 
Cd 111 He 0.9998 0.0656 0.154 0.00684 
Sb 121 No gas 0.9999 0.0414 0.101 0.0340 
Te 125 No gas 0.9998 0.0177 0.0541 0.0301 
Cs 133 No gas 0.9999 0.00288 0.00822 0.00320 
Hg 201 No gas 0.9999 0.106 0.226 0.0132 
Pb 208 No gas 0.9999 0.0205 0.0470 0.0155 
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Table 36:  The analysis information, correlation coefficient, DLs, and BECs for elements of 
interest in hair determined by EPA Method 6020B using the Agilent 7700 ICP-MS. 
Element m/z Mode r
2
 DL (ng g
-1
) QL (ng g
-1
) BEC (ng g
-1
) 
Na 23 No gas 0.9999 0.932 2.68 5.97 
Mg 24 No gas 0.9997 0.0102 0.0317 0.717 
Al 27 No gas 0.9994 0.261 0.759 1.34 
P 31 No gas 0.9995 6.30 5.87 19.9 
K 39 No gas 0.9998 3.93 13.1 4.02 
Ca 40 H2 0.9989 2.17 1.59 22.9 
V 51 He 0.9989 0.0738 0.210 0.0354 
Cr 52 He 0.9996 0.489 1.44 1.16 
Mn 55 He 0.9990 0.134 0.408 0.192 
Fe 56 He 0.9999 0.711 2.02 2.58 
Co 59 He 0.9994 0.138 0.392 0.0621 
Ni 60 He 0.9998 0.189 0.558 0.572 
Cu 63 He 0.9998 0.0610 0.193 0.182 
Zn 66 He 0.9998 0.828 2.21 2.18 
As 75 He 0.9994 0.0311 0.0948 0.0891 
Se 78 H2 0.9995 0.00986 0.0311 0.0280 
Sr 88 No gas 0.9991 0.0220 0.0653 0.0424 
Mo 95 He 0.9987 0.0558 0.169 0.0523 
Ag 107 No gas 1.0000 0.00212 0.00567 0.0158 
Cd 111 He 0.9985 0.0942 0.280 0.0450 
Sb 121 No gas 1.0000 0.00495 0.0134 0.0364 
Ba 137 No gas 0.9999 0.622 1.74 0.205 
La 139 No gas 0.9982 0.00335 0.00931 0.00935 
Hg 202 No gas 1.0000 0.0621 0.122 0.0554 
Pb 208 No gas 1.0000 0.0630 0.188 0.0716 
U 238 No gas 0.9999 0.00170 0.00439 0.00880 
 
Detection limits (DLs) were defined as the average of the blank concentration for 
each element plus three times the standard deviation of the blank measurements for that 
respective element.
77
  The DLs for all elements were below 1 ng g
-1
 except for Mg, Al, 
Ca, V, Fe, Zn, and As for the EPA Method 6020B blood analysis (Table 35); Fe and Zn 
for the EPA Method 6800 blood testing (Table 37); and P and K for the EPA Method 
6020B hair analysis (Table 36).  The quantification limits (QLs) were determined by 
taking ten times the standard deviation of the blank measurements for each respective 
element.
77
  The QLs were all under 2 ng g
-1
 except Mg, Al, Ca, V, Fe, and Zn for the 
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EPA Method 6020B blood testing (Table 35); Fe for the EPA Method 6800 blood 
analysis (Table 37); and Na, P, K, Fe, and Zn for the EPA Method 6020B hair testing 
(Table 36).  The background equivalent concentrations (BECs) were calculated by 
multiplying the background intensity signal with the concentration of the analyte and 
dividing by the difference of the analyte intensity minus the intensity of the 
background.
78
  The BECs were below 2 ng g
-1
 for all elements except for Al, Ca, Fe, and 
Cu in the EPA Method 6020B blood testing (Table 35); Fe and Cu in the EPA Method 
6800 blood analysis (Table 37); and Ca, Fe, Na, P, K, and Zn in the EPA Method 6020B 
hair testing (Table 36). 
Table 37:  The analysis information, correlation coefficient, DLs, QLs, and BECs for elements of 
interest in blood determined by EPA Method 6800 using the Agilent 7700 ICP-MS. 
Element Natural 
m/z 
Enriched 
m/z 
Mode DL (ng g
-1
) QL (ng g
-1
) BEC (ng g
-1
) 
Li 7 6 No gas 0.00563 0.0188 0.0224 
Cr 52 50 He 0.689 0.366 0.448 
Fe 56 57 He 2.49 2.74 4.45 
Cu 63 65 He 0.973 1.25 2.37 
Zn 66 68 He 1.02 1.97 0.569 
Se 78 77 H2 0.646 0.937 0.0571 
Mo 95 97 He 0.0220 0.0546 0.0214 
Cd 114 112 He 0.168 0.485 0.0261 
Sn 118 122 He 0.232 0.585 0.0195 
Sb 121 123 No gas 0.0207 0.0562 0.00584 
Hg 202 199 No gas 0.425 0.943 0.0262 
Pb 208 206 No gas 0.0404 0.0358 0.00945 
 
Additional confidence in the accuracy and precision of the results from the 
present study was achieved by using SRM 1598a and CRM GBW09101b to validate the 
sample preparation and analysis protocols.  These standards are certified for multiple 
elements at concentrations similar to those found in representative blood and hair 
samples, respectively.  Results obtained for SRM 1598a during this study using EPA 
Method 6020B and EPA Method 6800 are shown in Table 38 with the mean (n = 12) and 
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95% confidence intervals (CIs).  The measured values are in strong agreement with the 
certified and reference values for the EPA Method 6020B analysis, with overlapping CIs 
for all elements above the respective DL except for Ca.  The percent recovery for Ca was 
124% when comparing mean values, but improved to 113% when including the CIs.  For 
the EPA Method 6800 testing, the measured CIs overlapped with the certified or 
reference CIs for all 6 elements that were able to be quantified above the respective DL. 
Table 38:  Concentrations (ng g
-1
) of the certified, reference, and informational elements 
determined in SRM 1598a by EPA Methods 6020B and 6800 (n = 12, 95% CIs). 
Element 
Certified Value 
(ng g
-1
) 
EPA Method 6020B 
(ng g
-1
) 
EPA Method 6800 
(ng g
-1
) 
Cd 0.047 ± 0.004 <DL <DL 
Co 1.21 ± 0.07 <DL Not Determined 
Cs 0.62 ± 0.10 0.7999 ± 0.1615 Not Determined 
Cu 1,538 ± 88 1,567 ± 17 1,622 ± 11 
Fe 1,635 ± 58 1,874 ± 235 1,614 ± 10 
Mn 1.73 ± 0.32 <DL Not Determined 
Ni 0.91 ± 0.18 <DL Not Determined 
Rb 267 ± 18 272.0 ± 3.3 Not Determined 
Sb 0.973 ± 0.15 1.328 ± 0.450 1.166 ± 0.122 
Se 130.8 ± 5.6 124.9 ± 2.7 131.1 ± 3.8 
V 1.83 ± 0.11 <DL Not Determined 
Zn 857 ± 23 888.5 ± 16.3 879.7 ± 8.0 
 
Reference Value 
(ng g
-1
) 
EPA Method 6020B 
(ng g
-1
) 
EPA Method 6800 
(ng g
-1
) 
Al 2.2 ± 0.6 <DL Not Determined 
Ca 93 ± 7 (µg g
-1
) 115.0 ± 2.5 Not Determined 
Cr 0.32 ± 0.08 <DL <DL 
Hg 0.31 ± 0.18 <DL <DL 
Mo 5.4 ± 1.0 3.278 ± 1.465 6.386 ± 0.908 
 
Information Value 
(ng g
-1
) 
EPA Method 6020B 
(ng g
-1
) 
EPA Method 6800 
(ng g
-1
) 
As 0.3 <DL Not Determined 
K 258 (µg g
-1
) Not Determined Not Determined 
Na 3,115 (µg g
-1
) Not Determined Not Determined 
P 136 (µg g
-1
) Not Determined Not Determined 
S 915 (µg g
-1
) Not Determined Not Determined 
Te 0.032 <DL Not Determined 
<DL:  below detection limit 
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There were six elements which were measured at detectable quantities by both 
EPA Method 6020B and EPA Method 6800:  antimony, copper, iron, molybdenum, 
selenium, and zinc.  The results from each of the two EPA methods for these six elements 
are shown in Figure 50.  Both EPA Method 6020B and EPA Method 6800 produced 
results that were accurate, within the provided CIs for all six elements, while EPA 
Method 6800 provided better precision for all of these elements except for selenium. 
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Figure 50:  A comparison of EPA Method 6020B and EPA Method 6800 results for antimony, 
copper, iron, molybdenum, selenium, and zinc for SRM 1598a (n = 12, 95% CIs). 
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Similar accuracy was achieved for CRM GBW09101b during the hair analysis.  
Figure 51 and Table 39 show a comparison of the reference and informational values 
with the measured results including means (n = 12) and 95% CIs.  The measured values 
are in strong agreement with the certified and informational values, as the CIs for the 
measured values overlapped the certified CIs for 19 out of 21 elements.  The recovery 
efficiencies ranged from 64.0 to 125.8% based on a comparison of the mean listed values 
to the average measured quantities.  Only 2 of the 21 elements with certified values had 
either recoveries that differed by more than 20% from the mean value or that did not 
overlap CIs.  The overall accuracy of the elemental measurements in this study improves 
with the inclusion of the provided CIs. 
 
Figure 51:  Comparison of the EPA Method 6020B results to the CRM GBW09101b certified 
and information values (n = 12, 95% CIs). 
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Table 39:  Concentrations (µg g
-1
) of the certified and informational elements determined in 
CRM GBW09101b by EPA Methods 6020B (n = 12, 95% CIs). 
Element Certified Value (µg g
-1
) EPA Method 6020B (µg g
-1
) 
Ag 0.037 ± 0.002 0.03253 ± 0.00354 
Al 23.2 ± 2.0 25.88 ± 2.41 
As 0.198 ± 0.023 0.2337 ± 0.0664 
Ba 11.1 ± 1.3 7.108 ± 0.596 
Ca 1,537 ± 68 1,432 ± 49 
Cd 0.072 ± 0.010 0.06029 ± 0.02139 
Co 0.153 ± 0.015 0.1363 ± 0.0207 
Cr 8.74 ± 0.97 8.028 ± 0.502 
Cu 33.6 ± 2.3 34.91 ± 1.01 
Fe 160 ± 16 151.8 ± 7.0 
Hg 1.06 ± 0.28 1.220 ± 0.061 
I 0.96 ± 0.20 Not Determined 
Mg 248 ± 14 246.4 ± 6.2 
Mn 3.83 ± 0.39 2.799 ± 0.205 
Mo 1.06 ± 0.12 0.9018 ± 0.0647 
Na 445 ± 40 469.9 ± 10.9 
P 174 ± 43 157.4 ± 2.5 
Pb 3.83 ± 0.18 4.488 ± 0.637 
Sb 0.12 ± 0.02 0.1282 ± 0.0053 
Se 0.59 ± 0.04 0.5940 ± 0.0660 
Sr 8.17 ± 0.69 8.152 ± 0.092 
Zn 191 ± 16 208.8 ± 12.1 
 Information Value (µg g
-1
) EPA Method 6020B (µg g
-1
) 
K 14.4 10.64 ± 1.01 
La 0.029 0.03647 ± 0.00507 
S 4.62 Not Determined 
Cl 48.2 Not Determined 
Ti 2.1 Not Determined 
V 0.089 0.06904 ± 0.02800 
Br 0.59 Not Determined 
Ni 5.77 5.113 ± 0.361 
 
The precision determined by the 95% CIs was within 10% of the measured mean 
values for a large majority of the certified, reference, or information values for elements 
in SRM 1598a and CRM GBW09101b, with nearly half inside of 5% (Tables 38 and 39).  
This level of precision observed for these reference standards was maintained for the 
remainder of the study as most results had 95% CIs that were less than 10% of their mean 
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value, including a large number of them within 5%.  The EPA Method 6800 results for 
SRM 1598a were more precise compared to EPA Method 6020B for 5 of the 6 elements 
that were able to be quantified by both methods.  Overall, the blood measurements in this 
study obtained by EPA Method 6800 were more precise compared to those from EPA 
Method 6020B.  The current study also supplied 95% CIs for all detectable elemental 
quantities in the blood and hair samples. 
6.3.2.2 Elemental Analysis of Blood 
Paired-samples t-tests were performed on the elements in the three blood matrices 
to determine significance differences between the children with autism and controls.  The 
elements that produced significant results with p-values below 0.05 are shown in Table 
40.  Significant results were observed for Mg in plasma, serum, and RBCs, where 
children with autism had greater concentrations compared to controls with p-values of 1.3 
× 10
-4
, 2.4 × 10
-4
, and 6.8 × 10
-4
, respectively (Figures 52-54).  Another significant 
finding was seen in Figure 55 with RBC Fe as the children with autism had greater mean 
quantities than the control children (p-value = 0.0076).  Plasma Mo produced the final 
significant difference illustrated in Figure 56 with the children with autism having a 
greater average concentration compared to controls (p-value = 0.012).  The dashed lines 
in each figure indicate the matched pairs of children. 
Table 40:  The statistically significant results of the elemental blood analyses, with the children 
with autism displaying higher levels of each element along with the corresponding p-value from 
the paired-samples t-test. 
Variable P-Value 
Plasma Mg 0.00013 
Serum Mg 0.00024 
RBC Mg 0.00068 
RBC Fe 0.0076 
Plasma Mo 0.012 
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Figure 52:  The mean values of plasma magnesium in children with autism and controls with an 
n = 30 pairs.  The children with autism had significantly higher plasma magnesium than controls 
with a p-value of 1.3 × 10
-4
. 
 
Figure 53:  For n = 30 pairs, the average serum magnesium concentrations in children with 
autism were higher compared to controls (p-value = 2.4 × 10
-4
). 
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Figure 54:  The average red blood cell magnesium values for n = 30 pairs of children with autism 
and controls.  The children with autism had significantly higher red blood cell magnesium 
concentrations than controls (p-value = 6.8 × 10
-4
). 
 
Figure 55:  The children with autism had significantly higher red blood cell iron concentrations 
than controls according to the average values for 30 pairs of children (p-value = 0.0076). 
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Figure 56:  For n = 30 pairs, the average plasma molybdenum concentrations in children with 
autism were higher compared to controls (p-value = 0.012). 
Although the results were not significant using paired-samples t-tests, the results 
for the plasma zinc/serum copper ratio did indicate an important finding.  Both children 
with autism and controls demonstrated a suppressed zinc/copper ratio by all three 
measurement techniques as seen in Table 41.  These indicators agreed well with each 
other and differed significantly from a normal healthy zinc/copper ratio. 
Table 41:  The plasma zinc/serum copper ratio results for children with autism and controls from 
a commercial clinical laboratory, EPA Method 6020B, and EPA Method 6800. 
 Autism Control 
Commercial Laboratory 0.625 ± 0.046 0.661 ± 0.066 
EPA Method 6020B 0.6258 ± 0.0681 0.6841 ± 0.0691 
EPA Method 6800 0.6532 ± 0.0550 0.6652 ± 0.0641 
6.3.2.3 Elemental Analysis of Hair 
No elements analyzed in hair produced a significant difference between the two 
cohorts of children using a paired-samples t-test; however, trends of near significance 
were observed for two elements.  The results for Cr were nearly significant with a p-value 
of 0.051 as the children with autism tended to have lower concentrations of Cr in their 
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hair compared to controls (Figure 57).  A similar trend was seen for Pb in Figure 58, with 
an inclination of control children to have greater concentrations of Pb in their hair 
compared to children with autism (p-value = 0.057). 
 
Figure 57:  The average chromium hair concentrations for children with autism and matched 
controls.  The control children had nearly significantly greater concentrations of chromium in 
their hair compared to children with autism (p-value = 0.051). 
 
Figure 58:  For the 30 pairs of children who had their hair analyzed, a trend was observed with 
controls having more lead in their hair compared to controls (p-value = 0.057). 
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6.3.3 Clinical Laboratory Testing 
Upon completion of the clinical testing, the means (n = 30 pairs) and 95% CIs 
were calculated for all measured variables as part of the statistical analyses.  All of the 
clinical testing results are shown in Table 42.  The statistically significant findings from 
the clinical laboratory testing are shown in Table 43. 
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Table 42:  The results of the clinical laboratory testing performed for the children with autism 
and controls (n = 30 pairs, 95% CIs). 
Grouping Test Control Autism 
Metals/Elements 
Plasma Zinc (µgdL
-1
) 70.6 ± 4.7 72.3 ± 5.1 
Serum Copper (µg dL
-1
) 111.4 ± 9.4 118.3 ± 8.7 
Plasma Zinc/Serum Copper Ratio 0.661 ± 0.066 0.625 ± 0.046 
Selenium (µg L
-1
) 120.8 ± 4.3 125.5 ± 5.6 
Calcium (mg dL
-1
) 9.80 ± 0.13 9.97 ± 0.14 
Phosphorus (mg dL
-1
) 4.81 ± 0.20 4.87 ± 0.26 
Lymphocyte 
Subset Panel 
Lymphocyte Number (cells µL
-1
) 3,113 ± 397 4,108 ± 591 
CD3 Number (cells µL
-1
) 2,123 ± 262 2,759 ± 403 
CD3 Percent (%) 68.6 ± 2.2 67.2 ± 2.8 
CD4 Number (cells µL
-1
) 1,240 ± 161 1,628 ± 239 
CD4 Percent (%) 39.7 ± 2.5 39.8 ± 2.6 
CD8 Number (cells µL
-1
) 797 ± 133 1,008 ± 190 
CD8 Percent (%) 25.1 ± 2.4 24.0 ± 2.1 
CD4/CD8 Ratio 1.71 ± 0.23 1.75 ± 0.20 
CD19 Number (cells µL
-1
) 681 ± 125 791 ± 170 
CD19 Percent (%) 21.7 ± 2.3 19.1 ± 2.3 
Natural Killer Cell Number 
(cells µL
-1
) 
235.4 ± 49.6 470.7 ± 121.4 
Natural Killer Cell Percent (%) 7.83 ± 1.31 11.8 ± 2.7 
Serum 
Immunoglobulins 
IgA (mg dL
-1
) 107 ± 16 108 ± 24 
IgG (mg dL
-1
) 965 ± 106 961 ± 124 
IgM (mg dL
-1
) 86.5 ± 10.7 88.1 ± 14.8 
Complete Blood 
Count Including 
Differential and 
Platelets 
White Blood Cells (thousands µL
-1
) 7.45 ± 0.74 9.15 ± 1.04 
Red Blood Cells (million µL
-1
) 4.35 ± 0.12 4.49 ± 0.12 
Hemoglobin (g dL
-1
) 12.6 ± 0.3 12.9 ± 0.3 
 Hematocrit (%) 36.8 ± 0.9 37.6 ± 1.1 
Mean Corpuscular Volume 
(femtoliters) 
84.7 ± 0.9 83.9 ± 1.3 
Mean Corpuscular Hemoglobin 
(pictograms) 
29.1 ± 0.4 28.7 ± 0.5 
Mean Corpuscular Hemoglobin 
Concentration (g dL
-1
) 
34.3 ± 0.2 34.2 ± 0.3 
Red Blood Cell Distribution Width 
(%) 
13.6 ± 0.2 13.5 ± 0.3 
Platelet Count (thousands µL
-1
) 287 ± 18 323 ± 29 
Neutrophil Number (cells µL
-1
) 3,595 ± 538 4,366 ± 668 
Neutrophil Percent (%) 47.9 ± 3.9 47.7 ± 3.6 
Lymphocyte Number (cells µL
-1
) 3,099 ± 368 3,919 ± 525 
Lymphocyte Percent (%) 42.2 ± 4.0 43.2 ± 4.0 
Monocyte Number (cells µL
-1
) 532 ± 62 598 ± 86 
Monocyte Percent (%) 7.3 ± 0.7 6.6 ± 0.7 
Eosinophil Number (cells µL
-1
) 183 ± 47 222 ± 70 
Eosinophil Percent (%) 2.4 ± 0.5 2.2 ± 0.7 
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Basophil Number (cells µL
-1
) 38 ± 12 39 ± 6 
Basophil Percent (%) 0.4 ± 0.2 0.3 ± 0.2 
Erythrocyte Sedimentation Rate 
(mm hr
-1
) 
5.0 ± 2.3 5.7 ± 2.2 
Iron and Total 
Iron Binding 
Capacity (TIBC) 
Total Iron (µg dL
-1
) 74.4 ± 10.1 89.7 ± 12.3 
TIBC (µg dL
-1
) 369 ± 18 367 ± 19 
Percent Saturation (%) 20.4 ± 2.8 25.0 ± 3.9 
Ferritin (ng mL
-1
) 30.9 ± 6.1 28.4 ± 5.6 
Liver Function 
Aspartate Aminotransferase 
(units L
-1
) 
30.3 ± 1.8 28.2 ± 2.0 
Alanine Aminotransferase 
(units L
-1
) 
15.5 ± 2.0 14.6 ± 1.8 
Alkaline Phosphatase (units L
-1
) 209 ± 11 235 ± 36 
Liver Isoenzyme (%) 26.4 ± 2.3 27.6 ± 3.0 
Bone Isoenzyme (%) 69.7 ± 2.4 69.9 ± 2.6 
Intestine Isoenzyme (%) 3.9 ± 1.8 2.5 ± 1.3 
Macrohepatic Isoenzyme (%) 0 ± 0 0 ± 0 
Placental Isoenzyme (%) 0 ± 0 0 ± 0 
Immune 
Tolerance 
IgG Gliadin (units) 3.7 ± 0.8 3.2 ± 1.0 
IgA Gliadin (units) 7.9 ± 9.7 3.5 ± 1.6 
Tissue Transglutaminase Antibody 
(units mL
-1
) 
3.3 ± 0.6 2.9 ± 0.5 
Gluten IgG (µg mL
-1
) 11.6 ± 5.3 27.0 ± 13.1 
Soybean IgG (µg mL
-1
) 3.3 ± 1.1 4.4 ± 1.3 
Casein/Cowmilk IgG (µg mL
-1
) 13.8 ± 5.3 27.4 ± 13.1 
Protein Status 
Albumin (g dL
-1
) 4.62 ± 0.10 4.74 ± 0.13 
Ceruloplasmin (mg dL
-1
) 30.5 ± 1.7 30.4 ± 1.9 
Cholesterol (mg dL
-1
) 149 ± 9 157 ± 9.4 
Total Protein (g dL
-1
) 7.00 ± 0.14 7.22 ± 0.20 
Thyroid Studies 
Thyroid Stimulating Hormone 
(milli-international units L
-1
) 
2.31 ± 0.38 2.55 ± 0.38 
T3 Free (pg mL
-1
) 3.83 ± 0.14 3.83 ± 0.13 
T4 Free (ng dL
-1
) 1.15 ± 0.06 1.17 ± 0.08 
Vitamin Status 
Serum Folate (ng mL
-1
) 22.2 ± 1.1 21.6 ± 1.6 
Serum Methylmalonic Acid 
(nmol L
-1
) 
130 ± 14 193 ± 40 
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Table 43:  The statistically significant results and trends from the clinical laboratory testing with 
the corresponding p-value from the paired-samples t-test. 
Grouping Variable P-Value 
Lymphocyte Subset Panel 
Natural Killer Cell Number 0.0020 
Lymphocytes 0.0039 
CD3 Number 0.010 
CD4 Number 0.010 
Natural Killer Cell Percent 0.019 
CD8 Number 0.052 
Complete Blood Count including 
Differentials and Platelets 
Lymphocytes 0.0096 
Neutrophils 0.049 
Platelet Count 0.037 
White Blood Cells 0.0051 
Immune Tolerance 
Gluten IgG 0.0092 
Casein IgG 0.051 
Vitamin Status Methylmalonic Acid 0.0042 
 
 The lymphocyte subset panel demonstrated greatest number of significant 
findings using paired-samples t-tests.  The most statistically significant finding was 
natural killer cell number with a p-value of 0.0020 (Figure 59), with the children with 
autism having a greater number compared to controls.  The natural killer cell percent was 
also higher in the children with autism as seen in Figure 60 (p-value = 0.010).  The 
children with autism had a larger number of lymphocytes compared to controls with a p-
value of 0.0039 (Figure 61).  The children with autism had elevated CD3, total T cell, (p-
value = 0.010) and CD4, helper T cell, (p-value = 0.010) numbers compared to controls 
seen in Figures 62 and 63, respectively.  In addition to these statistically significant 
findings, a trend of higher CD8 numbers in children with autism compared to controls 
was observed with a p-value of 0.052 (Figure 64). 
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Figure 59:  The mean natural killer cell concentration in children with autism and controls.  For n 
= 30 pairs, the children with autism had significantly higher blood natural killer cell numbers than 
controls with a p-value of 0.0020. 
 
Figure 60:  For the 30 pairs of children studied, the children with autism had a significantly 
higher percentage of natural killer cells compared to controls with a p-value of 0.019. 
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Figure 61:  The average CD3 number in children with autism and controls.  The children with 
autism had significantly higher CD3 numbers than controls for n = 30 pairs with a p-value of 
0.010. 
 
Figure 62:  For n = 30 pairs, the children with autism had significantly higher CD4 numbers than 
controls with p = 0.010. 
  
 371 
 
Figure 63:  The lymphocyte concentration from the lymphocyte subset panel for the children 
with autism and controls.  The children with autism had significantly higher concentrations of 
lymphocytes with p = 0.0039. 
 
Figure 64:  For n = 30 pairs, the mean of CD8 numbers for children of autism and controls 
indicated a trend of higher CD8 numbers in children with autism with a p-value of 0.052. 
 The complete blood count with differential and platelets was another area where 
significant differences were observed between children with autism and controls.  The 
white blood cells produced the most significant discovery from this part of the clinical 
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testing.  They were elevated in the children with autism compared to controls with a p-
value of 0.0051 (Figure 65).  The lymphocytes measured as part of the complete blood 
count were also found to be significant as part of the complete blood count, just as they 
were in the testing performed as part of the lymphocyte subset panel.  The children with 
autism displayed greater numbers of lymphocytes versus controls as seen in Figure 66 (p-
value = 0.0096).  The next most significant finding was for platelets, with the children 
with autism having a higher number compared to controls with a p-value of 0.037 (Figure 
67).  The final finding from the complete blood count was for neutrophils.  The children 
with autism had higher quantities of neutrophils compared to controls as illustrated in 
Figure 68 (p-value = 0.049). 
 
Figure 65:  For n = 30 pairs, the children with autism demonstrated significantly higher white 
blood cell counts than controls with p = 0.0051. 
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Figure 66:  The average lymphocyte count from the complete blood count for children with 
autism and controls.  The children with autism had significantly higher lymphocyte counts than 
controls for n = 30 pairs with a p-value of 0.0096. 
 
Figure 67:  The average platelet counts in children with autism were higher compared to controls 
for n = 30 pairs (p-value = 0.037). 
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Figure 68:  For the 30 pairs of children studied, the mean neutrophil number was significantly 
greater in children with autism compared to controls with p = 0.049. 
 In addition to the other areas of the immune system studied, the results for 
immunoglobulins produced a significant result.  A higher amount of gluten IgG was 
observed in children with autism versus controls as illustrated in Figure 69 (p-value = 
0.0092).  A nearly significant trend was also seen with casein IgG with a p-value of 
0.051, as greater quantities found in children with autism compared to controls (Figure 
70). 
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Figure 69:  The average gluten IgG concnetrations in children with autism and controls.  The 
children with autism had significantly greater amounts of gluten IgG with a p-value of 0.0092. 
 
Figure 70:  For the 30 pairs of children study, a trend was observed of greater quantities of casein 
IgG in children with autism versus controls with a p-value of 0.051. 
 The other area of clinical testing that produced significant results was vitamin 
status, involving the testing of methylmalonic acid.  The children with autism had greater 
quantities of methylmalonic acid compared to controls with a p-value of 0.0042 (Figure 
71). 
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Figure 71:  The mean serum methylmalonic acid concentrations for children with autism and 
controls.  The children with autism had statistically significant greater quantities of 
methylmalonic acid with p = 0.0042. 
   One additional variable that was examined due to prior research was the 
plasma zinc/serum copper ratio.  The children with autism did a lower average plasma 
zinc/serum copper ratio compared to controls in this study, but the results were not 
statistically significant.  The children with autism had greater concentrations of both 
plasma zinc and serum copper compared to controls.  The other clinical tests performed 
did not produce any statistically significant results. 
6.3.4 Age Correlations 
A correlation (r) with age was computed to evaluate the effects development had 
on producing significant results in either of the two groups of children for each variable 
measured in this study.  The age correlation results were separated according to each 
group of children, with plots made for the variables with significant correlations with age.  
For each significant correlation, the plots for that variable from each of the two groups 
were displayed next to each other. 
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6.3.4.1 Behavioral Rating Scales 
6.3.4.1.1 Autism Group 
The behavioral rating scales were first group of variables investigated for age 
correlations, with the statistically significant results shown in Table 44.  The only 
significant correlation with age found in the children with autism was for ATEC I.  The 
children with autism tended to increase their ATEC I score as they get older with an r = 
0.37 and a p-value of 0.045 (Figure 72).  This increase in ATEC I score with age was not 
seen in the control children as they nearly all scored the highest possible score of 28 
independent of their age. 
Table 44:  The significant results of the rating scale results correlating with age along with the r 
and p-values for each group. 
Rating Scale Subscale 
Control Autism 
r p-value r p-value 
ATEC I 0.25 0.18 0.37 0.045 
PDDBI 
Autism Composite 0.39 0.035 0.045 0.81 
Approach/Withdrawal Problems 
RITUAL - 0.45 0.013 0.0013 0.99 
SOCPP - 0.78 4.5 × 10
-7
 - 0.015 0.94 
SEMPP - 0.82 3.5 × 10
-8
 0.087 0.65 
REPRIT/C - 0.63 1.7 × 10
-4
 0.073 0.70 
Receptive/Expressive Social Communication Abilities 
SOCAPP - 0.77 8.2 × 10
-7
 - 0.008 0.97 
EXPRESS - 0.85 1.9 × 10
-9
 - 0.059 0.75 
LMRL - 0.95 2 × 10
-15
 - 0.086 0.65 
EXSCA/C - 0.88 2.4 × 10
-10
 - 0.015 0.94 
REXSCA/C - 0.89 7.6 × 10
-11
 - 0.035 0.85 
The statistically significant findings are bolded. 
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Figure 72:  The age correlation for ATEC I for the control and autism groups.  The children with 
autism demonstrated a significant positive correlation with age with an r value of 0.37 and a p-
value of 0.045.  The control children had a non-significant p-value of 0.18 with r = 0.25. 
6.3.4.1.2 Control Group 
The age correlation produced many significant findings associated with the 
PDDBI behavioral rating scale in the control group.  The overall Autism Composite of 
the PDDBI was found to be significantly positively correlated with age in the control 
children with a correlation of 0.39 and a p-value of 0.035, while the children with autism 
had a p-value of 0.81 and an r of 0.045 (Figure 73).  In addition to the Autism Composite, 
some of the maladaptive behaviors measured on the AWP dimension produced 
significant correlations with age.  The results for the SEMPP domain are shown in Figure 
74, with a significant negative correlation with age seen in the control group (r = - 0.82, 
p-value = 3.5 × 10
-8
) and not in the children with autism (r = 0.087, p-value = 0.65).  The 
SOCPP domain also saw a significant negative correlation with age in the control 
children.  The control children had an r of - 0.78 with a p-value of 4.5 × 10
-7
, while the r 
was - 0.015 with a p-value of 0.94 for the children with autism (Figure 75).  Figure 76 
shows the age correlation for the RITUAL domain, with the control children having an r 
of - 0.45 with a p-value of 0.013 and the children with autism having an r of 0.0013 and a 
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p-value of 0.99.  In addition to the AWP domains that produced significant correlations, 
the REPRIT/C composite yielded a significant age correlation in the control children (r = 
- 0.63, p-value = 1.7 × 10
-4
) that was absent in the children with autism (r = 0.073, p-
value 0.70), seen in Figure 77. 
 
Figure 73:  The age correlation results for the Autism Composite of the PBBDI for children with 
autism and controls.  The control group had a significant positive correlation of age with r = 0.39 
and a p-value of 0.035, while the children with autism had a p-value of 0.81 and an r of 0.045. 
 
Figure 74:  The control children demonstrated a significant negative correlation with age (r = - 
0.82, p-value = 3.5 × 10
-8
) for the SEMPP domain of the PDDBI while the children with autism 
did not produce a significant correlation (r = 0.087, p-value = 0.65). 
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Figure 75:  The age correlation for the SOCPP domain of the PDDBI for children with autism 
and controls.  The control children had a significant negative correlation with age (r = - 0.78, p-
value = 4.5 × 10
-7
).  The children with autism did not show a significant correlation with age with 
r = - 0.015 and a p-value of 0.94. 
 
Figure 76:  The age correlation for the RITUAL domain of the PDDBI for children with autism 
and controls.  The control children had a significant negative correlation with age with r = - 0.45 
and a p-value of 0.013, while the results from children with autism did not correlate significantly 
with age with r = 0.0013 and a p-value of 0.99. 
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Figure 77:  For the REPRIT/C composite of the PDDBI, the control children produced a 
significant negative age correlation with r = - 0.63 and a p-value equal to 1.7 × 10
-4
.  The results 
for the children with autism were not significant with r = 0.073 and a p-value of 0.70. 
Additional significant correlations with age were found for the REXSCA 
dimension.  All of the REXSCA domains and composites produced negative age 
correlations in the control children.  The most significant domain was LMRL (Figure 78), 
with a significant negative correlation with age seen in the control group (r = - 0.95, p-
value = 2 × 10
-15
) and not in the children with autism (r = - 0.086, p-value = 0.65).  The 
EXPRESS domain also saw a significant negative correlation with the age in the control 
children.  The control children had an r of - 0.85 with a p-value of 1.9 × 10
-9
, while the r 
was - 0.059 with a p-value of 0.75 for the children with autism (Figure 79).  The final 
significant domain finding was for SOCAPP, with the control children having an r of - 
0.77 with a p-value of 8.2 × 10
-7
 and the children with autism having an r of - 0.008 with 
a p-value of 0.97 (Figure 80).  In addition to the REXSCA domains that yielded 
significant correlations, both composites produced significant correlations.  The 
REXSCA/C saw a negative correlation in the control children (r = - 0.89, p-value = 7.6 × 
10
-11
) that was not present in the children with autism (r = - 0.035, p-value = 0.85) seen in 
Figure 81.  The EXSCA/C results are shown in Figure 82, with a significant negative 
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correlation with age seen in the control group with an r of - 0.88 and a p-value of 2.4 × 
10
-10
 and not in the children with autism who had an r of - 0.015 and a p-value of 0.94. 
 
Figure 78:  The control children demonstrated a significant negative correlation with age (r = - 
0.95, p-value = 2 × 10
-15
) for the LMRL domain of the PDDBI, while the children with autism did 
not produce a significant correlation (r = - 0.086, p-value = 0.65). 
 
Figure 79:  The age correlation for the EXPRESS domain of the PDDBI for children with autism 
and controls.  The control children had a significant negative correlation with age (r = - 0.85, p-
value = 1.9 × 10
-9
).  The children with autism did not show a significant correlation with age with 
r = - 0.059 and a p-value of 0.75. 
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Figure 80:  The age correlation for the SOCAPP domain of the PDDBI for children with autism 
and controls.  The control children had a significant negative correlation with age with r = - 0.77 
and a p-value of 2 × 10
-15
 while the results from children with autism did not correlate 
significantly with age with r = - 0.0008 and a p-value of 0.97. 
 
Figure 81:  The age correlation for the REXSCA/C composite of the PDDBI for children with 
autism and controls.  The control children had a significant negative correlation with age with r = 
- 0.89 and a p-value of 7.6 × 10
-11
, while the results from children with autism did not correlate 
significantly with age with r = - 0.035 and a p-value of 0.85. 
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Figure 82:  For the EXSCA/C composite of the PDDBI, the control children produced a 
significant negative correlation with age with r = - 0.88 and a p-value equal to 2.4 × 10
-10
.  The 
results for the children with autism were not significant with r = - 0.015 and a p-value of 0.94. 
6.3.4.2 Elemental Analysis of Blood 
6.3.4.2.1 Autism Group 
The elemental analysis results of blood were the next group of variables 
investigated for age correlations.  The statistically significant positive and negative 
results are listed in Table 45.  Four elements in blood were determined to have significant 
correlations with age in the children with autism.  The most significant finding was for 
Zn in RBCs using EPA Method 6020B (Figure 83).  The children with autism had a 
correlation of 0.46 and a p-value of 0.0097, while the control children had an r = 0.24 and 
a p-value of 0.20.  The age correlation for RBC Se by EPA Method 6020B for the 
children with autism was r = 0.42 with a p-value of 0.023, whereas the control children 
had r = 0.20 and a p-value equal to 0.28 (Figure 84).  Serum Fe by EPA Method 6800 
was found to significantly negatively correlate with age as the children with autism 
having an r = - 0.38 and a p-value = 0.036 and the control children having a correlation 
value of - 0.20 and a p-value of 0.29 (Figure 85).  The final significant correlation was 
plasma Se by EPA Method 6020B seen in Figure 86.  The children with autism had a 
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significant positive age correlation of 0.36 and a p-value of 0.050 and the control children 
had r = 0.16 and a p-value of 0.41. 
Table 45:  The significant results of the elemental blood concentrations correlating with age 
along with the r and p-values for each group. 
Variable 
Control Autism 
r P-Value r P-Value 
EPA Method 6020B RBC Zn 0.24 0.20 0.46 0.0097 
EPA Method 6020B RBC Se 0.20 0.28 0.42 0.023 
EPA Method 6800 Serum Fe - 0.20 0.29 - 0.38 0.036 
EPA Method 6020B Plasma Se 0.16 0.41 0.36 0.050 
EPA Method 6020B Serum Cu - 0.46 0.011 0.044 0.81 
EPA Method 6020B Plasma Cu - 0.44 0.015 0.10 0.58 
EPA Method 6020B RBC Cu - 0.40 0.030 0.10 0.59 
EPA Method 6020B Serum Mo - 0.40 0.030 - 0.22 0.25 
EPA Method 6800 Plasma Cu - 0.43 0.018 0.047 0.80 
EPA Method 6800 RBC Zn 0.41 0.023 0.25 0.18 
EPA Method 6800 Serum Mo - 0.39 0.032 - 0.22 0.25 
EPA Method 6800 Serum Cu - 0.38 0.037 0.025 0.90 
The statistically significant findings are bolded. 
 
Figure 83:  The age correlation for red blood cell zinc by EPA Method 6020B for children with 
autism and controls.  The children with autism had a significant positive correlation with age with 
r = 0.46 and a p-value of 0.0097, while the results from children with autism did not significantly 
correlate with age with r = 0.24 and a p-value of 0.20. 
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Figure 84:  The correlation with age for red blood cell selenium by EPA Method 6020B for 
children with autism and controls.  The children with autism had a significant positive correlation 
with age (r = 0.42, p-value = 0.023).  The control children did not show a significant correlation 
with age with r = 0.20 and a p-value of 0.28. 
 
Figure 85:  The children with autism demonstrated a significant negative correlation with age (r 
= - 0.38, p-value = 0.036) for serum iron by EPA Method 6800, while the control children did not 
produce a significant correlation (r = - 0.20, p-value = 0.29). 
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Figure 86:  For plasma selenium by EPA Method 6020B, the children with autism produced a 
significant positive correlation with age with r = 0.36 and a p-value equal to 0.050.  The results 
for the control children were not significant with r = 0.16 and a p-value of 0.41. 
6.3.4.2.2 Control Group 
The EPA Method 6020B blood elemental results produced four significant age 
correlations in the control group.  The most significant finding was a negative correlation 
of serum Cu with age (Figure 87).  The control group’s correlation value was - 0.46 with 
a p-value of 0.011, while the children with autism had a correlation value of 0.044 and a 
p-value of 0.81.  The plasma Cu correlation for the control group was r = - 0.44 with a p-
value of 0.011, whereas the children with autism had an r = 0.044 and a p-value of 0.81 
(Figure 88).  Similar to serum and plasma, the RBC Cu concentrations were found to be 
significantly negatively correlated in the control children (r = - 0.40, p-value = 0.030), 
but not in the children with autism (r = 0.10, p-value = 0.59) seen in Figure 89.  The final 
significant finding by EPA Method 6020B was serum Mo (Figure 90).  The control 
children’s correlation value was - 0.40 and the p-value was 0.030, while the children with 
autism had a correlation value of - 0.22 and a p-value of 0.25. 
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Figure 87:  The age correlation for serum copper by EPA Method 6020B for children with 
autism and controls.  The control children had a significant negative correlation with age with r = 
- 0.46 and a p-value of 0.011, while the results from the control children did not significantly 
correlate with age with r = 0.044 and a p-value of 0.81. 
 
Figure 88:  The correlation with age for plasma copper by EPA Method 6020B for children with 
autism and controls.  The control children had a significant negative correlation with age (r = - 
0.44, p-value = 0.015).  The children with autism did not show a significant correlation with age 
with r = 0.10 and a p-value of 0.58. 
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Figure 89:  The control children demonstrated a significant negative correlation with age (r = - 
0.40, p-value = 0.030) for red blood cell copper by EPA Method 6020B, while the children with 
autism did not produce a significant correlation (r = 0.10, p-value = 0.59). 
 
 
Figure 90:  For serum molybdenum by EPA Method 6020B, the control children produced a 
significant negative correlation with age with r = - 0.40 and a p-value equal to 0.030.  The results 
for the children with autism were not significant with r = - 0.22 and a p-value of 0.25. 
Similar to EPA Method 6020B, the EPA Method 6800 results generated four 
significant age correlations in blood.  The most significant finding was a negative 
correlation with plasma Cu seen in Figure 91.  The control group’s correlation value was 
- 0.43 with a p-value of 0.011, whereas the children with autism had a correlation value 
of 0.047 and a p-value of 0.80.  The positive correlation value for RBC Zn in the control 
group was = 0.41 with a p-value of 0.023, while the children with autism had r = 0.25 and 
a p-value of 0.18 (Figure 92).  Serum Mo concentrations were found to be significantly 
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negatively correlated in the control children (r = - 0.39, p-value = 0.032), but not for the 
children with autism (r= - 0.22, p-value = 0.25) shown in Figure 93.  The final significant 
finding was for serum Cu (Figure 94).  The control children’s correlation with age was - 
0.38 and the p-value was 0.037, while the children with autism had a 0.025 correlation 
and a p-value of 0.90. 
 
Figure 91:  The age correlation for plasma copper by EPA Method 6800 for children with autism 
and controls.  The control children had a significant negative correlation with age with r = - 0.43 
and a p-value of 0.018, while the results from the control children did not significantly correlate 
with age with r = 0.047 and a p-value of 0.80. 
 
Figure 92:  The correlation with age for red blood cell zinc by EPA Method 6800 for children 
with autism and controls.  The control children had a significant positive correlation with age (r = 
0.41, p-value = 0.023).  The children with autism did not show a significant correlation with age 
with r = 0.25 and a p-value of 0.18. 
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Figure 93:  The control children demonstrated a significant negative correlation with age (r = - 
0.39, p-value = 0.032) for serum molybdenum by EPA Method 6800, while the children with 
autism did not produce a significant correlation (r = - 0.22, p-value = 0.25). 
 
Figure 94:  For serum copper by EPA Method 6800, the control children produced a significant 
negative correlation with age with r = - 0.38 and a p-value equal to 0.037.  The results for the 
children with autism were not significant with r = 0.025 and a p-value of 0.90. 
6.3.4.3 Elemental Analysis of Hair 
6.3.4.3.1 Autism Group 
The elemental analysis results in hair were also evaluated for age correlations.  
The significant age correlations with elements in hair are shown in Table 46.  The 
children with autism demonstrated four significant correlations with age.  The most 
significant one was for Zn with r = 0.54 and a p-value of 0.002, while the control children 
had r = 0.27 and a p-value of 0.15 (Figure 95).  The correlation for Mg was significant for 
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both the children with autism (r = 0.47, p-value = 0.0088) and controls (r = 0.43, p-value 
= 0.018) seen in Figure 96.  The Mo concentrations were found to have a significant 
negative correlation with age in the children with autism (r = - 0.42, p-value of 0.020), 
whereas the control children had non-significant results of r = - 0.026 and a p-value of 
0.89 (Figure 97).  The final significant finding was Sn shown in Figure 98.  The children 
with autism had a correlation with age of - 0.42 and a p-value of 0.021, while the control 
children had a - 0.25 correlation and a p-value of 0.19. 
Table 46:  The significant results of the elemental hair concentrations correlated with age with 
the r and p-values for each group. 
Element 
Control Autism 
r P-Value r P-Value 
Zn 0.27 0.15 0.54 0.002 
Mg 0.43 0.018 0.47 0.0088 
Mo - 0.026 0.89 - 0.42 0.020 
Sn - 0.25 0.19 - 0.42 0.021 
U 0.55 0.0016 - 0.033 0.86 
Cu 0.47 0.0086 0.36 0.048 
Ce 0.38 0.040 - 0.0056 0.98 
The statistically significant findings are bolded. 
The result for Cu in the autism group is not significant due to Cook’s distance 
assessment. 
 
 
Figure 95:  The age correlation for zinc in the hair of children with autism and controls.  The 
children with autism had a significant positive correlation with age with r = 0.54 and a p-value of 
0.002 while the results from the control children did not significantly correlate with age with r = 
0.27 and a p-value of 0.15. 
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Figure 96:  The correlation with age for hair magnesium for children with autism and controls.  
The positive correlation was significant for both the children with autism (r = 0.47, p-value = 
0.0088) and controls (r = 0.43, p-value = 0.018). 
 
Figure 97:  The children with autism demonstrated a significant negative correlation with age (r 
= - 0.42, p-value = 0.020) for molybdenum in the hair, while the control children did not produce 
a significant correlation (r = - 0.026, p-value = 0.89). 
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Figure 98:  For tin in the hair, the children with autism produced a significant negative 
correlation with age with r = - 0.42 and a p-value equal to 0.021.  The results for the control 
children were not significant with r = - 0.25 and a p-value of 0.19. 
6.3.4.3.2 Control Group 
The element that had the most significant correlation in the control children was 
U seen in Figure 99.  The control group’s correlation value was 0.55 with a p-value of 
0.0016, while the children with autism had a correlation of - 0.033 and a p-value of 0.86.  
The Cu correlation with age in the control group was 0.47 with a p-value of 0.0086, and 
the children with autism had results of r = 0.36 and a p-value of 0.048 (Figure 100).  
Although this p-value for the autism group is below the 0.05 cutoff, the correlation is 
driven by one nine year old child with a very high Cu concentration relative to all of the 
other children in the study.  A common way to measure the influence a data point has on 
the parameter estimates of a linear regression model is through the use of Cook's 
distance.
79
  If a data point is removed and the resulting parameter estimates change 
drastically, then the Cook's distance for this point will be large.  Recommended 
thresholds for identifying influential observations include a Cook's distance greater than 
4/n,
80
 where n is the number of data points or even a Cook's distance greater than 
1.
81
  The high Cu hair concentration for the nine year old child in the autistic group has a 
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Cook's distance of 1.8, which is reflective of a highly influential observation (the next 
highest Cook's distance is below 0.1).  Since the correlation between Cu hair and age for 
the autistic group is not significant (0.18) when this influential point is removed, the 
correlation between Cu hair and age for the autistic group will not be deemed significant.  
The final significant correlation was observed for Ce seen in Figure 101.  The control 
children’s correlation value was 0.38 with a p-value of 0.040, while the children with 
autism had a - 0.0056 correlation and a p-value of 0.98. 
 
Figure 99:  The age correlation for uranium in the hair of children with autism and controls.  The 
control children had a significant positive correlation with age with r = 0.55 and a p-value of 
0.0016, while the results from the children with autism did not significantly correlate with age 
significantly with r = - 0.033 and a p-value of 0.86. 
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Figure 100:  The control children demonstrated a significant positive correlation with age (r = 
0.47, p-value = 0.0086) for copper in the hair, while the children with autism did produce a 
significant correlation (r = 0.36, p-value = 0.048) which was driven by one child. 
 
Figure 101:  For cerium in the hair, the control children produced a significant positive 
correlation with age with r = 0.38 and a p-value equal to 0.040.  The results for the children with 
autism were not significant with r = - 0.0056 and a p-value of 0.98. 
6.3.4.4 Clinical Laboratory Testing 
6.3.4.4.1 Autism Group 
The clinical laboratory testing results were the final group of variables 
investigated for age correlations.  The statistically significant positive and negative 
results are listed in Table 47.  Four variables produced significant positive correlations 
with age in the children with autism.  The most significant positive correlation with age 
in children with autism was for IgG seen in Figure 102.  The children with autism had an 
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r of 0.52 with a p-value of 0.003, while the control children had a correlation of 0.33 and 
a p-value of 0.072.  The neutrophil percent was also significant in the children with 
autism (r = 0.48, p-value of 0.0079), but not in the control children (r = 0.36 and a p-
value of 0.053) shown in Figure 103.  The children with autism had a significant 
correlation with age for casein IgG seen in Figure 104.  The children with autism had an r 
of 0.47 and a p-value = 0.009 and the control children had an r of 0.11 and a p-value of 
0.55.  The final significant positive correlation with age in children with autism was IgA 
(Figure 105).  Both the children with autism (r = 0.40, p-value = 0.029) and the control 
children (r = 0.46, p-value = 0.011) produced significant positive age correlations with 
IgA. 
Table 47:  The significant results of the clinical laboratory testing correlated with age with the r 
and p-values for each group. 
 Control Autism 
Variable r p-value r p-value 
IgG 0.33 0.072 0.52 0.003 
Neutrophil Percent 0.36 0.053 0.48 0.0079 
Casein IgG 0.11 0.55 0.47 0.009 
IgA 0.46 0.011 0.40 0.029 
CD19 Number - 0.57 0.0011 - 0.64 0.0001 
Lymphocytes (subset) - 0.48 0.0078 - 0.50 0.0052 
Lymphocytes (CBC) - 0.46 0.010 - 0.48 0.0067 
Lymphocyte Percent - 0.39 0.033 - 0.48 0.0067 
CD4 Number - 0.28 0.13 - 0.47 0.0092 
CD19 Percent - 0.57 0.0011 - 0.46 0.011 
CD3 Number - 0.37 0.043 - 0.42 0.021 
AST - 0.41 0.025 - 0.38 0.036 
MCV 0.50 0.0049 0.088 0.64 
CD3 Percent 0.47 0.0091 0.12 0.52 
CD4 Percent 0.40 0.029 0.12 0.52 
Percent Iron Saturation 0.39 0.033 - 0.24 0.19 
Serum Copper - 0.45 0.013 - 0.012 0.95 
The statistically significant findings are bolded. 
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Figure 102:  The age correlation for IgG of children with autism and controls.  The children with 
autism had a significant positive correlation with age with r = 0.52 and a p-value of 0.003, while 
the results from the control children did not correlate with age significantly with r = 0.33 and a p-
value of 0.072. 
 
Figure 103:  For neutrophil percent, the children with autism produced a significant positive 
correlation with age with r = 0.48 and a p-value equal to 0.0079.  The results for the control 
children were nearly significant with r = 0.36 and a p-value of 0.053. 
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Figure 104:  The correlation with age for casein IgG for children with autism and controls.  The 
children with autism demonstrated a significant positive correlation with r = 0.47 and a p-value of 
0.009 while the control children did not produce a significant correlation with r = 0.11 and p-
value of 0.55. 
 
Figure 105:  The children with autism demonstrated a significant positive correlation with age (r 
= 0.40, p-value = 0.029) for IgA while the control children also produced a significant correlation 
(r = 0.46, p-value = 0.011). 
In addition to the positive correlations, eight negative correlations with age were 
observed in the children with autism from the clinical laboratory testing.  The most 
significant negative correlation with age was for the CD19 number seen in Figure 106.  
The children with autism had an r of - 0.64 with a p-value of 0.0001, and the control 
children also had a significant negative correlation with age with an r of - 0.57 and a p-
value of 0.0011.  The lymphocytes had a negative age correlation from the both the 
lymphocyte subset and the CBC (Figures 107 and 108).  From the lymphocyte subset, the 
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children with autism had an r of - 0.50 and a p-value of 0.0052, and the control children 
also had a significant negative correlation with age with an r of - 0.48 and a p-value of 
0.0078.  The lymphocytes measured as a part of the CBC were also negatively correlated 
with age for both the children with autism (r = - 0.48, p-value = 0.0067) and controls (r = 
- 0.46, p-value = 0.010).  The children with autism (r = - 0.48, p-value = 0.0067) and 
control children (r = - 0.39, p-value = 0.033) both produced significant negative 
correlations with age for lymphocyte percent seen in Figure 109.  The CD4 number was 
found to be significantly negatively correlated with age in both groups of children (Figure 
110).  The children with autism had an r of - 0.47 and a p-value of 0.0092, while the 
control children’s r was - 0.28 with a p-value of 0.13.  The age correlation with CD19 
percent for children with autism and controls was also found to be significant (Figure 
111).  The children with autism had an r of - 0.46 and a p-value of 0.011 and the control 
children had r = - 0.57 and a p-value equal to 0.0011.  CD3 number was also significantly 
negatively correlated with age in both the children with autism and controls (Figure 112).  
The values for the children with autism were r = - 0.42 and p-value = 0.021, while the 
controls had values of r = - 0.37 and p-value = 0.037.  The AST correlation was the last 
significant finding negatively correlating with age (Figure 113).  The children with 
autism had a significant negative correlation (r= - 0.38, p-value = 0.036), while the 
control children also had a significant negative correlation (r = - 0.41, p-value = 0.025). 
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Figure 106:  The age correlation for the CD19 number for children with autism and controls.  
The control children had a significant negative correlation with age with r = - 0.64 and a p-value 
of 0.0001, while the results from the control children also did negatively correlate with age 
significantly with r = - 0.57 and a p-value of 0.0011. 
 
Figure 107:  Both the children with autism (r = - 0.50, p-value = 0.0052) and control children (r 
= - 0.48, p-value = 0.0078) demonstrated a significant negative correlation with age for 
lymphocytes from the lymphocyte subset. 
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Figure 108:  The correlation with age for lymphocytes from the CBC for children with autism 
and controls.  The children with autism had a significant negative correlation with age (r = - 0.48, 
p-value = 0.0067).  The control children also did show a significant correlation with age with r = - 
0.46 and a p-value of 0.010. 
 
Figure 109:  For lymphocyte percent, the children with autism produced a significant negative 
correlation with age with r = - 0.48 and a p-value equal to 0.0067.  The results for the control 
children were also significant with r = - 0.39 and a p-value of 0.033. 
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Figure 110:  The age correlation for the CD4 number for children with autism and controls.  The 
control children had a significant negative correlation with age with r = - 0.47 and a p-value of 
0.0092, while the results from the control children did not correlate with age significantly with r = 
- 0.28 and a p-value of 0.13. 
 
Figure 111:  Both the children with autism (r = - 0.46, p-value = 0.011) and control children (r = 
- 0.57, p-value = 0.0011) demonstrated a significant negative correlation with age for CD19 
percent. 
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Figure 112:  The correlation with age for CD3 number for children with autism and controls.  
The children with autism had a significant negative correlation with age (r = - 0.42, p-value = 
0.021).  The control children also did show a significant negative correlation with age with r = - 
0.37 and a p-value of 0.043. 
 
Figure 113:  For AST, the children with autism produced a significant negative correlation with 
age with r = - 0.38 and a p-value equal to 0.036.  The results for the control children were also 
significant with r = - 0.41 and a p-value of 0.025. 
6.3.4.4.2 Control Group 
The clinical laboratory testing also produced four positive and one negative 
significant age correlations that were unique to the control group.  The most significant 
positive correlation of clinical variables in the control group was MCV (Figure 114).  The 
control children had an r of 0.50 with a p-value of 0.0049, while the children with autism 
had a correlation of 0.088 with a p-value of 0.64.  The age correlation for CD3 percent 
was significant for the controls (r = 0.47, p-value = 0.0091), but not for the children with 
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autism (r = 0.12, p-value = 0.52) seen in Figure 115.  The CD4 percent was also 
significantly positively correlated with age in the control children (r = 0.40, p-value = 
0.029), while the children with autism did not (r = 0.12, p-value = 0.52) as shown in 
Figure 116.  The final significant positive correlation with age in the control children was 
percent iron saturation (Figure 117).  The control children had a significant positive 
correlation with age (r = 0.39, p-value = 0.33), but the children with autism did not (r = - 
0.24, p-value = 0.19).  The only negative significant correlation with age observed in the 
control group was for commercial clinical laboratory serum copper (Figure 118).  The 
control group had an r of - 0.45 and a p-value of 0.013, while the children with autism 
had an r of - 0.012 with a p-value of 0.95. 
 
Figure 114:  The age correlation for MCV in children with autism and controls.  The control 
children had a significant positive correlation with age with r = 0.50 and a p-value of 0.0049 
while the results from the children with autism did not correlate significantly with age with r = 
0.088 and a p-value of 0.64. 
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Figure 115:  The correlation with age for CD3 percent for children with autism and controls.  
The positive correlation was significant for the control children (r = 0.47, p-value = 0.0091), but 
was not significant for children with autism (r = 0.12, p-value = 0.52). 
 
Figure 116:  The control children demonstrated a significant positive correlation with age (r = 
0.40, p-value = 0.029) for CD4 percent while the children with autism did not produce a 
significant correlation (r = 0.12, p-value = 0.52). 
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Figure 117:  For the percent saturation of iron, the control children produced a significant 
positive correlation with age with r = 0.39 and a p-value equal to 0.033.  The results for the 
children with autism were not significant with r = - 0.24 and a p-value of 0.19. 
 
Figure 118:  The age correlation for commercial clinical laboratory serum copper concentrations 
in children with autism and controls.  The control children had a significant negative correlation 
with age with r = - 0.45 and a p-value of 0.013 while the results from the children with autism did 
not correlate significantly with age with r = - 0.012 and a p-value of 0.95. 
6.3.5 Logistic Regression 
For all of the variables determined to be significant by the paired-samples t-test, 
logistic regression analysis was completed.  For each of the variables analyzed, a 1%, 
2%, and 3% prevalence of autism was used to determine the probability of an autism 
diagnosis for each statistically significant variable based on literature values. 
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6.3.5.1 Blood Elemental Logistic Regression Results 
For the elements in blood found to be statistically significant by the paired-
samples t-test, logistic regression analysis was performed.  In terms of diagnostic 
probability for a child with autism, the best indicator was for magnesium in plasma, 
serum, and RBCs.  The logistic regression analysis for plasma magnesium with a p-value 
of 0.0018 is seen in Figure 119.  For the highest concentration value found in this study, 
the diagnosis probability exceeds 40% using a 1% assumed prevalence, while a 60% 
likelihood is achieved based on the 3% frequency.  For serum magnesium, the logistic 
regression analysis is shown in Figure 120 with a p-value of 0.0020.  The diagnostic 
probabilities for serum magnesium are not as high as the plasma magnesium values, but 
for the greatest observed value they do reach over 20% for the 1% prevalence and 40% 
for the 3% prevalence.  For RBC magnesium, the p-value was 0.0085 for the logistic 
regression analysis seen in Figure 121 while the 1% prevalence reaches probabilities 
greater than 10% and the 3% prevalence approaches 30%.  The red blood cell iron 
concentration logistic regression is illustrated in Figure 122 with a p-value of 0.043.  
Compared to the magnesium logistic regression analysis curves, the diagnostic 
probabilities are not as clear for the red blood cell iron, but the autism possibility is 
greater than 5% based on a 1% prevalence and reaches nearly 15% with a 3% prevalence. 
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Figure 119:  Logistic regression results for plasma magnesium versus autism diagnosis 
probability for a 1%, 2%, and 3% prevalence of autism (p-value = 0.0018). 
 
Figure 120:  For 30 pairs of children, the serum magnesium logistic regression analysis with 1%, 
2%, and 3% autism prevalence (p-value = 0.0020). 
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Figure 121:  Logistic regression results for red blood cell magnesium versus autism diagnosis 
probability for a 1%, 2%, and 3% prevalence of autism (p-value = 0.0085). 
 
Figure 122:  For 30 pairs of children, the red blood cell iron logistic regression analysis with 1%, 
2%, and 3% autism prevalence (p-value = 0.043). 
6.3.5.2 Clinical Laboratory Testing 
After completing the logistic regression analysis for all of the significant variables 
from the clinical laboratory testing, the two best indicators of diagnosing a child with 
autism are natural killer cell number and percent.  For the highest natural killer cell 
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number value, the diagnostic probability of autism rises as high as 40% assuming only a 
1% prevalence of autism and this value reaches over 60% when assuming a 3% autism 
frequency as seen in Figure 123.  The diagnosis probability is similar for natural killer 
cell percent as it approaches 20% with a 1% prevalence and is over 40% with a 3% 
occurrence for the highest observed value shown in Figure 124.  The logistic regression 
curves for both lymphocyte measurements are presented in Figures 125 and 126.  They 
both approach 20% with a 3% autism prevalence.  The logistic regression curves for CD3 
number and CD4 number are seen in Figure 127 and 128.  For CD3 number, the 
diagnostic probability exceeds 20% for the highest values seen in the study with a 3% 
prevalence and 10% with a 1% prevalence.  The diagnostic probability is as high as 10% 
assuming a 3% prevalence for CD4 number and over 5% with a 1% prevalence.  
Indicators of loss of immune tolerance markers of white blood cells, and anti-gluten IgG 
antibodies, and platelets are seen in Figures 129-131.  White blood cells were the best 
immune tolerance indicator as the diagnostic probability reached over 60% with a 3% 
prevalence and nearly 40% with a 1% prevalence.  The IgG gluten antibodies produced 
results that showed nearly a 20% diagnostic probability with a 1% prevalence and a 40% 
diagnostic probability with a 3% prevalence.  For the highest values in the study, the 
platelets had nearly a 20% diagnostic probability with a 3% prevalence and 10% with a 
1% prevalence.  The logistic regression for methylmalonic acid is seen in Figure 132. The 
diagnostic probability reaches 100% for the highest value for a child with autism in the 
study.  For the next highest value, the diagnostic probability is over 50% for a 3% 
prevalence and almost 25% for a 1% prevalence. 
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Figure 123:  Logistic regression results for natural killer cell number versus autism diagnosis 
probability for a 1%, 2%, and 3% prevalence of autism (p-value = 0.0030). 
 
Figure 124:  For 30 pairs of children, the natural killer cell percent logistic regression analysis 
with 1%, 2%, and 3% autism prevalence (p-value = 0.015). 
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Figure 125:  From the lymphocyte subset panel, the logistic regression analysis for a 1%, 2%, 
and 3% prevalence of autism (p-value = 0.010). 
 
Figure 126:  With a p-value of 0.016, the logistic regression, with 1%, 2%, and 3% autism 
prevalence, of lymphocytes from the complete blood count was significant. 
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Figure 127:  The logistic regression of CD3 number assuming a 1%, 2%, and 3% prevalence of 
autism (p-value = 0.010). 
 
Figure 128:  For the 30 pairs of children analyzed, the logistic regression of CD4 number with 
1%, 2%, and 3% autism prevalence (p-value = 0.012). 
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Figure 129:  With a p-value of 0.015, the logistic regression of white blood cells was significant 
and shown with 1%, 2%, and 3% autism prevalence. 
 
Figure 130:  For the 30 pairs of children analyzed, the logistic regression of gluten IgG with 1%, 
2%, and 3% autism prevalence (p-value = 0.027). 
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Figure 131:  The logistic regression of the platelet count assuming a 1%, 2%, and 3% prevalence 
of autism (p-value = 0.046). 
 
Figure 132:  With a p-value of 0.0037, the logistic regression of methylmalonic acid was 
significant and shown with 1%, 2%, and 3% autism prevalence. 
6.3.6 Comparison of Commercial Clinical Laboratory and Analytical 
Testing Methods 
 Due to the results from the sleeping cleanroom study, a further comparison of the 
three different testing methods was completed for selected analytes.  SRM 1598a was 
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tested for copper, iron, selenium, and zinc by three different testing methods:  
commercial clinical laboratory, EPA Method 6020B, and EPA Method 6800.  SRM 
1598a is a standard with known quantities and is traceable to NIST.  A comparison of the 
results from the commercial clinical laboratory to the certified results is shown in Figure 
133.  For copper, the commercial clinical laboratory results were 13.9% below the mean 
value for SRM 1598a and 8.7% below the lower bound of uncertainty.  The commercial 
clinical laboratory results for iron were 27.4% under the mean SRM 1598a value and 
24.7% under the lower bound of uncertainty.  For selenium, the commercial clinical 
laboratory results were 20.5% above the mean value for SRM 1598a and 16.2% above 
the upper bound of uncertainty.  The commercial clinical laboratory results for zinc were 
14.8% below the mean SRM 1598a value and 12.4% below the lower bound of 
uncertainty.  For all of the commercial clinical laboratory results, only a mean value is 
provided without a confidence interval because only one measurement is performed. 
 This shortcoming of the commercial clinical results is not seen with the results 
from EPA Method 6020B or EPA Method 6800.  Both EPA Methods 6020B and 6800 
provide 95% confidence intervals because their results are based on multiple 
measurements, and in this study they are based on 12 total measurements from three 
independently prepared subsamples.  Results from the three different testing methods for 
SRM 1598a are shown in Table 48 and Figure 134.  For all four elements tested, the 
results from both EPA Method 6020B and EPA Method 6800 are within the bounds of 
uncertainty for all four elements.  Based on these data, the results from both EPA Method 
6020B and EPA Method 6800 are more accurate than the commercial clinical results 
along with providing precision through the use of confidence intervals.  These results for 
  
 418 
SRM 1598a provided the foundation of a further investigation comparing the different 
testing methods.  This investigation looked specifically at plasma zinc, serum copper, the 
plasma zinc/serum copper ratio, and serum selenium with the three testing methods 
compared against each other for these four variables. 
 
Figure 133:  Results for SRM 1598a from the commercial clinical laboratory for copper, iron, 
selenium, and zinc.  The certified SRM 1598a values are shown with a coverage factor of 2, 
approximating the 95% confidence intervals.  The commercial clinical laboratory results do not 
provide confidence intervals. 
Table 48:  Concentrations (ng g
-1
) of the elements determined in SRM 1598a by the commercial 
clinical laboratory, EPA Method 6020B, and EPA Method 6800.  The EPA Method 6020B and 
EPA Method 6800 results are shown with n = 12 and 95% CIs. 
Element 
Certified 
Value (ng g
-1
) 
Commercial Clinical 
Laboratory (ng g
-1
) 
EPA Method 
6020B (ng g
-1
) 
EPA Method 
6800 (ng g
-1
) 
Serum Copper 1,538 ± 88 1324 1,567 ± 17 1,622 ± 11 
Serum Iron 1,635 ± 58 1187 1,874 ± 235 1,614 ± 10 
Serum Selenium 130.8 ± 5.6 158 124.9 ± 2.7 131.1 ± 3.8 
Plasma Zinc 857 ± 23 730 888.5 ± 16.3 879.7 ± 8.0 
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Figure 134:  SRM 1598a results for copper, iron, selenium, and zinc from the commercial 
clinical laboratory, EPA Method 6020B, and EPA Method 6800.  The certified SRM 1598a 
values are shown with a coverage factor of 2, approximating the 95% confidence intervals.  No 
confidence intervals are provided with commercial clinical laboratory results.  The measurements 
from EPA Methods 6020B and 6800 are with n = 12 and 95% CIs.   
6.3.6.1 Commercial Clinical Laboratory Versus EPA Method 6020B 
The commercial clinical laboratory and EPA Method 6020B were compared first.  
For plasma zinc, the commercial clinical laboratory results were an average of 10.3% 
below the EPA Method 6020B measurements with a 95% CI of 7.0 to 13.6% below 
(Figures 135 and 136).  The correlation for these measurements is r = 0.72, which is 
significantly greater than zero (p-value of 4.1 × 10
-6
).  As expected, these results were 
significantly correlated, yet there was a consistent low-bias observed in the commercial 
clinical laboratory results. 
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Figure 135:  The plasma zinc concentrations from the commercial clinical laboratory and EPA 
Method 6020B.  The plot demonstrates the strong correlation between the measurement 
techniques (r = 0.72, p-value = 4.1 × 10
-6
). 
 
Figure 136:  A histogram of the relative percent difference of plasma zinc concentrations of the 
commercial clinical laboratory to EPA Method 6020B.  The commercial clinical laboratory 
results were an average of 10.3% lower than the EPA Method 6020B results with a 95% CI 
ranging from 7.0 to 13.6% below (p-value = 4.3 × 10
-8
). 
The comparison of the results was similar for serum copper.  In the samples, the 
commercial clinical laboratory results were an average of 9.8% below the EPA Method 
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6020 with a 95% CI ranging from 6.7 to 12.9% below (Figures 137 and 138).  The results 
have a significant positive correlation of r = 0.81 (p-value of 2.3 × 10
-8
). 
 
Figure 137:  A comparison of serum copper results from the commercial clinical laboratory and 
EPA Method 6020B.  With a correlation value of r = 0.81, the plot shows the strong correlation 
between the measurement techniques (p-value = 2.3 × 10
-8
). 
 
Figure 138:  The relative percent difference of serum copper concentrations from the commercial 
clinical laboratory compared to EPA Method 6020B.  The histogram illustrates the commercial 
clinical results (p-value = 2.9 × 10
-8
) for serum copper being an average of 9.8% less than the 
EPA Method 6020B results (95% CI - 6.7 to 12.9% below). 
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While the commercial clinical laboratory results for both the plasma zinc and 
serum copper were on average 10.3% and 9.8% below the EPA Method 6020B results, 
respectively, the plasma zinc/serum copper ratio results did not illustrate this bias.  A 
significant positive correlation was seen between the testing methods (r = 0.77, p-value of 
2.9 × 10
-7
).  The average commercial clinical laboratory result was 0.5% higher than the 
corresponding EPA Method 6020B measurement with the 95% CI ranging from 3.8% 
below to 4.7% above (Figures 139 and 140).  This interval contains zero, indicating no 
statistically significant difference between the two measurement techniques for this 
variable. 
 
Figure 139:  The plasma zinc/serum copper ratios from the commercial clinical laboratory and 
EPA Method 6020B.  The plot illustrates the significant positive correlation between the 
measurement techniques (r = 0.77, p-value = 2.9 × 10
-7
). 
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Figure 140:  A histogram of the relative percent difference of plasma zinc/serum copper ratios of 
the commercial clinical laboratory to EPA Method 6020B.  The commercial clinical laboratory 
results were an average of 0.5% greater than the EPA Method 6020B results with a 95% CI 
between 3.8 below to 4.7% above (p-value = 0.83). 
When comparing the results from the commercial clinical laboratory and EPA 
Method 6020B for serum selenium, the results are similar to what was observed for SRM 
1598a.  The commercial clinical laboratory results were an average of 6.6% greater than 
the EPA Method 6020B results with a 95% CI from 3.2 to 10.0% (Figures 141 and 142).  
The correlation is significantly greater than zero (r = 0.68, p-value = 2.0 × 10
-5
). 
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Figure 141:  The serum selenium concentrations comparing commercial clinical laboratory and 
EPA Method 6020B results.  With a correlation value of r = 0.68, the plot shows the strong 
correlation between the measurement techniques (p-value = 2.0 × 10
-5
). 
 
Figure 142:  The relative percent difference of serum selenium concentrations from the 
commercial clinical laboratory compared to EPA Method 6020B.  The histogram illustrates the 
commercial clinical results (p-value = 2.4 × 10
-4
) for serum selenium being an average of 6.6% 
more than the EPA Method 6020B results (95% CI-3.2 to 10.0%). 
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6.3.6.2 Commercial Clinical Laboratory Versus EPA Method 6800 
A second comparison of results was completed between the commercial clinical 
laboratory and EPA Method 6800.  The commercial clinical laboratory results for plasma 
zinc were an average of 8.7% under the values from EPA Method 6800 (Figures 143 and 
144).  The 95% CI ranged from 6.3 to 11.1% below the EPA Method 6800 values.  The 
results had a correlation of r = 0.83, which is significantly greater than zero (p-value of 
6.2 × 10
-9
).  As with the comparison between the commercial clinical laboratory and EPA 
Method 6020B, the commercial clinical laboratory results demonstrated a consistent low 
bias. 
 
Figure 143:  The plasma zinc concentrations from the commercial clinical laboratory and EPA 
Method 6800.  The plot demonstrates the significant positive correlation between the 
measurement techniques (r = 0.83, p-value = 6.2 × 10
-9
). 
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Figure 144:  A histogram of the relative percent difference of plasma zinc concentrations of the 
commercial clinical laboratory to EPA Method 6800.  The commercial clinical laboratory results 
were an average of 8.7% lower than the EPA Method 6800 results with a 95% CI between 6.3 to 
11.1% lower (p-value of 9.0 × 10
-10
).   
The results for the comparison of serum copper for the commercial clinical 
laboratory were an average of 6.1% below the EPA Method 6800 results (Figure 145 and 
146).  The 95% CI spans from 3.2 to 9.0% lower than the EPA Method 6800 results with 
a significant positive correlation of r = 0.82 and a p-value of 1.4 × 10
-8
. 
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Figure 145:  A comparison of serum copper results from the commercial clinical laboratory and 
EPA Method 6800.  With a correlation value of r = 0.82, the plot displays the strong correlation 
between the measurement techniques (p-value = 1.4 × 10
-8
). 
 
Figure 146:  A comparison of serum copper results from the commercial clinical laboratory and 
EPA Method 6800.  With a 95% CI between 3.2 and 9.0% lower, the commercial clinical 
laboratory results are an average of 6.1% below the EPA Method 6800 results (p-value = 8.1 × 
10
-5
). 
The comparison of the plasma zinc/serum copper ratios for the commercial 
clinical laboratory and EPA Method 6800 were very similar to the comparison between 
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the commercial clinical laboratory and EPA Method 6020B.  The commercial clinical 
laboratory results were an average of 2.0% lower than the EPA Method 6800 results 
(Figures 147 and 148).  However, the 95% CI overlaps zero, spanning from 4.7% below 
to 0.7% above, which indicates no significant difference between the measurement 
techniques for the plasma zinc/serum copper ratio.  The correlation for the results was r = 
0.91 and they had a p-value of 2.1 × 10
-12
. 
 
Figure 147:  The plasma zinc/serum copper ratios from the commercial clinical laboratory and 
EPA Method 6800.  The plot illustrates the significant positive correlation between the 
measurement techniques (r = 0.91, p-value = 2.1 × 10
-12
). 
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Figure 148:  A histogram of the relative percent difference of plasma zinc/serum copper ratios of 
the commercial clinical laboratory to EPA Method 6800.  The commercial clinical laboratory 
results (p-value = 0.14) were an average of 2.0% lesser than the EPA Method 6800 results (95% 
CI-4.7% less than to 0.7% greater than). 
Figures 149 and 150 illustrate the results comparing the commercial clinical 
laboratory and EPA Method 6800 results for serum selenium.  The commercial clinical 
laboratory results for serum selenium were an average of 0.3% below the EPA Method 
6800 results.  The 95% CI ranged from 2.5% under to 1.9% above the EPA Method 6800 
values.  The results had a correlation of r = 0.72 and a p-value of 4.4 × 10
-6
. 
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Figure 149:  The serum selenium concentrations comparing commercial clinical laboratory and 
EPA Method 6800 results.  With a correlation value of r = 0.72, the plot shows the strong 
correlation between the measurement techniques (p-value = 4.4 × 10
-6
). 
 
Figure 150:  The relative percent difference of serum selenium concentrations from the 
commercial clinical laboratory compared to EPA Method 6800.  The histogram illustrates the 
commercial clinical results (p-value = 0.72) for serum selenium being an average of 0.3% less 
than the EPA Method 6800 results (95% CI-2.5% below to 1.9% above). 
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6.3.6.3 EPA Method 6020B Versus EPA Method 6800 
The final method comparison was completed for EPA Method 6020B and EPA 
Method 6800.  The plasma zinc concentrations for EPA Method 6020B were an average 
of 2.4% higher than the EPA Method 6800 results (Figures 151 and 152).  Unlike the 
comparisons between EPA Method 6020B and EPA Method 6800 with the commercial 
clinical laboratory, the 95% CI for plasma zinc nearly overlapped zero as it spanned from 
0.5 to 4.4% above the EPA Method 6800 values.  The results had a significant positive 
correlation of r = 0.89 and a p-value of 2.1 × 10
-11
. 
 
Figure 151:  The plasma zinc concentrations from EPA Method 6020B and EPA Method 6800.  
The plot demonstrates the significant positive correlation between the measurement techniques (r 
= 0.89, p-value = 2.1 × 10
-11
). 
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Figure 152:  A histogram of the relative percent difference of plasma zinc concentrations of EPA 
Method 6020B to EPA Method 6800.  The EPA Method 6020B results (p-value = 0.017) were an 
average of 2.4% higher than the EPA Method 6800 results (95% CI-0.5 to 4.4%). 
The serum copper comparison between EPA Method 6020B and EPA Method 
6800 was similar to the comparison for those methods for plasma zinc.  Compared to the 
EPA Method 6800 results, the EPA Method 6020B results were only an average of 4.8% 
higher with the 95% CI ranging from 2.2 to 7.4% above, close to containing zero (Figures 
153 and 154).  The results have a correlation of r = 0.89 and a p-value of 2.8 × 10
-11
. 
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Figure 153:  A comparison of serum copper results from EPA Method 6020B and EPA Method 
6800.  With a correlation value of r = 0.89, the plot displays the strong correlation between the 
measurement techniques (p-value = 4.4 × 10
-11
). 
 
Figure 154:  A comparison of serum copper results from EPA Method 6020B and EPA Method 
6800.  With a 95% CI between 2.2 and 7.4%, the EPA Method 6020B results are an average of 
4.8% above the EPA Method 6800 results (p-value = 5.4 × 10
-4
). 
The comparison of the EPA Method 6020B and EPA Method 6800 results for the 
plasma zinc/serum copper ratio saw that the EPA Method 6020B results were an average 
of 0.4% below the EPA Method 6800 results (Figures 155 and 156).  The 95% CI 
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spanned zero ranging from 4.8% below to 4.0% above the EPA Method 6800 results.  
With the interval containing zero, there is no significant statistical difference between the 
measurement techniques.  The results had a correlation of r = 0.84 and a p-value of 3.1 × 
10
-9
. 
 
Figure 155:  The plasma zinc/serum copper ratios from EPA Method 6020B and EPA Method 
6800.  The plot shows the significant positive correlation between the measurement techniques (r 
= 0.84, p-value = 2.1 × 10
-9
). 
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Figure 156:  A histogram of the relative percent difference of plasma zinc/serum copper ratios of 
EPA Method 6020B to EPA Method 6800.  The EPA Method 6020B results (p-value = 0.86) 
were an average of 0.4% less than the EPA Method 6800 results (95% CI-4.8% less than to 4.0% 
greater than). 
The final comparison performed between EPA Method 6020B and EPA Method 
6800 results was serum selenium.  The mean values of the EPA Method 6020B results 
were an average of 5.5% below the EPA Method 6800 results (Figures 157 and 158).  
The 95% CI ranged from 2.7 to 8.3% lower, close to containing zero.  The correlation is 
0.67 and the p-value is 2.9 × 10
-5
. 
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Figure 157:  The serum selenium concentrations comparing EPA Method 6020B and EPA 
Method 6800 results.  With a correlation value of r = 0.67, the plot displays the strong correlation 
between the measurement techniques (p-value = 2.9 × 10
-5
). 
 
Figure 158:  The relative percent difference of serum selenium concentrations from EPA Method 
6020B compared to EPA Method 6800.  The histogram illustrates the EPA Method 6020B results 
(p-value = 2.2 × 10
-4
) for serum selenium being an average of 5.5% less than the EPA Method 
6800 results (95% CI-2.7 to 8.3%). 
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6.4 Discussion 
(Note:  The findings in the discussion section are the professional opinion of Dr. 
Scott Faber, MD, developmental pediatrician at The Children’s Institute, as the attending 
physician and co-principle investigator at the time of publication and are subject to 
further data analysis and interpretation.  The executive summary which encompasses the 
findings of this study is shown in Appendix A.)
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Thirty children newly diagnosed with autism or PDD-NOS were compared to 30 
age, sex, and SES matched control children in this study of toxicity exposure, 
immunological functioning, markers of liver, kidney, and thyroid functioning.  The 
genetic testing eliminated the possibility of genetic contributions in autism diagnosis, and 
without genetic contributions, ASD diagnosis was completely confirmed by behavioral 
rating scales.  The behavioral rating scale results clearly demonstrated that the children 
with autism or PDD-NOS indeed met the full, research based criteria for autism and the 
matched control children functioned within the normal range on the ADOS, the gold 
standard for clinical autism diagnosis,
63
 and the numerous other behavioral rating scales.  
The two groups of children were found to differ profoundly in functioning on the 
measures of the ADOS and other behavioral rating scales, as intended by the study 
design. 
In this study, one of the unique components was the application of multiple 
behavioral rating scales to control children in addition to children with autism.  The study 
found the Social Communication Questionnaire, Aberrant Behavior Checklist, Childhood 
Autism Rating Scale, Gilliam Autism Rating Scale-2, and PDD Behavior Inventory all 
demarcated the differences between the two groups of children nearly as accurately as the 
  
 438 
total ADOS did, as it had the smallest paired-samples t-test value.  Only the CARS and 
Autism Composite of the PDDBI had a lower p-value from a paired-samples t-test 
compared to the Communication subscale of the ADOS and no behavioral rating scale 
paired-samples t-test p-values were smaller than the p-value for the Social Interaction 
subscale of the ADOS.  For all of the subscales for all of the behavioral rating scales, the 
paired-samples t-test p-values were larger than the total ADOS and the Communication 
and Social Interaction ADOS subscales. 
Only one of the other behavioral rating scales utilized in this study, the Autism 
Treatment Evaluation Checklist, demonstrated less separation between the autism and 
control groups when compared to the other rating scales, as determined by the p-values of 
the paired-samples t-tests.  The total ATEC had the largest p-value of all of the 
behavioral rating scales and subscales in this study.  This finding is the result of how the 
ATEC scale was designed.  On two of the subscales, ATEC I and ATEC III, higher 
scores were found in the control children because they demonstrate better communication 
and awareness.  On, ATEC II and ATEC IV, which describe sociability and behavior, the 
control children had lower scores because these subscales were designed to determine 
shortcomings in these areas.  When the total ATEC is determined as a summation of the 
four ATEC subscales, the more significant differences seen for each of the four subscales 
determined by smaller paired-samples t-test p-values are eliminated because the control 
children score near the highest value possible on two subscales and near the lowest 
possible score on the other two subscales.  If the scoring was inverted for ATEC I and 
ATEC III, this loss of differentiation seen in the total ATEC could be eliminated and the 
ATEC could become a more useful tool in the diagnosis of autism and follow-up of 
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treatment effects.  This design of the ATEC could be the reason why the scientific 
literature has focused on using the ATEC to monitor improvement in children with 
autism when evaluating a treatment and not as a diagnostic tool differentiating children 
with autism from neurotypical children.  An additional contribution of this study is the 
finding that the CARS, which was originally validated for use by a trained clinician,
67
 
was able to very accurately differentiate children with autism from controls when 
completed by parents.   
In addition to using the behavioral rating scales to differentiate the two groups of 
children, the behavioral rating scales were correlated with age to determine the 
differences between the two groups taking development into account.  The PDDBI saw 
significant differences in age correlations between the control and autism groups for the 
Autism Composite and some of the maladaptive and adaptive domains and composites.  
In control children, the significant positive age correlation for the Autism Composite 
demonstrated either even greater maladaptive characteristics or smaller increases in 
adaptive behaviors as they develop, but the Autism Composite scores along with the 
domains that comprise it were consistently much lower than the cutoff value for autism 
diagnosis.  This normal development in the control children was seen through the 
negative correlation with age of the adaptive domains (SOCAPP, EXPRESS, and LMRL) 
and composites (EXSCA/C and REXSCA/C).  The control group also demonstrated 
multiple negative correlations in maladaptive domains (RITUAL, SOCPP, and SEMPP 
and the REPRIT/C composite).  These results supported a previous study that noted that 
the adaptive domains and the SOCPP and SEMPP maladaptive domains were able to 
display the expected increases with age.
71
  The PDDBI was created to tackle this problem 
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and the PDDBI offers age-dependent scores and the authors of that study note the 
difficulty of assessing adaptive behaviors with age due to the normal development.
71
  
However, this application of the PDDBI to normal, neurotypical, control children may be 
unique to this study because the PDDBI was designed to only be applied to children with 
an ASD.
71
  The other significant age correlation was with ATEC I in the children with 
autism.  This result showed children with autism significantly increased their speech, 
language, and communication skills with age.  These results reflect the ability of children 
with autism to improve these skills based on the criteria on the ATEC I subscale.  These 
criteria are basic verbal communication markers that nearly all of the control children 
completely demonstrated no matter how old they were.  Of note, some of the older 
children with autism were able to score close to the maximum value for ATEC I.  The 
ATEC I may be a good way to monitor the communication skills of children with autism 
while taking age into account. 
Upon completion of this study, the children with autism demonstrated 
characteristics of the TILT principle seen in many ways through the elemental, toxin, and 
glutathione testing that were a part of this study.  The elemental analysis findings are 
discussed first.  In this study, the children with autism displayed a set of elements that 
were significantly higher in concentration than their matched controls, most notably, 
plasma, serum, and red blood cell magnesium.  A normal concentration of magnesium is 
necessary for proper functioning of the central, peripheral, and autonomic nervous 
systems.  The metabolism of proteins, fats, nucleic acids, and carbohydrates is performed 
using many enzymes that utilize magnesium.  Proper brain development and homeostasis 
require magnesium resulting from copper-zinc superoxide dismutase activity.
83
  
  
 441 
Magnesium is a critical micronutrient that is essential in the maintenance of the 
calcium/magnesium flow across neuronal cell membranes.  It plays a key role in enzymes 
related to ATP and nucleic acid metabolism.
84
  Electrical activity propagates down 
neuronal axons through bursts of functioning of calcium channels.  The significantly 
higher concentrations of magnesium in children with autism may modulate calcium flow 
induced action potentials, decreasing already increased long term potentiation and 
dampening the effects of glutamate excitotoxicity.  Magnesium may also be preferentially 
mobilized from non-brain tissue, creating a risk for magnesium depletion in other body 
tissues, including the heart.  If this physiology is observed in subsequent studies, the 
increased incidence of autonomic instability in children with autism may be at least 
partially explained.  In addition, if the heart is depleted of magnesium, it may be at an 
increased risk for arrhythmia, supporting the careful monitoring of heart functioning by 
electrocardiogram in children with autism who receive psychopharmacological 
management.  Elevated concentrations of magnesium in blood are manifested through 
low blood pressure, drowsiness, decreased heart rate, reduction in bone-tendon reflexes, 
flaccid paralysis, hypoventilation, coma, and cardiac arrest.
84
  The concentration of 
certain proteins in serum have the ability to affect magnesium concentrations in plasma 
because 80% of magnesium in serum is attached to proteins.
84
  The homeostasis of 
magnesium is not accurately reflected by plasma concentrations because nearly all 
magnesium is accumulated in tissues.
84
 
Many studies have investigated magnesium concentrations in blood in children 
with autism.  Strambi led a small study which found children with ASDs had 
significantly decreased concentrations of plasma magnesium compared to controls.
84
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Audhya presented findings at the International Meeting for Autism Research conference 
where children with autism had lower red blood cell magnesium concentrations.
31
  
Magnesium was found to be at lower concentrations in the serum and whole blood of 
children with autism compared to controls at a possible significance in a study from 
Adams et al., but the differences for RBC magnesium concentrations were not found to 
be significant.
85
  However, this study showed strong correlations for magnesium 
concentrations between different blood matrices.
85
  A study from Saudi Arabia found no 
significant difference in the plasma magnesium concentrations of children with autism 
and controls, and while not significant, the children with autism had a greater mean 
concentration of magnesium compared to controls.
86
  The authors of this study suggest 
this is the result of adenylate energy charge equilibration fixing the decreased free energy 
resulting from the higher amount of ATPase in the Na
+
/K
+
 ion pump.
86
  Jory and 
McGinnis completed a study that found no difference in the amounts of magnesium in the 
red blood cells between children with autism and controls.
87
  The current study’s findings 
of increased magnesium in multiple matrices in children with autism, compared to 
controls, may be a function of the high heavy metal and chemical toxicity environment of 
the Western Pennsylvania area where the study was done.  The elevated magnesium may 
serve as a compensatory physiology for factors that are increasing glutamate and calcium 
caused neuronal excitotoxicity for children with autism living in this region.  The 
relationship of blood magnesium could be related to the concentration of magnesium in 
the hair of children with autism.  Studies have shown children with autism had 
significantly decreased concentrations of magnesium in their hair compared to controls.
88-
90
  One study noted smaller concentrations of magnesium in the hair of girls with autism 
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versus healthy girls.
83
  A study noted lower magnesium amounts in females with epilepsy 
compared to controls.
91
  Lech completed a study which observed lower hair magnesium 
concentrations in children with neurological diseases compared to controls.
92
  
Magnesium levels in hair in the current study did not differ between the two groups. 
Red blood cell iron was also significantly higher in children with autism than 
matched controls.  Iron is critical for hemoglobin functioning and deposition of oxygen to 
tissues.  It also has a key role in brain performance particularly at the early stages of 
development.
93
  If iron is increased in tissues, it can cause significant oxidative stress.  
Adams and colleagues completed a study that found children with autism had 
significantly higher concentrations of iron in red blood cells compared to controls.
85
  In 
the Adams study, 42% of children with autism had RBC iron concentrations higher than 
the 90
th
 percentile of the reference range for normal children.
85
  It also found significant 
correlation between RBC iron concentrations and PDDBI scores.
85
  This correlation 
could be an indicator of greater oxidative stress caused by surplus iron, but the authors 
call for further research.
85
  Concentrations of transferrin, an iron-binding protein, were 
determined to be significantly lower in children with autism compared to normal 
neurological developed siblings as an indicator of greater oxidative stress.
94
  An earlier 
study noted the presence of iron deficiency in a minority of children with ASDs.
93
  
Further study is required to determine if the increased red blood cell iron concentrations 
are a response to or contributor to oxidative stress in children with autism. 
Plasma molybdenum was found to be significantly greater in concentration in the 
children with autism.  This element plays a key role in sulfur metabolism, a component of 
chemical detoxification that is deficient in some children with autism.  Molybdenum is a 
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trace element that integrative practitioners have provided to treat pica in children with 
autism, with some success.  Molybdenum may play a role in balancing the plasma 
zinc/serum copper ratios in children with autism.  The higher amounts of molybdenum in 
children with autism observed may indicate increased mobilization from tissues or 
increased uptake by the body to serve the previously described needs.  Jory and 
McGinnis found elevated amounts of molybdenum in the red blood cells of children with 
autism compared to controls.
87
  They state that there is no known framework for this 
finding in the autism literature.
87
 
The plasma zinc/serum copper ratio is a potential biomarker of metallothionein 
functioning that determines the efficacy of the body’s elimination of toxic heavy metals 
such as mercury, arsenic, lead, cadmium, antimony, and chromium VI.  Although the 
results were not significant, all three measurements of the plasma zinc/serum copper ratio 
completed in this study indicated lower plasma zinc/serum copper ratios in children with 
autism compared to controls.  Poor detoxification of heavy metals has been implicated in 
liver dysfunction, the development of interstitial nephritis, and decreased function of the 
endocrine glands, especially the thyroid gland.  In a previous study by our research 
group, 230 children with autism were found to have a plasma zinc/serum copper ratio 
mean of 0.61, which was far lower than the 0.7 value representing the cutoff for the 
lowest 2.5% plasma zinc/serum copper ratios in the literature.
95
  Increased sensitivity to 
proteins has been connected with low zinc/copper ratios and the children in this study did 
create more IgG antibodies to glutens than controls.
89
 
Age correlations with the elements analyzed in blood resulted in the discovery of 
many significant findings with key elements.  The children with autism demonstrated 
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significant positive correlations between age and red blood cell zinc, red blood cell 
selenium, and plasma selenium.  The control children also showed a significant positive 
correlation with age for red blood cell zinc.  The increasing amounts of zinc and selenium 
in the red blood cells as the children aged may be secondary to the inducement of 
absorption of these micronutrients through the intestinal villi.  In addition, the young 
females in the study produced microestrogens by the time they were 5 or 6 years of age, 
inducing a positive increase in metallothionein system functioning
96
 that could feedback 
on intestinal enzymatic absorption characteristics.  These positive correlations between 
selenium and age were entirely absent in the control children.  The children with autism 
demonstrated a significant negative correlation with age for serum iron that was not seen 
at a significant level in the control children.  One study did not observe a change in iron 
concentrations with age in healthy children.
97
  This finding could relate to autism severity 
as Adams et al. found a strong positive correlation between RBC iron and PDDBI 
score.
85
  The control children demonstrated significant negative correlations of age with 
serum, plasma, and red blood cell copper concentrations.  The children with autism did 
not illustrate this correlation.  One study found serum copper concentrations decreasing 
with age in healthy children,
97
 and this finding was supported in another study.
98
  The 
serum correlation with age is likely secondary to the control children’s much more 
efficacious and efficient functioning of their metallothionein system.  Of note, serum 
molybdenum had a negative correlation with age only in the control children, and a 
micronutrient necessary for supporting zinc/copper homeostasis may be less induced for 
absorption in children with healthier zinc/copper and metallothionein functioning.  There 
are limited age correlations with elemental concentrations in the blood of children with 
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autism discussed in the scientific literature, and this study discovered some significant 
age correlations with elements in blood that can be expanded upon in future studies. 
Another area that can provide insight into the manifestation of the TILT 
mechanism is the concentration of elements in hair.  The concentrations of elements in 
hair reflect both the total body concentrations of these elements and the ability of the 
body to maintain each element’s effluent and the ability to release it into the hair follicle 
cell.  Exposure to environmental pollution has been studied through the elemental 
analysis of children’s hair.99  In this study, the pattern of the release of elements into the 
hair of children with autism differed significantly from controls, and elemental analysis 
in hair may be a relatively non-invasive method of early detection of metallothionein 
dysfunction in children with autism (i.e., cut a lock of hair from a child at 9 months of 
age and send it for elemental analysis by mass spectrometry).  Although not significant, 
the children with autism demonstrated lower concentrations of chromium and lead in hair 
than controls.  Children with autism have an increased risk of developing insulin 
dependent diabetes mellitus (IDDM).
100
  Since chromium plays an important part in the 
cellular response to insulin and glucose tolerance factor,
101
 abnormal absorption or 
excretion of it may play a role in the increased incidence of IDDM in children with 
autism.  Many studies have investigated the concentrations of elements in children with 
autism.  In Kuwait, Fido and colleagues found significantly decreased concentrations of 
chromium in children with autism compared to age and sex matched controls.
102
  In a 
second study, Fido and Al-Saad observed higher amounts of lead in children with 
autism.
103
  Yahuda and colleagues noted decreased chromium and lead concentrations in 
children with autism compared to controls.
101
  Kern led a study which discovered 
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significantly lower concentrations of lead in hair of children with autism compared to 
matched controls.
37
  Lakshmi Priya and Geetha found higher concentrations of lead in the 
hair of children with autism compared to controls in India.
89
  Blaurock-Busch et al. also 
observed higher amounts of lead in the hair of children with autism.
90
  Overall, many 
studies have been published which indicate lower concentrations of toxic metals, most 
notably mercury, in the hair of children with autism which support the hypothesis of 
detoxification problems in children with autism.
36, 104-105
  The results of this study give 
further credence to this hypothesis.  Although chromium is a nutrient, chromium 
speciation is necessary to evaluate toxicity, but this analysis was not completed as a part 
of this study due to the limitation of hair sample size. 
Similar to the elemental concentrations in blood, the elemental concentrations in 
hair were correlated with age to determine any possible differences in development 
between the two groups of children.  Hair concentrations were positively correlated with 
age of the children with autism for the critical micronutrients zinc and magnesium.  As 
children with autism age and their metalloprotein system becomes more inefficient, the 
maintenance of critical micronutrient concentrations may falter secondary to passive 
effluence into the hair.  Alternatively, the children with autism may be demonstrating 
compensation for increased heavy metal toxicity as they age, increasing both intestinal 
absorption of zinc and magnesium and hair effluent of these elements.  The control 
children also showed a positive correlation of magnesium concentration with age.  The 
children with autism demonstrated a negative correlation with age for molybdenum and 
tin.  Molybdenum could become greater in need as children age and the immune system 
continues to develop.  The negative tin correlation could indicate a greater ability for the 
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detoxification of tin or greater tin exposure with age.  The control children had a 
significant positive correlation with age for uranium, copper, and cerium.  The uranium 
and copper correlations show the increased detoxification capabilities of the control 
children for these elements as they aged, which were not found in the children with 
autism.  Cerium is a rare earth element with low to moderate toxicity, but an increased 
exposure to diesel fuel could result with age since cerium does not have a biological 
function in humans.  As with the blood elemental age correlations, the literature is limited 
in the number of studies that discuss correlating elemental concentrations in hair with age 
in children with autism, but the significant findings in this study can be supported with 
additional work.  A study from South Korea observed positive age correlations with zinc, 
calcium, magnesium, copper, and mercury concentrations in hair.
106
  The authors called 
for addition research in hair elemental concentrations for the evaluation of diet and 
relationship of the environment to diseases in children.
106
  Another study observed a 
decrease in hair zinc concentrations with age.
107
  Further studies are necessary to support 
and expand upon these findings in children with autism. 
The initiation of TILT that is seen through changes in elemental concentrations, 
toxin accumulation, and variations in glutathione concentrations may have manifested 
differences in immunological functioning between the two groups of children in the 
current study.  Much research in the literature supports the presence of a dysregulated 
immunological system in children with autism.
108
  The current study supports the 
literature by demonstrating significantly increased parameters of immunological 
functioning in children with autism compared to controls.  The children with autism 
demonstrated significantly increased concentrations of white blood cells compared to 
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matched controls.  White blood cells play a large role in the adaptive immune system and 
an elevated number of white blood cells could be an indicator of inflammation.  
Neutrophils were significantly elevated in children with autism.  Neutrophils primarily 
attack bacteria and fungi.  Both measures of lymphocytes in this study indicated greater 
numbers of them in children with autism compared to controls.  Lymphocytes can be 
identified as T cells, B cells, and natural killer cells.  Natural killer cell number and 
percent, a measure of innate immune system functioning, were very significantly higher 
in the children with autism that participated in this study compared to controls.  Ashwood 
et al. observed 40% higher levels of natural killer cells in children with autism compared 
to controls.
109
  The authors of that study suggest children with autism have a greater 
autoimmune response observed through the higher natural killer cell number resulting 
from elevated levels of cytokines and other homeostatic and growth factors.
109
  Many 
studies have shown natural killer cell activity is decreased in children with autism.
110-112
  
One of these studies noted a correlation of natural killer cell activity to the intracellular 
level of glutathione. 
112
  Another study found elevated amounts of perforin, granzyme B, 
and interferon gamma while studying the natural killer cells in children with autism.
113
  
Enstrom and colleagues noted the important role natural killer cells play in the 
dysregulation of the immune system of children with ASDs.
113
  The lower activity of 
natural killer cells in children with autism could explain the larger number and higher 
percentage of natural killer cells. 
The findings of the lymphocyte subset panel show support of changes in the 
adaptive immune system of children with autism compared to controls.  The CD3 
number, the total T cell number and a marker of the number of CD3 T cells need for 
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immune system activation or suppression, were greater in children with autism against 
matched controls.  The CD4 number was significantly increased in children with autism 
versus controls.  CD4 cells, helper T cells, regulate and activate B cells.  CD4 cell 
overproduction can lead to over creation of cross reacting antibodies that attack the 
body’s own tissues.  Compared to controls, a trend of elevated CD8 numbers in children 
with autism was seen.  CD8 T cells, suppressor T cells, are responsible for controlling B 
cell production of antibodies.  One study noted increased CD3 and CD8 frequency in the 
mucosal lamina propia of children with autism.
114
  A study demonstrated higher numbers 
of total lymphocytes, T lymphocytes, and suppressor/cytotoxic T lymphocyte ratio in 
low-functioning children with autism compared to high-functioning children with autism,  
and this study also correlated intelligence quotient with these three immune system 
markers.
115
  However, the children in that study were older than those in the current 
study.  One study has shown that abnormal innate immune system reactions could 
produce changes to the adaptive immune system.
51
  Overall, these results support the 
overstimulation of the innate and adaptive immune systems in children with autism 
compared to controls.   
The altered lymphocyte subset panel results and differences in complete blood 
counts of children with autism suggest the presence of overreacted immune responses in 
children with autism.  Children with autism in this study had significantly higher platelet 
counts than controls.  In the clinical setting, elevated platelet count has been noted to be 
present in the context of chronic intestinal inflammation.  This study demonstrated that 
anti-gluten IgG antibodies were significantly elevated in children with autism compared 
to controls, suggesting that the IgG gluten antibodies were superior to antigliadin 
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antibodies in delineating which children were sensitive to gluten.  In the clinical milieu, 
anti-gluten IgG antibodies have predicted significant gluten sensitivity.  Children with 
autism demonstrated a trend towards higher concentrations of anti-casein IgG antibodies 
versus controls.  In 2013, Lau and colleagues published a study that demonstrated 
elevated IgG antibodies in children with autism compared to controls.
116
  This study also 
showed higher anti-gliadin IgG antibodies in children with autism who had 
gastrointestinal symptoms compared with children who did not suffer from them.
116
  
Another study found 83.3% of children with autism had increased amounts of IgG and 
IgA casein antibodies and 50% had increased IgG and IgA antibodies.
117
  A study of girls 
with Rett syndrome demonstrated significantly higher levels of IgA antibodies to gliadin, 
gluten, and casein and IgG antibodies to gliadin and gluten compared to controls.
118
  The 
elimination of both of these proteins has resulted in increased digestion and 
improvements in behavior in children with ASDs.
119-120
  Children with autism 
demonstrated higher concentrations of serum methylmalonic acid compared to controls.  
These elevated concentrations of methylmalonic acid could be indicative of a deficiency 
of vitamin B12 and greater oxidative stress.  Vitamin B12 status can most precisely and 
accurately be determined by methylmalonic acid.
121
  Excess urinary methylmalonic acid 
is a sign of vitamin B12 deficiency.  Adams led a study that showed urinary 
methylmalonic acid concentrations decreased in children and adults with autism after the 
use of a vitamin/mineral supplement.
122
  In another study by Adams et al., children with 
autism had a greater mean urine methylmalonic acid concentration, but it was not 
significantly greater than neurotypical children.
85
  This study also found a significant 
correlation between urinary methylmalonic acid concentration and PDDBI score.
85
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Clinical testing produced significant correlations with age that showed the 
differences in development of the immune system in children with autism and controls.  
Both groups of children displayed a negative age correlation for lymphocytes and 
lymphocyte percent.  Lee et al. showed lymphocyte numbers and percent decrease 
gradually with age in healthy children.
123
  A study from Saudi Arabia observed declines 
with age in total lymphocytes with age in healthy children.
124
  The T and B cell subsets 
produced numerous significant age correlations in each group of children in this study.  
Both the CD19 number and percent demonstrated significant negative correlations with 
age in both groups of children.  One study noted a 6.5-fold decrease in CD19 B 
lymphocytes from age 2 until adulthood in healthy subjects.
125
  Another study showed 
decreased CD20 B cell number and percent with age.
123
  The Saudi Arabian study 
observed decreases in the percentage and number of B cells with age.
124
  Both groups of 
children showed significant negative correlations for CD3 number.  One study noted a 
three-fold decrease from age 2 to adulthood in CD3 lymphocytes in healthy subjects.
125
  
The authors note the importance of number of immune cells as opposed to the percentage 
of these cells.
125
  T cells were noted to decline with age in healthy children with age in 
the study from Saudi Arabia.
124
  Lin et al. showed T cell counts declined with age in 
healthy Chinese children.
126
  Only the children with autism had a significant negative age 
correlation for CD4 number; however, the control children had a negative trend with age.  
The control children showed a significant positive correlation with age in the control 
children for CD3 percent and CD4 percent.  The study by Lee et al. showed an increase 
in CD3 percent with age in neurotypical children.
123
  The children with autism and 
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control children showed a positive correlation with age for the neutrophil percent, 
indicating no significant difference in physiology between groups for this marker. 
The children with autism lacked a significant age correlation with the percent of 
iron saturation that was seen in the control children suggesting that poorer absorption of 
iron could be occurring in older children with autism.  The AST was negatively 
correlated with age in both groups of children, possibly indicating increased liver 
functioning with age.  Only the control children had a negative correlation of serum 
copper with age.  This finding is similar to what was observed during the analytical 
elemental analysis indicating a greater ability to detoxify and subsequent more efficient 
metallothionein system functioning in control children compared to the children with 
autism. 
The children with autism demonstrated positive correlations with age for IgG and 
IgA antibodies.  The control children also had significant positive age correlation for IgA 
antibodies and a trend of increasing IgG antibodies indicating that both groups have a 
development of the humoral immune system antibody production with age.  The results 
of the current study are supported by Heuer et al. noting that very small amounts of IgG 
are produced during infancy and adult concentrations are reached between ages 6 and 
8.
127
  The children with autism displayed a positive correlation with age for anti-casein 
IgG antibodies, while control children did not have a significant age correlation for anti-
casein IgG antibodies.  This finding indicates older children with autism had a propensity 
to overproduce these antibodies and had an increased sensitivity to casein, which could 
be a result of their exposure to toxicants and resultant in loss of immune tolerance.  The 
results observed in the current study of the changes in the immune system between 
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children with autism and controls are supported by the scientific literature, but further 
scientific research is needed to evaluate changes in the immune system with age in 
children with autism. 
Upon completion of this study, the children with autism who were studied 
demonstrated the potential characteristics of TILT.  Children growing up in Pittsburgh 
and the surrounding area are exposed to an environment where 73% of mercury 
emissions are the result of anthropogenic activity.
26
  The toxicant insult is added upon by 
the exposure to other heavy metals; organic toxins including PBDEs, PCBs, and VOCs; 
pesticides; and molds, fungi, and other biologicals that occur every day.  It is this 
overload of toxic exposure in the modern environment, which has been exposed to the 
effects of over 80,000 chemicals, that forms the foundation of the toxic exposure that 
could manifest itself through the different characteristics observed in children with 
autism.  The children with autism in this study demonstrated poorer effluent of certain 
chemical and metal toxins, more immune dysregulation, and a significant loss of immune 
tolerance to glutens, compared to their matched peer controls.  The children with autism 
illustrated more oxidative stress, as noted by having significantly less reduced/oxidized 
glutathione rations than controls.  A potential link between glutathione concentrations 
and immune dysregulation was shown in another research team’s study where a greater 
percentage of oxidized glutathione, a smaller amount of reduced glutathione, and a lower 
reduced/oxidized glutathione ratios were observed in the activated CD4 T cells in 
children with autism.   
In addition to determining the differences in children with autism and controls and 
discovering correlations in each group, the study was able to perform logistic regression 
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analysis on the variables which produced significant differences between children with 
autism and controls.  The logistic regression analysis allows for the probability of autism 
diagnosis to be determined based on the measured value for a particular variable.  This 
data can potentially be used for diagnostic purposes in a clinical setting.  The ability to 
combine multiple measured variables and combine them with the diagnostic probability 
for autism could provide the possibility of creating a screening test for the early diagnosis 
of autism.  A large screening set of these biomarkers that could be collected by a 
fingerstick or a single vacutainer tube could potentially create a means of prediction of 
physiological risk for the development of autism and other neurodevelopmental 
disorders.  This study may yield a means of assessing “actionable data” that allows for 
early prediction or perhaps amelioration of some of the physiologic mechanisms 
underlying decreased detoxification capabilities and the immune dysregulation that 
contributes to the development of autism. 
One other area where this study differentiates itself from the other studies 
conducted is the quality and fidelity of the measurements that were used to determine the 
statistically significant findings through higher accuracy and precision.  In this study, 
many steps were taken to ensure that the measurements were of the greatest quality 
possible.  Accuracy was validated using SRMs, CRMs, or standards traceable to NIST 
and, they were implemented in all of the analytical measurements in this study.  The use 
of these standards allowed for the validation of the sample preparation, analysis 
parameters, and instrument performance.  The sample preparation was meticulous in all 
of the types of analytical analysis in this study as it was performed exclusively in a 
cleanroom environment.  The glutathione sample preparation was performed in a nitrogen 
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glove box to prevent species interconversion from oxygen in the air to minimize 
oxidation and species interconversion.  The blood used for the VOC analysis was drawn 
into special VOC free tubes that were prepared by and obtained from the Centers for 
Disease Control.  The sample preparation and analysis was completed using standardized 
EPA Methods for the elemental and persistent organic pollutant analyses.  Enriched, 
stable isotopes were used in conjunction with these standardized methods to improve the 
accuracy and precision of the measurements.  The measurements that were obtained were 
achieved through the use of multiple subsamples from a single sample and multiple 
replicate measurements were performed from each subsample.  This use of measurements 
allowed for proper statistics to be implemented that allowed for the most statistical data 
to be extracted from the results.  The values from the commercial clinical laboratory only 
provide a single value with no statistics.  The new values with statistics and confidence 
intervals provide a better assessment of a measurement and the test results can create 
better clinical understanding and more actionable data improving clinical care. 
Overall, this study accomplished many diverse things in multiple different 
disciplines.  This study observed many statistically significant differences between 
children with autism and age, gender, and SES matched controls.  The results of this 
study establish the presence of greater metallothionein system dysfunction, chemical 
detoxification disturbances, immune dysregulation, and subsequent loss of immune 
tolerance in the children with autism compared to controls, and support the presence of 
the TILT theory of disease progression in children with autism.  This study is one of the 
first to demonstrate changes in elemental, chemical, glutathione, and immune parameters 
in children with autism and controls in relation to age.  The study results suggest that 
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various chemicals are detoxified differently between children with autism and controls.  
The magnesium, zinc, selenium, and glutathione data support the presence of a 
compensatory physiology in children with autism, exposed to high heavy metal and 
chemical stress of living in Western Pennsylvania.  Benzene, toluene, and xylene 
concentrations in children with autism and controls were much higher than previously 
determined national norms, suggesting increased exposure for all Western 
Pennsylvanians to these toxins.  Overall, these changes demonstrated that children with 
autism present with characteristics of the TILT theory of disease.  Further research 
studies are necessary to support and continue the findings observed in this study. 
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Appendix A 
 
(Note: The findings in Appendix A are the professional opinion of Dr. Scott 
Faber, MD, developmental pediatrician at The Children’s Institute, as the attending 
physician and co-principle investigator at the time of publication and are subject to 
further data analysis and interpretation.)
1
 
Quantification of Inorganic and Organic Compounds in the Blood and Hair of 
Children with Autism and Controls Along with Correlation with Autism Severity: 
Executive Summary 
In late 2009 and early 2010 a team composed of members of The Children’s 
Institute clinical staff,  faculty and graduate students at Duquesne University’s Chemistry 
and Biochemistry Department, and researchers at the Nova Southeastern Medical School, 
created a research project designed to study a marker of genetic mutation, elemental 
concentrations, chemical toxins, and behavioral rating scale and Autism Diagnostic 
Observation Schedule (ADOS) results in children with autism versus age, sex, and 
socioeconomically matched controls.  The study was vetted by a team of international 
experts prior to acceptance by the Institutional Review Board of Duquesne University in 
the spring of 2010.  Enrollment of children with autism and controls occurred from 5/10 
to 6/12 at The Children’s Institute.  New methods of studying chemical concentrations 
were developed at Duquesne University, including the first accurate measurement of 
glutathione and its subtypes, a critical protein supporting metal and chemical 
detoxification, along with a unique method of measuring volatile organic compounds.  
For two years blood and hair samples were obtained by a nurse especially adept at 
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obtaining blood work from children with autism, and transported to Duquesne University 
for subsampling, separation, analysis and storage.  Blood values results were obtained 
from equipment that worked often 24 hours a day for weeks at a time at Duquesne 
University, to obtain the elemental and chemical xenobiotic data, a private lab which 
provided biomedical and immunological results, and a research lab at Nova Southeastern 
University in Florida, which performed the genetic mutation studies.  Data analysis, done 
in conjunction with the Department of Computer Science and Mathematics at Duquesne 
University, has been ongoing since early 2012 and the full set of elemental, chemical, 
genetic mutation, and behavioral rating scale data, comprising over 300,000 data points, 
became available for analysis in early 6/13.  This summary seeks to provide a brief 
overview of the underlying reasons for embarking on such a study, the key findings to 
date, and early interpretations of the meaning of this data for children with autism. 
The incidence of autism has been increasing significantly over the past 30 years, 
according to numerous studies emanating from the MIND Institute of the University of 
California at Davis and the Center for Disease Control of the United States.  The increase 
of diagnostic prevalence, from approximately 1 in 10,000 children to 1 in 50 children, 
including large increases in autism diagnosis for the most severe children, speaks against 
this phenomenon being created solely by genetic etiology.  The presence of adverse 
genetic / environmental interaction increasing the incidence and prevalence of autism has 
been supported by studies in the recent literature implicating exposure to air pollution in 
utero and during the first years of life, exposure to pesticides while in utero, and chemical 
and heavy metal pollution from living near busy highways and industrial sources.  In the 
spring of 2010 studies were published supporting the concept that copy number variant 
  
 471 
changes, small areas of duplication and deletion of DNA, were associated with the 
diagnosis of autism.  Many theorists wondered whether these copy number variant 
changes were being created by increased exposure to environmental toxicants and 
whether they adversely affected chemical and metal detoxification. 
In the 1990s a new theoretical model of development of disease called the 
Toxicant Induced Loss of Tolerance or TILT model was promoted.  Researchers from 
Harvard University and the University of Texas at San Antonio wrote theoretical and 
case report work supporting the concept that certain individuals were prone to being 
sensitized to chemicals and heavy metals, leading to over functioning of certain aspects 
of the immune system, also called immune dysregulation, and subsequent loss of immune 
tolerance to chemical, metal, and food stimuli.  This loss of immune tolerance caused a 
host of central nervous system symptoms in this model.  Given the extraordinary increase 
in prevalence of autism over the past few decades, this model appeared extremely 
promising at explaining at least some of the symptomatology seen in children with 
autism. 
Over the past two decades some studies have demonstrated that children with 
autism have deficiencies in detoxifying heavy metals as they display differences in 
selenium and zinc levels needed for removal of toxic metals, compared to controls.  
Children with autism also have demonstrated significantly decreased methylation and 
sulfation abilities compared to controls in the literature, which adversely affects their 
ability to remove xenobiotic chemicals. 
Over the past decade, a new field of scientific inquiry called exposomics was 
developed, which sought to explain disease causation and progression from the level of 
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DNA (genomics), the prime code for protein production, to messenger RNA, the signal 
and template for protein production, to the qualities and levels of protein concentrations 
(proteomics), up to epigenetic mechanisms, the numerous ways that protein production 
from DNA can be modified without changing the genome.  The current study, in a similar 
fashion, was designed to measure numerous levels of possible causative mechanisms in 
children with autism, through genetic mutation using the Glycophorin A test, noting the 
levels of heavy metal and chemical concentration through exacting measurement, 
studying immune functioning through the performance of t and b cell subsets, examining 
the degree of loss of immune tolerance to certain proteins through the performance of 
IgG antibody levels to casein, gluten, and soy, and studying behavioral phenotype 
through rating scale and ADOS performance. 
The initial round of data analysis has revealed the following findings from this 
study: 
1. A subset of 3 children with autism appeared to experience much more total allele 
loss and duplication mutation than other children with autism, suggesting the 
presence of a group of children with the behavioral phenotype of autism who may 
be especially susceptible to such mutation. 
2. Children with autism had significantly increased blood levels of magnesium and 
iron compared to controls suggesting that their metalloprotein system essential in 
heavy metal elimination was more stressed than controls and they were increasing 
blood levels of magnesium and iron to compensate. Magnesium can calm central 
nervous system excitotoxicity, and increased iron may promote oxygenation in 
stressed tissues.  The children with autism also had increased molybdenum levels 
  
 473 
compared to controls.  Molybdenum supports methylation and sulfation essential 
for chemical detoxification. 
3. The children with autism demonstrated a trend towards less chromium and lead in 
their hair compared to controls suggesting difficulty with effluent of these 
elements from the body. 
4. The children with autism displayed a strikingly different pattern of chemical 
toxicity concentration compared to controls, as they tended to have higher blood 
concentrations of compounds associated with automobile exhaust and one flame 
retardant.  The control children were found to have higher levels of chlorinated 
pesticides in their blood.  This data supports the literature which implicates 
exposure to highway pollutants as a possible contributor to the development of 
autism.  This data also suggests that children with autism may have particular 
difficulty with mobilizing pesticides from their tissues. 
5. Children with autism and the control group had numerous blood concentrations of 
chemicals that greatly exceeded published national averages, including pesticides 
and hydrocarbons such as xylene, toluene, and benzene.  Children in Western 
Pennsylvania may be at high exposure risk for these compounds. 
6. Children with autism had a strong trend towards positive correlation between their 
total ADOS scores (indicating autism severity) and mean toxin concentration. 
7. Children with autism had significantly higher levels of total glutathione and 
reduced glutathione compared to controls, while they had significantly less total / 
oxidized and reduced / oxidized glutathione compared to controls.  This data 
indicates that children with autism in Western Pennsylvania are producing more 
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reduced and total glutathione than their healthy peers and children with autism 
who live in less toxic regions of North America, in response to the increased toxic 
burden of this region, as a compensatory physiology.  However, they demonstrate 
decreased reduced / oxidized and total / oxidized glutathione ratios compared to 
their peers, similar to other children with autism described in the literature.  Their 
compensatory physiology fails to control their increased oxidative stress in this 
region.  
8. Children with autism demonstrated significant immune dysregulation compared to 
controls, as displayed by significantly elevated CD3 / total T cell number, CD4 / 
helper cell number, natural killer cell number and natural killer cell percent, 
compared to controls.  They had significantly increased platelet counts compared 
to controls, supporting the presence of more generalized inflammation in their 
bodies, than controls. 
9. Children with autism had significantly elevated anti-gluten IgG antibodies 
compared to controls and a strong trend towards elevated anti-casein IgG 
antibodies compared to controls.  As children with autism aged their anti-casein 
IgG antibodies increased significantly, a finding not noted in control children.  
These results support recent literature suggesting increased gluten and casein 
sensitivity in children with autism compared to controls. 
10. Methylmalonic acid levels were tested as higher concentrations of methylmalonic 
acid in serum may indicate a vitamin B12 deficiency.  In this study, the children 
with autism had significantly greater quantities of blood methylmalonic acid 
  
 475 
compared to controls supporting the presence of relative B12 deficiency in 
children with autism compared to controls. 
11. Logistic regression results for natural killer cell number, white blood cell number, 
antigluten IgG antibody concentration, and methylmalonic acid concentration are 
most promising of the variables measured for determining diagnostic probability 
of autism in children age 2-9. 
12.  Of interest, control children could increase uranium and cerium significantly in 
their hair as they aged while children with autism demonstrated small negative 
correlations with these substances as they aged.  This finding suggests that 
children with autism may have more difficulty eliminating these elements from 
their bodies as they age. 
Overall, the results of this study establish the presence of greater metallothionein 
system dysfunction, chemical detoxification disturbances, immune dysregulation, and 
subsequent loss of immune tolerance in children with autism compared to controls, and 
support the presence of the Toxicant Induced Loss of Tolerance or TILT model of disease 
progression in children with autism.  This study is one of the first to demonstrate changes 
in elemental, chemical and immune parameters in children with autism in relation to age.  
The study results suggest that various chemicals are detoxified differently between 
children with autism and controls.  The magnesium, zinc, selenium, and glutathione data 
support the presence of compensatory physiology in children with autism, exposed to the 
high heavy metal and chemical stress of living in Western Pennsylvania.  Benzene, 
toluene, and xylene concentrations in children with autism and controls were much 
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higher than previously determined national norms, suggesting significant exposure for 
Western Pennsylvanian children to these toxins. 
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